{"title": "PDF", "author": "PDF", "url": "www.idipaz.es/ficheros/files/prensa/IdiPAZ%20Scientific%20Report%202018.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Scientific \nReport Scientific \nReport Index 2  \n1\n2\n3\n4  3\n1\n2\n3\n4\n  5\n  6\n  13\n  23\n  27\n  40\n  43\n  68\n  95\n  106\n  108\n  110\n  111\n1\n2\n3\n4\n \n  113\n  114\n  135\n  161\n  212\n  278\n  327\n1\n2\n3\n4\n  351\nIntrod uction\nExecutive summary\nInformation Groups  \nby Area\nAssociated Clinicians2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and Teaching\n2.4 Innovation and Transfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\t Scientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n3.1 Neuroscience Area\n3.2 Cardiovascular Area\n3.3 Infectious Diseases and Immunity Area\n3.4 Large System Pathologies Area\n3.5 Cancer and Human Molecular Genetics Area\n3.6 Surgery, Transplant and Health Technologies AreaScientific \nReport \n1\n2\n3\n4Executive \nsummary\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians3  \n3Information Groups \nby Area\n1Introduction\n2\nExecutive summary\nAssociated Clinicians\n4\nDr. Eduardo L\u00f3pez-Collazo\nScientific Director of IdiPAZ\nDr. Rafael P\u00e9rez-Santamarina Feij\u00f3o\nManaging Director of HULP\nChairman of the Board of FIBHULPThe Hospital La Paz Institute for Health Research (Instituto de Investi -\ngaci\u00f3n Sanitaria del Hospital Universitario La Paz)-IdiPAZ was created in \n2009, as a result of the relationship that has been forged over the years \nbetween La Paz University Hospital (HULP), the Autonomous University \nof Madrid (UAM), and the Foundation for Biomedical Research of La Paz \nUniversity Hospital (FIBHULP). Recently, we have incorporated Fuenla -\nbrada University Hospital to our structure, and we are also very excited \nwith the upcoming incorporation of Getafe University Hospital and the \nEuropean University of Madrid.\nSince its establishment, IdiPAZ has promoted the configuration of multi -\ndisciplinary teams capable of addressing several facets of translational re -\nsearch, with the mind always focused on the generation of innovation and \nthe transfer of results to the healthcare system. Over the years, we have \nmaintained a progressive growth of our scientific activity, which is organi -\nzed into six research areas: neurosciences, cardiovascular, infectious disea -\nses and immunity, large system pathologies, cancer and human molecular \ngenetics and surgery, transplants and health technologies. The increasing \nscientific contributions performed by our research groups over the last \nyears have placed IdiPAZ amongst the top three health research Institutes \nwith the best scientific evaluation of Spain. \nThe Scientific Report of IdiPAZ provides us an opportunity to recognize \nthese achievements of our researchers, and reflects the effort of the 55 \nresearch groups that currently constitute IdiPAZ, as well as the associated \nclinical groups. \nIdiPAZ\u2019s excellent position in clinical research is evidenced by its scien -\ntific performance figures. Particularly regarding scientific production, we \npublished more than 1,200 articles in 2018, of which 928 were original \npapers. In addition, the overall impact factor reached almost 5,600 points, \nexceeding for the first time the 5,000 points threshold. There has been \nalso a consolidation in the quality of the source journals, and more than \n514 of the manuscripts were published in journals in the first quartile of \ntheir subject area. \n2018\nScientific \nReport \n1\n2\n3\n4Introduction4  \n1\n2\n3\n4Executive \nsummary\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe 2018 Scientific Report also shows data reflecting the com -\nmitment of IdiPAZ to biomedical research training. The involve -\nment of the university in most of the research groups has resul -\nted in a high participation in graduate programs, generating 34 \nDoctoral Theses in 2018; 5 of them being qualified with an In -\nternational Mention. Additionally, in our attempt to promoting \nresearch and science in the society, we hosted many scientific \nactivities as: the European Researchers\u2019 Night, the Science and \nInnovation Week, the International Day of Woman and Girl in \nScience, and other several events of scientific dissemination, all \norganized with the aim of actively involving citizens in science, \ntechnology and innovation, contributing to join the youngest \npublic, promoting scientific vocations and eliminating gender \nbarriers. In parallel, our institution is making a great effort to \npromote IdiPAZ brand and collaborations both national and \ninternationally. For this purpose, in 2018 we signed agreements, \nstarted projects, organized activities and workshops and initia -\nted relationships with new partners to increase our visibility \nand current potential, while improving our plans for the future \ntaking into account the internationalization aspects.\nRegarding our innovation performance indicators, we must \nhighlight the fact that at December 31 2018, our Innovation \nSupport Unit (UAI) had 184 innovation projects or ideas in \nactive state, 26 of which were in the capture phase, 65 in the \nevaluation phase, 12 in development, 49 in transfer and 32 in \nthe market. IdiPAZ researchers and groups work in research \nnetworks (CIBER and RETICs) that involve collaboration to \nimprove results, as well as in international consortia. Finally, we \nhave done an effort to continue and improve our translational \nresearch with a direct application to the care of our patients; \nand in this strategic process, 371 new contracts for clinical \ntrials were signed in 2018.\nThe excellence of our research institute is based on the cons -\ntant struggle of our human capital to improve patient\u2019s health; \ntherefore, we would like to express our admiration for them, who enable IdiPAZ to continue advancing towards a promising \nfuture. There have been many achievements and we are con -\nfident that we will achieve many more. Our human potential \nand desire to continue progressing represent the best guaran -\ntee of continued success. We are especially grateful to all our \nresearchers, members of the Governing Council, the Executive \nCommittee, Internal Scientific Advisory Board, the External \nScientific Advisory Board, Committees, Platforms and all the \nprofessionals involved in the day-to-day work of the Institute, \nfor the magnificent performed work during these years and the \nachieved results. \nIn 2019, we are celebrating the 10th anniversary of IdiPAZ, thus \nit represents a pretty special occasion to show and dissemi -\nnate our strengths and the achievements we have accomplis -\nhed over this decade. Proudly, we can show to the scientific \ncommunity and the civilian society all those merits that have \nallowed our Institution to be national and internationally re -\ncognized as a Center of Excellence, and be on a par with the \nbest scientific institutes worldwide.\nHospital Universitario La Paz\nFundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica\nScientific \nReport \n1\n2\n3\n4Introduction\n3\nInformation Groups \nby Area\n1Introduction\n2\nExecutive summary\nAssociated Clinicians\n45  \n1\n2\n3\n4Information \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.7.5  Cell Culture Unit\n2.7.6  Sanger Sequencing Facility\n2.7.7  Image Laboratory\n2.7.8  Flow Cytometry Laboratory\n2.7.9  Radioisotope Laboratory\n2.7.10  Biostatistics Section\n2.7.11  Documentalist\n2.7.12  PAIN Platform\n2.7.13  Internationalization Platform\n2.7.14  Tissue Engineering and 3D Printing Platform\n2.7.15  Food, Nutrition and Health Platform\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Communication\n2.2 Research Structure\n2.3 Training Report and Teaching\n2.3.1  Training Committee\n2.3.2  Training Courses\n2.3.3  Doctoral Theses\n2.4 Innovation and Transfer Activities\n2.4.1  Innovation and Transfer Activities\n2.4.2  Patents and Trademarks\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.7.1  Biobank\n2.7.2  UCICEC\n2.7.3  Experimental Surgery\n2.7.4  Simulation Platform (CEASEC)2.1 Global Analysis\n2.1.1  Scientific Analysis\n2.1.2  Annual Accounts\n2.8 Scientific Production\n2.8.1  Journal Analysis\n2.8.2  High Impact PublicationsScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8 Scientific Production\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n6  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.1 Global  \nAnalysis\nIn 2018, the scientific production of IdiPAZ inclu -\nded more than 1,200 publications that reached, \nfor the first time, almost 5,600 points of total im -\npact factor. Of the total of publications, 46.7% are \ndocuments belong to IdiPAZ, so the author the \nfirst, the last or the corresponding author of the \npublication is a researcher of the institute.\nTotalImpact  \nfactorMean impact \nfactor\nPublications 1,243 5,599.02 4.50\nOwned Publications 581 1,974.52 3.40\nUn-owned Publications 662 3624.50 5.48\nOriginals 928 4,360.68 4.70\nOwned Originals 368 1127.43 3.06\nUn-owned Originals 560 3,233.26 5.77\nTOTAL IMPACT FACTOR BETWEEN 2009-2018 MEAN IMPACT FACTOR BETWEEN 2009-20182.1.1\t Scientific\tAnalysisScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8 Scientific Production\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n7  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.1 Global Analysis\nIn 2018, the scientific production of IdiPAZ included more than 1,200 publications that reached, for the first time, almost 5,600 points of total impact factor. Of the total of publi -\ncations, 46.7% are documents belong to IdiPAZ, so the author the first, the last or the corresponding author of the publication is a researcher of the institute.\nTOTAL IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018\nMEAN IMPACT FACTOR FOR ORIGINAL PAPERS BETWEEN 2009-2018\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8 Scientific Production\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n8  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.1 Global Analysis\n 2.1 Global Analysis\nConsidering originals published by IdiPAZ researchers, 928 articles, we keep the trend of the last years, exceeding the 4,000-point threshold (4,360.7 points). Moreover, about \n18% of the originals published in this year were in first-decile journals of their subject area, and 43% were in first quartile journals.\nIdiPAZ researchers evidenced their participation in national and international scientific networks, with near 85% of the total documents published in collaboration, which 88.6% \nof the originals publications. In addition, collaboration among IdiPAZ research groups is also reflected by the percentage of intramural collaboration, which reached almost 11% \nfor all manuscripts and for originals.\nTOTAL IMPACT FACTOR FOR ORIGINAL PAPERS  \nBETWEEN 2009-2018MEAN IMPACT FACTOR FOR ORIGINAL PAPERS  \nBETWEEN 2009-2018\nPAPERS WITH INTERNTATIONAL COLLABORATION  \nBETWEEN 2009-2018\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8 Scientific Production\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n9  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.1 Global Analysis\n 2.1 Global Analysis\nIdiPAZ researchers evidenced their participation in national and international scientific networks, with near 85% of the total \ndocuments published in collaboration, which 88.6% of the originals publications. In addition, collaboration among IdiPAZ re -\nsearch groups is also reflected by the percentage of intramural collaboration, which reached almost 11% for all manuscripts \nand for originals.\nOWNED ORIGINALS BETWEEN 2009-2018\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n10  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.1.2 Annual Accounts2.1 Global Analysis\n 2.1 Global Analysis\nIn accordance with the Law 19/2013, of December 9th, of transparency, access to public information and good governance, the Foundation for Biomedical Research \nof La Paz University Hospital (FIBHULP) makes their information public, with the objective of guaranteeing institutional transparency: \nhttp://www.idipaz.es/PaginaDinamica.aspx?IdPag=550&Lang=ES\nIn 2018, the FIBHULP received a Nominative Grant of the Consejer\u00eda de \nSanidad de la Comunidad de Madrid in favor of charging the 312D program \n\u201cBiomedical Research Foundations\u201d, to fund the following parts:\n\u2022 Researchers and personal of support of the I3, I3SNS, Miguel Servet II \nand Juan Rod\u00e9s Programs.\n\u2022\tIntensification\tPrograms\tof\thealth\tprofessionals.\n\u2022\tActivities\t of\tpromotion\t and\tdissemination\t research\tand\tscientific\tcul-\nture.\n\u2022 Accreditations of the research activity.\n\u2022 Support to the T echnical Units or Platforms for Research and Mana -\ngement of I+D+i.ECONOMIC INCOME 2018 ECONOMIC INCOME OVERHEAD- 2018\nEconomic income 2018\nSummary\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n11  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.1 Global Analysis\n 2.1 Global Analysis\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n12  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.1 Global Analysis\n 2.1 Global Analysis\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n13  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.2 Research  \nStructure\nScientific\tDirector\nEduardo L\u00f3pez-Collazo\nScientific\tAssistant\tDirector\nIgnacio Zapardiel Guti\u00e9rrez\nTechnical\tAssistant\tDirector\nPaloma G\u00f3mez Campelo\nExecutive Committee\nChairman\nRafael P\u00e9rez-Santamarina Feij\u00f3o. Chairman of the \nBoard of FIBHULP; permanent delegation to Rodolfo \n\u00c1lvarez-Sala Walther\nMembers\nJuan Antonio Vargas N\u00fa\u00f1ez. Dean of UAM Medical School\nEduardo L\u00f3pez-Collazo. Scientific Director IdiPAZ\nFrancisco Garc\u00eda R\u00edo. HULP Representative\nFrancisco Arnalich Fern\u00e1ndez. UAM Representative\nSecretary\nAna Coloma Zapatero. Director of FIBHULPGoverning Council\nChairman\nAna D\u00e1vila-Ponce de Le\u00f3n Mundo. Health Care Vice \nCouncillor CM\nDeputy Chairman\nRafael Garesse Alarc\u00f3n. Chancelor of UAM\nMembers\nRafael P\u00e9rez-Santamarina Feij\u00f3o. Chairman of the Board \nof FIBHULP\nRodolfo \u00c1lvarez-Sala Walther.  FIBHULP Patron\nT eresa Chavarr\u00eda Gim\u00e9nez. FIBHULP Patron\nJos\u00e9 Mar\u00eda Mu\u00f1oz y Ram\u00f3n. FIBHULP Patron\nJuan Antonio Vargas N\u00fa\u00f1ez. FIBHULP Patron  \nEduardo L\u00f3pez-Collazo. Scientific Director of IdiPAZ\nAlmudena Castro Conde. FIBHULP Patron\nExuperio D\u00edez T ejedor. FIBHULP Patron\nFernando Rodr\u00edguez Artalejo. UAM Representative\nAmparo Cano Garc\u00eda. UAM Representative\nFrancisco Javier Garc\u00eda-Samaniego Rey. FIBHULP Patron\nSecretary\nAna Coloma Zapatero. Director of FIBHULP\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n14  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.2 Research Structure\nExternal\tScientific\tCommittee\nJuan Tamargo Men\u00e9ndez. \nProfessor. Institute of Pharmacology and Toxicology, Spanish National Research Council (CSIC)- \nComplutense University of Madrid. Madrid\nReiner Albert Veitia. \nProfessor G\u00e9nomique fonctionnelle Universit\u00e9 Denis Diderot, Paris VII. Group leader of the Molecular \nOncology and Ovarian Pathologies, l\u2019Institut Jacques Monod. Paris\nJoaqu\u00edn Arribas L\u00f3pez. \nPrincipal investigator. Vall d\u00b4Hebron Hospital. Barcelona\nJacinta Cecilia Bustamante. \nAssociate Professor. Paris Descartes University, Laboratory of Human Genetics of Infectious diseases \n(INSERM U980), Imagine Institut. Center for the Study of Primary Immunodeficiencies, Necker \nEnfants-Malades Hospital. Paris\nCarlos Belmonte Mart\u00ednez. \nProfessor. Miguel Hern\u00e1ndez University. Institute of Neuroscienciences. Alicante\nIsabel Fabregat Romero. \nCentre d\u00b4Oncologia Molecular. L\u00b4Hospitalet, IDIBELL- Bellvitge Biomedical Research Institute. Barcelona\nCarmen Maroto Vela. \nProfessor. Chief of Microbiology. Clinical Hospital University of Granada. Granada\nSantiago Moreno Guill\u00e9n.\nChief of Infectious diseases Service. Ram\u00f3n y Cajal Hospital. Professor. Alcal\u00e1 University. Madrid\nJuan Pedro Bola\u00f1os Hern\u00e1ndez.\nDepartament of Biochemistry and Molecular Biology. University of Salmanca. Institute of Functional \nBiology and Genomics. Salamanca.\nSantiago Rodr\u00edguez de C\u00f3rdoba. \nProfessor. Cellular and Molecular Medicine Department. Center of Biological Research. CSIC. Madrid\nGoverning Council\nChairman\nEduardo L\u00f3pez Collazo, Scientific Director\nSecretary\nInmaculada Ib\u00e1\u00f1ez de C\u00e1ceres.\nNora Buta CollMembers\nCommittee representatives\nJavier de Castro Carpe\u00f1o, Innovation Support Unit Coordinator\nJos\u00e9 Jonay Ojeda Feo, Quality Comitee Coordinator\nB\u00e1rbara Mart\u00ednez de Miguel, Training Comitee Coordinator\nAssistant Directors\nPaloma G\u00f3mez Campelo\nIgnacio Zapardiel Guti\u00e9rrez\nHULP representatives\nFrancisco Garc\u00eda R\u00edo\nAntonio P\u00e9rez Mart\u00ednez\nJaime Feliu Batlle\nJos\u00e9 Luis Merino\nMar\u00eda Guti\u00e9rrez Fern\u00e1ndez\nNuria Vilaboa D\u00edaz\nNora Butta Coll\nBlanca Fuentes Gimeno\nInmaculada Ib\u00e1\u00f1ez de C\u00e1ceres\nMar\u00eda Auxiliadora Bajo\nRosario Perona Abell\u00f3n\nUAM representatives\nAmparo Cano Garc\u00eda\nGuillermo Reglero Rada\nFernando Rodr\u00edguez Artalejo\nMercedes Salaices S\u00e1nchez\nFrancisco Arnalich Fern\u00e1ndez\nBel\u00e9n P\u00e9rez Gonz\u00e1lez\nResearchers in training representatives\nPhD: Alejandro Mart\u00edn Quir\u00f3s\nPredoctoral: Karla Marina Montalb\u00e1n\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n15  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.2 Research Structure\nResearch Ethics Committee\nPresident\nAlmudena Castro Conde. Head of Section of Cardiology Department \nVicepresesident\nJes\u00fas Fr\u00edas Iniesta. Head of the Clinical Pharmacology Department. Representative of Research \nCommittee\nTechnical Secretary\nEmma Fern\u00e1ndez de Uzquiano. Head of the Technical Secretary\nMembers\nJos\u00e9 Manuel A\u00f1\u00f3n Elizalde. Head of Section of Intensive Medicine Department\nJos\u00e9 Ignacio Bernardino de la Serna. Assistant Physician-Internal Medicine Department\nAntonio Bu\u00f1o Soto. Head of Clinical Laboratory Department\nNora Butta Coll. Head of Research Laboratory of Coagulopathies and Alterations of Haemostasis. \nResearcher of the IdiPAZ\nFernando Caba\u00f1as Gonz\u00e1lez. Head of Pediatrics and Neonatology. Quiron Salud Madrid \nUniversity Hospital. Researcher of the IdiPAZ\nFiliberto Chuli\u00e1 Fern\u00e1ndez. Lawyer, Head of the legal Department\nMariana D\u00edaz Almiron. Data analyst. Biostatistics Platform\nMar\u00eda Dolores Diestro T ejada. Assistant Physician- Gynaecology and Obstetrics Department \nJaime Fern\u00e1ndez-Bujarrabal Villoslada. Assistant Physician- Pneumology Department\nElena Garc\u00eda Higuera. Assistant Physician-Anesthesia/Resuscitation Department\nMar\u00eda Justa Garc\u00eda-Matres Cort\u00e9s. Assistant Physician \u2013 Urology Department. Representative \nof Clinical Ethics Committee\nPedro Herranz Pinto. Head of Dermatology Department\nCarlos Lahoz Rallo. Assistant Physician-Internal Medicine Department\nNuria Rodr\u00edguez Salas. Assistant Physician -Medical Oncology Department\nMiriam Romero Portales. Assistant Physician- Digestive System Department\nFilomena Trocoli Gonz\u00e1lez. Nurse. Supervisor of Nephrology Department\nElena Villama\u00f1\u00e1n Bueno. Assistant Clinical Pharmacist- Pharmacy Department\nRosa Villanueva Pe\u00f1a. Assistant Physician-Psychiatry Department\nMembers from outside the institution\nEvaristo Molin\u00e9 Jorques. Layperson and Patient representative\nEva Prieto Utiel. Assistant Clinical Pharmacist of Primary Care-Pharmacy DepartmentTechnical Secretary\nEmma Fernandez Uzquiano. Head of Technical Secretary of Research Ethics Committee\nPaz Lavilla Uriol. Physician of Technical Secretary of Research Ethics Committee\nSol de Gracia Garc\u00eda. Administrative Assistant\nMar\u00eda Isabel Arribas \u00c1lvarez. Administrative\nAnimal Welfare Organ\nCarmen Fern\u00e1ndez Criado. Director of the Veterinary Office of the Faculty of Medicine of the \nUAM. Specialist in Animal Health and Welfare as an external consultant\nFernando Carceller Benito. Deputy Neurosurgery Service HULP as optional and researcher of \nthe \u201cNeurology and Cerebrovascular Disease\u201d from IdiPAZ\nNuria Vilaboa D\u00edaz. IdiPAz\u00b4s resercher. Internal consultant\nCarlota Largo Aramburu. Head of the animal Service HULP Experimental Surgery Specialist in \nAnimal Health and Welfare Center\nQuality Assurance Committee\nCoordinator\nJos\u00e9 Jonay Ojeda Feo\nMembers\nBlanca Fuentes Gimeno\nAlberto Mart\u00edn Vega\nMar\u00eda Luisa D\u00edaz Mart\u00ednez\nMargarita Rodrigo Angulo\nGema Vall\u00e9s P\u00e9rez\nPaloma G\u00f3mez Campelo\nMar\u00eda Dolores P\u00e9rez Garre\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n16  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\nTraining Committee\nCoordinator\nB\u00e1rbara Mart\u00ednez de Miguel\nMembers\nAna Mar\u00eda Briones Alonso\nMar\u00eda Fern\u00e1ndez Velasco\nJuli\u00e1n Nevado Blanco\nAlejandro Mart\u00edn Quir\u00f3s\nAlberto Borobia P\u00e9rez\nPaloma G\u00f3mez Campelo\nInmaculada Ib\u00e1\u00f1ez de C\u00e1ceres\nBeatriz Vila Cordero\nMar\u00eda Isabel S\u00e1nchez P\u00e9rez\nRoc\u00edo Rosas Alonso\nV\u00edctor Manuel T oledano Real\nMercedes Ruiz Balibrea\nLuc\u00eda Medina Royo\nSilvia G\u00f3mez Senent\nPilar S\u00e1nchez-Corral G\u00f3mez\nEquality\tand\tDiversity\tCommittee\nMembers\nEduardo L\u00f3pez-Collazo\nMar\u00eda Quintanar Jaime\nPaloma G\u00f3mez Campelo\nNora Butta Coll\nFrancisco Gil Gadea\nJos\u00e9 Avenda\u00f1o Ortiz\nTechnical Secretary\nMercedes Ruiz Balibrea\nLucia Medina Royo\nDocumentation\tService\nRa\u00fal Rom\u00e1n Ca\u00f1izaresFIBHULP\nDirector\nAna Coloma Zapatero \nHuman Reesources Manager\nHead: Ana Gloria Herrera Puerta\nMar\u00eda Quintanar Jaime\nPrivate Projects Manager\nHead: Francisco Gil Gadea\nNathalia Garc\u00eda Quero\nClinical Trial Manager\nHead: Sara Moral \u00c1lamo\nDesir\u00e9e Hern\u00e1ndez L\u00f3pez\nPublic Projects Manager\nHead: Silvia Arce Santamar\u00eda \nRaquel Carmona del Mazo\nInstitutional Projects Manager\nJos\u00e9 Luis Narro Villanueva\nMarisa T ejedor BotelloInternational Projects \nManager\nSantiago Rello Varona\nMarta Mar\u00edn Barba\nContracting Manager and \nHead of Legal Department\nSara Fern\u00e1ndez Morata\nAccountants:\nHead: Laura L\u00f3pez Revuelta\nM\u00f3nica Garc\u00eda L\u00f3pez\nResearcher Reception and \nAttention\nCarmen Garc\u00eda Artiaga2.2 Research Structure\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n17  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\nNeuroscience Area\nGROUP DIRECTOR\nPsychiatry and Mental Health Consuelo de Dios Perrino\nNeurology and Cerebrovascular Diseases Exuperio D\u00edez Tejedor\nNeuroprotective Strategies in Neurodegenerative \nDiseases Antonio Cuadrado Pastor\nInvolvement of Glycinergic and Glutamatergic \nSystems in CentralNervous System PathologiesFrancisco Zafra G\u00f3mezCoordinator:  Exuperio D\u00edez Tejedor\nCardiovascular Area\nGROUP DIRECTOR\nResearch on Invasive Clinical Cardiology \u2013  \nICCI-PazJos\u00e9 Luis L\u00f3pez-Send\u00f3n \nHentschel\nCardiovascular Epidemiology and Nutrition Fernando Rodr\u00edguez \nArtalejo\nCoagulopathies and Alterations of Haemostasis V\u00edctor Jim\u00e9nez Yuste\nVascular Physiology and Pharmacology Mercedes Salaices S\u00e1nchez\nVascular Pharmacology and Metabolism \n(FARMAVSM) Carlos F. S\u00e1nchez Ferrer \nCardiolog\u00eda HUFAlejandro Curcio \nRuig\u00f3mezCoordinator:  Jos\u00e9 Luis L\u00f3pez-Send\u00f3n \n Hentschel2.2 Research Structure\nResearch \nAreasCardiovascular \nAreaSurgery, \nTransplant \nand Health \nTechnologies \nArea\nInfectious \nDiseases\tand \t\nImmunity AreaCancer \nand Human \nMolecular \nGenetics Area\nLarge System  \nPathology \nAreaNeuroscience \nAreaScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n18  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.2 Research Structure\nLarge System  \nPathology Area\nGROUP DIRECTOR\nInternal Medicine and Systemic Diseases Francisco Arnalich \nF\u00e9rnandez\nOrganic Dysfunction and Failure in  \nthe Aggression Abelardo Garc\u00eda de \nLorenzo y Mateos\nRespiratory Diseases Francisco Garc\u00eda R\u00edo\nRegulation of Gene Expression and by Hypoxia Luis del Peso Ovalle\nNephrology Rafael Selgas Guti\u00e9rrez\nNeonatology Adelina Pellicer Mart\u00ednez \nAging and Fragility in the ElderlyJuan Ignacio Gonz\u00e1lez \nMontalvo \nMolecular Hepatology Paloma Jara Vega\nDiagnosis and Treatment of Allergic Diseases Santiago Quirce Gancedo \nGynecologic Oncology Ignacio Zapardiel \nGuti\u00e9rrez\nPatient Blood Management Manuel Quintana D\u00edaz\nEndocrine Diseases Lucrecia Herranz de la \nMorena \nUrology Luis Mart\u00ednez-Pi\u00f1eiro \nLorenzo \nHealth Care Nurses Research Jes\u00fas Castro Toro \nMaternal and Fetal Medicine Jos\u00e9 Luis Bartha Rasero \nEmergency and Critical Pathology Alejandro Mart\u00edn Quir\u00f3sCoordinator:  Francisco Garc\u00eda R\u00edoInfectious\tDiseases\tand \t\nImmunity Area\nGROUP DIRECTOR\nAIDS and Infectious Diseases Jos\u00e9 Ram\u00f3n Arribas L\u00f3pez\nMolecular Microbiology Jes\u00fas Mingorance Cruz\nImmuno-RheumatologyMar\u00eda Eugenia Miranda \nCar\u00fas\nInnate Immune Response Eduardo L\u00f3pez-Collazo\nDiagnosis and Treatment of Diseases associated \nwith Abnormalities of the Complement SystemMargarita L\u00f3pez Trascasa  \nPilar S\u00e1nchez-Corral \nG\u00f3mez\nLymphocyte Pathophysiology in  \nImmunodeficienciesEduardo L\u00f3pez Granados\nDrug Hypersensibility and Innate Immune  \nResponseTeresa Bell\u00f3n Heredia\nPediatric Respiratory, Systemic and Neurological \nInfections & Host Immune Response Cristina Calvo Rey \nPediatric Systemic Infections; HIV, tuberculosis, \nImported and Emergent Diseases Mar\u00eda Jos\u00e9 Mellado Pe\u00f1a\nTranslational Research in Pediatric Oncology, \nHematopoietic Transplantation and Cell Therapy Antonio P\u00e9rez Mart\u00ednez\nEnfermedades Intestinales HUFFernando Bermejo  \nSan Jos\u00e9 Coordinator:  Eduardo L\u00f3pez-CollazoScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n19  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.2 Research Structure\nSurgery, Transplant and \nHealth Technologies Area\nGROUP DIRECTOR\nCongenital Malformation Surgery Leopoldo Mart\u00ednez \nMart\u00ednez\nBone Pathophysiology and Biomaterials Nuria Vilaboa D\u00edaz\nCellular Engineering Mar\u00eda Paz de Miguel \nGonz\u00e1lez\nClinical Pharmacology Jes\u00fas Fr\u00edas Iniesta \nOsteoarticular Surgery Research \u2013 GICOA Enrique G\u00f3mez Barrena\nReconstructive and Regenerative Research Luis Land\u00edn Jarillo \nTransplant Francisco Hern\u00e1ndez \nOliveros\nRehabilitaci\u00f3n HUFJuan Carlos Miangolarra \nPageCoordinator:  Leopoldo Mart\u00ednez Mart\u00ednezCancer and Human \nMolecular Genetics Area\nGROUP DIRECTOR\nINGEMM- Institute of Medical and Molecular \nGenetics Pablo Lapunzina Bad\u00eda\nTranslational Oncology Jaime Feli\u00fa Battle\nExperimental Therapies and Biomarkers  \nin Cancer Inmaculada Ib\u00e1\u00f1ez de \nC\u00e1ceres\nJavier de Castro Carpe\u00f1o\nOto-Neurosurgery Research Luis Lassaletta Atienza\nCancer Molecular Pathology and Therapeutic  \nTargetsDavid Hardisson Hern\u00e1ez\nMechanisms of T umour Progression Amparo Cano Garc\u00eda\nAnimal and Cell Models for Detection and \nCharacterization of Leukemic Stem Cells Carmela Cal\u00e9s Bourguet\nResearch and Diagnosis of Inherited Metabolic \nDiseases Mar\u00eda Bel\u00e9n P\u00e9rez \nGonz\u00e1lez\nRegulation of Ciliary Structure and Function by \nPhosphoinositides Francesc Garc\u00eda Gonzalo\nOncolog\u00eda HUF Manuel Hidalgo MedinaCoordinator:  Amparo Cano Garc\u00edaScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n20  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.2 Research Structure\nPUBLIC RESEARCH CONTRACTS\nRam\u00f3n y Cajal Stabilisation Contracts (I3) - CM\n\u2022 Karen Elise Heath. INGEMM - Institute of Medical and Molecular Genetics Group\n\u2022 Jes\u00fas Mingorance Cruz. Molecular Microbiology Group\n\u2022 Rebeca P\u00e9rez de Diego. Innate Immune Response Group\nMiguel Servet Stabilisation Contracts (I2) - ISCIII/ CM\n\u2022 T eresa Bell\u00f3n Heredia. Drug Hypersensibility and Innate Immune Response Group\n\u2022 Juan \u00c1ngel Fresno Vara. Translational Oncology Group\n\u2022 \u00c1ngel Campos Barros. INGEMM - Institute of Medical and Molecular Genetics Group\n\u2022 Mar\u00eda Paz de Miguel Gonz\u00e1lez. Cellular Engineering Group\n\u2022 Eduardo L\u00f3pez-Collazo. Innate Immune Response Group\n\u2022 Juan Antonio Rey Herranz. Oto-Neurosurgery research Group\n\u2022 Berta Rod\u00e9s Soldevila. AIDS and Infectious Diseases Group\n\u2022 Pilar S\u00e1nchez-Corral G\u00f3mez. Diagnosis and Treatment of Diseases Associated with Abnor -\nmalities of the Complement System Group\n\u2022 Mar\u00eda Rosa T orres Jim\u00e9nez. Metabolic-Vascular Unit Group\n\u2022 David Vicent L\u00f3pez. Molecular Hepatology Group\n\u2022 Nuria Vilaboa D\u00edaz. Bone Pathophysiology and Biomaterials Group\n\u2022 Nora Viviana Butta Coll. Coagulopathies and Alterations of Haemostasis Group\n\u2022 Mar\u00eda Inmaculada Ib\u00e1\u00f1ez de C\u00e1ceres. Experimental Therapies and Biomarkers in Cancer \nGroup\n\u2022 Rosa Mar\u00eda Rodr\u00edguez P\u00e9rez. Diagnosis and Treatment of Allergic Diseases Group\nMiguel Servet Contracts Type I - ISCIII\n\u2022 Mar\u00eda Dolores Guti\u00e9rrez Fern\u00e1ndez (MS15/00069). Neurology and Cerebrovascular \nDiseases Group\n\u2022 Carolina Cubillos Zapata (MS18/00208). Respiratory Diseases Group\nMiguel Servet Contracts Type II - ISCIII\n\u2022 Mar\u00eda Fern\u00e1ndez Velasco (CPII16/00047). Innate Immune Response Group \n\u2022 Laura Salda\u00f1a Quero (CPII16/00038). Bone Pathophysiology and Biomaterials Group\nIntensification Contracts - ISCIII\n\u2022 Jos\u00e9 Ram\u00f3n Arribas L\u00f3pez. AIDS and Infectious Diseases Group\n\u2022 Francisco Jos\u00e9 Garc\u00eda R\u00edo. Respiratory Diseases GroupR\u00edo Hortega Contracts - ISCIII\n\u2022 Rosa de Miguel Buckley (CM17/00064). AIDS and Infectious Diseases Group\n\u2022 Rosa Guti\u00e9rrez Z\u00fa\u00f1iga (CM18/00175). Neurology and Cerebrovascular Diseases Group\nJuan Rod\u00e9s Contracts - ISCIII\n\u2022 Tal\u00eda Sainz Acosta (JR16/00021). Pediatric Systemic Infections; HIV, Tuberculosis, Imported \nand Emergent Diseases\n\u2022 Roc\u00edo Montejano S\u00e1nchez (JR18/00039). AIDS and Infectious Diseases Group\nMarie Sk\u0142odowska-Curie Actions - Horizon 2020. \nEuropean Union\n\u2022 Elie Dahdouh. Molecular Microbiology Group\nJuan de la Cierva Contracts \u2013 Ministry of Science, \nInnovation and Universities\n\u2022 Laura Otero Ortega (IJCI-2017-33505). Neurology and Cerebrovascular Diseases Group\nPredoctoral Fellowship - ISCIII\n\u2022 Andr\u00e9s Esteban Cantos (FI17/00192). AIDS and Infectious Diseases Group\n\u2022 Mar\u00eda del Carmen G\u00f3mez de Frutos (FI17/00188). Neurology and Cerebrovascular \nDiseases Group\n\u2022 Fernando Laso Garc\u00eda (FI18/00026). Neurology and Cerebrovascular Diseases Group\nPredoctoral Contract - Ministry of Science, Innovation \nand Universities\n\u2022 Francisca D\u00edaz Gonz\u00e1lez (FPU17/04055). INGEMM - Institute of Medical and Molecular \nGenetics\nPredoctoral La Caixa Fundation Contracts\n\u2022 Karla Marina Montalb\u00e1n Hern\u00e9ndez (INPhiNIT). Innate Immune Response Group\nTechnical Support Stabilisation Contracts - CM\n\u2022 Francisco Gay\u00e1 Moreno. AIDS and Infectious Diseases Group\n\u2022 Mar\u00eda T eresa Vallejo Cremades. Congenital Malformation Surgery Group\n\u2022 Beatriz Sanz Minguela. Cell Culture UnitScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n21  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.2 Research Structure\nBioinformatics Technician Support Research \nContracts - ISCIII\n\u2022 Mar\u00eda Sol\u00eds L\u00f3pez (CA18/00033). INGEMM - Institute of Medical and Molecular \nGenetics\nYouth Guarantee Contracts - CM\nGraduate\n\u2022 Alba Pinto Garc\u00eda (PEJ-2017-AI/SAL-5716). Psychiatry and Mental Health\nPredoctoral\n\u2022 Marta Cadenas Mart\u00edn (PEJD-2018-PRE/BMD-8872). Cellular Engineering Group\n\u2022 Alfonso Navarro Zapata (PEJD-2018-PRE/BMD-9122). Translational Research in \nPediatric Oncology, Hematopoietic Transplantation and Cell Therapy Group\n\u2022 Sonia Alcolea Ruiz (PEJD-2018-PRE/BMD-9430). Pediatric Respiratory, Systemic \nand Neurological Infections & Host Immune Response Group\n\u2022 Jorge Garc\u00eda Gim\u00e9nez (PEJD-2018-PRE/BMD-9417). Associated Clinician\n\u2022 Leila Maestro Paramio (PEJD-2018-PRE/BMD-7965). Bone Pathophysiology and \nBiomaterials Group\n\u2022 Marta Gil Fern\u00e1ndez (PEJD-2018-PRE/BMD-8091). Innate Immune Response \nGroup\n\u2022 Roberto Mediavilla T orres (PEJD-2018-PRE/BMD-9039). Psychiatry and Mental \nHealth\nTechnical Support\n\u2022 Virginia Rufo Rabad\u00e1n (PEJ-2017-TL/BMD-6201). INGEMM - Institute of Me -\ndical and Molecular Genetics\n\u2022 Sonia Jim\u00e9nez Rodr\u00edguez (PEJ-2017-TL/BMD-6939). Molecular Microbiology \nGroup\n\u2022 C\u00e9sar V\u00e9lez Casanova (PEJ-2017-TL/BMD-6873). Diagnosis and Treatment of \nDiseases Associated with Abnormalities of the Complement System\n\u2022 Artur Mart\u00edn Franklin (PEJ-2017-TL/BMD-5831). AIDS and Infectious Diseases \nGroup Programme Organisation Total\nRam\u00f3n y Cajal Stabilisation Contracts (I3) CM 3\nMiguel Servet Stabilisation Contracts (I2) ISCIII/ CM 14\nT echnical Support Stabilisation Contracts CM 3\nTOTAL ESTABLISHED 20\nMiguel Servet Contracts CP Type 1 ISCIII 2\nMiguel Servet Contracts CP Type 1I ISCIII 2\nIntensification Contracts ISCIII 2\nR\u00edo Hortega Contracts ISCIII 2\nJuan Rod\u00e9s Contracts ISCIII 2\nMarie Sk\u0142odowska-Curie Actions EU 1\nJuan de la Cierva ContractsMinistry of Science, Innovation \nand Universities1\nPredoctoral Fellowship ISCIII 3\nPredoctoral ContractMinistry of Science, Innovation \nand Universities1\nPredoctoral La Caixa Fundation Contracts La Caixa 1\nBioinformatics T echnician Support Research \nContracts ISCIII 1\nY outh Guarantee Contracts CM 12\nTOTAL PROGRAMMES 30\nTOTAL ESTABLISHED + PROGRAMMES 50\nPlattforms ISCIII 7\nFIS Projects ISCIII 9\nEuropean Projects EU 9\nResearch Network ISCIII 6\nResearch Network CM 5\nSAF/MAT MINECO 1\nCommercial clinical trials EECC Promoters 36\nPrivate projects Pharmaceutical Industry 67\nIn-house Projects FIBHULP 6\nRETOS MINECO 3\nSpin-off CM 1\nTOTAL EMPLOYEES DEPENDET ON RESEARCH PROJECTS 150\nPrivate projects Pharmaceutical Industry 10\nTOTAL FELLOWS DEPENDET ON RESEARCH PROJECTS 10\nTOTAL STAFF DEPENDENT ON RESEACRH PROJECTS 160\nT echnical Unit Staff FIBHULP 15\nTOTAL TECHNICAL UNIT 15\nTOTAL 225Scientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n22  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\nRESEARCHER PROFILE\nThis draft classification aims to communicate the various characteristics that researchers of IdiPAZ have in at this moment of their career, and stratified by gender.2.2 Research Structure\nEURAXESS RESEARCHER PROFILE\nR1\nR2\nR3\nR4EURAXESS RESEARCHER PROFILE BY GENDER\nMen\nR1 R2 R3 R4 T otalWomenScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n23  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.3 Training Report  \nand Teaching\n2.3.1 Training Committee\nOne of the main priorities of IdiPAZ Research Institute is to encourage and develop training programs \nfor researchers, with special attention to the scientific training in research methodology.\nIdiPAZ\u2019s Training Committee is responsible for designing, planning and evaluating the training ac -\ntivities given by the Institute, as well as ensuring the development of a global \nTraining Plan that meets the proposed objectives. The main objective of \nIdiPAZ\u2019s Training Committee is to draw up, promote and evaluate the \ntraining plan, aimed at maintaining or improving the skills or actions of \nidiPAZ\u2019s basic or clinical researchers.\nThe committee is composed of competent training professionals from \nthe different structures of IdiPAZ and guarantees the representation of \nall the different types of IdiPAZ members, as well as the correct coordi -\nnation between all the training activities that make up the plan.\nIdiPAZ\u2019s Training Plan includes the HULP training offer, the UAM offer \nand the implementation of the Institute\u2019s own training offer in line with \nits strategic objectives and linked to the detection of new training needs \nnot covered by the existing training offers from each of those entities. \nThe objective of the Institute\u2019s own training offer is to complement the \ntraining provided by both HULP and UAM.\nThe design of the plan includes, as origin and addressees, healthcare \nprofessionals with research activity as well as research professionals.\nThe detection of training needs arises as a result of communication \nwith area coordinators and group directors, analysis of the Needs As -\nsessment Surveys submitted by members of the Institute, reception and \nanalysis of new proposals or suggestions from IdiPAZ members, selec -\ntion of activities with successive editions planned, reception and analysis \nof proposals made within the Continuing Medical Training Committee \nthat meet the requirements of interest in research, analysis of new training proposals \nby IdiPAZ\u2019S Training Committee itself and other study techniques. \nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n24  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.3 Training Report and Teaching\nAdapting to \nthe Institute\u2019s \nstrategic \nobjectivesResearch \nTraining\nIdiPAZ Opportunities\n\u2022 HULP Continuing Education\n\u2022 UAM Training Opportunities\n\u2022 Institute OpportunitiesIdiPAZ \nTRAINING \nPLAN\nIdiPAZ Demand\n\u2022 Researh Areas \nArea Coordinators\n\u2022 Research Groups \nGroups Director\nAimed at \nbasic and \nclinical \nresearchesResearch \nArea Training\n2.3.2 Training courses conducted \nby IdiPAZ2.3.3\t Scientific\tculture\tactivities\nTitle Head Dates Assistants Hours\nCurso de ingl\u00e9s cient\u00edfico Sim\u00f3n Bartlett13th-16th \nnovember 15 12\nAn\u00e1lisis de datos biom\u00e9dicos \ncon SPSS: Nivel b\u00e1sicoRosario Madero \nJarabo21st-24th \nmay21 12\nInvestigaci\u00f3n cl\u00ednica y \nlectura cr\u00edtica. B\u00fasqueda y \nrecuperaci\u00f3n de la literatura \ncient\u00edficaJuan Jos\u00e9 R\u00edos \nBlanco10th-13th \ndecember- 12Title Date Speakers\nSemana de \nla CienciaT\u00e9 con ciencia8th novemberInmaculada Ib\u00e1\u00f1ez de \nC\u00e1ceres\n13th november Antonio P\u00e9rez Mart\u00ednez\n16th november Eduardo L\u00f3pez Collazo\nAl otro lado del \nlaboratorio: Jornada de \npuertas abiertas y visita \nguiada al edificio IdiPAZ \ny los laboratorios8th november Gema Vall\u00e9s P\u00e9rez\nV\u00edctor Toledano Real\nMar\u00eda Teresa Vallejo \nCremades\nIrene Cuevas Gordo13th november\n16tth november\nVen a conocer la \ngen\u00e9tica del futuro: \nJornada de puertas \nabiertas y visita guiada al \nInstituto de Gen\u00e9tica del \nHospital Universitario La \nPaz-INGEMM6th november\nJuli\u00e1n Nevado Blanco\n13th november\nJornada de puertas \nabiertas y visita guiada a \nla UCICEC y Biobanco15th novemberAlberto Borobia P\u00e9rez\nPaloma G\u00f3mez Campelo\nMarina Arranz \u00c1lvarez\nJornada de puertas \nabiertas al laboratorio \nde Microbiolog\u00eda y charla \ncon el investigador Elie \nDahdouh16th november Elie Dahdouh\nImpresi\u00f3n 3D en el \n\u00e1mbito hospitalario: \nPlataforma de Ingenier\u00eda \nTisular e Impresi\u00f3n 3D \n(PITI3D)15th novemberDaniel Cerme\u00f1o \nPampliega\nCarlos Biec Amigo\nMario Ju\u00e1rez Rodr\u00edguez\nD\u00eda \nInternacional  \nde la Mujer \ny la Ni\u00f1a en \nla ciencia Fast Meeting: 5 cient\u00edficas \nen investigaci\u00f3n11th febraryInmaculada Ib\u00e1\u00f1ez de \nC\u00e1ceres,\nDolores Diestro Tejada\n\u00c1ngela del Pozo Mat\u00e9\nDolores P\u00e9rez Garr\u00e9\nOlga Vera PuenteScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n25  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.3 Training Report and Teaching\n2.3.4\t IdiPAZ\tDoctoral\tTheses\nAgrifoglio Rotaeche A . Farmacocin\u00e9tica de micafungina en una poblaci\u00f3n de \npacientes quemados cr\u00edticos[dissertation]. Madrid: Universidad Aut\u00f3noma de \nMadrid: 2018(21/06/2018). \nDirectors: Cachafeiro Fuci\u00f1os L, S\u00e1nchez S\u00e1nchez SM\nBenito Mu\u00f1oz C . Estructura-funci\u00f3n del transportador neuronal de glicina \nGlyT2:localizaci\u00f3n del sitio Na3 y determinantes de inhibici\u00f3n[dissertation]. \nMadrid: Aut\u00f3noma de Madrid: 2018(30/11/2018). \nDirector: L\u00f3pez Corcuera B\nBravo Lubjetic L . Experiencia en el manejo del rabdomiosarcoma orbitario \nen el hospital universitario La Paz, 1982-2015[dissertation]. Madrid: UAM: \n2018(15/06/2018). \nDirector: Peralta Calvo J\nCelaya Pu\u00e9rtolas A . Papel del IGF-1 en la protecci\u00f3n frente a la p\u00e9rdida \nauditiva inducida por el ruido [dissertation]. Madrid: UAM: 2018(12/11/2018). \nDirector: Varela Nieto I\nChinea B. Importancia de la leche humana y sus caracter\u00edsticas nutricionales. Efec -\ntos a corto, medio y largo plazo[dissertation]. Madrid: UCM: 2018(21/03/2018). \nDirector: Saenz Pipaon Marcos M\nCorral S\u00e1nchez D . Producci\u00f3n de c\u00e9lulas Natural Killer activadas con inter -\nlequina-15 para uso cl\u00ednico en pacientes pedi\u00e1tricos con c\u00e1ncer[dissertation]. \nMadrid: UAM: 2018(22/10/2018). \nDirector: P\u00e9rez Mart\u00ednez A\nCorvillo Rodr\u00edguez F.  Estudio de los mecanismos inmunopatol\u00f3gicos en li -\npodistrofias adquiridas de tipo parcial y generalizado[dissertation]. Madrid: \nUAM: 2018(22/06/2018). \nDirector: L\u00f3pez Trascasa M\nCruz Castellanos P . Expresi\u00f3n de genes relacionados con la angiog\u00e9nesis \ncomo predictores de respuesta al tratamiento combinado (cirug\u00eda y quimio -\nterapia) en el carcinoma de ovario seroso de alto grado[dissertation]. Madrid: \nUAM: 2018(19/12/2018). \nDirectors: Redondo S\u00e1nchez A, Mendiola Sabio M\nFrancisco Recuero I . Papel de la Aurora quinasa B en la regulaci\u00f3n epige -\nn\u00e9tica inducida por el virus de la hepatitis C[dissertation]. Madrid: UAM: \n2018(25/10/2018). \nDirector: Garc\u00eda-Samaniego JGarz\u00f3n Moll H, L\u00f3pez Santamar\u00eda M . Tratamiento endovascular de los shunts \nportosistemicos cong\u00e9nitos[dissertation]. Madrid: UAM: 2018(16/10/2018). \nDirector: Ponce Dorrego MD\nGuill\u00e9n Sacoto MA . Diabetes gestacional en embarazos m\u00faltiples. Impacto \ndel control metab\u00f3lico materno para el feto. S\u00edndrome metab\u00f3lico y alte -\nraci\u00f3n de l metabolismo hidro carbonado materno postparto[dissertation]. \nMadrid: UAM: 2018 (04/04/2018). \nDirector: Herranz de la Morena L\nHern\u00e1ndez Oliveros F . Estudio cl\u00ednico experimental del papel del bazo en \nla prevenci\u00f3n de la enfermedad de injerto contra hu\u00e9sped en el trasplante \nintestinal[dissertation]. Madrid: UAM: 2018(16/02/2018). \nDirectors: L\u00f3pez Santamar\u00eda M, T ovar Larrucea JA\nIsidoro Garc\u00eda L . Potencial efecto hipotensor de esteroides sexuales \nmasculinos[dissertation]. Madrid: UAM/UNAM: 2018(17/05/2018). \nDirectors: Ferrer Parra M, Perusqu\u00eda M\nLlorente Gin\u00e9s P . Role of proteases implicated in the lysosomal pathway on \napp processing in a cellular model of neurodegeneration\n[dissertation]. Madrid: UAM: 2018(20/12/2018). \nDirector: Bullido G\u00f3mez-Heras MJ  \nL\u00f3pez de S\u00e1 y Areses E. Manejo del s\u00edndrome post-parada cardiaca[dissertation]. \nMadrid: UAM: 2018(12/07/2018). \nDirector: L\u00f3pez-Send\u00f3n JL\nL\u00f3pez de Uralde Villanueva I . Indicios de sensibilizaci\u00f3n central en el dolor \ncr\u00f3nico inespec\u00edfico de cuello con caracter\u00edsticas neurop\u00e1ticas[dissertation]. \nMadrid: URJC: 2018(27/06/2018). \nDirectors: Fern\u00e1ndez Carnero J; La T ouche Arbizu R\nMart\u00ednez del Prado MP . Valor pron\u00f3stico del an\u00e1lisis de marcadores mole -\nculares mediante prote\u00f3mica dirigida en c\u00e1ncer de mama precoz con recep -\ntores hormonales positivos[dissertation]. Madrid: UAM: 2018(22/03/2018). \nDirector: Espinosa Arranz E\nMoraleda P\u00e9rez S . Eficacia de la toxina botul\u00ednica A en el tratamiento de la \npar\u00e1lisis facial perif\u00e9rica. Comparaci\u00f3n de diferentes escalas en la evaluaci\u00f3n \nde la funci\u00f3n facial[dissertation]. Madrid: UAM: 2018(30/11/2018). \nDirector: Lassaletta Atienza LScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n26  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.3 Training Report and Teaching\nMoreno Fern\u00e1ndez S . Efecto de un hidrolizado de prote\u00ednas de clara de hue -\nvo en un modelo de obesidad inducido por dieta. Evaluaci\u00f3n de su eficacia y \nseguridad en humanos [dissertation]. Madrid: Universidad Aut\u00f3noma\nde Madrid: 2018(23/10/2018). \nDirectors: Miguel Castro M, Garc\u00e9s M \nMunayco S\u00e1nchez AJ . Gesti\u00f3n de Hospitales de Campa\u00f1a (Cirug\u00eda de \nControl de Da\u00f1os) para desplazados internos en un teatro de operacio -\nnes b\u00e9lico. Despliegue y activaci\u00f3n bajo el fuego[dissertation]. Madrid: UAM: \n2018(26/10/2018). \nDirectors: Quintana D\u00edaz M, Carbayo Herencia J\nPajares Cabetas M . Transcription factor NRF2 regulates de expression of \nautophagy genes[dissertation]. Madrid: Universidad Aut\u00f3noma de\nMadrid: 2018(19/10/2018). \nDirector: Cuadrado Pastor A  \nPardo Rovira P . Valor pron\u00f3stico de la reversibilidad bronquial en pacientes \ncon enfermedad pulmonar obstructiva cr\u00f3nica[dissertation]. Madrid: UAM: \n2018(19/06/2018). \nDirector: Garc\u00eda R\u00edo F\nParra R\u00e1mirez PA . Utilidad de la ecograf\u00eda con contraste en la locali -\nzaci\u00f3n de lesiones paratiroideas en pacientes con hiperparatiroidismo \nprimario[dissertation]. Madrid: UAM: 2018 (31/05/2018). \nDirector: \u00c1lvarez Escol\u00e1 C\nPonce Dorrego MD . Tratamiento endovascular de los shunts portosist\u00e9micos \ncong\u00e9nitos[dissertation]. Madrid: UAM: 2018(16/10/2018). \nDirectors: \u00c1lvarez-Sala Walther R, Garz\u00f3n Moll G \nRubio Caballero C . Changes in gut microbiota associated to inflammation \nduring ageing ans non-alcoholic steatohepatitis[dissertation]. \nMadrid: Universidad Aut\u00f3noma de Madrid: 2018(14/12/2018). \nDirector: Mart\u00ednez Valverde A  \nRu\u00edz P\u00e9rez D . Atenuaci\u00f3n del rechazo inmunitario con c\u00e9lulas madre mesen -\nquimales derivadas de tejido adiposo en un modelo experimental murino de \ntrasplante de pulm\u00f3n[dissertation]. Madrid: UCM: 2018(10/12/2018). \nDirectors: Garc\u00eda R\u00edo F , Largo Aramburu C, \u00c1lvarez G\u00f3mez de Segura I\nSilva Obreg\u00f3n JA . Fragilidad como predictor de mortalidad en ancianos \ningresados en UCI por patolog\u00eda m\u00e9dica. Modelo predictor de mortalidad \nhospitalaria[dissertation]. Madrid: UAM: 2018(20/12/2018). \nDirectors: Quintana D\u00edaz M, Huerta \u00c1lvarez CTapia Serrano G . Seguridad del paciente neonatal en el uso de productos \nsanitarios relacionados con la alimentaci\u00f3n[dissertation]. Madrid: UCM: \n2018(23/02/2018). \nDirectors: Pacheco del Cerro E, Rivas Paterna AB\nTung Chen Y . Utilidad de la ecograf\u00eda en el manejo de fluidos y la terapia de \ntransfusi\u00f3n en la hemorragia digestiva en el \u00e1mbito de urgencias[dissertation]. \nMadrid: UAM: 2018(03/12/2018). \nDirectors: Quintana D\u00edaz M, Blancas G\u00f3mez Casero R\nUtrilla Contreras MJ . Estudio de las c\u00e9lulas inmunocompetentes, macr\u00f3fagos, \nc\u00e9lulas cebadas, de la angiog\u00e9nesis y de la linfangiog\u00e9nesis en la piel de los \nbordes quir\u00fargicos de \u00falceras por quemaduras[dissertation]. Madrid: UAM: \n2018(16/03/2018). \nDirectors: Hardisson Hernaez D, Regadera Gonzalez JF\nVal Blasco A . Role of nucleotide-binding oligomerization domain type I \n(NOD1) in human and experimental heart failure[dissertation]. Madrid: UAM: \n2019(11/01/2018). \nDirector: Fern\u00e1ndez Velasco M\nVega Mata N . Diagn\u00f3stico molecular de las anomal\u00edas vasculares cong\u00e9nitas \ny su repercusi\u00f3n terap\u00e9utica[dissertation]. Oviedo: Universidad de Oviedo: \n2018(12/4/2018). \nDirector: L\u00f3pez Guti\u00e9rrez JC\nVera Puente O . Regulaci\u00f3n epigen\u00e9tica de la expresi\u00f3n de ARNs no codifi -\ncantes y su implicaci\u00f3n en la respuesta terap\u00e9utica en c\u00e1ncer de pulm\u00f3n no \nmicroc\u00edtico y c\u00e1ncer de ovario[dissertation]. Madrid: UAM:\n2018(25/05/2018). \nDirector: Ib\u00e1\u00f1ez de C\u00e1ceres I  \nVillalpando Grajeda DM . Beneficial effects of docosahexaenoic acid supple -\nmentation in vascular function of orchidectomized rats[dissertation]. Madrid: \nUAM: 2018(09/02/2018). \nDirector: Ferrer Parra M.\nVillar Lorenzo A . Papel del sustrato del receptor de la insulina 2 en la suscep -\ntibilidad al da\u00f1o colest\u00e1tico en el h\u00edgado[dissertation]. Madrid: Universidad \nAut\u00f3noma de Madrid: 2018(25/10/2018). \nDirector: Mart\u00ednez Valverde AScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n27  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.4 Innovation and  \nTransfer Activities\n2.4.1 Innovation and Transfer Activities\nThe Innovation Support Unit (or Innovation Unit) of FIBHULP was created in June 2010 within the \nframework of the ITEMAS Network \u2013currently called ITEMAS Platform- of the Carlos III Institute of \nHealth. Since its creation, the Innovation Support Unit has contributed to promoting and protecting \ninnovative/ground breaking research conducted by IdiPAZ. The Innovation Unit also intends to harness \nour institute\u2019s considerable innovative potential generated, as a step prior to its subsequent transfer \nto society.\nTherefore, one of the main commitments of the Innovation Unit is that researchers and health per -\nsonnel perceive it as a resource at their service, to provide support and advice in all that relates to the \nidentification, management, protection, transfer, marketing and dissemination of their research results.\nACTIVITIES\nThe main aim of the Innovation Support Unit is to identify the potential transferable research results \ngener ated within our institute and to accompany and support the researcher throughout the whole \ninnovation process: from the birth of the idea to its placement on the market.\nSince the Innovation Unit has been in operation, several projects sponsored by the institute itself have \nbeen managed and different collaboration agreements have been signed with important private institu -\ntions and organisa tions to promote innovation.\nOur main objectives are:\n\u2022 Promoting a culture of innovation and entrepreneurship within the institute by fostering the gene -\nration of innovative ideas and solutions that meet the needs of patients and society, in general, and \nsupporting their development through various initiatives.\n\u2022 Actively searching and identifying knowledge and research results emerged within the institute and \ntransferable to the market.\n\u2022 Fostering and managing the protection and transfer of knowledge and research results to society and \npromoting the current technology portfolio of the institute while getting an economic return which \nallows its reinvestment in research and development.Scientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n28  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\u2022 Promoting the participation of industry in the innovation process acting as a \nstakeholder actively involved in it.\n\u2022 Formalising business alliances, including technology companies as well as indus -\ntrial and financial partners, to develop collaborative projects and to transfer the \nresults to the market.\n\u2022 Generating resources that achieve the greatest impact on society, enabling a bet -\nter quality health care and at the same time contributing to the sustainability of \nthe National Health System.\n\u2022 Boosting a fruitful collaboration among all entities that make up the ITEMAS \nPlatform.\nIn the last years the UAI has definitely consolidated its presence and visibility in the \nwhole environment Hospital-Institute. Its impact in the Hospital has been stren -\ngthened by the creation of both the Innovation Platform and the Innovation Com -\nmittee as two linked structures within the organisation. The Innovation Platform is \nan initiative launched from the Hospital\u2019s Management Board in order to promote, \nextend, enhance and stimulate innovation throughout the Hospital. The main mis -\nsion of the Innovation Platform is to build a culture of innovation among all Hospital \nand Institute staff. The Innovation Unit is integrated into this platform as its main \ndriver and, as such, it establishes its objectives and marks its lines of action and will \nbe responsible for channelling the entire workload. It also forms part of the Innova -\ntion Committee, a decision-making body on the ideas to be supported by FIBHULP .\nAmong the greatest achievements of the Innovation Support Unit are the following:\n1. The UAI has become one of IdiPAZ\u2019s most in-demand and requested plat -\nforms as it is responsible for promoting, supporting and managing all inno -\nvation projects.\nAt December 31 2018, the UAI had 184 innovation projects or ideas in active sta -\nte, 26 of which were in the capture phase, 65 in the evaluation phase, 12 in develo -\npment, 49 in transfer and 32 in the market. According to these data, it follows that \n17% of the projects have been successfully exploited and positioned in the market, \nvery positive percentage (although far lower than the aspired figure) given the \nprecariousness of the times we go through and the resources (both human and \nfinancial) with which the UAI counts. Among the various types of projects handled \nby the UAI it is particularly noteworthy the volume of medical device-type pro -\njects, followed by projects such as \u201cBio\u201d, \u201cHealth ICT\u201d and \u201ceHealth\u201d. Although the \nUAI has more than nine years of experience, most of the activity (157 projects) \nand its achievements have taken place in the last five years, period 2014-2018. \n2. The UAI has built a wide and diverse technology portfolio. Each year the \nnumber of innovation projects managed by the UAI increases with respect \nto the previous year, also increasing the number of Hospital services, re -search groups and professionals in general who join IdiPAZ\u2019s innovation \ncommunity. \nDuring the period 2014-2018, the UAI filed 17 priority patents (13 Spanish pa -\ntents, 3 European patents and 1 US patent) and 15 PCT; 10 national or regional \nphase entry applications were filed (4 at the EPO, 4 at the USPTO and 2 at other \npatent offices) and 23 patents were granted (20 at the OEPM, 2 at the EPO and \n1 at the USPTO).\nUAI\u2019s portfolio of patent families in active state during period 2014-2018 reached \nthe figure of 46 patent families.\nAs for the software, during the period 2014-2018 the UAI registered 18 new \ncomputer applications.\nSpecial mention should also be made to the UAI trademark portfolio. During the \nperiod 2014-2018, 17 trademark applications were filed and 15 were granted. \nIt is important to note that these trademarks, besides allowing IdiPAZ to distin -\nguish its products or services from competitors\u2019 products or services, are asso -\nciated with the know-how of the institution, know-how that has been transferred \nalong with the distinctive sign in the case of the license agreements signed by the \ninstitution in respect of trademarks.\n3. The UAI has prepared a catalogue of technology offers -based on specifi -\ncation sheets- which includes the complete portfolio of exploitable IdiPAZ \nresults. This catalogue aims to promote the transfer of IdiPAZ\u2019s technology \nportfolio to the industrial sector, generate collaborative projects for tech -\nnological development and foster the exploitation of research results. Those \nvalidated specification sheets are published on IdiPAZ\u2019s website. The catalo -\ngue is updated as the Institute\u2019s technology portfolio grows.\n4. The UAI has been, is, and will continue to be the principal architect for \nthe transfer and exploitation of IdiPAZ\u2019s technology portfolio. During the \nperiod 2014-2018 the UAI succeeded in signing 35 license agreements of \nintellectual property rights (copyright). On the other hand, during the same \nperiod of time the UAI managed to achieve the following values in terms of \ntransfer: 10 patents, 11 software, and 16 trademarks in commercial exploi -\ntation, which meant a significant achievement in terms of economic return.\n5. Thanks to UAI\u2019s support and management it has been possible to create \nand consolidate the first technology-based company of the Hospital (and \nalso of the region of Madrid) according to the regulations established by the \nDepartment of Health of the Community of Madrid. The spin-off concer -\nned, Biomedica Molecular Medicine, exploits the research results in oncolo -\ngy \u2013specifically, a genomic test to determine whether breast cancer patients \nshould have chemotherapy \u2013 designed by some members of IdiPAZ. 2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n29  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians6. Through the promotion of a culture of innovation, the UAI has managed \nto create a large community of innovative professionals. Over the last year \nits promotional activity has consisted in the celebration of several working \ndays, workshops, seminars, etc.:\n\u2022 \u201cLa Paz 3.D: gesti\u00f3n de la tridimensionalidad\u201d Workshop, June 12, 2018\n\u2022 \u201cLa innovaci\u00f3n: un nuevo camino hacia la excelencia en La Paz\u201d Workshop, \nOctober 10, 2018\n\u2022 \u201cD\u00eda internacional de la mujer y la ni\u00f1a en la ciencia\u201d Workshop, February 11, \n2018\n\u2022 Working meeting between the EPO and the Innovation Support Unit of Idi -\nPAZ, May 8, 2018\nIn addition, the UAI has collaborated with important institutions and private enti -\nties to promote innovation, in particular it has participated in various forums and \nround tables organised by various stakeholders of the biomedical sector.\n7. The UAI has succeeded in creating a wide-ranging network of contacts. By \nvirtue of its membership in the ITEMAS Platform, the Unit has continued to \nstrengthen ties and creating synergies with the members of this Platform in \norder to achieve its established objectives.\nApart from the above results it is important to emphasize that several innovation \nprojects managed by the Innovation Unit have been awarded with prestigious \nawards and aids over the last year:\n\u2022 2nd and 3rd Award obtained in the third edition of the Healthstart Program \nfor two of our innovation projects: STENT -BAND project led by Rosario Ma -\ndero Jarabo, former Head of the Biostatistics Service at IdiPAZ; and OSTO -\nCUTTER project led by Paloma de la Quintana Jim\u00e9nez, stoma therapy nurse \nat HULP . Healthstart is the program of the Madrimasd Knowledge Foundation \n(Madri+d Foundation) and the Medical T echnology Innovation Platform (ITE -\nMAS Platform), promoted by the Institute of Health Carlos III (ISCIII) for the \nacceleration of technological start-ups of the Community of Madrid in the \nhealthcare sector, \n\u2022 Aid intended to carry out Feasibility Studies granted by the Foundation for \nHealth Innovation and Prospective in Spain (FIPSE) to one of our innovation \nprojects. The innovation project is FACE MIRROR, and is led by Dr. Alfonso Gil \nMart\u00ednez.ORGANISATION\nSince its implementation, the Innovation Support Unit has been integrated into the \norganisational structure of FIBHULP , as one of the Support Platforms for IdiPAZ \nresearch.\nThe Innovation Unit is directed by Dr. Javier de Castro Carpe\u00f1o, M.D. and Ph.D. \nin Medicine and a member of the Medical Oncology Department of the La Paz \nUniversity Hospital/ Autonomous University of Madrid and of the Translational \nOncology Unit of IdiPAZ.\nThe Innovation Unit also consists of a team of two experts in fostering innovation \nand protecting research results and technology transfer: \nEstela S\u00e1nchez Sim\u00f3n, Law Graduate; and\nMar\u00eda Dolores P\u00e9rez Garre, Bachelor of Chemical Sciences.\nCONTACT\nCoordinator\nJavier de Castro Carpe\u00f1o\njavier.decastro@salud.madrid.org\nPhone: (+34) 91 207 12 34\nMembers\nEstela S\u00e1nchez Sim\u00f3n\ne_sanchez.innovacion@idipaz.es\nPhone: (+34) 91 207 12 34\nMar\u00eda Dolores P\u00e9rez Garre\nmaria.dolores.perez@idipaz.es\nPhone: (+34) 91 207 12 342.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n30  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.4.2 Patents and trademarks\nNeuroscience Area\nPsychiatry and Mental Health Group\nRodr\u00edguez Vega B , authors; FIBHULP , assignee. Brand name: En  \ncalma; ESM 3.695.071; 2017 December 12.\nRodr\u00edguez Vega B, Mediavilla Torres R,  authors;  \nFIBHULP , assignee. Brand name: SocialMind; ESM  \n3.748.550; 2018 December 17.\nNeurology and Cerebrovascular Diseases Group\nBallesteros Garc\u00eda P, L\u00f3pez Larrubia P, Dom\u00ednguez Mateo L, Marco Contelles \nJL, Cerd\u00e1n Garc\u00eda-Esteller S,  inventors; Universidad Nacional de Educaci\u00f3n a \nDistancia, CSIC, assignees. Set of magnetic resonance imaging and spectrosco -\npy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. \nP200300936; 2003 April 23.\nValdivieso Amate F, Bullido G\u00f3mez-Heras MJ, Mart\u00ednez Garc\u00eda A , inventors; \nUAM, assignee. Method of identifying compounds that induce or inhibit endo -\nplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, \nEP2221379, US20100304384; 2007 November 13.\nValdivieso \u00c1mate F, Burgos Mu\u00f1oz JS, Ram\u00edrez Moreno C, Sastre Merl\u00edn I , inven-\ntors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can \nbe used for the treatment and/or prevention of infections and diseases caused by hu -\nman herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, \nAT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.\nValdivieso \u00c1mate F, Montoli\u00fa JL, Pozueta Larios J , inventors; UAM, CSIC, \nassignees. Alzheimer\u2019s disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, \nUS20090222932, CA2638983, JP2009517066; 2005 December 02.\nVerg\u00e9s Milano J, Garc\u00eda Garc\u00eda A, Ruh\u00ed Roura R, Montell Bonaventura E, Gar-\nc\u00eda L\u00f3pez M, Al\u00e1ez Vers\u00f3n CR, Escaich Ferrer J, Egea M\u00e1iquez J, Lorrio Gonz\u00e1-\nlez S, Negredo Madrigal P , inventors; BIOIB\u00c9RICA S.A., UAM, assignees. Sulpha -\nted disaccharides for the treatment of neurodegenerative and/or neurovascular \ndiseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; \n2010 December 22.\nNeuroprotective Strategies in Neurodegenerative \nDiseases Group\nCuadrado Pastor A, Innamorato NG , inventors: CSIC, UAM. Use of sulforaphane \nas supplementary therapy for early-stage neurodegenerative disease. P201231693; \n2012 November 06.\nLe\u00f3n Mart\u00ednez R, Egea Ma\u00edquez J, Buend\u00eda Abaitua I, Parada P\u00e9rez E, Nava-\nrro Gonz\u00e1lez de Mesa E , inventors; Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica \ndel Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE \nS.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the \ntreatment of neurodegenerative diseases. P201300667; 2013 July 17.\nLe\u00f3n Mart\u00ednez R, Buend\u00eda Abaitua I, Navarro Gonz\u00e1lez de Mesa E, Michalska \nP, Gameiro Ros I, L\u00f3pez Vivo A, Egea Ma\u00edquez J, Garc\u00eda L\u00f3pez M, Garc\u00eda Garc\u00eda \nA, inventors; Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario \nde La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived \nfrom 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurode -\ngenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 Octo -\nber15.\nCardiovascular Area\nResearch on Invasive Clinical Cardiology-  \nICCI-PAZ Group\nRiera del Moral LF , inventor; FIBHULP , assignee. Aortic endoprosthesis for the \ntreatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n31  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansFilgueiras Rama D, L\u00f3pez de S\u00e1 y Areses E, Millet Roig J, Calvo Saiz CJ, in-\nventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), \nFIBHULP , Universidad Polit\u00e9cnica de Valencia, assignees. Method of predicting or \nprognosticating neurological performance in patients who have suffered a car -\ndiac arrest and optionally comatose status due to ventricular fibrillation. PCT/\nEP2015/076893, EP3020333; 2014 November 17.\nVascular Physiology and Pharmacology Group\nGarc\u00e9s Rim\u00f3n M, Miguel Castro M, L\u00f3pez-Alonso Fandi\u00f1o R, L\u00f3pez-Miranda \nGonz\u00e1lez V, Uranga Ocio J , inventors; CSIC, Universidad Rey Juan Carlos, as -\nsignees; Use of multifunctional bioactive products derived from the enzymatic \nhydrolysis of egg white proteins for treating metabolic syndrome. P201331767, \nPCT/ES2014/070880; 2013 December 04.\nGonz\u00e1lez-Mu\u00f1iz R, Miguel Castro M, P\u00e9rez de Vega MJ, Balsera-Paredes B, S \nMoreno , inventors; CSIC, assignee. Compounds with antioxidant activity and uses \nthereof. P201630362; 2016 March 29.\nGonz\u00e1lez-Mu\u00f1iz R, P\u00e9rez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S , \ninventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses \nthereof; P201531450; 2015 November 08.\nMiguel Castro M, Garc\u00e9s Rim\u00f3n M, L\u00f3pez-Alonso Fandi\u00f1o R, Sandoval \nHuertas M , inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food \ncompositions having gel or foam textures and comprising hydrolyzed egg pro -\nducts. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, \nJP2015130856, MX2014015135; 2013 December 20.\nMiguel Castro M, L\u00f3pez-Alonso Fandi\u00f1o R, Ramos Gonz\u00e1lez MM, Aleixan-\ndre de Arti\u00f1ano A , inventors; CSIC, assignee. Production of and antihyperten -\nsive properties of peptides derived from egg white proteins. P200501246 PCT/\nES2006/070067; 2005 May 23.\nMiguel Castro M, L\u00f3pez-Alonso Fandi\u00f1o R, Recio S\u00e1nchez MI, Ramos Gon-\nz\u00e1lez MM, Aleixandre de Arti\u00f1ano A , inventors; CSIC, assignee. Bioactive pep -\ntides derived from the proteins of egg white by means of enzymatic hydroly -\nsis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, \nDE602004012289, DK1661913, JP2007523045; 2003 July 31.\nP\u00e9rez Gir\u00f3n JV, Ruiz-Castellanos MJ, de Luis Jim\u00e9nez O, P\u00e9rez Boto V, Sanz \nGonz\u00e1lez R, Hern\u00e1ndez V\u00e9lez MC, Mas Guti\u00e9rrez JA, Alonso Gordo MJ, Sala\u00edces \nS\u00e1nchez M, Ros P\u00e9rez M, Coloma Jerez A, Asenjo Barahona A, Sanz Monta\u00f1a \nJL, Puente Prieto J, Jensen J , inventors; NANOATE, S.L., assignee. Method for \nproducing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.\nRecio S\u00e1nchez MI; Quir\u00f3s del Bosque A, Hern\u00e1ndez Ledesma B, G\u00f3mez Ruiz \nJA, Miguel Castro M, Amigo Garrido L, L\u00f3pez Exp\u00f3sito I, Ramos Gonz\u00e1lez MM, Aleixandre de Arti\u00f1ano A, (Contreras G\u00f3mez M) , inventors; CSIC, assignee. Bio -\nactive peptides identified in enzymatic hydrolyzates of milk caseins and method of ob -\ntaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, \nAU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, \nJP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.\nInfectious Diseases and \nImmunity Area\nAIDS and Infectious Diseases Group\nRomero G\u00f3mez M, Sol\u00e1 Lamoglia R, Gonz\u00e1lez Garc\u00eda JJ , inventors; Servicio \nAndaluz de Salud, Universidad de Sevilla, Fundaci\u00f3 Institut Mar D\u2019Investigacions \nM\u00e8diques, FIBHULP , assignees. Kit for decision making in patients with Hepatitis \nC genotypes 1 and 4. P201330731; 2013 May 21.\nMolecular Microbiology Group\nVicente Mu\u00f1oz M, Mingorance Cruz J, Rueda Gonz\u00e1lez MS , inventors; CSIC, \nassignee. Method for determining state of growth and viability of bacterial FTsZ \npopulation, whether natural or cultivated, is based on determining existence of \nFTsZ rings in actively growing individual cells. P200200370; 2002 February 15.\nMingorance Cruz J, Cast\u00e1n Garc\u00eda P, Franco de Sarabia Rosado PM , inventors; \nBIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assig -\nnee. Composition, method and kit for detecting bacteria by means of sequencing. \nPCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; \n2009 October 22.\nMingorance Cruz J, Cast\u00e1n Garc\u00eda P, Franco de Sarabia Rosado PM , inventors; \n2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and \nyeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.\nImmuno-Rheumatology Group\nPascual-Salcedo Pascual MD, Balsa Criado A, Pla-\nsencia Rodr\u00edguez C , authors; FIBHULP , assignee. Brand \nname: BioDrug Analysis BIDA. CM 13.808.531, 2015 \nMarch 10.\n2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n32  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansFern\u00e1ndez Luna JL, Mart\u00ednez Taboada VM, L\u00f3pez Hoyos M, Torices del Val S, \nMu\u00f1oz Cacho P, Varela Egocheaga I, Juli\u00e1 Cano A, Marsal Barril S, Balsa Criado \nA, inventors; FIBHULP , Fundaci\u00f3n Instituto de Investigaci\u00f3n Marqu\u00e9s de Valdecilla, \nServicio C\u00e1ntabro de Salud, Universidad de Cantabria, FUNDACI\u00d3 HOSPITAL \nUNIVERSITARI VALL D\u00b4HEBRON - INSTITUT DE RECERCA (VHIR), assignees. \nMethod for predicting the clinical response to anti-inflammatory agent therapies. \nP201600636, PCT/ES2017/000089; 2016 July 26.\nInnate Immune Response Group\nLlamas Mat\u00edas MA, L\u00f3pez-Collazo E , inventors; FIBHULP , Llamas Mat\u00edas MA, \nEmpireo S.L., assignees. Method for determine the risk of developing an infectious \ndisease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27. \nDiagnosis and Treatment of Diseases Associated with \nAbnormalities of the Complement System Group\nL\u00f3pez Trascasa M , authors; FI -\nBHULP , assignee. Brand name: COM -\nPLEMENT est; CM 009.658.791; \n2011, January 14.\nLumphocyte Pathophysiology in Immunodeficiencies \nGroup\nVan Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, P\u00e9rez \nAndr\u00e9s M, Van Zelm MC, Kalina T, Vlkova M, L\u00f3pez Granados E, Blanco \u00c1l-\nvarez E, Kienzler AK , inventors; Erasmus University Medical Center Rotterdam, \nassignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. \nPCT/NL2015/050762, US62/072,498; 2014 Oct 30. \nDrug Hypersensibility and Innate Immune Response \nGroup\nSelgas Guti\u00e9rrez R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, \nVaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn Fern\u00e1ndez R , inventors; FIBHULP , \nUniversidad de Alcal\u00e1, assignees. Use of compounds derived from salts of pyrida -\nzine[1\u2019,6\u2019:1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, \nPCT/ES2014/070603; 2013 July 25.\nSelgas Guti\u00e9rrez R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, \nVaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn Fern\u00e1ndez R , inventors; FI -\nBHULP , Universidad de Alcal\u00e1, assignees. Use of compounds derived from salts of \npiridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/\nES2014/070603; 2013 July 25.\nS\u00e1nchez Ni\u00f1o MD, Ortiz Ardu\u00e1n A ; FIBHULP , Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz. Pharmaceutical composition and its use in the manufac -\nture of a medicament for treating chronic kidney disease and method for scree -\nning compounds. P201430081, PCT/ES2015/070039; 2014 January 27.\nTranslational Research in Pediatric Oncology, \nHematopoietic Transplantation and Cell Therapy Group\nVela Cuenca M, Gonz\u00e1lez Navarro P, Valent\u00edn Quiroga J, Escudero L\u00f3pez A, \nP\u00e9rez Mart\u00ednez A, Fern\u00e1ndez Casanova L , inventors; FIBHULP , CNIO, assignees. \nAnti-CXCR4 antibody combined with activated and expanded natural killer cells \nfor cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.\nLarge System Pathologies \nArea\nOrganic Dysfunction and Failure in the Agression Group\nHerrero Ambrosio A, Ram\u00edrez Garc\u00eda E, Ojeda Feo JJ, P\u00e9-\nrez Rodr\u00edguez J, Asensio Mart\u00edn MJ, Gonz\u00e1lez S\u00e1nchez ML, \nMoro Agud M, Lorente Romeo M, L\u00f3pez Nieto M, G\u00f3mez \nRioja R , authors; FIBHULP , assignee. Brand name: SINOIRES; \nCM 13.080.056; 2014 July 14.\n \nNephrology Group\nSelgas Guti\u00e9rrez R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, \nVaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn Fern\u00e1ndez R , inventors; FIBHULP , \nUniversidad de Alcal\u00e1, assignees. Use of compounds derived from salts of pyrida -\nzine[1\u2019,6\u2019:1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, \nPCT/ES2014/070603; 2013 July 25.\nSelgas Guti\u00e9rrez R, Bell\u00f3n Heredia T, Rodr\u00edguez Sanz AI, \u00c1lvarez Builla J, \nVaquero L\u00f3pez JJ, S\u00e1nchez Alonso P, Alajar\u00edn Fern\u00e1ndez R , inventors; FI -\nBHULP , Universidad de Alcal\u00e1, assignees. Use of compounds derived from salts of \npiridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/\nES2014/070603; 2013 July 25.\nAguilera Peralta AI, L\u00f3pez-Cabrera M, Selgas Guti\u00e9rrez R, Steppan S, \nPasslickdeetjen J , inventors; Fresenius Medical Care Deutschland GMBH, as -\nsignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/\nEP2015/074955; 2014 October 31.2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n33  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansL\u00f3pez-Cabrera M, Aguilera Peralta AI, Selgas Guti\u00e9rrez R, Passlickdeetjen \nJ. Buechel J, Steppan S , inventors; Fresenius Medical Care AG & Co. KGaA, as -\nsignee. Method and kit for diagnosing epitelial to mesenchymal transition of the \nperitoneum (EMT -Chip). DE102015115158.8; 2015 September 09. \nS\u00e1nchez Ni\u00f1o MD, Ortiz Ardu\u00e1n A ; FIBHULP , Instituto de Investigaci\u00f3n Sanitaria \nFundaci\u00f3n Jim\u00e9nez D\u00edaz. Pharmaceutical composition and its use in the manufac -\nture of a medicament for treating chronic kidney disease and method for selec -\nting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.\nNeonatology Group\nSegovia I\u00f1igo C, Montes Bueno MT , inventors; Segovia I\u00f1igo C, assignee. Positio -\nning device for neonates (Utility model). U201330102; 2013 January 31.\nDiagnosis and Treatment of Allergic Diseases Group\nValenta R, Constantin C, Quirce Gancedo, SE , inventors; Phadia AB, assig -\nnee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, \nAU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; \n2007 November 30. \nCaballero Molina MT, Prior G\u00f3mez N, Remor Bitencourt EA, authors, FIBHULP , \nassignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF \nLIFE. CM 13.083.068; 2014 July 15.\nS\u00e1nchez Herreros R, Mart\u00ednez Fern\u00e1ndez J, Castro Morera A, Gasset Vega \nM, Rodr\u00edguez P\u00e9rez RM, Pedrosa Delgado M, Quirce Gancedo S , inventors; \nFIBHULP , CSIC, assignees. Food allergen extracts and methods of producing and \nusing the same. EP16382413.9 (Publication Number pending); 2016 September 06. \ndel Pozo Abej\u00f3n V, Sastre Dominguez J, Rodrigo-Mu\u00f1oz JM, Sastre Turri\u00f3n B, \nQuirce Gancedo S, Ca\u00f1as Ma\u00f1as JA , inventors; FIISFJD, Centro de Investigaci\u00f3n \nBiom\u00e9dica en Red (CIBER), FIBHULP , Fundaci\u00f3n Conchita R\u00e1bago de Jim\u00e9nez \nD\u00edaz, assignees. In vitro method for identifying severity levels in bronchial asthma \npatients. P201730739, PCT/ES2018/070390; 2017 May 29.\nGynecologic Oncology Group\nZapardiel Guti\u00e9rrez I, de Santiago Garc\u00eda J , inventors; FIBHULP , assignee. La -\nparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.\nZapardiel Guti\u00e9rrez I, de Santiago Garc\u00eda J , inventors; FIBHULP , assignee. Surgi -\ncal device. P201330532, PCT/ES2014/070277; 2013 April, 15.Urology Group\nBotella Cubells LM, Albi\u00f1ana D\u00edaz V, Villar G\u00f3mez de las Heras K , inven -\ntors; CSIC, Alianza Espa\u00f1ola de Familias de Von Hippel-Lindau-VHL, assig -\nnee; Compounds for treating von Hippel-Lindau diseases. P201731019, PCT/\nES2018/071220; 2018 August 18\nBotella Cubells LM , inventor; CSIC, assignee; Inhibidores de TGF-\u00df1 y pro -\nductores de endoglina para su uso en el tratamiento de epiderm\u00f3lisis bullosa. \nP201831072; 2018 November 07\nBotella Cubells LM , inventor; CSIC, assignee; Treatment and prevention of glio -\nblastoma. EP18382917; 2018 December 12\nEmergency and Critical Pathology\nCarballo Cardona C ; author; FIBHULP , assignee. Trademark name: Diagether. \nCM15869911, 2016 September 29.\nAssociated Clinician\nde la Oliva Senovilla P , inventor; FIBHULP , Instituto de Salud Carlos III, assignees. \nShut-off valve for the interruption technique used in the analysis of respiratory \nmechanics. PCT/ES2005/000271, EP1897578; 2005 May 16.\nCancer and Human \nMolecular Genetics Area\nINGEMM- Institute of Medical and Molecular Genetics \nGroup\nFriedman S, Li D, Narla G, Martignetti J, Heath K , inventors; Mount Sinai \nSchool of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppres -\nsor protein, and diagnostics, therapeutics, and screening based on this protein. \nPCT/US2001/025046, EP1332362, CA2419064, AU8479001, US2005181374, \nUS2011059899; 2000 August 09.\nINGEMM , author; FIBHULP , assignee. Brand name: INGEMM INSTITUTO DE GE -\nN\u00c9TICA M\u00c9DICA Y MOLECULAR \nDEL HOSPITAL UNIVERSITARIO LA \nPAZ; ESM 2.884.849, USM 77.891.143, \nCM 8.746.869; 2009 July 16, 2009 De -\ncember 11, 2009 December 10.2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n34  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansINGEMM, author;  FIBHULP , assignee. Brand name: KaryoArray; \nUSM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27. \nINGEMM, author;  FIBHULP , assignee. Brand \nname: OverGrowthArray; ESM 2.958.709-3, \nUSM 85.334.932, CM 10.009.256; 2010 Decem -\nber 02, 2011 June 01, 2011 May 31. \nINGEMM, author;  FIBHULP , assignee. Brand name: \nMetabolArray; ESM 2.958.711-5, USM 85.334.903, CM \n10.009.348; 2010 December 02, 2011 June 01, 2011 \nMay 31. \nPalomares M, Lapunzina P, Nevado J, Vallespin \nE, Vallcorba I, Melero J, authors; FIBHULP , Hospi -\ntal Infanta Cristina (Badajoz) Fundesalud, assignees. \nBrand name: OncoHematoArray; ESM 2.958.703-4, \nUSM 85.334.842, CM 10.009.181; 2010 December \n02, 2011 June 01, 2011 May 31. \nINGEMM, author;  FIBHULP , assignee. Brand name: OncoA -\nrray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 \nJanuary 05, 2011 July 05, 2011 July 01.\nLapunzina P, Nevado J, Solera J, Vallespin E, Mart\u00ednez P, Mar-\nt\u00ednez-Gonz\u00e1lez V, authors;  FIBHULP , assignee. Brand name: ON -\nCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 \nMay 16.\nMoreno JC, Moya CM, Vallespin E, Lapunzina P, \nNevado J,  authors; FIBHULP , assignee. Brand name: \nThyroArray; USM 85.686.688, CM 10.904.951; \n2012 July 25, 2012 May 23.Lapunzina Bad\u00eda P, Borobia P\u00e9rez \nAM, Carcas Sansu\u00e1n AJ, Tenorio Cas-\nta\u00f1o JA, Arias Lajara P, Lubomirov \nJristov R, authors; FIBHULP , UAM, as -\nsignees. Brand name: PharmArray; USM \n86.004.412, CM 11.608.403; 2013 July \n08, 2013 February 27\nLapunzina Bad\u00eda PD, Borobia P\u00e9rez \nAM, Carcas Sansu\u00e1n AJ, Tenorio Cas-\nta\u00f1o JA, Arias Lajara P, Fr\u00edas Iniesta \nJ, Dapia Garc\u00eda I, Mu\u00f1oz M, authors; \nFIBHULP , UAM, assignees. Brand name: \nClinPharmarray., CM15489511; 2016 \nMay 31, 2016 September 07. \nPalomares Bralo M, Vallesp\u00edn Garc\u00eda E, del Pozo \nMate A, Santos Simarro F, authors; FIBHULP , \nassignee. Brand name: RD-Seq Sequencing Rare \nDiseases; CM 17.911.029; 2018 May 31. \nTranslational Oncology Group\nCejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, de Castro Carpe\u00f1o J, Moreno \nGarc\u00eda V, Burgos Lizalde E, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ , inventors; \nFIBHULP , UAM, Empresa P\u00fablica Hospital del Norte, assignees. Genomic finger -\nprint for predicting the clinical response to an antitumor therapy in colorectal \ncancer. P201130863, PCT/ES2012/070379; 2011 May 26. \nCejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, Gonz\u00e1lez Bar\u00f3n M, de Castro \nCarpe\u00f1o J, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ , inventors; FIBHULP , UAM, \nassignees. Genomic fingerprint for the prognosis of the evolution of colorectal ade -\nnocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.\nCejas Guerrero P, Gonz\u00e1lez Bar\u00f3n M, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ, \nPerona Abell\u00f3n R , inventors; FIBHULP , UAM, CSIC, assignees. Use of trefoil fac -\ntor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. \nP200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.\nEspinosa Arranz E, Fresno Vara JA, G\u00e1mez Pozo A, L\u00f3pez Vacas R, Berges Soria \nJ, inventors; FIBHULP , assignee. Method for tumor subclassification. P201430887, \n2014 June 09. \nEspinosa Arranz E, Fresno Vara JA, G\u00e1mez Pozo A, S\u00e1nchez Navarro I , inven -\ntors; FIBHULP , assignee. Method for tumor subclassification. P200803509, PCT/\nES2009/070533; 2008 December 11. 2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n35  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansMiranda Utrera N, Castellano D, Villacampa Aub\u00e1 F, Fresno Vara JA, G\u00e1mez \nPozo A , inventors; FIBH12O, FIBHULP , assignees. Prognostic method for deter -\nmining the risk of relapse in renal cancer patients with a clear cell type of renal \ncarcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, \nEP16774644.5, US20180346990, CN108174608; 2015 September 23.\nMoreno Rubio J, Cejas Guerrero P, Feli\u00fa Batlle J, Ram\u00edrez de Molina AI, Regle-\nro Rada G, Vargas Alonso T, Molina Arranz S, Gonz\u00e1lez-Vallinas Garrach\u00f3n M , \ninventors; FIBHULP , Fundaci\u00f3n Imdea Alimentacion, assignees. Methods and kits \nfor the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 \nDecember 10.\nRedondo S\u00e1nchez A, Hardisson Herna\u00e9z D, Barriuso Feijoo J, Mendiola Sabio \nM, inventors; FIBHULP , assignee. Method to obtain useful data for the prediction of \na patient\u2019s clinical response to an anticancer treatment. P200930400; 2009 July 01.\nRedondo S\u00e1nchez A, Hardisson Herna\u00e9z D, Barriuso Feijoo J, Mendiola Sabio \nM, inventors; FIBHULP , assignee. Method to obtain useful data for the predic -\ntion of a patient\u2019s pathological response to an anticancer treatment. P200930438; \n2009 July 10.\nExperimental Therapies and Biomarkers in Cancer \nGroup\nCejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, de Castro Carpe\u00f1o J, Moreno \nGarc\u00eda V, Burgos Lizalde E, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ,  inventors; \nFIBHULP , UAM, Empresa P\u00fablica Hospital del Norte, assignees. Genomic finger -\nprint for predicting the clinical response to an antitumor therapy in colorectal \nc\u00e1ncer. P201130863, PCT/ES2012/070379; 2011 May 26. \nCejas Guerrero P, Belda Iniesta C, Feli\u00fa Batlle J, Gonz\u00e1lez Bar\u00f3n M, de Castro \nCarpe\u00f1o J, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ , inventors; FIBHULP , UAM, \nassignees. Genomic fingerprint for the prognosis of the evolution of colorectal ade -\nnocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.\nCejas Guerrero P, Gonz\u00e1lez Bar\u00f3n M, Casado S\u00e1enz E, S\u00e1nchez Hern\u00e1ndez JJ, \nPerona Abell\u00f3n R , inventors; FIBHULP , UAM, CSIC, assignees. Use of trefoil fac -\ntor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. \nP200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.\nIb\u00e1\u00f1ez de C\u00e1ceres I, Belda Iniesta C, Pern\u00eda Arias O, Perona Abell\u00f3n R, Cor-\nt\u00e9s Sempere M ; inventors. FIBHULP , CSIC, UAM, Fundaci\u00f3n Hospital de Ma -\ndrid, assignees. Method for predicting the response to a treatment consisting \nof radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/\nES2014/070433, EP3006572, US20160122828; 2013 May 29.\nIb\u00e1\u00f1ez de C\u00e1ceres I, de Castro Carpe\u00f1o J, Vera Puente O, Pern\u00eda Arias O, Rodr\u00ed-guez Antol\u00edn C, Gonz\u00e1lez Mu\u00f1oz VM, Mart\u00edn Palma ME, Salgado Figueroa AM , \ninventors; FIBHULP , FIBIOHRC, assignees. MAFG as a potential therapeutic target \nto restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (Pu -\nblication Number pending), PCT/EP2018/068156; 2017 September 15.\nIb\u00e1\u00f1ez de C\u00e1ceres I, Pern\u00eda Arias O, de Castro Carpe\u00f1o J, Vera Puente O, \nJim\u00e9nez Hern\u00e1ndez J, Perona Abell\u00f3n R, Rojo Todo F , inventors; FIBHULP , \nCSIC, UAM, Instituto de Investigaci\u00f3n Sanitaria FJD, assignees. Determination of \nmethylation and miRNA levels in response to a platinum-based antitumor com -\npound. P201530997, PCT/ES2016/070516; 2015 July 09.\nMart\u00ednez M\u00e1\u00f1ez R, Murgu\u00eda Ib\u00e1\u00f1ez JR, Perona Abell\u00f3n R, Agostini A, Mon-\ndrag\u00f3n Mart\u00ednez L, Moreno Torres M, Mangu\u00e1n Garc\u00eda C, Marcos Mart\u00ednez \nMD, Soto Camino J, Sancen\u00f3n Galarza F , inventors; Universidad Polit\u00e9cnica de \nValencia, CSIC, Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Bioingenier\u00eda, Bio -\nmateriales y Nanomedicina (CIBER-BBN), Centro de Investigaci\u00f3n Biom\u00e9dica en \nRed de Enfermedades Raras (CIBERER), assignees. Release of substances into \nsenescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, \nUS2015306037; 2012 September 04.\nPerona Abell\u00f3n R, S\u00e1nchez P\u00e9rez I, Machado Pinilla R, Sastre Garz\u00f3n L, Murgu\u00eda \nIb\u00e1\u00f1ez JR , inventors; CSIC, UAM, Universidad Polit\u00e9cnica de Valencia, assignees. \nSequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce te -\nlomerase activity, method for obtaining same, therapeutic compositions and appli -\ncations thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, \nUS2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, \nPT1947175; 2005 October 14.\nPerona Abell\u00f3n R, Sastre Garz\u00f3n L, Machado Pinilla R, S\u00e1nchez P\u00e9rez I , in-\nventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing \npharmaceutical compositions for treating illnesses relating to cellular senescence. \nP200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, \nCA2706467; 2007 November 23. \nPerona Abell\u00f3n R, Sastre Garz\u00f3n L, Pintado Berninches L, Carrillo Garc\u00eda \nJ, Molina Pach\u00f3n A, Irradiccio Silva L, Mangu\u00e1n Garc\u00eda C , inventors; CSIC, \nUAM, Advanced Medical Projects, Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CI -\nBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by \noxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, \nEP3061815 PCT/ES2014/070803; 2013 October 25.\nOto-Neurosurgery Research Group\nPolak M, Roca-Ribas Serd\u00e1 F, Gavil\u00e1n Bouzas J, Lassaletta Atienza L, Mir\u00f3 \nCastillo N, Rodrigo Dacosta J , inventors; MED-EL Elektromedizinische Geraete 2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n36  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansGmbH, assignee. Hearing treatment in patients with questionable cochlear nerve \nfunctionality. US2011275953, PCT/US2011/035312; 2010 May 05. \nCobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Mart\u00ednez \nVega R, Cediel Algovia R , inventors; CSIC, UCM, assignees. Anechoic acoustic \nchamber for evaluating the auditory function in laboratory animals. P201031720; \n2010 November 23.\nCobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R , inventors; \nCSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for \nhearing test with animals. Procedimiento para dise\u00f1ar una c\u00e1mara ac\u00fastica rever -\nberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; \n2008 October 14.\nCancer Molecular Pathology and Therapeutics Targets \nGroup\nRedondo S\u00e1nchez A, Hardisson Herna\u00e9z D, Barriuso Feijoo J, Mendiola Sabio \nM, inventors; FIBHULP , assignee. Method to obtain useful data for the prediction of \na patient\u2019s clinical response to an anticancer treatment. P200930400; 2009 July 01.\nRedondo S\u00e1nchez A, Hardisson Herna\u00e9z D, Barriuso Feijoo J, Mendiola Sabio \nM, inventors; FIBHULP , assignee. Method to obtain useful data for the predic -\ntion of a patient\u2019s pathological response to an anticancer treatment. P200930438; \n2009 July 10.\nMechanisms of Tumour Progression Group\nGarc\u00eda Garc\u00eda JF, Mart\u00edn Moreno AM, Roncador G, Mart\u00ednez Torrecuadra \nJL, Moreno Bueno G , inventors; Fundaci\u00f3n MD Anderson International Espa\u00f1a, \nFundaci\u00f3n Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), assignees; \nMethod for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 \nAugust 14.\nHergueta Redondo M, Sanz PG, Rojo A, Garc\u00eda JF, Moreno-Bueno G , inventors; \nUAM, CSIC, Fundaci\u00f3n MD Anderson International Espa\u00f1a, assignees; Gasdermin \nB2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in \nHer2+ tumors. P201231560; 2012 October 10.\nMat\u00edas-Guiu Gu\u00eda FJ, Dolcet Roca FJ, Revent\u00f3s Puigjaner J, Col\u00e1s Ortega E, \nPrat D\u00edaz de Losada J, Palacios Calvo J, Abal Posada M, L\u00f3pez L\u00f3pez R, Mo-\nreno Bueno G, Gil Moreno A , inventors; Institut de Recerca Biom\u00e8dica de Lleida \nFundaci\u00f3 Doctor Pifarr\u00e9, Universitat deLleida, Fundaci\u00f3 Hospital Universitari Vall \nd\u2019Hebron-Institut de Recerca, Fundaci\u00f3 Institut de Recerca de L\u2019Hospital de la San -\nta Creu i Sant Pau, Servicio Andaluz de Salud, Servizo Galego de Sa\u00fade, Fundaci\u00f3n \nMD Anderson International Espa\u00f1a, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease \nin endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.\nOlmeda Casadom\u00e9 D, Moreno Bueno G, Portillo P\u00e9rez F, Cano Garc\u00eda A , inven -\ntors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast \ncancer. P200702342, PCT/ES2008/000563; 2007 August 28.\nOlmeda Casadom\u00e9 D, Peinado Selgas H, Portillo P\u00e9rez F, Nieto Toledano MA, \nCano Garc\u00eda A , inventors; UAM, assignee. Materials and methods for the dere -\npression of the E-cadherin promoter. US20060003956; 2004 March 03.\nAnimal and Cell Models for Detection and \nCharacterisation of Leukemic Stem Cells Group\nCampanero Garc\u00eda MR, Molina Privado I , inventors; CSIC, UAM, assignees. \nMethod for identifying patients with sporadic Burkitt\u2019s lymphoma, identification \nmethod and use of compounds for the treatment of sporadic Burkitt\u2019s lymphoma. \nP200702595, PCT/ES2008/070182; 2007 October 03.\nMolina Privado I, Campanero Garc\u00eda MR, Rodr\u00edguez Mart\u00ednez M , inventors; \nCSIC, UAM, assignees; Method for the differential diagnosis between Burkitt lym -\nphoma and diffuse large B-cell lymphoma. P200900651; 2009 March 09.\nZapata Hern\u00e1ndez JM, P\u00e9rez Chac\u00f3n G , inventors; CSIC, UAM, assignees; Use of \nan indolic compound with nucleophilic substituents at C3 and the dimeric variants \nthereof in the production of a pharmaceutical composition that can be used in \nthe treatment of B-lymphoid neoplasms. P201331397, PCT/ES2014/070726; 2013 \nSeptember 25.\nResearch and Diagnosis of Inherited Metabolic \nDiseases Group\nP\u00e9rez Gonz\u00e1lez B, Ruiz Desviat L, Jorge Finnigan A, Ugarte P\u00e9rez M, Mart\u00ednez \nRuiz A, Underhaug J, Barnejee R , inventors; UAM, Universidad de Bergen, Uni -\nversidad de Michigan, assignees; Compounds useful for the treatment of methyl -\nmalonic aciduria. P201330171; 2013 February 11.\nP\u00e9rez Gonz\u00e1lez B, G\u00e1mez Abascal A, Yuste Checa P, Arduim Brasil S, Ugar-\nte P\u00e9rez M, Mart\u00ednez Ruiz A, Underhaug J , inventors; UAM, Universidad de \nBergen, assignees; Compounds for treating congenital disorders of glycosylation. \nEP16382373.5; 2016.\nAssociated Clinician\nGlar\u00eda Enr\u00edquez A, Ma\u00f1as Rueda A, Vel\u00e1zquez Soto R , inventors; FIBHULP , as -\nsignee. Isolation and immobilization device for test animals. P201031519, PCT/\nES2011/070709; 2010 October 14.2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n37  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansSurgery, Transplant and \nHealth Technologies Area\nBone Pathophysiology and Biomaterials Group\nFabiilli M, Wilson C, Padilla F, Mart\u00edn Saavedra FM , inventors; The regents of \nthe University of Michigan, assignee. Ultrasound-triggerable agents for tissue en -\ngineering; PCT/US2013/044817, US2013/0330389; 2012 June 08.\nGonz\u00e1lez Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich \nRodr\u00edguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga \nN, Pacha Olivenza MA, Fern\u00e1ndez Calder\u00f3n MC, Salda\u00f1a Quero L, Gonz\u00e1lez \nMart\u00edn ML, P\u00e9rez Giraldo C, Gallardo Moreno AM , inventors; CSIC, Fundaci\u00f3n \nT ecnalia Research & Innovation, FIBHULP , Universidad de Extremadura, Centro \nde Investigaci\u00f3n Biom\u00e9dica en Red (CIBER). Moldable, biodegradable, biocom -\npatible and bioresorbable implant material, method for its preparation and uses \nthereof. P201530683; 2015 May 18.\nMart\u00edn Saavedra FM, Vilaboa D\u00edaz NE, Cebri\u00e1n Hernando V, Arruebo Gordo \nM, Santamar\u00eda Ramiro J, G\u00f3mez Navascu\u00e9s L , inventors; FIBHULP , CIBER-BBN, \nUniversidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; \nP201330894, PCT/ES2014/070484; 2013 June 14.\nVilaboa D\u00edaz NE, Calzado Mart\u00edn A, Crespo Garc\u00eda L, Salda\u00f1a Quero L, Moreo \nCalvo P, Alastru\u00e9 Vera V , inventors; FIBHULP , CIBER-BBN, assignees. Chamber de -\nvice for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; \n2013 January 16.\nVilaboa D\u00edaz NE, G\u00f3nzalez Carrasco JL, Multigner Dom\u00ednguez M, Lieblich \nRodr\u00edguez M, Mu\u00f1oz Hern\u00e1ndez M, Frutos Torres E, Salda\u00f1a Quero L , inven -\ntors; FIBHULP , CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Mag -\nnesium/polymer composite biomaterial for biomedical applications; P201030950, \nPCT/ES2011/070440; 2010 June 21.\nVilaboa D\u00edaz NE, Gonz\u00e1lez Carrasco JL, Salda\u00f1a Quero L, Frutos Torres E . \ninventors; FIBHULP , CSIC, CIBER-BBN, assignees. Method to obtain a metallic-\ncoated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.\nVoellmy R, Vilaboa D\u00edaz NE , inventors; HSF Pharmaceuticals S.A., assignee. Inhibi -\ntors of heat shock factor I and uses thereof. US 62/495,501; 2016 September 16.\nVoellmy R, Vilaboa D\u00edaz NE . Inventors; HSF Pharmaceuticals SA. Assignees. Compounds that induce protein unfolding and a mitigated response thereto, and \nmethods of use thereof. US 62/764,569. 2018 August 08\nVoellmy R, Vilaboa D\u00edaz NE . Inventors; HSF Pharmaceuticals SA. Assignees. In -\nhibitors of heat shock factors and uses thereof. US62/499,650. 2017 Febrary 17\nCellular Engineering Group\nde Miguel Gonz\u00e1lez MP, Arnalich Montiel F, Royuela MM , inventors; FIBHULP , \nFundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario Ram\u00f3n y Ca -\njal, Universidad de Alcal\u00e1, assignees. Corneal endothelium injector; P201131222, \nPCT/ES2012/070543; 2011 July 18.\nClinical Pharmacology Group\nHerrero Ambrosio A, Ram\u00edrez Garc\u00eda E, Ojeda Feo JJ, P\u00e9-\nrez Rodr\u00edguez J, Asensio Mart\u00edn MJ, Gonz\u00e1lez S\u00e1nchez ML, \nMoro Agud M, Lorente Romeo M, L\u00f3pez Nieto M, G\u00f3mez \nRioja R , authors; FIBHULP , assignee. Brand name: SINOIRES; CM \n13.080.056; 2014 July 14.\nCarcas Sansu\u00e1n AJ , author; Carcas Sansu\u00e1n AJ, assignee. \nBrand name: IBJ IberoAmerican Journals; ESM 3.063.048; \n2013 February 12.\nCarcas Sansu\u00e1n AJ , author; Carcas Sansu\u00e1n AJ, assignee \nBrand name: IberoAmerican Journals Plus; ESM 3.063.052; \n2013 February 12.\n \nCarcas Sansu\u00e1n AJ , author; Carcas Sansu\u00e1n AJ, assignee \nBrand name: IberoAmerican Journals Clinical Pharmacology; \nESM 3.063.053; 2013 February 12.\n \nCarcas Sansu\u00e1n AJ, author; Carcas Sansu\u00e1n AJ, assignee Brand \nname: IberoAmerican Journals Medicine; ESM 3.063.049; \n2013 February 12.2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n38  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansLapunzina Bad\u00eda P, Borobia P\u00e9rez AM, Carcas Sansu\u00e1n AJ, Tenorio Casta\u00f1o JA, \nArias Lajara P, Lubomirov Jristov R , authors; FIBHULP , UAM, assignees. Brand \nname: PharmArray; USM 86.004.412, \nCM 11.608.403; 2013 July 08, 2013 \nFebruary 27.\nCarcas Sansu\u00e1n AJ, Borobia P\u00e9rez AM , authors; FIBHULP , assig -\nnee. Brand name: CRDataX; CM 13.681.614; 2015 May 28.\nLapunzina Bad\u00eda PD, Borobia P\u00e9rez AM, Carcas Sansu\u00e1n AJ, Tenorio Casta\u00f1o \nJA, Arias Lajara P, Fr\u00edas Iniesta J, Dapia Garc\u00eda I, Mu\u00f1oz M , authors; FIBHULP ,\nUAM, assignees. Brand name: \nClinPharmarray. USM87054978, \nCM15489511; 2016 May 31, 2016 \nSeptember 07. \nOsteoarticular Surgery Research- GICOA Group\nArenas Vara MA, Conde del Campo A, De Damborenea Gonz\u00e1lez JJ, Matykina \nE, Esteban Moreno J, G\u00f3mez Barrena E, P\u00e9rez-Jorge Peremarch C, P\u00e9rez \nTanoira R , inventors; CSIC, Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9 -\nnez D\u00edaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/\nES2011/070342; 2010 May 14.\nTransplant Group\nHern\u00e1ndez Oliveros F, Nana G\u00f3mez Mayoral N, Raya Gonz\u00e1lez L, Guijarro \nFern\u00e1ndez E , authors; FIBHULP , HePA, U-TAD, Guijarro Fern\u00e1ndez E, assignees. \nBrand name: VTR Virtual Transplant Reality; CM 18.000.131; 2018 December 14.\nAssociated Clinician\nCastell G\u00f3mez JT , inventor; FIBHULP , assignee. System of \u201cpartial\u201d or \u201ctotal\u201d ope -\nnings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16.\nGarc\u00eda Fern\u00e1ndez J , inventor; FIBHULP , assignee. Anaesthesia machine simulator. \nP200702128, PCT/ES2008/070109, US20090044803; 2007 July 30.\nde Miguel del Campo E, Posadas Ma\u00f1anes SJ, Reglero Rada GJ, Largo Aram-\nburu C, Garc\u00eda Grande A, Merino Mart\u00edn JJ, Caz Bonillo V, Fornari Reale T, \nRodr\u00edguez Garc\u00eda-Risco M, Se\u00f1orans Rodr\u00edguez FJ , inventors; FIBHULP , UAM, \nassignees. Composition for the protection of tissues from the digestive tract and \nthe nervous system of radiotherapy patients; P200931189; 2009 December 17.Goldman Tarlovky L , inventor; FIBHULP , assignee. System and method to obtain \ndata on a patient\u2019s breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16.\nde Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale \nT, Rodr\u00edguez Garc\u00eda-Risco M, Jaime de Pablo L, Santoyo D\u00edez S, Se\u00f1orans \nRodr\u00edguez FJ, Garc\u00eda Grande A, Merino Mart\u00edn J, Caz Bonillo JV, Posadas Ma-\n\u00f1anes SJ , inventors; FIBHULP , UAM, assignees. Composition for the reduction of \nsymptoms associated with menopause; P201031225, PCT/ES2011/070586; 2010 \nAugust 05.\nCastell G\u00f3mez JT , inventor; FIBHULP , assignee. Surgical device for interrupted \nsuture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 Oc -\ntober 07.\n\u00c1lvarez Gallego M , inventor; FIBHULP , assignee. Device for the extraction of \nsurgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; \n2010 October 07.\nde Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero \nRada GJ, Mar\u00edn Mart\u00edn F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodr\u00ed-\nguez A, Ib\u00e1\u00f1ez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodr\u00edguez Garc\u00eda-\nRisco M, Santoyo D\u00edez S, Gonz\u00e1lez Lorente M, Arranz Guti\u00e9rrez E, Gil Ram\u00edrez \nA, inventors; FIBHULP , UAM, CSIC, assignees. Functional heart-healthy beverage \ncontaining wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 \nJune 16.\nReglero Rada GJ, de Miguel del Campo E, Mar\u00edn Mart\u00edn F, Fornari Reale \nT, Prodanov Prodanov M, Ruiz Rodr\u00edguez A, Largo Aramburu C, Tabernero \nUrbieta M, Ib\u00e1\u00f1ez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodr\u00edguez \nGarc\u00eda-Risco M, Santoyo D\u00edez S, Gonz\u00e1lez Lorente M, Arranz Guti\u00e9rrez E, Gil \nRam\u00edrez A , inventors; FIBHULP , UAM, CSIC, assignees. Method to obtain extract \nof hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.\nBrian Gahan P, Stroun M, Garc\u00eda del Olmo D, Garc\u00eda Arranz M, Vega Clemente \nML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP , assignees. Method for \nblocking tumour growth. EP2808027; 2013 May 29.\nCastell G\u00f3mez JT, Carrascal Morillo T , inventors; FIBHULP , UNED, assignees. \nSynthetic surgical mesh. P201331453, PCT/ES2014/000161; 2013 October 03.\n\u00c1lvarez Gallego M, Castej\u00f3n Sisam\u00f3n C, Garc\u00eda Prada JC, Meneses Alon-\nso J, inventors; FIBHULP , UC3M, assignees. Rectoscope. P201630551, PCT/\nES2017/070249, EP17788865.8, US20190200853; 2016 April 29.\nFroil\u00e1n Torres C, de Mar\u00eda Pallar\u00e9s P, D\u00edaz Lantada A, Ortego Garc\u00eda P , inven-\ntors; FIBHULP , UPM, assignees. Endoscopic accessory. P201730569; 2017 March 31. \nAzabal Agudo A, Ruiz-Valdepe\u00f1as Mart\u00edn de Almagro S; Juli\u00e1n Garc\u00eda Rivera \n2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n39  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\nF, de la Quintana Jim\u00e9nez P , inventors; UP DEVICES AND TECHNOLOGIES, \nS.L., FIBHULP , assignees. Dispositivo de corte autom\u00e1tico de discos de ostom\u00eda. \nP201830718. 2018 July 16.\nRam\u00edrez de Molina A, Tabernero Urbieta M, Reglero Rada G, Torres Olivares C, \nLargo Aramburu C, Santamar\u00eda Ramiro M, Polo Paredes G, Ruiz P\u00e9rez D, de \nMiguel del Campo E, \u00c1lvarez de Segura I , inventors; Fundaci\u00f3n IMDEA Alimen -\ntaci\u00f3n, UAM, FIBHULP , IGENFARMA, assignees. Composici\u00f3n para la reducci\u00f3n \ndel declive metab\u00f3lico asociado al envejecimiento y/o el tratamiento de transtor -\nnos relacionados al metabolismo l\u00edpidico. P201830740; 2018 July 20. \nOther Trademarks of IdiPAZ\nFIBHULP , author; FIBHULP , assignee. Brand name: IdiPAZ Ins -\ntituto de Investigaci\u00f3n Hospital Universitario La Paz; USM \n85.078.878, CM 8.871.873; 2010 July 06, 2010 February 10. \nFIBHULP , author; FIBHULP , assignee. Brand name: CEASEC \nCentro Avanzado de Simulaci\u00f3n y Entrenamiento Cl\u00ednico; ESM \n3.567.901-8; 2015 June 22. \nFIBHULP , author; FIBHULP , assignee. Brand name: InnoPAZ \nPlataforma de Innovaci\u00f3n Hospital Universitario La Paz; \nESM 3.572.575-3; 2015 July 27. \nFIBHULP , author; FIBHULP , assignee. Brand name: CEASEC Centro Avanzado de \nSimulaci\u00f3n y Entrenamiento Cl\u00ednico; ESM 3.567.901-8; 2015 June 22. Associated Clinician\nG\u00f3mez Candela C, L\u00f3pez Plaza B, Bermejo L\u00f3pez L , authors; FIBHULP , assignee. \nBrand name: NUTRinvest Grupo de investigaci\u00f3n en \nNutrici\u00f3n y Alimentos Funcionales; ESM 3.649.812-2; \n2017 February 02.\nDe la Quintana Jim\u00e9nez P , authors; FIBHULP , assignee. Brand name: \n#OdeOstom\u00eda; CM 016922734; 2017 September 21\nDe la Quintana Jim\u00e9nez P , authors; FIBHULP , assignee. Brand name: CM \n016922858; 2017 September 21\nDe la Quintana Jim\u00e9nez P , authors; FIBHULP , assignee. Brand name: \nOstom\u00eda; CM 017131822; 2017 August 22.\n2.4 Innovation and Transfer Activities\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5\tQuality\tCommitte\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n40  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.5 Quality  \nCommitte\nThe vision of IdiPAZ is to be a reference centre for multidisciplinary translational biomedical research at the national and european level. T o achieve this \nobjective, the institution combines its efforts to ensure the quality of all its processes, thus ensuring the provision of the best service, research and teaching.\nIdiPAZ is committed to a comprehensive quality model backed by the maturity of the quality management team of the IdiPAZ institutions. T o support and \nfacilitate quality, the institution maintains a Quality Committee.\nDuring 2018, the Quality Committee fostered these principles but also achieved specific quality goals. Because of the context analysis carried out by the \nCommission itself, three professionals from the IdiPAZ common platforms have been included as members of the Quality Committee. On the other hand, \nthe IdiPAZ management system has been maintained under the requirements of the ISO 9001:2015 and the UNE 166002:2014, including currently in its \nscope five units/platforms: the Automatic Sequencing laboratory, the Innovation Support Unit, the Central Research and Clinical \nTrials Unit, the T echnical Secretariat and the Quality Committee itself. A working quality plan for IdiPAZ \nis still in process to further expand the scope to new platforms and units until \nthe reaccreditation process will take place in 2020.\nMoreover, considering that IdiPAZ is a continuously evolving organisation, \nthe Quality activities of our institution has been enriched by the diffe -\nrent achievements made by its organizations. \nThe Hospital Universitario La Paz, with its accumulative experien -\nce about quality of care improvement, has continued working \nintensively during this year. Protocols, clinical pathways and \nparticipation in clinical practice guidelines have been deve -\nloped and reviewed. The attached tables show the clinical \npathways reviewed in 2018 as well as the protocols \ndeveloped or updated in the same period. In addi -\ntion, the staff members continuously collaborate in \nthe improvement of the institution by participating \nin clinical committees and creating improvement \ngroups, as well as implementing satisfaction surveys \nfor patients and professionals. Also during 2018 \nhospital departments quality management systems \nare being integrated in an overall management sys -\ntem according to the standards ISO 9001:2015, \nISO 14001:2015, ISO 22000:2005 and IQNetSR10. \nThe hospital has also 26 accredited units within the \nSpanish National Accreditation System.Scientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5\tQuality\tCommitte\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n41  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.5 Quality Committe\nProtocol / Clinical pathway Status\nAcompa\u00f1amiento en el bloque quir\u00fargico infantil Review\nAcompa\u00f1amiento en la unidad de reanimaci\u00f3n de cuidados cr\u00edticos quir\u00fargicos Review\nActivaci\u00f3n de reanimaci\u00f3n cardiopulmonar en el hospital y su entorno New\nActuaci\u00f3n ante casos sospechosos o confirmados de gripe en adultos Review\nActuaci\u00f3n ante casos sospechosos o confirmados de gripe/VRS en ni\u00f1os Review\nActuaci\u00f3n ante un accidente de trabajo por ca\u00edda o s\u00edncope - UAAN New\nActuaci\u00f3n frente a mordeduras de animales Review\nAlteraciones palpebrales Review\nAnalgosedaci\u00f3n en el Servicio de Medicina Intensiva New\nAnsiolisis/sedaci\u00f3n en Laboratorio de Ecocardiograf\u00eda New\nAntiagregaci\u00f3n/anticoagulaci\u00f3n en endoscopia Review\nAscitis en urgencias New\nAsistencia al parto vaginal normal (poco intervencionista) Review\nAtenci\u00f3n en consulta de alto riesgo por c\u00e1ncer colorrectal y seguimiento de \np\u00f3liposReview\nBiopsia de ganglio centinela en c\u00e1ncer de cavidad oral New\nBore grave de colitis ulcerosa Review\nCardio-onco-hematolog\u00eda New\nCataratas cong\u00e9nitas e infantiles Review\nCierre percut\u00e1neo de orejuela New\nCircuito de insulinizaci\u00f3n al alta New\nColedocolitiasis Review\nColitis isqu\u00e9mica Review\nConsulta de alta resoluci\u00f3n de n\u00f3dulo tiroideo (implementaci\u00f3n) Review\nControl microbiol\u00f3gico en hemodi\u00e1lisis adultos New\nControl microbiol\u00f3gico en hemodi\u00e1lisis infantil New\nCreaci\u00f3n y mantenimiento de acceso vasculares para hemodi\u00e1lisis New\nDetecci\u00f3n y control de pacientes portadores de microorganismos \nmultirresistentes de transmisi\u00f3n por contactoReview\nDiabetes-II Review\nDisecci\u00f3n endosc\u00f3pica submucosa Review\nDislipemia Review\nDolor precordial Review\nEncefalopat\u00eda hep\u00e1tica en urgencias New\nEnfermedad de Chagas NewProtocol / Clinical pathway Status\nEnfermedad de Fabry Review\nEnfermedad del viajero menos prevalentes Review\nEnfermedad hep\u00e1tica grasa no alcoh\u00f3lica New\nEnfermedad tromboemb\u00f3lica venosa (tratamiento y profilaxis) Review\nEnfermedades tropicales m\u00e1s prevalentes Review\nEsclerosis sist\u00e9mica Review\nEsofagitis eosinof\u00edlica New\nEsofagitis por ca\u00fasticos Review\nEstudio de la hiponatremia New\nFatiga cr\u00f3nica Review\nGesti\u00f3n de derrames, p\u00e9rdida y/o desaparici\u00f3n de residuos en el Hospital La \nPaz, H. Cantoblanco, H. Carlos III y CEPsReview\nGu\u00eda de antis\u00e9pticos New\nGu\u00eda de pr\u00e1ctica cl\u00ednica de insuficiencia cardiaca Review\nGu\u00eda de transfusi\u00f3n pedi\u00e1trica New\nGu\u00eda obesidad-gestaci\u00f3n y documentaci\u00f3n para el paciente con obesidad, DG, \nDM preconcepcional y control preconcepcional New\nHemorragia digestiva alta no varicosa en urgencias New\nHemorragia digestiva alta varicosa en urgencias New\nHepatitis aguda alcoh\u00f3lica Review\nHipertensi\u00f3n Pulmonar Review\nHipertensi\u00f3n Arterial Review\nInfecci\u00f3n en paciente inmunodeprimido Review\nInfecci\u00f3n nosocomial Review\nIngresos por STEMI (c\u00f3digo infarto) Review\nInserci\u00f3n y mantenimiento de cat\u00e9teres vasculares centrales Review\nInsuficiencia cardiaca Review\nInsuficiencia hep\u00e1tica aguda Review\nLimpieza y desinfecci\u00f3n de endoscopios digestivos Review\nLimpieza y desinfecci\u00f3n de endoscopios ginecol\u00f3gicos Review\nLimpieza y desinfecci\u00f3n de endoscopios neumol\u00f3gicos Review\nLimpieza y desinfecci\u00f3n de endoscopios urol\u00f3gicos Review\nLupus y s\u00edndrome antifosfol\u00edpido Review\nManejo anafilaxia en las consulta de vacunaci\u00f3n New\nManejo de contactos de pacientes con tuberculosis NewScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5\tQuality\tCommitte\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n42  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansProtocol / Clinical pathway Status\nManejo de enfermedad inflamatoria intestinal en urgencias Review\nManejo de la esofagitis eosinof\u00edlica New\nManejo de paciente con enfermedad infecciosa de alto riesgo en la urgencia \npedi\u00e1tricaNew\nManejo enfermedad perianal enfermedad inflamatoria intestinal con cirug\u00eda Review\nManejar de paciente con enfermedad infecciosa de alto riesgo en la urgencia New\nMantenimiento del carro de parada Review\nMicroftalm\u00eda y anoftalm\u00eda Review\nPatolog\u00eda infecci\u00f3n VIH Review\nPrevenci\u00f3n de endocarditis infecciosa en pacientes portadores de pr\u00f3tesis \nvalvulares cardiacas y dispositivos intravascularesReview\nPrevenci\u00f3n de la bacteriemia relacionada con la asistencia sanitaria: manejo \nde dispositivos intravascularesReview\nPrevenci\u00f3n de la infecci\u00f3n del tracto urinario relacionada con la asistencia \nsanitariaReview\nPrevenci\u00f3n de la neumon\u00eda relacionada con la asistencia sanitaria Review\nProfilaxis antibi\u00f3tica en prequir\u00fargica y predesbridamiento enzim\u00e1tico en el \npaciente quemadoNew\nProtocolo de actuaci\u00f3n ante situaciones de obras Review\nProtocolo de bioseguridad ambiental microbiol\u00f3gica en quir\u00f3fanos y salas TMO Review\nProtocolo de declaraci\u00f3n de enfermedades de declaraci\u00f3n obligatoria Review\nProtocolo de gesti\u00f3n de la esterilizaci\u00f3n New\nProtocolo de gesti\u00f3n de m\u00f3dulos de normohipotermia New\nProtocolo de limpieza hospitalaria Review\nProtocolo de recomendaciones de medicina preventiva en la preparaci\u00f3n y \nconservaci\u00f3n de las f\u00f3rmulas infantiles en polvo y leche maternaNew\nProtocolo Pie Diab\u00e9tico New\nPtosis palpebral Review\nQueratoplastias en ni\u00f1os Review\nReanimaci\u00f3n inicial del paciente quemado Review\nRecomendaci\u00f3n para la reserva de sangre en cirug\u00eda programada Review\nRecurrencia de enfermedad inflamatoria intestinal Review\nRetinopat\u00eda diab\u00e9tica en ni\u00f1os Review\nRuta asistencial de atenci\u00f3n a pacientes con dolor New\nRuta asistencial disfunci\u00f3n tiroidea (TSH) New\nRuta asistencial n\u00f3dulo tiroideo New\nSedaci\u00f3n paliativa y para el tratamiento de otros s\u00edntomas en Cuidados \nPaliativos Pedi\u00e1tricosNewProtocol / Clinical pathway Status\nSeguimiento de p\u00f3lipo Review\nS\u00edndrome metab\u00f3lico Review\nSolicitud de pruebas de diagn\u00f3stico cardiol\u00f3gico: ECG, Holter, Rx t\u00f3rax, \necocardiograf\u00eda transtor\u00e1cica, ecocardiograf\u00eda transesof\u00e1gica y 3D, test de \nisquemia, TC y RM, cateterismoReview\nTC cardiaco y RM cardiaca Review\nToma de muestras endoscopios digestivos Review\nToma de muestras endoscopios ginecol\u00f3gicos Review\nToma de muestras endoscopios neumol\u00f3gicos Review\nToma de muestras endoscopios urol\u00f3gicos Review\nTransici\u00f3n diabetes (infantil - adulto) New\nTraslado intrahospitalario en urgencias pedi\u00e1tricas New\nTuberculosis en enfermedad inflamatoria intestinal Review\nUso de los inmunomoduladores en la enfermedad inflamatoria intestinal New\nUso de megadosis vit C en el paciente quemado cr\u00edtico Review\nUtilizaci\u00f3n de potasio intravenoso Review\nUtilizaci\u00f3n de sueros de alto riesgo Review\nVacunaci\u00f3n del paciente con asplenia New\nVacunaci\u00f3n del paciente con hepatopat\u00eda cr\u00f3nica New\nVacunaci\u00f3n del paciente con implante coclear New\nVacunaci\u00f3n del paciente con insuficiencia renal cr\u00f3nica New\nVacunaci\u00f3n del paciente con trasplante de progenitores hematopoy\u00e9ticos New\nVacunaci\u00f3n del paciente con trasplante de \u00f3rgano s\u00f3lido New\nVacunaci\u00f3n del paciente con trasplante de \u00f3rgano s\u00f3lido New\nVacunaci\u00f3n del paciente con tratamiento inmunosupresor New\nVacunaci\u00f3n del paciente con VIH New\nVasculitis necrotizantes sist\u00e9micas Review\nV\u00eda biliar en urgencias New\nV\u00eda cl\u00ednica de atenci\u00f3n al ictus pedi\u00e1trico New\nV\u00eda cl\u00ednica de gastrostom\u00eda endosc\u00f3pica percut\u00e1nea Review\nV\u00eda cl\u00ednica de hemorragia digestiva alta con hipertensi\u00f3n portal Review\nV\u00eda cl\u00ednica de hemorragia digestiva alta sin hipertensi\u00f3n portal Review\nV\u00eda cl\u00ednica de recuperaci\u00f3n intensificada en cirug\u00eda tor\u00e1cica (RICTO). New\nV\u00eda cl\u00ednica multiservicio sobre FRA-AKI en unidades de cr\u00edticos Review\nV\u00eda cl\u00ednica trasplante renal reciente Review2.5 Quality Committe\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n43  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.6 Clinical  \nTrials\nAcero Pe\u00f1a A.  Estudio observacional retrospectivo para evaluar la efectividad de la inyecci\u00f3n intrav\u00edtrea \n(IVT) de Aflibercept en la pr\u00e1ctica cl\u00ednica en pacientes sin tratamiento previo con degeneraci\u00f3n macular \nasociada a la edad neovascular (DMAEN1). Type: EPA-OD. \nHULP code: PI-3017. Sponsored\u00b4s protocol code: BAY -AFL-2017-01.\nSponsored by: Bayer Hispania S.L. Signed date: 12/04/2018\nAguilar-Amat Prior MJ . Determinantes de la calidad de vida en pacientes con s\u00edndrome de Lennox-\nGastaut. Type: EPA-OD. \nHULP code: PI-3313. Sponsored\u00b4s protocol code: EIS-VAL-2017-01.\nSponsored by: EISAI Farmac\u00e9utica S.A. Signed date: 14/09/2018\nAguilar-Amat Prior MJ . Estudio de extensi\u00f3n abierto y multic\u00e9ntrico para evaluar la seguridad y efi -\ncacia a largo plazo de Lacosamida como tratamiento complementario para las crisis t\u00f3nico-cl\u00f3nicas \ngeneralizadas primarias no controladas en pacientes con epilepsia idiop\u00e1tica generalizada. Type: Clinical \nTrial, phase III. \nHULP code: Anexo-I 4920. Sponsored\u00b4s protocol code: EP0012.\nSponsored by: UCB Biosciencies GMBH. Signed date: 11/07/2018\nAlcolea Batres S . Estudio observacional retrospectivo para determinar el estado de riesgo de pacientes \ncon hipertensi\u00f3n arterial pulmonar en Espa\u00f1a. Type: EPA-OD. \nHULP code: PI-3044. Sponsored\u00b4s protocol code: ACT -HAP-01-2017.\nSponsored by: Actelion Pharmaceuticals Espa\u00f1a. Signed date: 23/01/2018\nAlonso Babarro A . Estudio multic\u00e9ntrico, descriptivo y transversal para determinar la prevalencia, las \ncaracter\u00edsticas cl\u00ednicas y el tratamiento de la disnea en crisis en pacientes con c\u00e1ncer de pulm\u00f3n avan -\nzado. Estudio Inspirados. Type: EPA-OD. \nHULP code: PI-2958. Sponsored\u00b4s protocol code: KYO-DIS-2017-01.\nSponsored by: Kyowa Kirin Farmac\u00e9utica S.L.U. Signed date: 05/01/2018\nAlonso Dorrego JM . Estudio en fase III, multic\u00e9ntrico, aleatorizado, doble ciego, de grupos paralelos y \ncontrolado con placebo para evaluar la eficacia y la seguridad de uno o m\u00e1s tratamientos intradetrusor \ncon 600 u 800 unidades de Dysport\u00ae para el tratamiento de la incont. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4713. Sponsored\u00b4s protocol code: D-FR-52120-223.\nSponsored by: Ipsen Innovation. Signed date: 22/08/2018\nAlonso Dorrego JM. Tratamiento de carcinoma urotelial no invasivo de alto grado de la vejiga mediante N\u00ba \ny dosis est\u00e1ndar de instilaciones intravesicales con una dosis est\u00e1ndar de BCG. Type: Clinical Trial, phase III. \nHULP code: 5084. Sponsored\u00b4s protocol code: EAU-RF-2008-01.\nSponsored by: Fundaci\u00f3n Para La Investigaci\u00f3n de La Asociaci\u00f3n Europea de Urolog\u00eda. Signed date: 04/09/2018\nAlonso Melgar A . Estudio en fase III multic\u00e9ntrico y abierto de ALXN1210 en ni\u00f1os y adolescentes con \ns\u00edndrome hemol\u00edtico urin\u00e9mico at\u00edpico (SHUA). Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4796. Sponsored\u00b4s protocol code: ALXN1210-Ahus-312.Scientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n44  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansSponsored by: Alexion Pharmaceutical Inc. Signed date: 10/12/2018\nAlonso Pacheco ML . Estudio multic\u00e9ntrico, observacional, no intervencionista, trans -\nversal y retrospectivo, para evaluar la calidad de vida en condiciones de pr\u00e1ctica cl\u00ednica \nhabitual, en pacientes con psoriasis moderada a severa tratados con Metotrexato en \nEspa\u00f1a (First). Type: EPA-OD. \nHULP code: PI-3278. Sponsored\u00b4s protocol code: NOV-MET -2018-01.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 27/08/2018\n\u00c1lvarez Rom\u00e1n MT . Estudio cl\u00ednico de fase III, prospectivo, aleatorizado y multic\u00e9n -\ntrico para comparar la seguridad y la eficacia de BAX 855 tras la profilaxis guiada por \nFC dirigida a dos concentraciones m\u00ednimas de FVIII distintas en sujetos con hemofilia \na grave. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4547. Sponsored\u00b4s protocol code: 261303.\nSponsored by: Baxter Innovations GMBH. Signed date: 20/03/2018\n\u00c1lvarez Rom\u00e1n MT . Estudio de fase I/II internacional, abierto y multic\u00e9ntrico de la \nseguridad y del aumento de dosis de BAX 888, un vector de virus adenoasociado de \nserotipo 8 (VAA8) que expresa un factor VIII con el dominio B (B-DOMAIN DELE -\nTED FACTOR VIII, BDD-FVIII) en sujetos con hemofilia a grave administrado como \ninfusi\u00f3n \u00fanica por v\u00eda intravenosa. Type: Clinical Trial, phase I. \nHULP code: 4930. Sponsored\u00b4s protocol code: 201501.\nSponsored by: Baxalta Innovations Gmhb. Signed date: 17/01/2018\n\u00c1lvarez Rom\u00e1n MT . Estudio epidemiol\u00f3gico transversal para comprender el enfoque \nactual del tratamiento en la atenci\u00f3n regular de pacientes con hemofilia B en Espa\u00f1a \ny Portugal. Type: EPA-OD. \nHULP code: PI-3254. Sponsored\u00b4s protocol code: IIS-2017-12-04.\nSponsored by: CSL Behring S.A. Signed date: 26/07/2018\n\u00c1lvarez Rom\u00e1n MT . Evaluaci\u00f3n en abierto y multic\u00e9ntrica de la seguridad y la eficacia \nde la proteina de fusi\u00f3n del factor VIII FC recombinante de la coagulaci\u00f3n (RFIIIFC; \nBIIB031) en la prevencion y el tratamiento de episodios de sangrado en pacientes con \nhemofilia a grave. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4214. Sponsored\u00b4s protocol code: 997HA306.\nSponsored by: Biogen Idec Ltd. Signed date: 17/09/2018\n\u00c1lvarez Rom\u00e1n MT . Evaluaci\u00f3n en abierto y multic\u00e9ntrico de la seguridad y la efi -\ncacia de una proteina de fusi\u00f3n del factor IX recombinante de la coagulacion y FC \n(RFIXFC;BIIB029) en la prevenci\u00f3n y el tratamiento de episodios de sangrado en \npacientes con hemofilia B grave. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4143. Sponsored\u00b4s protocol code: 998HB303.\nSponsored by: Biogen Idec Ltd. Signed date: 08/05/2018\n\u00c1lvarez Rom\u00e1n MT . Seguridad y eficacia de T uroctocog Alfa Pegol (N8-GP) en pacien -\ntes con hemofilia a no tratados previamente. Type: Clinical Trial, phase IIIa. \nHULP code: Anexo-III 4125. Sponsored\u00b4s protocol code: NN7088-3908.\nSponsored by: Novo Nordisk Pharma S.A. Signed date: 12/04/2018\n\u00c1lvarez-Sala Walther R . Estudio de fase 3, multic\u00e9ntrico, aleatorizado, doble ciego y \ncontrolado con comparador para evaluar la seguridad y la eficacia de Delafloxacino intravenoso con cambio a v\u00eda oral en sujetos adultos con neumon\u00eda bacteriana adqui -\nrida en la comunidad. Type: Clinical Trial, phase IIIa. \nHULP code: Anexo-I 4545. Sponsored\u00b4s protocol code: ML-3341-306.\nSponsored by: Melinta Therapeutics Inc. Signed date: 04/01/2018\n\u00c1lvarez-Sala Walther R . Estudio fase IIB, aleatorizado (estratificado), doble ciego \n(abierto para promotor), de grupos paralelos, controlado con placebo, de b\u00fasqueda \nde dosis de Nemiralisib (GSK2269557) a\u00f1adido al est\u00e1ndar de tratamiento frente solo \nal est\u00e1ndar de tratamiento. Type: Clinical Trial, phase II. \nHULP code: 4905. Sponsored\u00b4s protocol code: 200879.\nSponsored by: Glaxosmithkline S.A. Signed date: 22/01/2018\n\u00c1lvarez-Sala Walther R . Estudio observacional transversal para caracterizar la EPOC \ngrave en Espa\u00f1a. Type: EPA-OD. \nHULP code: PI-2984. Sponsored\u00b4s protocol code: CGI-COR-2017-01.\nSponsored by: Chiesi Farmaceutici S.P .A. Signed date: 05/02/2018\nAntorrena Miranda MI . Factores de riesgo asociados con la progresi\u00f3n de la insufi -\nciencia card\u00edaca (IC) en pacientes con fibrilaci\u00f3n auricular tratados con un anticoagu -\nlante oral directo (Rivaroxaban). Type: EPA-SP . \nHULP code: PI-3015. Sponsored\u00b4s protocol code: BAY -RIV-2017-01 FARAON.\nSponsored by: Bayer Hispania S.L. Signed date: 06/03/2018\nAres Segura S . Estudio de dosis ascendente \u00fanicas, aleatorizado, doble ciego y con -\ntrolado con placebo para evaluar la seguridad, la tolerabilidad y la farmacocin\u00e9tica de \nMK-1654 en neonatos prematuros y a t\u00e9rmino. Type: Clinical Trial, phase II. \nHULP code: Anexo-I 5068. Sponsored\u00b4s protocol code: MK-1654.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 14/09/2018\nAres Segura S . Estudio de dosis ascendente \u00fanicas, aleatorizado, doble ciego y con -\ntrolado con placebo para evaluar la seguridad, la tolerabilidad y la farmacocin\u00e9tica de \nMK-1654 en neonatos prematuros y a t\u00e9rmino. Type: Clinical Trial, phase II. \nHULP code: 5068. Sponsored\u00b4s protocol code: MK-1654.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 25/04/2018\nAres Segura S . Estudio de fase III, abierto y aleatorizado para evaluar la eficacia y \nseguridad de Alectinib adyuvante frente a la quimioterapia adyuvante con un derivado \ndel Platino en pacientes con carcinoma de pulm\u00f3n no microc\u00edtico positivo para la \ncinasa del linfoma anapl\u00e1sico en estadio IB (tumores \u2265 4 CM) A IIIA completamente \nextirpado. Type: Clinical Trial, phase III. \nHULP code: 5014. Sponsored\u00b4s protocol code: 5014 BO40336.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 15/06/2018\nArmada Maresca F . Influencia de factores cl\u00ednicos y gen\u00e9ticos en la evoluci\u00f3n fun -\ncional y anat\u00f3mica a largo plazo en una cohorte de pacientes con DMAE h\u00fameda \ntratados seg\u00fan pr\u00e1ctica cl\u00ednica habitual. Type: EPA-AS. \nHULP code: PI-2825. Sponsored\u00b4s protocol code: CUN-RAN-2016-01.\nSponsored by: Universidad de Navarra-Cl\u00ednica Universidad de Navarra. Signed date: 25/01/2018\nArribas L\u00f3pez JR . Estudio de fase 2B aleatorizado, doble ciego, controlado con place -\nbo para evaluar la actividad antiviral, los resultados cl\u00ednicos, la seguridad, la tolerabili -2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n45  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansdad y farmacocin\u00e9tica de los tratamientos administrados por v\u00eda oral de Lumicitabina \n(JNJ-6404157). Type: Clinical Trial, phase II. \nHULP code: 5035. Sponsored\u00b4s protocol code: 64041575MPN2001.\nSponsored by: Janssen Cilag International NV. Signed date: 20/04/2018\nArribas L\u00f3pez JR . Estudio de fase III, aleatorizado, multic\u00e9ntrico, con grupos paralelos \ny de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del \ncambio a Dolutegravir m\u00e1s Lamivudina en adultos infectados por el VIH 1 con supre -\nsi\u00f3n virol\u00f3gica. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4885. Sponsored\u00b4s protocol code: 204862.\nSponsored by: VIIV Healthcare Uk Limited. Signed date: 21/11/2018\nArribas L\u00f3pez JR . Estudio de fase III, aleatorizado, multic\u00e9ntrico, con grupos paralelos \ny de ausencia de inferioridad para evaluar la eficacia, la seguridad y la tolerabilidad del \ncambio a Dolutegravir m\u00e1s Lamivudina en adultos infectados por el VIH 1 con supre -\nsi\u00f3n virol\u00f3gica. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4885. Sponsored\u00b4s protocol code: 204862.\nSponsored by: VIIV Healthcare Uk Limited. Signed date: 10/01/2018\nArribas L\u00f3pez JR . Estudio fase 3B, aleatorizado, doble ciego, para evaluar el cambio de \nun tratamiento con una combinaci\u00f3n a dosis fija (CDF) de Efavirenz/Emtricitabina/T e -\nnofovir Disoproxil Fumarato (EFV/FTC/TDF) a una CDF de Emtricitabina/Rilpivirina/\nT enofovir Alafenamida. Type: Clinical Trial, phase IIIb. \nHULP code: Anexo-II 4375. Sponsored\u00b4s protocol code: GS-US-366-1160.\nSponsored by: Gilead Sciences Inc. Signed date: 11/07/2018\nArribas L\u00f3pez JR . Estudio fase III, multic\u00e9ntrico, abierto, randomizado, para evaluar el \ncambio a MK 1439a en pacientes con supresi\u00f3n virol\u00f3gica infectados por el VIH-1 en \nun r\u00e9gimen de un inhibidor de proteasa potenciado con Ritonavir y dos inhibidores de \nla transcriptasa. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4441. Sponsored\u00b4s protocol code: 1439A-024.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 20/03/2018\nAsencio Dur\u00e1n M . Estudio de fase III multic\u00e9ntrico, randomizado, con doble enmas -\ncaramiento, controlado, con comparador activo para evaluar la eficacia y seguridad \nde RO6867461 en pacientes con edema macular diab\u00e9tico (Rhine). Type: Clinical Trial, \nphase III. \nHULP code: 5116. Sponsored\u00b4s protocol code: GR40398.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 16/10/2018\nBalsa Criado A . Ensayo fase 3B, aleatorizado, doble ciego para evaluar la eficacia y \nseguridad de Abatacept sc en combinaci\u00f3n con Metotrexato comparado con Me -\ntotrexato en monoterapia para conseguir la remisi\u00f3n cl\u00ednica en adultos con artritis \nreumatoide temprana sin tratamiento previo con Metotrexato. Type: Clinical Trial, \nphase IIIb. \nHULP code: Anexo-III 4470. Sponsored\u00b4s protocol code: IM101-550.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 21/03/2018\nBalsa Criado A . Estudio abierto, de 8 semanas, para comparar la comodidad y facilidad \nde uso de cinco pautas de tratamiento distintas de inyecciones intraarticulares de CNTX5 4975-05 en sujetos con dolor cr\u00f3nico de rodilla por artrosis moderada a \ngrave. Type: Clinical Trial, phase III. \nHULP code: 5179. Sponsored\u00b4s protocol code: CNTX-4975I-OA-303.\nSponsored by: Centrexion Therapeutics Corp. Signed date: 13/12/2018\nBalsa Criado A . Estudio aleatorizado, doble ciego y controlado con placebo para \nevaluar la eficacia y la seguridad de Sarilumab en pacientes con arteritis de c\u00e9lulas \ngigantes. Type: Clinical Trial, phase III. \nHULP code: 5137. Sponsored\u00b4s protocol code: EFC15068.\nSponsored by: Sanofi Aventis S.A. Signed date: 14/11/2018\nBalsa Criado A . Estudio en faseI/III aleatorizado y de grupos paralelos para evaluar la \neficacia, la farmacocin\u00e9tica y la seguridad de CT -P13 subcut\u00e1neo y CT -P13 intravenoso \nen pacientes con artritis reumatoide activa. Type: Clinical Trial, phase I. \nHULP code: Anexo-I 4825. Sponsored\u00b4s protocol code: CT -P13 3.5.\nSponsored by: Celltrion Inc. Signed date: 03/04/2018\nBalsa Criado A . Estudio multic\u00e9ntrico, aleatorizado, doble ciego, controlado con pla -\ncebo para evaluar la seguridad, tolerabilidad y eficacia de Secukinumab en pacientes \ncon spondiloartritis axial no radiogr\u00e1fica activa durante un periodo de 2 a\u00f1os. Type: \nClinical Trial, phase III. \nHULP code: Anexo-I 4596. Sponsored\u00b4s protocol code: CAIN457H2315.\nSponsored by: Novartis Farmac\u00e9utica SA. Signed date: 08/12/2018\nBalsa Criado A . Estudio multic\u00e9ntrico, internacional, aleatorizado, doble ciego, contro -\nlado con alendronato para determinar la eficacia y seguridad de AMG 785 en el tra -\ntamiento de mujeres con osteoporosis postmenop\u00e1usica. Type: Clinical Trial, phase III. \nHULP code: Anexo-V 3576. Sponsored\u00b4s protocol code: 20110142.\nSponsored by: Amgen S.A. Signed date: 17/01/2018\nBaltasar Tello P . Estudio observacional retrospectivo del tratamiento de la leucemia \nlinfoc\u00edtica cr\u00f3nica (LLC) con Ibrutinib en la pr\u00e1ctica cl\u00ednica habitual (IBRORS LLC). \nType: EPA-OD. \nHULP code: PI-3319. Sponsored\u00b4s protocol code: JAN-IBR-2018-01.\nSponsored by: Janssen-Cilag Espa\u00f1a S.A. Signed date: 13/07/2018\nBaltasar Tello P . Evaluaci\u00f3n retrospectiva no intervencional posterior a la autori -\nzaci\u00f3n del uso de Idelalisib en pacientes con leucemia linfoc\u00edtica cr\u00f3nica (LLC) en \nreca\u00edda/refractaria (R/R) en Espa\u00f1a. Type: EPA-OD. \nHULP code: PI-3477. Sponsored\u00b4s protocol code: GS-ES-312-4397.\nSponsored by: Gilead Sciences Inc. Signed date: 12/12/2018\nBarranco Sanz MPE. Estudio observacional prospectivo para evaluar la carga m\u00e9dica y \nsu asociaci\u00f3n al uso de corticosteroides orales en pacientes con asma grave en Espa\u00f1a. \nEstudio Levante. Type: EPA-SP . \nHULP code: PI-3046. Sponsored\u00b4s protocol code: PI-3046 EPA-SP AST -COR-2017-02 Y D3250R00031.\nSponsored by: Astrazeneca Farmac\u00e9utica Spain S.A. Signed date: 08/02/2018\nBarrio G\u00f3mez de Ag\u00fcero I . Estudio de extensi\u00f3n, fase III, abierto para evaluar la \nseguridad y la eficacia del tratamiento a largo plazo con VX 661 en combinaci\u00f3n con 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n46  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansIvacaftor en sujetos a partir de 12 a\u00f1os con fibrosis qu\u00edstica, homocig\u00f3ticos o hetero -\ncig\u00f3ticos para la mutaci\u00f3n F5. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4529. Sponsored\u00b4s protocol code: VX14-661-110.\nSponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 26/04/2018\nBartha Rasero JL . Estudio aleatorizado, multic\u00e9ntrico, doble ciego, controlado con \nplacebo y grupos paralelos para evaluar la efectividad de la cepa Lactobacillus Saliva -\nrius V4II-90 en la reducci\u00f3n de la colonizaci\u00f3n por estreptococos del grupo B (GBS) \nde mujeres embarazadas. Type: Producto Alimentario. \nHULP code: 5120. Sponsored\u00b4s protocol code: STB/17.02.\nSponsored by: Recordati Espa\u00f1a S.L. Signed date: 26/10/2018\nBartha Rasero JL . Un estudio de prueba de concepto de fase 2A, doble ciego, de gru -\npo paralelo, aleatorizado y controlado con placebo que eval\u00faa la eficacia, la seguridad \ny la farmacocin\u00e9tica de OBE022 combinado con Atosiban tras su administraci\u00f3n por \nv\u00eda oral a mujeres EMB. Type: Clinical Trial, phase II. \nHULP code: 4942. Sponsored\u00b4s protocol code: 4942 17-OBE022-003.\nSponsored by: Obseva S.A. Signed date: 24/01/2018\nBartha Rasero JR . Estudio piloto para evaluar el efecto de la cepa Lactobacillus Sali -\nvarius PS11610 sobre la microbiota del tracto genital femenino y masculino en parejas \ncon problemas de fecundidad. Type: Producto Alimentario. \nHULP code: pi-3245. Sponsored\u00b4s protocol code: FEC/18.01.\nSponsored by: Probisearch S.L. Signed date: 12/09/2018\nBeato Merino MJ . Estudio observacional y retrospectivo de las caracter\u00edsticas cl\u00ednicas \ny patol\u00f3gicas del carcinoma de c\u00e9lulas de Merkel (CCM) entre 2012 y 2016 en Espa\u00f1a. \nType: EPA-OD. \nHULP code: PI-3459. Sponsored\u00b4s protocol code: MECCAS GET -QUI-2018-01.\nSponsored by: Grupo Espa\u00f1ol de T umores Hu\u00e9rfanos e Infrecuentes. Signed date: 27/11/2018\nBernardino de La Serna JI . estudio en fase III para evaluar el efecto de la Pitavastatina \npara prevenir los acontecimientos vasculares en personas con infecci\u00f3n por VIH -1. \nType: Clinical Trial, phase III. \nHULP code: 5170. Sponsored\u00b4s protocol code: EU5332.\nSponsored by: Research Organisation Kc Ltd. Signed date: 05/12/2018\nBernardino de La Serna JI . Estudio en fase IIIB, multic\u00e9ntrico, abierto, para evaluar \nel cambio desde una pauta combinada de dosis fija de Elvitegravir/Cobicistat/Emcitra -\nbina/T enofovir Alafenamida o una pauta que contenga T enofovir Disoproxil Fumarato \na una combinaci\u00f3n de dosis fijs de Bictegravir/Emtricitabina/T enofovir Alafenamida en \nsujetos de edad avanzada, de \u226565 a\u00f1os de edad, infectados por VIH-1 con supresi\u00f3n \nvirol\u00f3gica. Type: Clinical Trial, phase IIIb. \nHULP code: 4974. Sponsored\u00b4s protocol code: 4974 GS-US-380-4449.\nSponsored by: Gilead Sciences Inc. Signed date: 09/01/2018\nBlanco Ba\u00f1ares MJ . Estudio de vida real en pacientes con acontecimientos tromb\u00f3 -\nticos o hemorr\u00e1gicos graves siendo tratados con antagonistas de la vitamina K (AVK) \nen hematolog\u00eda. Estudio Eventho. Type: EPA-OD. \nHULP code: PI-2999. Sponsored\u00b4s protocol code: PI-2999 EPA-OD.\nSponsored by: Pfizer Inc. Signed date: 05/02/2018Borobia P\u00e9rez A . Ensayo cl\u00ednico, piloto, doble ciego, aleatorizado, controlado con \nplacebo para evaluar la eficacia comparada de Ibuprofeno combinado con diferentes \ndosis de Tramadol y Tramadol 100 mg por v\u00eda intravenosa en pacientes con dolor mo -\nderado a intenso tras cirug\u00eda. Type: Clinical Trial, phase III. \nHULP code: 5080. Sponsored\u00b4s protocol code: FMLD-FEBETRADI-PILOT -43.\nSponsored by: Farmalider S.A. Signed date: 01/08/2018\nBurgos Garc\u00eda A . Colorectal cancer omics collection. Type: Producto Sanitario. \nHULP code: Anexo-I PI-3334. Sponsored\u00b4s protocol code: CRC-OC-001.\nSponsored by: Universal Diagnostics. Signed date: 15/11/2018\nBurgos Garc\u00eda A . Colorectal cancer omics collection. Type: Producto Sanitario. \nHULP code: PI-3334. Sponsored\u00b4s protocol code: CRC-OC-001.\nSponsored by: Universal Diagnostics. Signed date: 11/09/2018\nBurgue\u00f1o Garc\u00eda M . Ensayo cl\u00ednico, piloto, doble ciego, aleatorizado, controlado con \nplacebo para evaluar la eficacia comparada de Ibuprofeno combinado con diferentes \ndosis de Tramadol y Tramadol 100 mg por v\u00eda intravenosa en pacientes con dolor mo -\nderado a intenso tras cirug\u00eda. Type: Clinical Trial, phase III. \nHULP code: 5080. Sponsored\u00b4s protocol code: FMLD-FEBETRADI-PILOT -43.\nSponsored by: Farmalider S.A. Signed date: 01/08/2018\nCaballero Molina MT . BCX7353-204: estudio abierto para evaluar la seguridad a largo \nplazo de BCX7353 oral diario en pacientes con angioedema hereditario tiposI y II. \nType: Clinical Trial, phase II. \nHULP code: 4993. Sponsored\u00b4s protocol code: BCX7353-204.\nSponsored by: Biocryst Pharmaceuticals Inc. Signed date: 05/02/2018\nCaballero Molina MT . BCX7353-302: un estudio fase 3, aleatorizado, doble ciego, \ncontrolado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de dos \ndosis diferentes de BCXS7353 como tratamiento oral para la prevenci\u00f3n de ataques \nen pacientes con angioedema. Type: Clinical Trial, phase III. \nHULP code: 4984. Sponsored\u00b4s protocol code: BCX7353-302.\nSponsored by: Biocryst Pharmaceuticals Inc. Signed date: 16/05/2018\nCaballero Molina MT . Registro de pacientes de Firazyr-IOS (Icatibant Outcome Sur -\nvey). Type: EPA-LA. \nHULP code: Anexo-III 3080. Sponsored\u00b4s protocol code: IOS.\nSponsored by: Shire Pharmaceuticals Iberica S.L. Signed date: 20/09/2018\nCalvo Rey C . Desarrollo neurol\u00f3gico en ni\u00f1os con infecci\u00f3n del SNC por parechovi -\nrus humano. Type: NO-EPA. \nHULP code: PI-2440. Sponsored\u00b4s protocol code: PI-2440 BOLSA.\nSponsored by: Cristina Calvo Rey. Signed date: 19/07/2018\nCalvo Rey C . Estudio de fase IIA sin enmascaramiento en lactantes con infecci\u00f3n de \nlas v\u00edas respiratorias bajas por el virus sincitial respiratorio, seguido de una parte con \ndoble enmascaramiento controlada con placebo, para evaluar la seguridad, la tolera -\nbilidad, la farmacocin\u00e9tica y el efecto antiv\u00edrico de RV521 (REVIRAL 1). Type: Clinical \nTrial, phase II. 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n47  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansHULP code: 5196. Sponsored\u00b4s protocol code: REVC003.\nSponsored by: Reviral Ltd. Signed date: 30/10/2018\nCalvo Rey C . Estudio en fase II, doble ciego y controlado con placebo para evaluar la \nactividad antiviral, los resultados cl\u00ednicos, la seguridad, la tolerabilidad y las relaciones \nentre farmacocin\u00e9tica y farmacodin\u00e1mica de dosis diferentes de JNJ-53718678 en ni -\n\u00f1os \u226528 d\u00edas y \u22643 a\u00f1os de edad con infecci\u00f3n respiratoria aguda debido a la infecci\u00f3n \npor el virus respiratorio sincitial. Type: Clinical Trial, phase II. \nHULP code: 5152. Sponsored\u00b4s protocol code: 53718678RSV2002.\nSponsored by: Janssen-Cilag Espa\u00f1a S.A. Signed date: 05/10/2018\nCalvo Rey C . Estudio en fase III, multic\u00e9ntrico, aleatorizado, doble ciego y controlado \ncon placebo para evaluar la eficacia y la seguridad de Pimodivir en combinaci\u00f3n con la \npr\u00e1ctica cl\u00ednica habitual en pacientes adolescentes, adultos y ancianos con gripe A no \nhospitalizados. Type: Clinical Trial, phase III. \nHULP code: 4998. Sponsored\u00b4s protocol code: 63623872FLZ3002.\nSponsored by: Janssen Pharmaceutica NV. Signed date: 04/07/2018\nCalvo Rey C . Estudio en fase III, multic\u00e9ntrico, aleatorizado, doble ciego y controlado \ncon placebo para evaluar la eficacia y la seguridad de Pimodivir en combinaci\u00f3n con la \npr\u00e1ctica cl\u00ednica habitual en pacientes adolescentes, adultos y ancianos hospitalizados \ncon gripe A. Type: Clinical Trial, phase III. \nHULP code: 4997. Sponsored\u00b4s protocol code: 63623872FLZ3001.\nSponsored by: Janssen Pharmaceutica NV. Signed date: 03/07/2018\nCanales Albendea MA . (R-CHP) en comparaci\u00f3n con Rituximab y chop (R-CHOP) \nen pacientes con linfoma difuso de c\u00e9lulas grandes tipo B no tratado anteriormente. \nType: Clinical Trial, phase III. \nHULP code: Anexo-I 4956. Sponsored\u00b4s protocol code: GO39942.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 21/06/2018\nCanales Albendea MA . (R-CHP) en comparaci\u00f3n con Rituximab y Chop (R-Chop) en \npacientes con linfoma difuso de c\u00e9lulas grandes tipo B no tratado anteriormente. Type: \nClinical Trial, phase III. \nHULP code: 4956. Sponsored\u00b4s protocol code: GO39942.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 01/03/2018\nCanales Albendea MA . Ensayo de fase I/IB, multic\u00e9ntrico, sin enmascaramiento para \nevaluar la seguridad y la farmacocin\u00e9tica de dosis crecientes de BTCT4465A en mono -\nterapia y en combinaci\u00f3n con Atezolizumab en pacientes con linfoma no Hodgkiniano \nde linfocitos B y leucemia linfoc\u00edtica cr\u00f3nica recidivantes o resistentes. Type: Clinical \nTrial, phase I. \nHULP code: 5151. Sponsored\u00b4s protocol code: GO29781.\nSponsored by: Genentech Inc. Signed date: 05/12/2018\nCanales Albendea MA . Estudio de fase 2B aleatorizado, abierto y de dos grupos, de \nSelinexor (KPT -330) en asociaci\u00f3n con Dexametasona (SEL-DEX) a dosis bajas en \npacientes con linfoma difuso de c\u00e9lulas B grandes (LDCBG). Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4305. Sponsored\u00b4s protocol code: KCP-330-009.\nSponsored by: Karyopharm Therapeutics Inc. Signed date: 26/07/2018Canales Albendea MA . Estudio de fase IB/II, abierto para evaluar la seguridad y la \nfarmacocin\u00e9tica de GDC-0199 (ABT -199) en combinaci\u00f3n con Rituximab (R) o Obi -\nnutuzumab (G) m\u00e1s Ciclofosfamida, Doxorrubicina, Vincristina y Prednisona (CHOP) \nen pacientes con linfoma no Hodgkin. Type: Clinical Trial, phase Ib. \nHULP code: Anexo-II 4354. Sponsored\u00b4s protocol code: GO27878.\nSponsored by: Kite Pharma Inc. Signed date: 26/10/2018\nCanales Albendea MA . Estudio de fase IB/IIpara evaluar la seguridad, tolerancia y acti -\nvidad antitumoral de Polatuzumab Vedotin (DCDS4501A) en combinaci\u00f3n con Rituxi -\nmab (R) u Obinutuzumab (G) m\u00e1s Bendamustina (B), en pacientes con linfoma folicular \no linfoma difuso de c\u00e9lulas. Type: Clinical Trial, phase I. \nHULP code: Anexo-I 4456. Sponsored\u00b4s protocol code: GO29365.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 19/02/2018\nCanales Albendea MA . Estudio de fase II, abierto, de 2 cohortes y multic\u00e9ntrico de \nINCB050465, un inhibidor de PI3K\u03b4, en linfoma de c\u00e9lulas del manto en recidiva o \nresistente al tratamiento, previamente tratado con o sin un inhibidor de la BTK (Cita -\ndel-205). Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4949. Sponsored\u00b4s protocol code: INCB 50465-205.\nSponsored by: Incyte Corporation. Signed date: 16/10/2018\nCanales Albendea MA . Estudio de fase II, abierto, de 2 Cohortes y multic\u00e9ntrico de \nINCB050465, un inhibidor dePI3K\u03b4, en linfoma de c\u00e9lulas del manto en recidiva o \nresistente al tratamiento, previamente tratado con o sin un inhibidor de la BTK (Cita -\ndel-205). Type: Clinical Trial, phase II. \nHULP code: 4949. Sponsored\u00b4s protocol code: INCB 50465-205.\nSponsored by: Incyte Corporation. Signed date: 05/03/2018\nCanales Albendea MA . Estudio en fase II de TAK-659 en pacientes con linfoma difuso \nde c\u00e9lulas B grandes recidivante o resistente despu\u00e9s de dos o m\u00e1s l\u00edneas previas de \nquimioterapia. Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4928. Sponsored\u00b4s protocol code: C34004.\nSponsored by: Millennium Pharmaceuticals Inc. Signed date: 10/04/2018\nCanales Albendea MA . Estudio en fase II multic\u00e9ntrico, estudio abierto de INCB050465, \nun inhibidor PI3K\u03b4, en el tratamiento del linfoma folicular recidivante o resistente (CI -\nTADEL-203). Type: Clinical Trial, phase II. \nHULP code: 4939. Sponsored\u00b4s protocol code: INCB 50465-203.\nSponsored by: Incyte Corporation. Signed date: 01/03/2018\nCarballo Cardona C . Ensayo cl\u00ednico fase IIIB, aleatorizado, abierto, para evaluar el alivio \ndel dolor con Metoxiflurano inhalado, en comparaci\u00f3n con el protocolo actual para \nel tratamiento del dolor de origen traum\u00e1tico, en adultos atendidos en unidades de \nurgencias espa\u00f1olas. Type: Clinical Trial, phase IIIb. \nHULP code: Anexo-I 4803. Sponsored\u00b4s protocol code: InMEDIATE.\nSponsored by: Mundipharma Pharmaceuticals S.L. Signed date: 19/02/2018\nCastelo Fern\u00e1ndez B . Estudio en fase 3, aleatorizado, doble ciego sobre Avelumab \ncombinado con la quimiorradioterapia de referencia (Cisplatino m\u00e1s radioterapia defi -\nnitiva) en comparaci\u00f3n con la quimiorradioterapia de referencia en el tratamiento de \nprimera l\u00ednea de pacientes. Type: Clinical Trial, phase III. 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n48  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansHULP code: Anexo-I 4861. Sponsored\u00b4s protocol code: 4861 B9991016.\nSponsored by: Pfizer S.L.U. Signed date: 15/06/2018\nCastelo Fern\u00e1ndez B . A phase II study of Durvalumab (MEDI4736) plus Tremeli -\nmumab for the treatment of patients with progressive, refractory advanced thyroid \ncarcinoma-the duthy trial. Type: Clinical Trial, phase II. \nHULP code: 5202. Sponsored\u00b4s protocol code: GETNE-T1812.\nSponsored by: Grupo Espa\u00f1ol de T umores Neuroendocrinos (Getne). Signed date: 17/12/2018\nCastelo Fern\u00e1ndez B . Ensayo aleatorizado, global, en fase III de Nivolumab con Epaca -\ndostat en combinaci\u00f3n con quimioterapia (Platino + 5-Fluorouracilo) en comparaci\u00f3n \ncon la pauta posol\u00f3gica extreme (Cetuximab + Platino + 5-Fluorouracilo) como trata -\nmiento de primera l\u00ednea en pacientes con carcinoma de c\u00e9lulas escamosas de cabeza y \ncuello (CCECC) recurrente o metast\u00e1sico. Type: Clinical Trial, phase III. \nHULP code: 4987. Sponsored\u00b4s protocol code: CA209-9NA.\nSponsored by: Incyte Corporation. Signed date: 09/04/2018\nCastelo Fern\u00e1ndez B . Estudio de calidad de vida en pacientes con dolor irruptivo \noncol\u00f3gico atendidos en los servicios de oncolog\u00eda m\u00e9dica. Type: EPA-SP . \nHULP code: PI-3018. Sponsored\u00b4s protocol code: ANG-ANA-2017-01.\nSponsored by: Angelini Farmac\u00e9utica S.A. Signed date: 29/01/2018\nCastelo Fern\u00e1ndez B . Estudio de fase II, aleatorizado, con doble enmascaramiento \ny controlado con placebo de Cemiplimab en comparaci\u00f3n con la combinaci\u00f3n de \nCemiplimab m\u00e1s ISA101B en el tratamiento de sujetos con c\u00e1ncer orofar\u00edngeo (COF) \nVPH-16 positivo resistente al platino. Type: Clinical Trial, phase II. \nHULP code: 5124. Sponsored\u00b4s protocol code: ISA101B-HN-01-17.\nSponsored by: Isa Therapeutics B.U. Signed date: 12/11/2018\nCastelo Fern\u00e1ndez B . Estudio de fase III, aleatorizado y abierto para evaluar Pembro -\nlizumab como tratamiento neoadyuvante y en combinaci\u00f3n con la asistencia habitual \ncomo tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello loco -\nrregionalmente avanzado (CECC LA), extirpable, en estadio III-IVA. Type: Clinical Trial, \nphase III. \nHULP code: Anexo-I 4953. Sponsored\u00b4s protocol code: MK-3475-689.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 12/03/2018\nCastelo Fern\u00e1ndez B . Estudio en fase 3, aleatorizado, doble ciego sobre Avelumab \ncombinado con la quimiorradioterapia de referencia (cisplatino m\u00e1s radioterapia de -\nfinitiva) en comparaci\u00f3n con la quimiorradioterapia de referencia en el tratamiento \nde primera l\u00ednea de pacientes con carcinoma epidermoide localmente avanzado de \ncabeza y cuello. Type: Clinical Trial, phase III. \nHULP code: 4861. Sponsored\u00b4s protocol code: 4861 B9991016.\nSponsored by: Pfizer S.L.U. Signed date: 07/02/2018\nCastelo Fern\u00e1ndez B . Estudio en fase III, aleatorizado, con doble enmascaramiento y \ncontrolado con placebo, de Nivolumab o Nivolumab con Cisplatino, en combinaci\u00f3n \ncon radioterapia en participantes con carcinoma de c\u00e9lulas escamosas de cabeza y \ncuello (CCEC) localmente avanzado elegibles o no para recibir tratamiento con cis -\nplatino. Type: Clinical Trial, phase III. HULP code: 4975. Sponsored\u00b4s protocol code: CA209-9TM.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 26/03/2018\nCastelo Fern\u00e1ndez B . Estudio sin enmascaramiento de fase II sobre Tipifarnib en \nneoplasias malignas no hematol\u00f3gicas avanzadas con mutaciones hras. Type: Clinical \nTrial, phase II. \nHULP code: 4992. Sponsored\u00b4s protocol code: KO-TIP-001.\nSponsored by: Karma Oncology Ltd. Signed date: 05/10/2018\nCastillo Grau P . Estudio de fase 3, aleatorizado, controlado con placebo, de 52 sema -\nnas de duraci\u00f3n, para evaluar la seguridad y la eficacia de Seladelpar en sujetos con \ncolangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al \u00e1cido \nursodesoxic\u00f3lico. Type: Clinical Trial, phase III. \nHULP code: 5148. Sponsored\u00b4s protocol code: CB8025-31735.\nSponsored by: Cymabay Therapeutics Inc. Signed date: 16/11/2018\nCastillo Grau P . Recogida de muestras de sangre para la evaluaci\u00f3n de biomarcadores \nen el carcinoma hepatocelular. Type: NO-EPA. \nHULP code: pi-3289. Sponsored\u00b4s protocol code: 2017-01.\nSponsored by: Exact Sciences Corporation. Signed date: 13/12/2018\nCastro Conde A . Estudio multic\u00e9ntrico espa\u00f1ol sobre la prevalencia e incidencia de la \ninsuficiencia cardiaca en pacientes con diabetes tipo 2 en consultas hospitalarias del \n\u00e1mbito nacional. Type: NO-EPA. \nHULP code: PI-3231. Sponsored\u00b4s protocol code: DIABET -IC.\nSponsored by: Sociedad Espa\u00f1ola de Cardiolog\u00eda (SEC). Signed date: 30/05/2018\nCastro Conde A . Estudio multic\u00e9ntrico, aleatorizado, abierto, de grupos paralelos para \nestudiar la seguridad y no inferioridad de una nueva estrategia terap\u00e9utica (polip\u00edldora \ncardiovascular de FUSTER-CNIC-FERRER) versus tratamiento habitual en la reduc -\nci\u00f3n del CLDL y la presi\u00f3n arterial en pacientes con enfermedad cardiovascular ate -\nrotromb\u00f3tica. Ensayo Apolo. Type: Clinical Trial, phase III. \nHULP code: 4977. Sponsored\u00b4s protocol code: FMD-TRI-2017-01.\nSponsored by: Ferrer Internacional S.A. Signed date: 04/07/2018\nChaverri Rada D . Ensayo en fase III, aleatorizado y controlado con placebo de Arimo -\nclomol en escleorosis lateral amiotro\u00f3fica. Type: Clinical Trial, phase III. \nHULP code: 5181. Sponsored\u00b4s protocol code: ORARIALS-01.\nSponsored by: Worldwide Clinical Trials. Signed date: 11/10/2018\nCliment Alcal\u00e1 FJ . Estudio abierto y comparativo con tratamiento activo, de la segu -\nridad y la eficacia extrapolada en pacientes pedi\u00e1tricos que requieren anticoagulaci\u00f3n \npara el tratamiento de un acontecimiento tromboemb\u00f3lico venoso. Type: Clinical Trial, \nphase III. \nHULP code: 4852. Sponsored\u00b4s protocol code: B06610137.\nSponsored by: Pfizer Inc. Signed date: 12/01/2018\nCruz Castellanos P . Investigaci\u00f3n de la mutaci\u00f3n T790M en sangre mediante diferen -\ntes metodolog\u00edas. Type: NO-EPA. \nHULP code: PI-3106. Sponsored\u00b4s protocol code: RING (GECP 17/03).2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n49  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansSponsored by: Grupo Espa\u00f1ol C\u00e1ncer Pulm\u00f3n. Signed date: 09/04/2018\nCustodio Carretero AB . Ensayo cl\u00ednico de fase III, aleatorizado, controlado con tra -\ntamiento activo, con enmascaramiento parcial y con detecci\u00f3n de biomarcadores, de \nPembrolizumab en monoterapia y en combinaci\u00f3n con Cisplatino + 5-Fluorouracilo \nfrente a placebo + Cisplatino + 5-Fluorouracilo como tratamiento de primera l\u00ednea en \nsujetos con adenocarcinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica (UGE) avanzado. \nType: Clinical Trial, phase III. \nHULP code: Anexo-I 4689. Sponsored\u00b4s protocol code: MK-3475-062.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 08/11/2018\nCustodio Carretero AB . Ensayo cl\u00ednico de fase III, aleatorizado, doble ciego y con -\ntrolado con placebo, de Pembrolizumab (MK-3475) en combinaci\u00f3n con Cisplatino y \n5-Fluorouracilo frente a un placebo en combinaci\u00f3n con Cisplatino y 5-Fluorouracilo \ncomo tratamiento . Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4823. Sponsored\u00b4s protocol code: MK3475-590.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 12/03/2018\nCustodio Carretero AB . Ensayo cl\u00ednico fase 2, aleatorizado, abierto, de Relatlimab \n(ANTI-LAG-3) m\u00e1s Nivolumab en combinaci\u00f3n con quimioterapia frente a Nivolumab \nen combinaci\u00f3n con quimioterapia como tratamiento de primera l\u00ednea en pacientes \ncon adenocarcinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica. Type: Clinical Trial, phase II. \nHULP code: 5140. Sponsored\u00b4s protocol code: CA224-060.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 03/10/2018\nCustodio Carretero AB . Estudio fase 3 internacional, multic\u00e9ntrico, doble ciego y \naleatorizado, de la eficacia de Zolbetuximab (IMAB362) m\u00e1s Capox, en comparaci\u00f3n \ncon placebo m\u00e1s Capox, como tratamiento de primera l\u00ednea en sujetos con adenocar -\ncinoma g\u00e1strico o de la uni\u00f3n gastroesof\u00e1gica localmente avanzado irresecable o me -\ntast\u00e1sico, Claudin (CLDN)18.2 positivo y HER2 negativo. Type: Clinical Trial, phase III. \nHULP code: 5143. Sponsored\u00b4s protocol code: 8951-CL-0302.\nSponsored by: Astellas Pharma Global Development Inc. Signed date: 13/11/2018\nde Andr\u00e9s Ares J . Ensayo cl\u00ednico en fase III multic\u00e9ntrico, aleatorizado, doble ciego, \ncontrolado por placebo, con grupos paralelos para investigar la eficacia, seguridad y \ntolerabilidad de Naloxona HCL LP comprimidos en pacientes con estre\u00f1imiento indu -\ncido por opioides. Type: Clinical Trial, phase III. \nHULP code: 4957. Sponsored\u00b4s protocol code: 0217/DEV.\nSponsored by: Develco Pharma Schweiz AG. Signed date: 15/01/2018\nde Castro Carpe\u00f1o J . Brigatinib en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no pe -\nque\u00f1as avanzado con linfoma anapl\u00e1sico cin\u00e1sico positivo (ALK+) cuyo c\u00e1ncer ha pro -\ngresado durante el tratamiento con Alectinib o Ceritinib. Type: Clinical Trial, phase II. \nHULP code: 5111. Sponsored\u00b4s protocol code: 2002.\nSponsored by: Pharmaceuticals Inc. Signed date: 17/09/2018\nde Castro Carpe\u00f1o J . Ensayo cl\u00ednico de grupos paralelos, aleatorizado, de fase III de \nOSE2101 como tratamiento de segunda l\u00ednea o tercera l\u00ednea en comparaci\u00f3n con el \ntratamiento est\u00e1ndar (Docetaxel o Pemetrexed) en pacientes con HLA-A2 positivo y carcinoma broncopulmonar no microc\u00edtico metast\u00e1sico (IV) o localmente avanzado \n(IIIB) no apto para radioterapia. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4593. Sponsored\u00b4s protocol code: OSE2101C301.\nSponsored by: Ose Immunotherapeutics. Signed date: 23/05/2018\nde Castro Carpe\u00f1o J . Ensayo cl\u00ednico fase II, no randomizado en primera l\u00ednea de Ate -\nzolizumab en combinaci\u00f3n con Carboplatino y Pemetrexed en pacientes con c\u00e1ncer \nde pulm\u00f3n no microc\u00edtico estadio IV con meg\u00e1stasis cerebrales asintom\u00e1ticas. Type: \nClinical Trial, phase II. \nHULP code: 5073. Sponsored\u00b4s protocol code: 5073 GECP 17/05 (ML40238).\nSponsored by: Fundaci\u00f3n GECP . Signed date: 05/06/2018\nde Castro Carpe\u00f1o J . Ensayo de fase II de un \u00fanico grupo para investigar T epotinib \nen el adenocarcinoma pulmonar en estadio IIIB/IV con alteraciones por omisi\u00f3n del \nex\u00f3n 14 de Met (METEX14) tras fallar, como m\u00ednimo, un tratamiento activo anterior, \nincluido uno con doblete de platino. Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4657. Sponsored\u00b4s protocol code: MS200095-022.\nSponsored by: Merck KGAA. Signed date: 10/01/2018\nde Castro Carpe\u00f1o J . Ensayo fase III, randomizado, doble ciego, controlado con place -\nbo, multic\u00e9ntrico, internacional con Osimertinib como tratamiento de mantenimiento \nen pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (estadio III) localmente avanzado e \nirresecable, con mutaci\u00f3n. Type: Clinical Trial, phase III. \nHULP code: 5104. Sponsored\u00b4s protocol code: D516C00048.\nSponsored by: Astrazeneca Farmac\u00e9utica Spain S.A. Signed date: 30/07/2018\nde Castro Carpe\u00f1o J . Estudio abierto y aleatorizado de combinaciones de REGN2810 \na dosis est\u00e1ndar y alta (Cemiplimab; anticuerpo ANTI-PD-1) e Ipilimumab (anticuerpo \nANTI-CTLA-4) en el tratamiento de segunda l\u00ednea de pacientes con c\u00e1ncer de pulm\u00f3n \nno microc\u00edtico metast\u00e1sico con tumores que expresan <50 % de PDL1. Type: Clinical \nTrial, phase II. \nHULP code: 5059. Sponsored\u00b4s protocol code: R2810-ONC-1763.\nSponsored by: Regeneron Pharmaceuticals Inc. Signed date: 12/07/2018\nde Castro Carpe\u00f1o J . Estudio cesto, abierto, multic\u00e9ntrico, global, en fase II con En -\ntrectinib para el tratamiento de pacientes con tumores s\u00f3lidos localmente avanzados \no metast\u00e1sicos que albergan reordenaciones en los genes NTRK1/2/3, ROS1 o ALK. \nType: Clinical Trial, phase II. \nHULP code: Anexo-II 4648. Sponsored\u00b4s protocol code: RXDX-101-02.\nSponsored by: Ignyta Inc. Signed date: 21/12/2018\nde Castro Carpe\u00f1o J. Estudio de extensi\u00f3n y observacional a largo plazo multic\u00e9ntrico, \nabierto en pacientes incluidos previamente en un estudio cl\u00ednico de Atezolizumab pro -\nmocionado por Genentech y/o F . Hoffmann-la roche LTD. Type: Clinical Trial, phase III. \nHULP code: 5032. Sponsored\u00b4s protocol code: BO39633.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 31/05/2018\nde Castro Carpe\u00f1o J . Estudio de fase 3, aleatorizado y controlado con placebo para \nevaluar la seguridad y la eficacia de Pemetrexed + quimioterapia a base de platino + \nPembrolizumab (MK-3475) con o sin Lenvatinib (E7080/MK-7902) como intervenci\u00f3n 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n50  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansde primera l\u00ednea en partcicipantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico, no epider -\nmoide, metast\u00e1sico (LEAP-006). Type: Clinical Trial, phase III. \nHULP code: 5220. Sponsored\u00b4s protocol code: MK-7902-006.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 29/12/2018\nde Castro Carpe\u00f1o J . Estudio de fase II/III, aleatorizado, abierto y de dos partes, de \nDinutuximab e Irinotec\u00e1n versus Irinotec\u00e1n como tratamiento de segunda l\u00ednea en \nsujetos con c\u00e1ncer de pulm\u00f3n microc\u00edtico en recidiva o resistente. Type: Clinical Trial, \nphase II. \nHULP code: Anexo-I 4832. Sponsored\u00b4s protocol code: DIV-SCLC-301.\nSponsored by: United Therapeutics Corporation. Signed date: 19/03/2018\nde Castro Carpe\u00f1o J . Estudio de fase III, multic\u00e9ntrico, aleatorizado, abierto de \nLDK378 oral frente a quimioterapia estandar en pacientes adultos con cancer de \npulmon de celulas no peque\u00f1as avanzado con reordenamiento de ALK (ALK-positivo) \nque han sido tratados previamente con quimioterapia. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4022. Sponsored\u00b4s protocol code: CLDK378A2303.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 08/01/2018\nde Castro Carpe\u00f1o J . Estudio de fase III, multic\u00e9ntrico, aleatorizado, abierto de \nLDK378 oral frente a quimioterapia est\u00e1ndar en pacientes adultos con c\u00e1ncer de \npulm\u00f3n de c\u00e9lulas no peque\u00f1as avanzado con reordenamiento de ALK (ALK-positivo) \nque han sido tratados previamente con quimioterapia. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4022. Sponsored\u00b4s protocol code: CLDK378A2303.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 23/11/2018\nde Castro Carpe\u00f1o J . Estudio de pr\u00e1ctica cl\u00ednica en condiciones reales para evaluar la \ntoma de decisiones en el tratamiento de segunda l\u00ednea conforme a las normas asisten -\nciales y basado en los perfiles de Foundation Medicine\u00ae en pacientes con c\u00e1ncer de \npulm\u00f3n no microc\u00edtico. Type: NO-EPA. \nHULP code: PI-3376. Sponsored\u00b4s protocol code: ML40221.\nSponsored by: Roche Farma S.A. Signed date: 17/09/2018\nde Castro Carpe\u00f1o J . Estudio en fase I, abierto y no aleatorizado para evaluar el \nefecto de una o varias dosis orales de Osimertinib (Tagrisso\u2122) en la farmacocin\u00e9tica \nde un f\u00e1rmaco sonda de Glicoprote\u00edna P (Fexofenadina) en pacientes con CPNM con \nEGFRM avanzado que haya progresado en un tratamiento previo con TKI del EGFR. \nType: Clinical Trial, phase I. \nHULP code: Anexo-I 4774. Sponsored\u00b4s protocol code: D5160C00036.\nSponsored by: Astrazeneca AB. Signed date: 07/11/2018\nde Castro Carpe\u00f1o J . Estudio en fase I, abierto, no aleatorizado y multic\u00e9ntrico para \nevlauar la farmacocin\u00e9tica, la seguridad y la tolerabilidad de Osimertinib tras la admi -\nnistraci\u00f3n de una dosis oral \u00fanica de 80 mg a pacientes con tumores s\u00f3lidos avanzados \ny funci\u00f3n renal normal o disfunci\u00f3n renal grave. Type: Clinical Trial, phase I. \nHULP code: Anexo-I 4775. Sponsored\u00b4s protocol code: D5160C00035.\nSponsored by: Astrazeneca AB. Signed date: 07/11/2018\nde Castro Carpe\u00f1o J . Estudio en fase III abierto, multic\u00e9ntrico de Brigatinib (AP26113) frente a Crizotinib en pacientes con c\u00e1ncer de pulm\u00f3n avanzado positivo para ALK \npositiva. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4698. Sponsored\u00b4s protocol code: AP26113-13-301.\nSponsored by: Ariad Pharmaceutical Inc. Signed date: 19/07/2018\nde Castro Carpe\u00f1o J . Estudio en fase III, aleatorizado y abierto de Brigatinib (Alun -\nbrigtm) en comparaci\u00f3n con Alectinib (Alecensa\u00ae) en pacientes con c\u00e1ncer de pul -\nm\u00f3n no microc\u00edtico avanzado positivo para cinasa de linfoma anapl\u00e1sico que han pro -\ngresado con Crizotinib (XALKORI\u00ae). Type: Clinical Trial, phase III. \nHULP code: 5149. Sponsored\u00b4s protocol code: BRIGATINIB-3001.\nSponsored by: Ariad Pharmaceutical Inc. Signed date: 22/11/2018\nde Castro Carpe\u00f1o J . Estudio exploratorio de los efectos biol\u00f3gicos y los biomar -\ncadores de Nivolumab en combinaci\u00f3n con Ipilimumab en pacientes con c\u00e1ncer de \npulm\u00f3n no microc\u00edtico (CPNM) en estadio IV o recurrente sin tratamiento previo \n(Checkmate 592: evaluaci\u00f3n de la v\u00eda del punto de control y de Nivolumab en ensayos \ncl\u00ednicos 592. Type: Clinical Trial, phase IV. \nHULP code: 5107. Sponsored\u00b4s protocol code: CA209-592.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 15/06/2018\nde Castro Carpe\u00f1o J . Estudio fase III, aleatorizado, abierto, de Nazartinib en mo -\nnoterapia frente a f\u00e1rmaco a elecci\u00f3n del investigador (Erlotinib o Gefitinib) como \ntratamiento de primera l\u00ednea en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no peque -\n\u00f1as localmente avanzado o metast\u00e1sico con mutaciones activadoras de EGFR. Type: \nClinical Trial, phase III. \nHULP code: 5066. Sponsored\u00b4s protocol code: CEGF816A2302.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 05/06/2018\nde Castro Carpe\u00f1o J . Estudio internacional multic\u00e9ntrico de fase III, aleatorizado, \ndoble ciego, controlado con placebo, de MEDI4736 como tratamiento secuencial en \npacientes con c\u00e1ncer pulmonar de c\u00e9lulas no peque\u00f1as, localmente avanzado, no re -\nsecable (estad\u00edo III) que no han progresado despu\u00e9s de la terapia de quimiorradiaci\u00f3n \nconcurrente definitiva con base de platino (Pacific). Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4235. Sponsored\u00b4s protocol code: D4191C00001.\nSponsored by: Astrazeneca AB. Signed date: 26/11/2018\nde Castro Carpe\u00f1o J . Estudio multic\u00e9ntrico, abierto y de un solo grupo, del perfil \nmolecular de pacientes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico con mutaci\u00f3n del EGFR \nlocalmente avanzado o metast\u00e1sico, tratados con Osimertinib. Type: Clinical Trial, phase \nII. \nHULP code: 4929. Sponsored\u00b4s protocol code: D5161C00003.\nSponsored by: Astrazeneca AB. Signed date: 24/04/2018\nde La Oliva Senovilla P . Estudio aleatorizado, controlado con placebo, doble ciego y \nmultic\u00e9ntrico de la eficacia y la seguridad de LJPC-501 en pacientes pedi\u00e1tricos de > \n2 a 17 a\u00f1os de edad con hipotensi\u00f3n resistente a la catecolamina asociada a choque \ndistributivo. Type: Clinical Trial, phase II. \nHULP code: 5129. Sponsored\u00b4s protocol code: LJ501-CRH04.\nSponsored by: La Jolla Pharmaceutical Company. Signed date: 21/08/20182.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n51  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansde La Quintana Jim\u00e9nez P. Estudio cl\u00ednico observacional postcomercializaci\u00f3n, prospec -\ntivo e internacional del producto para Ostom\u00eda Flexima\u00ae/Softima 3s\u00ae. Type: NO-EPA. \nHULP code: PI-3253. Sponsored\u00b4s protocol code: KISSS.\nSponsored by: B.Braun Medical S.A. Signed date: 19/11/2018\nde Lucas Laguna R . Ensayo aleatorizado, abierto, multic\u00e9ntrico para evaluar la eficacia \nde Secukinumab subcut\u00e1neo despu\u00e9s de doce semanas de tratamiento y evaluar la \nseguridad, tolerabilidad y eficacia a largo plazo en pacientes de 6 a menos de 18 a\u00f1os \nde edad con psoriasis. Type: Clinical Trial, phase III. \nHULP code: 5043. Sponsored\u00b4s protocol code: CAIN457A2311.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 27/04/2018\nde Lucas Laguna R . Estudio de fase 3, multic\u00e9ntrico, aleatorizado, comparativo con \nplacebo, con enmascaramiento doble y grupos paralelos, en el que se eval\u00faa la farma -\ncocin\u00e9tica, la eficacia y la seguridad de Baricitinib en ni\u00f1os enfermos ambulatorios con \ndermatitis at\u00f3pica. Type: Clinical Trial, phase III. \nHULP code: 5215. Sponsored\u00b4s protocol code: I4V-MC-JAIP .\nSponsored by: Lilly S.A. Signed date: 05/12/2018\nde Lucas Laguna R . Estudio de fase III, multic\u00e9ntrico, aleatorizado, doble ciego, con -\ntrolado con placebo y un comparador activo para evaluar la eficacia y seguridad de \nBMS-986165 en pacientes con psoriasis en placas de moderada a grave. Type: Clinical \nTrial, phase III. \nHULP code: 5195. Sponsored\u00b4s protocol code: IM011046.\nSponsored by: Bristol-Myers Squibb Emea Sarl. Signed date: 27/11/2018\nde Lucas Laguna R . Estudio de seguridad y eficacia preliminar de la infusi\u00f3n de c\u00e9lulas \nmadre mesenquimales haploid\u00e9nticas derivadas de m\u00e9dula \u00f3sea para el tratamiento de \nla epidermolisis bullosa distr\u00f3fica recesiva. Type: Clinical Trial, phase I. \nHULP code: 4923. Sponsored\u00b4s protocol code: MESENSISTEM-EB.\nSponsored by: Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital Universitario La Paz. \nSigned date: 09/01/2018\nde Lucas Laguna R . Estudio fase 2B de b\u00fasqueda de dosis, multic\u00e9ntrico, aleatorizado, \ndoble ciego, controlado con placebo para investigar la eficacia y la seguridad de Ligeli -\nzumab (QGE031) en pacientes adolescentes con urticaria cr\u00f3nica espont\u00e1nea (UCE). \nType: Clinical Trial, phase II. \nHULP code: 5031. Sponsored\u00b4s protocol code: CQGE031C2202.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 18/05/2018\nDe Paz Arias R . Estudio cl\u00ednico de fase 2, aleatorizado, controlado y abierto para com -\nparar la eficacia y la seguridad de Pevonedistat m\u00e1s Azacitidina frente a Azacitidina en \nmonoterapia en pacientes con s\u00edndromes mielodispl\u00e1sicos de alto riesgo, leucemia mie -\nlomonoc\u00edtica cr\u00f3nica y leucemia miel\u00f3gena aguda pobre en blastos. Type: Clinical Trial, \nphase II. \nHULP code: Anexo-I 4571. Sponsored\u00b4s protocol code: Pevonedistat-2001.\nSponsored by: Millennium Pharmaceuticals Inc. Signed date: 14/03/2018\nDe Paz Arias R . Estudio cl\u00ednico de fase 3, abierto, aleatorizado y controlado de Pe -\nvonedistat m\u00e1s Azacitidina frente a Azacitidina en monoterapia como tratamiento de primera l\u00ednea en pacientes con s\u00edndromes mielodispl\u00e1sicos de alto riesgo, leucemia \nmielomonoc\u00edtica cr\u00f3nica. Type: Clinical Trial, phase III. \nHULP code: 4950. Sponsored\u00b4s protocol code: PEVONEDISTAT -3001.\nSponsored by: Millennium Pharmaceuticals Inc. Signed date: 22/02/2018\nDe Paz Arias R . Estudio de extension abierto del tratamiento de Bosutinib para pa -\ncientes con leucemia mieloide cronica (LMC) que han participado previamente en los \nEstudios de Bosutinib B1871006 o B1871008. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 3925. Sponsored\u00b4s protocol code: B1871040.\nSponsored by: Pfizer Inc. Signed date: 19/03/2018\nDe Paz Arias R . Estudio fase III, prospectivo, aleatorizado, abierto, con dos brazos de \ntratamiento, para evaluar la tasa de remision libre de tratamiento (RLT) en pacientes \ncon LMC cromosoma filadelfia positivo, despues de dos duraciones distintas de trata -\nmiento de consolidaci\u00f3n con Nilotinib 300 mg BID. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 3831. Sponsored\u00b4s protocol code: CAMN107AIC05.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 23/04/2018\nDe Paz Arias R . Estudio multic\u00e9ntrico, de un \u00fanico brazo, de remisi\u00f3n libre de tra -\ntamiento de Nilotinib, en pacientes con leucemia mieloide cr\u00f3nica en fase cronica \ncon BCR-ABL1 positivo, que han alcanzado un estado de enfermedad residual minima \n(ERM) duradera con tratamiento. Type: Clinical Trial, phase II. \nHULP code: Anexo-II 3807. Sponsored\u00b4s protocol code: CAMN107I2201.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 12/01/2018\nD\u00edaz-Agero \u00c1lvarez P . Estudio aleatorizado, comparativo, de no inferioridad, para \nevaluar la eficacia y la seguridad de Hemopatch comparado con Tachosil en la preven -\nci\u00f3n o reducci\u00f3n de las fugas de aire posquir\u00fargicas tras la resecci\u00f3n pulmonar. Type: \nClinical Trial, phase IV. \nHULP code: 5010. Sponsored\u00b4s protocol code: BXU513667.\nSponsored by: Baxter Healthcare Corporation. Signed date: 22/06/2018\nDom\u00ednguez Ortega FJ . Estudio piloto sobre el control del asma en pacientes con rini -\ntis al\u00e9rgica a polen de gram\u00edneas tratados con inmunoterapia sublingual de 5 gram\u00edneas \n(Staloral\u00ae) vs placebo. 5 graps. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4284. Sponsored\u00b4s protocol code: DOM-STA-2014-01.\nSponsored by: Stallergenes Iberica S.A. Signed date: 10/01/2018\nElorza Fern\u00e1ndez MD . Ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, abierto, controlado \ncon comparador activo, para evaluar la eficacia y la seguridad de Rivaroxaban a un \nr\u00e9gimen de dosis ajustado seg\u00fan la edad y el peso, en ni\u00f1os con tromboembolismo \nvenoso agudo. Type: Clinical Trial, phase III. \nHULP code: 4180B. Sponsored\u00b4s protocol code: 59-7939/14372.\nSponsored by: Bayer AG. Signed date: 23/02/2018\nEscobar Cervantes C . Patrones de prescripci\u00f3n de Edoxab\u00e1n en Europa: un estudio \nde utilizaci\u00f3n del medicamento mediante la revisi\u00f3n retrospectiva de historias cl\u00ednicas. \nType: EPA-OD. \nHULP code: PI-3107. Sponsored\u00b4s protocol code: DSE-EDO-01-14-EU.2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n52  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansSponsored by: Daiichi-Sankyo Europe GMBH. Signed date: 14/02/2018\nEspinosa Arranz E . Ensayo cl\u00ednico abierto, multic\u00e9ntrico, de un solo grupo, de Ni -\nvolumab (BMS 936558) en sujetos con melanoma en estadio III (Irresecable) o IV \nconfirmado mediante histolog\u00eda, en progresi\u00f3n despu\u00e9s de un tratamiento previo con \nun anticuerpo monoclonal ANTICTLA4. Type: Clinical Trial, phase II. \nHULP code: Anexo-II 4239. Sponsored\u00b4s protocol code: CA209-172.\nSponsored by: Bristol Myers Squibb S.L. Signed date: 30/08/2018\nEspinosa Arranz E . Ensayo de extensi\u00f3n de fase III, abierto y multic\u00e9ntrico para estu -\ndiar la seguridad y eficacia a largo plazo en participantes con tumores avanzados que \nactualmente est\u00e1n en tratamiento o en seguimiento en un ensayo de Pembrolizumab. \nType: Clinical Trial, phase III. \nHULP code: 5076. Sponsored\u00b4s protocol code: MK-3475-587.\nSponsored by: Merck Sharp and Dohme de Espa\u00f1a S.A. Signed date: 03/05/2018\nEspinosa Arranz E . Ensayo de fase 3, aleatorizado y controlado con placebo para \nevaluar la seguridad y la eficacia de Pembrolizumab (MK-3475) y Lenvatinib (E7080/\nMK-7902) en comparaci\u00f3n con Pembrolizumab en monoterapia como intervenci\u00f3n \nde primera l\u00ednea en participantes con con melanoma avanzado (LEAP-003). Type: Cli -\nnical Trial, phase III. \nHULP code: 5198. Sponsored\u00b4s protocol code: MK-7902-003 (E7080-G000-312).\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 14/11/2018\nEspinosa Arranz E . Estudio abierto y multic\u00e9ntrico en fase II de DS-8201A, un Anti-\nHER2 conjugado anticuerpo-f\u00e1rmaco (CAF) para sujetos con c\u00e1ncer de mama HER2 \npositivo irresecable y/o metast\u00e1sico que son resistentes o refractarios a T -DM1. Type: \nClinical Trial, phase II. \nHULP code: Anexo-I 4934. Sponsored\u00b4s protocol code: DS8201-A-U201.\nSponsored by: Daiichi Sankyo Inc. Signed date: 09/10/2018\nEspinosa Arranz E . Estudio abierto y multic\u00e9ntrico en fase II de DS-8201A, un ANTI-\nHER2 conjugado anticuerpo-f\u00e1rmaco (CAF) para sujetos con c\u00e1ncer de mama HER2 \npositivo irresecable y/o metast\u00e1sico que son resistentes o refractarios a T -DM1. Type: \nClinical Trial, phase II. \nHULP code: 4934. Sponsored\u00b4s protocol code: DS8201-A-U201.\nSponsored by: Daiichi Sankyo Inc. Signed date: 09/03/2018\nEspinosa Arranz E . Estudio aleatorizado de fase II, abierto y multic\u00e9ntrico para eva -\nluar la seguridad y la eficacia de IMCGP100 en comparaci\u00f3n con la elecci\u00f3n del inves -\ntigador en pacientes con HLA-A*0201 positivo y que no hayan recibido tratamiento \nprevio para el melanoma maligno uveal avanzado. Type: Clinical Trial, phase II. \nHULP code: 5090. Sponsored\u00b4s protocol code: IMCgp100-202.\nSponsored by: Immunocore Ltd. Signed date: 09/10/2018\nEspinosa Arranz E . Estudio de fase 3, abierto y de un solo grupo para evaluar la se -\nguridad y la eficacia de Pembrolizumab (MK-3475) como tratamiento de primera l\u00ednea \nen participantes con carcinoma de c\u00e9lulas de Merkel avanzado (Keynote-913). Type: \nClinical Trial, phase III. HULP code: 5190. Sponsored\u00b4s protocol code: MK-3475-913.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 06/11/2018\nEspinosa Arranz E . Estudio de fase IB multic\u00e9ntrico, sin enmascaramiento para eva -\nluar la seguridad y la eficacia de Ipatasertib en combinaci\u00f3n con Atezolizumab y Pa -\nclitaxel o Nab-Paclitaxel en pacientes con c\u00e1ncer de mama triple negativo localmente \navanzado o metast\u00e1sico. Type: Clinical Trial, phase I. \nHULP code: 5012. Sponsored\u00b4s protocol code: CO40151.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 26/01/2018\nEspinosa Arranz E . Estudio de fase IB multic\u00e9ntrico, sin enmascaramiento para eva -\nluar la seguridad y la eficacia de Ipatasertib en combinaci\u00f3n con Atezolizumab y Pa -\nclitaxel o Nab-Paclitaxel en pacientes con c\u00e1ncer de mama triple negativo localmente \navanzado o metast\u00e1sico. Type: Clinical Trial, phase I. \nHULP code: Anexo-I 5012. Sponsored\u00b4s protocol code: CO40151.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 26/10/2018\nEspinosa Arranz E . Estudio en fase I/II, abierto, multic\u00e9ntrico, de la seguridad y la efica -\ncia de IMCGP100 usando la pauta posol\u00f3gica con aumento intrapaciente en pacientes \ncon melanoma uveal avanzado. Type: Clinical Trial, phase I. \nHULP code: 5074. Sponsored\u00b4s protocol code: IMCGP100-102.\nSponsored by: Immunocore Ltd. Signed date: 11/07/2018\nEspinosa Arranz E . Estudio observacional descriptivo sobre las caracter\u00edsticas y evo -\nluci\u00f3n del melanoma avanzado y metast\u00e1sico en Espa\u00f1a. Type: EPA-SP . \nHULP code: PI-3208. Sponsored\u00b4s protocol code: GEM-IPI-2018-01.\nSponsored by: Grupo Espa\u00f1ol Multidisciplinar de Melanoma Gem Gem. Signed date: \n25/06/2018\nEspinosa Arranz E . Un estudio de fase IB para evaluar el uso de Cobimetinib m\u00e1s \nAtezolizumab en pacientes con melanoma con BRAFV600 de tipo salvaje avanzado \nque hayan experimentado progresi\u00f3n. Type: Clinical Trial, phase I. \nHULP code: 5040. Sponsored\u00b4s protocol code: CO39721.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 08/06/2018\nEspinosa Rom\u00e1n L . Carga de la enfermedad de la hipofosfatemia ligada al cromosoma \nX (XLH-QOL en adelante). Type: NO-EPA. \nHULP code: PI-3004. Sponsored\u00b4s protocol code: XLH-QoL-2017-02.\nSponsored by: Kyowa Kirin Farmac\u00e9utica S.L.U. Signed date: 18/01/2018\nFeliu Batlle J . Estudio aleatorizado, multic\u00e9ntrico, doble ciego, controlado con placebo, \nde fase 2/3 del inhibidor de la tirosina quinasa de Bruton, Ibrutinib, en combinaci\u00f3n con \nNab-Paclitaxel y Gemcitabina frente a placebo en combinaci\u00f3n con Nab-Paclitaxel y \nGemcitabi. Type: Clinical Trial, phase II. \nHULP code: Anexo-II 4502. Sponsored\u00b4s protocol code: PCYC-1137-CA.\nSponsored by: Pharmacyclis Llc. Signed date: 22/02/2018\nFeliu Batlle J . Estudio de fase 3 aleatorizado para evaluar el uso de Eryaspase en \ncombinaci\u00f3n con quimioterapia, comparada con quimioterapia sola como tratamiento \nde segunda l\u00ednea en pacientes con adenocarcinoma pancre\u00e1tico. Type: Clinical Trial, \nphase III. 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n53  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansHULP code: 5105. Sponsored\u00b4s protocol code: GRASPANC 2018-01.\nSponsored by: Erytech Pharma. Signed date: 05/06/2018\nFeliu Batlle J . Estudio de fase III, abierto y aleatorizado de Atezolizumab en combina -\nci\u00f3n con Bevacizumab en comparaci\u00f3n con Sorafenib en pacientes con carcinoma he -\npatocelular localmente avanzado o metast\u00e1sico no tratado. Type: Clinical Trial, phase III. \nHULP code: 4973. Sponsored\u00b4s protocol code: YO40245.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 13/02/2018\nFeliu Batlle J . Estudio en fase II, multic\u00e9ntrico y abierto, para investigar la eficacia, \nla seguridad y la farmacocin\u00e9tica del anticuerpo monoclonal ANTI-PD-1,BGB-A317, \nen pacientes con carcinoma hepatocelular irresecable tratado anteriormente. Type: \nClinical Trial, phase II. \nHULP code: 4996. Sponsored\u00b4s protocol code: BGB-A317-208.\nSponsored by: Beigene Ltd. Signed date: 09/05/2018\nFeliu Batlle J . Estudio en fase III, aleatorizado, doble ciego y controlado con place -\nbo para evaluar la eficacia y seguridad de GS-5745 en combinaci\u00f3n con mFOLFOX6 \ncomo tratamiento de primera l\u00ednea en pacientes con adenocarcinoma g\u00e1strico avanza -\ndo o de la uni\u00f3n gastroesof\u00e1gica. Type: Clinical Trial, phase III. \nHULP code: Anexo-III 4569. Sponsored\u00b4s protocol code: GS-US-296-1080.\nSponsored by: Gilead Sciences Inc. Signed date: 13/02/2018\nFeliu Batlle J . Estudio fase 1b/2 de BMS-813160 en combinaci\u00f3n con quimioterapia \no Nivolumab en pacientes con tumores s\u00f3lidos avanzados. Type: Clinical Trial, phase I. \nHULP code: 5169. Sponsored\u00b4s protocol code: CV202-103.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 31/10/2018\nFeliu Batlle J . Estudio multic\u00e9ntrico en adenocarcinoma de p\u00e1ncreas resecable con \nfactores de mal pron\u00f3stico sobre la definici\u00f3n de nuevos marcadores de metilaci\u00f3n \npredictivos de respuesta radiol\u00f3gica al tratamiento con Nab-Paclitaxel-Gemcitabina. \nCorrelaci\u00f3n Farmacoprot. Type: EPA-AS. \nHULP code: PI-3128. Sponsored\u00b4s protocol code: AVB-NAB-2018-01.\nSponsored by: Complejo Hospitalario de Navarra. Signed date: 12/03/2018\nFeliu Batlle J . Refine: estudio observacional de Regorafenib en carcinoma hepatoce -\nlular. Type: EPA-LA. \nHULP code: PI-3112. Sponsored\u00b4s protocol code: BAY -REG-2018-01.\nSponsored by: Bayer Hispania S.L. Signed date: 23/05/2018\nFrank Garc\u00eda A . Estudio de extensi\u00f3n en fase III, multic\u00e9ntrico, a largo plazo sobre la \nseguridad y eficacia de AVP-786 (Bromhidrato de [D6]-Dextrometorfano Deuterado \n[D6-DM]/Sulfato de Quinidina [Q]) para el tratamiento de la agitaci\u00f3n en pacientes \ncon demencia de tipo Alzheimer. Type: Clinical Trial, phase III. \nHULP code: 5155. Sponsored\u00b4s protocol code: 15-AVP-786-303.\nSponsored by: Pharmaceuticals Inc. Signed date: 20/09/2018\nFrank Garc\u00eda A . Estudio de fase IIB/III,multic\u00e9ntrico, aleatorizado, con doble ciego, \ncontrolado con placebo y de grupos paralelos para investigar la eficacia y la seguridad \nde JNJ-54861911 en sujetos asintom\u00e1ticos con riesgo de desarrollar demencia de \nalzheimer. Type: Clinical Trial, phase II. HULP code: Anexo-I 4448. Sponsored\u00b4s protocol code: 54861911ALZ2003.\nSponsored by: Janssen Cilag International NV. Signed date: 16/03/2018\nFrank Garc\u00eda A . Estudio de fase III multic\u00e9ntrico, aleatorizado, doble ciego, controlado \ncon placebo, con dise\u00f1o de grupos paralelos, para evaluar la eficacia, la seguridad y la \ntolerabilidad de AVP-786 (Bromhidrato de Deudextrometorfano [D6-DM]/Sulfato de \nQuinidina [Q]). Type: Clinical Trial, phase III. \nHULP code: 4976. Sponsored\u00b4s protocol code: 4976 17-AVP-786-305.\nSponsored by: Ph Research S.L. Signed date: 30/01/2018\nGaebelt NE . Ensayo de inmunogenicidad y seguridad de una vacuna conjugada anti -\nmeningoc\u00f3cica tetravalente en investigaci\u00f3n administrada de forma concomitante con \nlas vacunas pedi\u00e1tricas de rutina a ni\u00f1os peque\u00f1os y lactantes sanos en europa. Type: \nClinical Trial, phase III. \nHULP code: 5164. Sponsored\u00b4s protocol code: MET58.\nSponsored by: Sanofi Pasteur Inc. Signed date: 25/09/2018\nGallego Mart\u00ednez A . Estudio observacional retrospectivo para evaluar las estrategias \nde tratamiento en pr\u00e1ctica cl\u00ednica y la evoluci\u00f3n cl\u00ednica de los pacientes con c\u00e1ncer de \novario avanzado en Espa\u00f1a: Estudio Ovoc (evaluaci\u00f3n objetiva del c\u00e1ncer de ovario). \nType: EPA-OD. \nHULP code: PI-3330. Sponsored\u00b4s protocol code: ML40141.\nSponsored by: Roche Farma S.A. Signed date: 24/09/2018\nGarc\u00eda Garc\u00eda S . Ensayo cl\u00ednico de fase II de demostraci\u00f3n de viabilidad para evaluar \nla eficacia y la seguridad de MEDI3902 en la prevenci\u00f3n de la neumon\u00eda nosocomial \ncausada por pseudomonas aeruginosa en pacientes sujetos a ventilaci\u00f3n mec\u00e1nica. \nType: Clinical Trial, phase III. \nHULP code: Anexo-I 4540. Sponsored\u00b4s protocol code: HELIOS-AP .\nSponsored by: Sociedad Espa\u00f1ola de Carburos Met\u00e1licos. Signed date: 16/11/2018\nGarc\u00eda Rio FJ . Caracterizaci\u00f3n de la variable \u201cminutos diarios de marcha\u201d como una \nmedida \u00fatil de actividad f\u00edsica en pacientes con EPOC. Type: NO-EPA. \nHULP code: PI-3342. Sponsored\u00b4s protocol code: FUC-EPO-2018-01.\nSponsored by: Coordinadora Catalana de Fundaci\u00f3nes. Signed date: 25/09/2018\nGarc\u00eda Rio FJ . Estudio observacional para la validaci\u00f3n de un cuestionario para la acti -\nvidad f\u00edsica de pacientes con epoc en la pr\u00e1ctica cl\u00ednica: cuestionario saq-copd (spanish \nactivity questionnaire in copd. Type: NO-EPA. \nHULP code: PI-3011. Sponsored\u00b4s protocol code: AST -SAQ-2017-01.\nSponsored by: Astrazeneca Farmac\u00e9utica Spain S.A. Signed date: 28/03/2018\nGarc\u00eda Rio FJ . Importancia de la evaluaci\u00f3n de la respuesta y la estandarizaci\u00f3n con \nprote\u00f3mica en la obstrucci\u00f3n buscando desenlaces novedosos y significativos. Type: \nEPA-SP . \nHULP code: PI-3340. Sponsored\u00b4s protocol code: SEP-ICS-2017-01.\nSponsored by: Fundaci\u00f3n Espa\u00f1ola del Pulm\u00f3n. SEPAR. Signed date: 02/08/2018\nGarc\u00eda S\u00e1nchez A . Estudio cl\u00ednico de fase 3, multic\u00e9ntrico, aleatorizado, doble ciego y \ncontrolado con tratamiento activo para evaluar la seguridad y la eficacia de Lenvatinib 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n54  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians(E7080/MK-7902) en combinaci\u00f3n con Pembrolizumab (MK-3475) frente a Lenvatinib \nen el tratamiento. Type: Clinical Trial, phase III. \nHULP code: 5194. Sponsored\u00b4s protocol code: MK7902-002.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 06/11/2018\nGarc\u00eda-Samaniego Rey J . Estudio cl\u00ednico de fase III, aleatorizado, doble ciego, contro -\nlado con placebo para evaluar la seguridad y eficacia de Selonsertib en pacientes con \nesteatohepatitis no alcoh\u00f3lica (EHNA) y fibrosis en puentes (F3). Type: Clinical Trial, \nphase III. \nHULP code: Anexo-II 4785. Sponsored\u00b4s protocol code: GS-US-384-1943.\nSponsored by: Gilead Sciences Inc. Signed date: 27/08/2018\nGarc\u00eda-Samaniego Rey J . Estudio en fase III, aleatorizado, doble ciego y controlado con \nplacebo para evaluar la seguridad y la eficacia de Selonsertib en pacientes con cirrosis \ncompensada debida a esteatohepatitis no alcoh\u00f3lica (EHNA). Type: Clinical Trial, phase \nIII. \nHULP code: Anexo-II 4786. Sponsored\u00b4s protocol code: GS-US-384-1944.\nSponsored by: Gilead Sciences Inc. Signed date: 27/08/2018\nGasior Kabat M . Estudio de fase 2 de LY2784544 en pacientes con neoplasias mielo -\nproliferativas. Type: Clinical Trial, phase II. \nHULP code: Anexo-V 3558. Sponsored\u00b4s protocol code: I3X-MC-JHTB.\nSponsored by: Lilly S.A. Signed date: 20/07/2018\nGil Garay E . Artroplastia total de cadera con el v\u00e1stago femoral alteon\u2122 Tapered \nWedge de Exactech\u00ae. Type: EPA-SP . \nHULP code: PI-2913. Sponsored\u00b4s protocol code: CR14-001.\nSponsored by: Exactech International Operation AG. Signed date: 09/02/2018\nG\u00f3mez Barrena E . A post-market domestic (US) and international data collection to \nassess the Optetrak\u00ae knee system. Type: EPA-SP . \nHULP code: PI-3335. Sponsored\u00b4s protocol code: CR5-007.\nSponsored by: Exactech International Operation AG. Signed date: 30/10/2018\nG\u00f3mez Barrena E . Ensayo cl\u00ednico fase II para evaluar el efecto del HC-SVT -1001 \n(c\u00e9lulas mesenquimales troncales adultas aut\u00f3logas de tejido adiposo expandidas e \nincluidas en biomaterial de fosfato tric\u00e1lcico) en el tratamiento quir\u00fargico de pseu -\ndoartrosis atr\u00f3ficas de huesos largos. Type: Clinical Trial, phase II. \nHULP code: Anexo-III 4278. Sponsored\u00b4s protocol code: STEMQUIRI/12ES01.\nSponsored by: Salvat S.A. Signed date: 22/06/2018\nG\u00f3mez Barrena E . Estudio prospectivo, multic\u00e9ntrico para evaluar la eficacia y la \nseguridad de una inyecci\u00f3n \u00fanica de Hialuronato S\u00f3dico en pacientes con artrosis de \nrodilla. Type: Producto Sanitario. \nHULP code: 5175. Sponsored\u00b4s protocol code: TM-SH2%/301.\nSponsored by: T edec-Meiji Farma, S.A. Signed date: 24/09/2018\nG\u00f3mez Barrena E . Evaluation of safety, feasibility and preliminary efficacy of MSCS \nfrom third party donors in the treatment of patients with osteonecrosis of the femoral \nhead after allogeneic stem cell transplantation. Type: Clinical Trial, phase II. HULP code: 5016. Sponsored\u00b4s protocol code: ALOFEM.\nSponsored by: Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica Hospital Universitario La Paz. \nSigned date: 19/12/2018\nG\u00f3mez Candela C . Estudio c\u00ednico nutricional en agudo para evaluar el efecto sobre \nla saciedad de una goma con aroma encapsulado en un colectivo de personas sanas. \nType: Producto Alimentario. \nHULP code: 5003. Sponsored\u00b4s protocol code: GOMINOLA.\nSponsored by: Creaciones Arom\u00e1ticas Industriales S.A. Signed date: 03/04/2018\nG\u00f3mez Candela C . Estudio cl\u00ednico nutricional para evaluar el efecto sobre la sacie -\ndad y el perfil lip\u00eddico del consumo habitual de un preparado de miel rico en fibra \ny Polifenoles en un colectivo de personas con sobrepeso/obesidad. Type: Producto \nAlimentario. \nHULP code: 5049.\nSponsored by: Primo Mendoza S.L. Signed date: 09/08/2018\nG\u00f3mez Candela C . Estudio cl\u00ednico-nutricional cruzado y aleatorizado con 3 brazos \nde estudio (yogur rico en fibra (dextrina, harina de avena integral y salvado de trigo); \nyogur rico en proteina (proteina de guisante); yogur control), para evaluar las propie -\ndades saciantes. Type: Producto Alimentario. \nHULP code: 5007. Sponsored\u00b4s protocol code: 5007.\nSponsored by: Go Fruselva. Signed date: 01/06/2018\nG\u00f3mez Candela C . Estudio de intervenci\u00f3n nutricional para evaluar el efecto sobre \nla saciedad de una conserva de bonito en aceite de oliva enriquecida en fibra o poli -\nfenoles de un colectivo de personas sanas con sobrepeso. Type: Producto Alimentario. \nHULP code: 5048. Sponsored\u00b4s protocol code: 5048.\nSponsored by: Friobas Basilio S.L. Signed date: 13/06/2018\nG\u00f3mez Candela C . Estudio prospectivo, observacional de una alimentaci\u00f3n por sonda \ncon alto contenido cal\u00f3rico y proteico, con carbohidratos de liberaci\u00f3n lenta y \u00e1ci -\ndos grasos monoinsaturados (AGMI) en una poblaci\u00f3n malnutrida con diabetes. Type: \nNO-EPA. \nHULP code: PI-3167. Sponsored\u00b4s protocol code: DA14.\nSponsored by: Abbott Laboratories S.A. Signed date: 05/06/2018\nG\u00f3mez Candela C . T olerancia y eficacia de una f\u00f3rmula de nutrici\u00f3n enteral polim\u00e9rica \nhiperproteica/hipercal\u00f3rica, enriquecida en fibra, aceite de oliva virgen extra y omega \n3 en pacientes hospitalizados. Type: Producto Alimentario. \nHULP code: 5005. Sponsored\u00b4s protocol code: 5005.\nSponsored by: Adventia Pharma S.L. Signed date: 20/03/2018\nG\u00f3mez Prieto P . A phase IBIIi trial of combined SGN-35 (Brentuximabvedotin) the -\nrapy with Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone \n(BREPEM) for older patients with untreated Hodgkin lymphoma (HL). Type: Clinical \nTrial, phase I. \nHULP code: 5009. Sponsored\u00b4s protocol code: BrEPEM-LH-22017.\nSponsored by: Gel-Tamo. Signed date: 01/06/20182.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n55  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansG\u00f3mez Senent S . Estudio postcomercializaci\u00f3n observacional de cohortes en pacien -\ntes con enfermedad inflamatoria intestinal (EII) tratados con Inflectra (Infliximab) en la \npr\u00e1ctica cl\u00ednica habitual (Connect-IBD). Type: EPA-SP . \nHULP code: Anexo-I PI-2082. Sponsored\u00b4s protocol code: ZOB INF 1402.\nSponsored by: Hospira Productos Farmac\u00e9uticos Y Hospitalarios S.L. Signed date: 16/07/2018\nG\u00f3mez Traseira C . Efecto de la intervenci\u00f3n \u2018Escalera de la leche\u2019 en el desarrollo de \ntolerancia y en el reconocimiento de ep\u00edtopos de c\u00e9lulas B en ni\u00f1os al\u00e9rgicos a pro -\nte\u00ednas de leche de vaca. Type: Producto Alimentario. \nHULP code: PI-3274. Sponsored\u00b4s protocol code: PI-3274.\nSponsored by: Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Cl\u00ednico San Carlos. \nSigned date: 21/06/2018\nGonz\u00e1lez Garc\u00eda JJ . Ensayo cl\u00ednico abierto, aleatorizado y multic\u00e9ntrico para compa -\nrar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento TAF/FTC/DRV/\nCOBI cs. ABC/3TC/DTG en pacientes infectados por el VIH-1 na\u00efve de tratamiento \nantirretroviral. Type: Clinical Trial, phase IV. \nHULP code: 5184. Sponsored\u00b4s protocol code: SYMTRI.\nSponsored by: Asociacion RIS ( Red de Investigacion en SIDA). Signed date: 27/12/2018\nGonz\u00e1lez Garc\u00eda JJ . Estudio adaptativo, aleatorizado, doble ciego (abierto para el pro -\nmotor), controlado con placebo para investigar el efecto antiviral, la seguridad, la tole -\nrabilidad y la farmacocin\u00e9tica de GSK3640254 en adultos con infecci\u00f3n por VIH-1 sin \ntratamiento previo. Type: Clinical Trial, phase II. \nHULP code: 5200. Sponsored\u00b4s protocol code: 208132.\nSponsored by: Laboratorios VIIV Healthcare S.L. Signed date: 30/11/2018\nGonz\u00e1lez Mart\u00ednez B . Estudio intergrupo para ni\u00f1os o adolescentes con linfoma no-\nHodkin B o leucemia linfobl\u00e1stica de c\u00e9lulas B; evaluaci\u00f3n de eficacia y seguridad de \nRituximab en pacientes de alto riesgo. Type: Clinical Trial, phase II. \nHULP code: Anexo-II 3546. Sponsored\u00b4s protocol code: IGR2009/1593.\nSponsored by: Sociedad Espa\u00f1ola de Oncolog\u00eda y Hematolog\u00eda Pedi\u00e1tricas. \nSigned date: 20/11/2018\nGonz\u00e1lez P\u00e9rez de Villar N . Registro nacional de pacientes con diabetes tipo 1. Type: \nEPA-OD. \nHULP code: PI-2912. Sponsored\u00b4s protocol code: SED1.\nSponsored by: Sociedad Espa\u00f1ola de Diabetes (SED). Signed date: 07/06/2018\nGrac\u00eda Rio FJ . Caracterizaci\u00f3n de la variable minutos diarios de marcha como una \nmedida \u00fatil de actividad f\u00edsica en pacientes con EPOC. Type: NO-EPA. \nHULP code: Anexo-I PI-3342. Sponsored\u00b4s protocol code: FUC-EPO-2018-01.\nSponsored by: Coordinadora Catalana de Fundaci\u00f3nes. Signed date: 26/11/2018\nHardisson Hern\u00e1ndez D . Ensayo en fase III, aleatorizado y doble ciego para evaluar la \neficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en comparaci\u00f3n \ncon el placebo en pacientes con insuficiencia card\u00edaca cr\u00f3nica con fracci\u00f3n de eyec -\nci\u00f3n reducida (ICC-FER). Type: NO-EPA. \nHULP code: pi-3051. Sponsored\u00b4s protocol code: SYS-OR2-2017-01.\nSponsored by: Sysmex Europe GMBH. Signed date: 12/04/2018Hern\u00e1ndez Guti\u00e9rrez A . Seguridad y beneficios del dispositivo de captura de c\u00e9lulas \ntumorales metast\u00e1sicas en pacientes con c\u00e1ncer de ovario avanzado. Type: Producto \nSanitario. \nHULP code: Anexo-I 4723. Sponsored\u00b4s protocol code: MTRAP-2016-01.\nSponsored by: Mtrap Inc. Signed date: 20/12/2018\nHerranz Pinto P.  Ensayo aleatorizado, doble ciego, controlado con placebo, de grupos \nparalelos, multic\u00e9ntrico, de fase 3 que investiga la eficacia, la seguridad y la tolerabilidad \nde Tralokinumab administrado en combinaci\u00f3n con corticosteroides t\u00f3picos a pacien -\ntes adultos. Type: Clinical Trial, phase III. \nHULP code: 5159. Sponsored\u00b4s protocol code: LP0162-1346.\nSponsored by: Leo Pharma A/S. Signed date: 05/11/2018\nHerranz Pinto P . Ensayo de extensi\u00f3n a largo plazo, multic\u00e9ntrico, abierto y de un \nsolo brazo, para evaluar la seguridad y eficacia de Tralokinumab en pacientes con der -\nmatitis at\u00f3pica que participaron previamente en ensayos cl\u00ednicos con Tralokinumab \n- Ecztend. Type: Clinical Trial, phase III. \nHULP code: 5158. Sponsored\u00b4s protocol code: LP0162-1337.\nSponsored by: Leo Pharma A/S. Signed date: 13/12/2018\nHerranz Pinto P . Estudio de fase 3, multic\u00e9ntrico, aleatorizado, doble ciego y compa -\nrado con placebo, para evaluar la eficacia y la seguridad de Baricitinib en pacientes con \ndermatitis at\u00f3pica de moderada a grave. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4951. Sponsored\u00b4s protocol code: I4V-MC-JAHM.\nSponsored by: Lilly S.A. Signed date: 20/06/2018\nHerranz Pinto P . Estudio de fase 3, multic\u00e9ntrico, doble ciego, en el que se eval\u00faan la \nseguridad y la eficacia a largo plazo de Baricitinib en pacientes adultos con dermatitis \nat\u00f3pica. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4958. Sponsored\u00b4s protocol code: I4V-MC-JAHN.\nSponsored by: Lilly S.A. Signed date: 19/09/2018\nHerranz Pinto P . Estudio de fase 3, multic\u00e9ntrico, doble ciego, en el que se eval\u00faan la \nseguridad y la eficacia a largo plazo de Baricitinib en pacientes adultos con dermatitis \nat\u00f3pica. Type: Clinical Trial, phase III. \nHULP code: 4958. Sponsored\u00b4s protocol code: I4V-MC-JAHN.\nSponsored by: Lilly S.A. Signed date: 09/02/2018\nHerranz Pinto P . Estudio de fase 3B, multic\u00e9ntrico, aleatorizado, en doble ciego, con -\ntrolado con principio activo de comparaci\u00f3n (Secukinumab) y de grupos paralelos, \npara evaluar la eficacia y la seguridad de Bimekizumab en adultos con psoriasis (PSO) \nen placas cr\u00f3nica de grado moderado o severo. Type: Clinical Trial, phase III. \nHULP code: 5109. Sponsored\u00b4s protocol code: PS0015.\nSponsored by: UCB Biosciencies GMBH. Signed date: 04/12/2018\nHerranz Pinto P . Estudio en fase 3, aleatorizado y abierto que eval\u00faa la eficacia de \nAxicabtagene Ciloleucel en comparaci\u00f3n con el tratamiento est\u00e1ndar en pacientes \ncon linfoma difuso de c\u00e9lulas B grandes recidivante/resistente (ZUMA-7). Type: Clinical \nTrial, phase III. \nHULP code: 5133. Sponsored\u00b4s protocol code: KTE-C19-107 (ZUMA-7).2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n56  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansSponsored by: Kite Pharma Inc. Signed date: 02/11/2018\nHerranz Pinto P . Estudio en fase III de retirada aleatorizada, doble ciego, controlado \ncon placebo y multic\u00e9ntrico para investigar la eficacia y la seguridad de PF-04965842 \nen pacientes de 12 o m\u00e1s a\u00f1os de edad con dermatitis at\u00f3pica moderada o grave con \nla opci\u00f3n de un tratamiento de rescate para aquellos pacientes que presenten un em -\npeoramiento de la enfermedad. Type: Clinical Trial, phase III. \nHULP code: 5141. Sponsored\u00b4s protocol code: B7451015.\nSponsored by: Pfizer Inc. Signed date: 03/12/2018\nHerranz Pinto P . Estudio en fase III de retirada aleatorizada, doble ciego, controlado \ncon placebo y multic\u00e9ntrico para investigar la eficacia y la seguridad de PF-04965842 \nen pacientes de 12 o m\u00e1s a\u00f1os de edad con dermatitis at\u00f3pica moderada o grave con \nla opci\u00f3n de un tratamiento de rescate para aquellos pacientes que presenten un em -\npeoramiento de la enfermedad. Type: Clinical Trial, phase III. \nHULP code: 5089. Sponsored\u00b4s protocol code: B7451014.\nSponsored by: Pfizer Inc. Signed date: 20/11/2018\nHerranz Pinto P . Estudio multic\u00e9ntrico, aleatorizado, con doble enmascaramiento y \ncontrolado con placebo, para evaluar la eficacia y seguridad de Mirikizumab con Se -\ncukinumab y placebo en pacientes con psoriasis en placas moderada a grave - Oasis. \nType: Clinical Trial, phase III. \nHULP code: 5056. Sponsored\u00b4s protocol code: I6T -MC-AMAJ.\nSponsored by: Lilly S.A. Signed date: 07/05/2018\nHierro Llanillo L . Ensayo abierto y con un solo grupo para evaluar la farmacocin\u00e9tica, \nla seguridad y la eficacia de Daclatasvir (DCV) en combinaci\u00f3n con Sofosbuvir (SOF) \nen ni\u00f1os de entre 3 y menos de 18 a\u00f1os con infecci\u00f3n por los genotipos del 1 al 6 del \nvirus de la hepatitis cr\u00f3nica (HCC). Type: Clinical Trial, phase II. \nHULP code: 5118. Sponsored\u00b4s protocol code: AI44423.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 07/08/2018\nHierro Llanillo L . Estudio abierto de extensi\u00f3n para evaluar la eficacia y la seguridad a \nlargo plazo de A4250 en ni\u00f1os con colestasis intrahep\u00e1tica familiar progresiva de tipo \n1 y 2 (PEDFIC 2). Type: Clinical Trial, phase III. \nHULP code: 4970. Sponsored\u00b4s protocol code: A4250-008.\nSponsored by: Albireo AB. Signed date: 01/10/2018\nHierro Llanillo L . Estudio de fase 3 aleatorizado, con doble enmascaramiento, con -\ntrolado con placebo, para demostrar la eficacia y la seguridad de A4250 en ni\u00f1os con \ncolestasis intrahep\u00e1tica familiar progresiva de tipos 1 y 2 (PEDFIC 1). Type: Clinical Trial, \nphase III. \nHULP code: 4969. Sponsored\u00b4s protocol code: A4250-005.\nSponsored by: Albireo AB. Signed date: 17/04/2018\nHierro Llanillo L . Estudio de fase 3 aleatorizado, con doble enmascaramiento, con -\ntrolado con placebo, para demostrar la eficacia y la seguridad de A4250 en ni\u00f1os con \ncolestasis intrahep\u00e1tica familiar progresiva de tipos 1 y 2 (PEDFIC 1). Type: Clinical \nTrial, phase III. \nHULP code: Anexo-I 4969. Sponsored\u00b4s protocol code: A4250-005.Sponsored by: Albireo AB. Signed date: 17/09/2018\nHiguera G\u00f3mez O . Evaluaci\u00f3n de la calidad de vida de pacientes con estre\u00f1imiento \ninducido por opioides en tratamiento con Naloxegol. Estudio de un a\u00f1o de seguimien -\nto. Type: EPA-SP . \nHULP code: PI-2874. Sponsored\u00b4s protocol code: KYO-NAL-2017-01.\nSponsored by: Kyowa Kirin Farmac\u00e9utica S.L.U. Signed date: 10/01/2018\nHiguera G\u00f3mez O . Paciente fr\u00e1gil con dolor irruptivo: an\u00e1lisis de la pr\u00e1ctica cl\u00ednica. \nType: EPA-OD. \nHULP code: PI-3343. Sponsored\u00b4s protocol code: KYO-FRA-2018-01.\nSponsored by: Kyowa Kirin Farmac\u00e9utica S.L.U. Signed date: 22/08/2018\nHumala Barbier KK . Estudio de fase III, aleatorizado, doble ciego, multic\u00e9ntrico y \ncontrolado con placebo, de Pracinostat en combinaci\u00f3n con Azacitidina en pacientes \u2265 \n18 a\u00f1os con leucemia mieloide aguda (LMA) de diagn\u00f3stico reciente no aptos para la \nquimioterapia de inducci\u00f3n habitual. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4853. Sponsored\u00b4s protocol code: FRAN-16-52.\nSponsored by: Helsinn Healthcare S.A. Signed date: 17/04/2018\nHumala Barbier KK . Estudio en fase 3, multic\u00e9ntrico, doble ciego, aleatorizado y con -\ntrolado con placebo para evaluar AG-120 en combinaci\u00f3n con Azacitidina en sujetos \nde 18 a\u00f1os de edad o m\u00e1s con leucemia mieloide aguda con una mutaci\u00f3n de IDH1 sin \ntratamiento previo. Type: Clinical Trial, phase III. \nHULP code: 4866. Sponsored\u00b4s protocol code: AG120-C-009.\nSponsored by: Agios Pharmaceuticals Inc. Signed date: 11/01/2018\nHumala Barbier KK . Estudio observacional prospectivo sobre la supervivencia glo -\nbal y la calidad de vida en pacientes mayores de 60 a\u00f1os diagnosticados de leucemia \nmieloide aguda en Espa\u00f1a, tratados seg\u00fan la pr\u00e1ctica cl\u00ednica habitual. Estudio SVLMA. \nType: EPA-SP . \nHULP code: PI-3081. Sponsored\u00b4s protocol code: CEL-LMA-2017-01.\nSponsored by: Celgene S.L. Signed date: 10/09/2018\nIniesta P\u00e9rez S . Ensayo multic\u00e9ntrico, aleatorizado, doble ciego, controlado con pla -\ncebo para investigar la eficacia y seguridad de dos concentraciones de PKB171 frente \na placebo en parejas con astenozoospermia que desean concebir. Type: Clinical Trial, \nphase II. \nHULP code: 5092. Sponsored\u00b4s protocol code: PKB171-02.\nSponsored by: Scope International AG. Signed date: 23/08/2018\nIv\u00e1\u00f1ez Mora V . Estudio aleatorizado, doble ciego, controlado con placebo, de b\u00fas -\nqueda de dosis para evaluar la eficacia y la seguridad de Padsevonil como tratamiento \nadyuvante de crisis focales en sujetos adultos con epilepsia f\u00e1rmacorresistente. Type: \nClinical Trial, phase II. \nHULP code: 5026. Sponsored\u00b4s protocol code: EP0091.\nSponsored by: UCB Biosciencies GMBH. Signed date: 26/09/2018\nJim\u00e9nez Mart\u00edn C . Evaluaci\u00f3n de la consistencia cl\u00ednica y la solidez anal\u00edtica de Immu -\nnobiogram\u00ae como herramienta biotecnol\u00f3gica de diagn\u00f3stico in vitro para ayudar a la 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n57  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicianstoma de decisiones en el ajuste del tratamiento inmunodepresor del trasplante renal\u201d. \nEstudio Transbio. Type: NO-EPA. \nHULP code: PI-3105. Sponsored\u00b4s protocol code: BHP-IBG-2017-01.\nSponsored by: Biohope Scientific Solutions For Human Health S.L. Signed date: 13/02/2018\nJim\u00e9nez Mart\u00edn C . Impacto de los niveles de Tacr\u00f3limus en la prevenci\u00f3n del rechazo \nen pacientes de edad avanzada receptores de trasplante renal de novo: estudio obser -\nvacional prospectivo en las condiciones de la pr\u00e1ctica cl\u00ednica habitual. Estudio Bit\u00e1cora. \nType: EPA-SP . \nHULP code: PI-3314. Sponsored\u00b4s protocol code: CHI-TAC-2018-01.\nSponsored by: Chiesi Farmaceutici S.P .A. Signed date: 01/10/2018\nJim\u00e9nez yuste VM . Atlas-A/B: estudio de fase 3 para evaluar la eficacia y la seguridad \nde Fitusir\u00e1n en pacientes con hemofilia A o B sin anticuerpos inhibidores de los facto -\nres VIII o IX. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4919. Sponsored\u00b4s protocol code: ALN-AT3SC-004.\nSponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/12/2018\nJim\u00e9nez Yuste VM . Atlas-A/B: estudio de fase 3 para evaluar la eficacia y la seguridad \nde Fitusir\u00e1n en pacientes con hemofilia A o B sin anticuerpos inhibidores de los facto -\nres VIII o IX. Type: Clinical Trial, phase III. \nHULP code: 4919. Sponsored\u00b4s protocol code: ALN-AT3SC-004.\nSponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/02/2018\nJim\u00e9nez Yuste VM . Atlas-INH: estudio en fase 3 para evaluar la eficacia y la seguridad \nde Fitusir\u00e1n en pacientes con hemofilia A o B y anticuerpos inhibidores de los factores \nVIII o IX. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4918. Sponsored\u00b4s protocol code: ALN-AT3SC-003.\nSponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/12/2018\nJim\u00e9nez Yuste VM . ATLAS-INH: estudio en fase 3 para evaluar la eficacia y la seguridad \nde Fitusir\u00e1n en pacientes con hemofilia A o B y anticuerpos inhibidores de los factores \nVIII o IX. Type: Clinical Trial, phase III. \nHULP code: 4918. Sponsored\u00b4s protocol code: ALN-AT3SC-003.\nSponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/02/2018\nJim\u00e9nez Yuste VM . ATLAS-PPX: estudio abierto, internacional, de cambio de trata -\nmiento para evaluar la eficacia y la seguridad de la Profilaxis con Fitusiran en pacientes \ncon hemofilia A y B que recibian previamente Profilaxis con factores o agentes de \npuenteo. Type: Clinical Trial, phase III. \nHULP code: 4900. Sponsored\u00b4s protocol code: ALN-AT3SC-009/EFC15110.\nSponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 19/12/2018\nJim\u00e9nez Yuste VM . Estudio abierto, multic\u00e9ntrico y no controlado de la eficacia de \nRFVIIIFCrfviiifc para la inducci\u00f3n de tolerancia inmune (ITI) en sujetos con hemofilia a \ngrave con inhibidores que se someten al primer tratamiento de ITI. Type: Clinical Trial, \nphase IV. \nHULP code: Anexo-I 4899. Sponsored\u00b4s protocol code: 997HA402.\nSponsored by: Bioverativ Therapeutics Inc. Signed date: 31/01/2018Jim\u00e9nez Yuste VM . Estudio no intervencionista, prospectivo, en el que se eval\u00faan las \nhemorragias, las infusiones de factor VIII y los resultados percibidos por el paciente, en \npersonas con hemofilia a grave. Type: EPA-SP . \nHULP code: PI-3377. Sponsored\u00b4s protocol code: 270-902.\nSponsored by: Biomarin Pharmaceutical Inc. Signed date: 24/10/2018\nJim\u00e9nez Yuste VM . Explorer \u21225- ensayo multic\u00e9ntrico para evaluar la eficacia y segu -\nridad de la administraci\u00f3n de Concizumab en profilaxis en pacientes con hemofilia a \ngrave sin inhibidores. Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4821. Sponsored\u00b4s protocol code: NN7415-4255.\nSponsored by: Novo Nordisk A/S. Signed date: 04/06/2018\nJim\u00e9nez Yuste VM . Safety and efficacy of turoctocog Alfa pegol (n8-gp) in prophylaxis \nand treatment of bleeds in previously N8-GP treated patients with severe haemophilia \na \u201d (Pathfinder 8. Type: Clinical Trial, phase III. \nHULP code: 5061. Sponsored\u00b4s protocol code: NN7088-4410.\nSponsored by: Novo Nordisk A/S. Signed date: 13/06/2018\nLisbona Catal\u00e1n A . Estudio multic\u00e9ntrico espa\u00f1ol sobre la prevalencia e incidencia de \nla insuficiencia cardiaca en pacientes con diabetes tipo 2 en consultas hospitalarias del \n\u00e1mbito nacional. Type: NO-EPA. \nHULP code: PI-3231. Sponsored\u00b4s protocol code: DIABET -IC.\nSponsored by: Sociedad Espa\u00f1ola de Cardiolog\u00eda (SEC). Signed date: 30/05/2018\nLoeches Yague B . Estudio aleatorizado, multic\u00e9ntrico, doble ciego, para comparar la \neficacia y la seguridad de Ceftobiprol Medocaril con las de la Daptomicina en el trata -\nmiento de la bacteriemia por Staphylococcus Aureus, incluida la endocarditis infeccio -\nsa. Type: Clinical Trial, phase III. \nHULP code: 5171. Sponsored\u00b4s protocol code: BPR-CS-009.\nSponsored by: Basilea Pharmac\u00e9utica Ltd. Signed date: 14/11/2018\nL\u00f3pez Arrieta JM . Estudio en fase II, multic\u00e9ntrico, aleatorizado, doble ciego y \ncontrolado con placebo, en grupos paralelos, que eval\u00faa la eficacia y seguridad de \nMTAU9937A en pacientes con enfermedad de Alzheimer de fase prodr\u00f3mica a leve. \nType: Clinical Trial, phase II. \nHULP code: 4924. Sponsored\u00b4s protocol code: GN39763.\nSponsored by: Genentech Inc. Signed date: 18/05/2018\nL\u00f3pez Arrieta JM . Estudio en fase II, multic\u00e9ntrico, aleatorizado, doble ciego y contro -\nlado con placebo, en grupos paralelos, que eval\u00faa la eficacia y seguridad de MTAU9937a \nen pacientes con enfermedad de Alzheimer de fase prodr\u00f3mica a leve. Type: Clinical \nTrial, phase II. \nHULP code: Anexo-I 4924. Sponsored\u00b4s protocol code: GN39763.\nSponsored by: Genentech Inc. Signed date: 01/08/2018\nL\u00f3pez Carrasco A . Estudio aleatorizado, controlado con placebo, doble ciego, de gru -\npos paralelos, multic\u00e9ntrico, de dosis-respuesta para evaluar la eficacia y seguridad de \ndiferentes dosis orales de BAY 1128688 en mujeres con endometriosis sintom\u00e1tica \ndurante un tratamiento. Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4904. Sponsored\u00b4s protocol code: BAY 1128688/17472.2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n58  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansSponsored by: Bayer AG. Signed date: 18/09/2018\nL\u00f3pez Carrasco A . Estudio aleatorizado, doble ciego, de grupos paralelos, multic\u00e9ntri -\nco y de fase IIB para evaluar la eficacia y seguridad de dos dosis diferentes de Vilapri -\ns\u00e1n (BAY 1002670) frente a placebo en mujeres con endometriosis sintom\u00e1tica. Type: \nClinical Trial, phase II. \nHULP code: 5079. Sponsored\u00b4s protocol code: BAY1002670/15792.\nSponsored by: Bayer AG. Signed date: 25/09/2018\nL\u00f3pez de La Gu\u00eda A . Estudio en fase 2, multic\u00e9ntrico, abierto y de incremento es -\ncalonado y ampliaci\u00f3n de la dosis de Venetoclax en combinaci\u00f3n con Pomalidomida \ny Dexametasona en pacientes con Mieloma m\u00faltiple recidivante o resistente. Type: \nClinical Trial, phase II. \nHULP code: 5082. Sponsored\u00b4s protocol code: M16-085.\nSponsored by: Abbvie Deutschland GMBH. Signed date: 24/10/2018\nL\u00f3pez de La Gu\u00eda A . Estudio observacional para describir el impacto de las combi -\nnaciones de tratamiento con Daratumumab frente a otros tratamientos alternativos \nen pacientes con mieloma m\u00faltiple en reca\u00edda /refractario (MMRR). Datos de pr\u00e1ctica \ncl\u00ednica habitual en Espa\u00f1a (G\u00e9minis). Type: EPA-SP . \nHULP code: PI-3315. Sponsored\u00b4s protocol code: JAN-DAR-2018-01.\nSponsored by: Janssen-Cilag Espa\u00f1a S.A. Signed date: 14/09/2018\nL\u00f3pez de Sa Areces E . Ensayo pivotal europeo COOL-AMI: un ensayo multic\u00e9ntrico, \nprospectivo, aleatorizado y controlado en el que se eval\u00faan la seguridad y la eficacia \ndel enfriamiento como tratamiento adyuvante en las intervenciones percut\u00e1neas de \npacientes con infarto agudo. Type: Producto Sanitario. \nHULP code: 5113. Sponsored\u00b4s protocol code: COOL-AMI EU EDC 35.\nSponsored by: Zoll Circulation Inc. Signed date: 05/07/2018\nL\u00f3pez de Sa Areces E . Estudio cl\u00ednico unic\u00e9ntrico de una serie de casos para evaluar \nla viabilidad de integrar la hipotermia terap\u00e9utica con el sistema IVTM de Zoll como \nadjuvante de la angioplastia coronaria percut\u00e1nea en pacientes con infarto agudo de \nmiocardio. Type: Producto Sanitario. \nHULP code: Anexo-I 4749. Sponsored\u00b4s protocol code: COOL-AMI.\nSponsored by: Zoll Circulation Inc. Signed date: 19/01/2018\nL\u00f3pez de Sa Areces E . Estudio de fase IIB, randomizado, controlado con placebo para \nevaluar la seguridad y la eficacia de MEDI6012 en el infarto de miocardio agudo con \nelevaci\u00f3n del segmento. Type: Clinical Trial, phase II. \nHULP code: 5029. Sponsored\u00b4s protocol code: D5780C00007.\nSponsored by: Medimmune. Signed date: 05/03/2018\nL\u00f3pez Fern\u00e1ndez T. Epiq-affiniti ultrasound system study for cardiology. Type: NO-EPA. \nHULP code: PI-2996. Sponsored\u00b4s protocol code: 253494.\nSponsored by: Philips Ultrasound Inc. Signed date: 04/04/2018\nL\u00f3pez Oliva MO . Suspensi\u00f3n de la profilaxis con Valganciclovir en trasplantados rena -\nles CMV-seropositivo que mantienen la inmunidad celular CD8+ CMV-espec\u00edfica tras \nrecibir Timoglobulina. Type: Clinical Trial, phase III. HULP code: Anexo-I 4892. Sponsored\u00b4s protocol code: FCO-TIM-2015-01.\nSponsored by: Fundaci\u00f3n Para La Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (Fibico-Imibic). \nSigned date: 22/10/2018\nL\u00f3pez Ortego P . Ensayo cl\u00ednico fase I para establecer la seguridad del uso de c\u00e9lu -\nlas mesenquimales alog\u00e9nicas en pacientes prematuros con displasia broncopulmonar. \nType: Clinical Trial, phase I. \nHULP code: 4734. Sponsored\u00b4s protocol code: PULMESCEL-01.\nSponsored by: Fundaci\u00f3n Hospital Ram\u00f3n y Cajal. Signed date: 12/10/2018\nL\u00f3pez Ortego P . Retrospective cohort safety study of captopril administered for \nprevention or treatment of heart failure in paediatric patients from birth to 1 year of \nage. Type: EPA-OD. \nHULP code: pi-3351. Sponsored\u00b4s protocol code: PRO-CAP-2018-01.\nSponsored by: Proveca Ltd. Signed date: 17/10/2018\nL\u00f3pez-Send\u00f3n Hentsche JL . Estudio de fase III fundamental, multic\u00e9ntrico, aleatoriza -\ndo, doble ciego, controlado con placebo, de grupos paralelos y determinado por los epi -\nsodios para evaluar la eficacia y la seguridad de Vericiguat, un estimulador de la guanilato \nciclasa soluble (GCS) por v\u00eda oral, en sujetos con insuficiencia card\u00edaca con fracci\u00f3n de \neyecci\u00f3n disminuida (ICFED): estudio Victoria (Vericiguat Global Study in Subjects with \nHeart Failure with Reduced Ejection Fraction). Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4685. Sponsored\u00b4s protocol code: 1242-001.\nSponsored by: Merck Sharp and Dohme de Espa\u00f1a S.A. Signed date: 10/09/2018\nL\u00f3pez-Send\u00f3n Hentschel JL . Ensayo de fase III, aleatorizado y doble ciego para eva -\nluar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en com -\nparaci\u00f3n con placebo en pacientes con insuficiencia card\u00edaca cr\u00f3nica con fracci\u00f3n de \neyecci\u00f3n preservada (ICC-FEP). Type: Clinical Trial, phase III. \nHULP code: 4988. Sponsored\u00b4s protocol code: 1245.110.\nSponsored by: Boehringer Ingelheim International GMBH. Signed date: 14/03/2018\nL\u00f3pez-Send\u00f3n Hentschel JL . Ensayo en fase III, aleatorizado y doble ciego para eva -\nluar la eficacia y la seguridad de una dosis diaria de 10 mg de Empagliflozina en compa -\nraci\u00f3n con el placebo en pacientes con insuficiencia card\u00edaca cr\u00f3nica con fracci\u00f3n de \neyecci\u00f3n reducida (ICC-FER). Type: Clinical Trial, phase III. \nHULP code: 5001. Sponsored\u00b4s protocol code: 1245.121.\nSponsored by: Boehringer Ingelheim International GMBH. Signed date: 10/04/2018\nL\u00f3pez-Sendon Hentschel JL . Estudio aleatorizado, doble ciego, controlado con pla -\ncebo, de grupos paralelos, multic\u00e9ntrico, para demostrar los efectos de Sotagliflozina \nsobre los eventos cardiovasculares y renales en pacientes con diabetes tipo 2, factores \nde riesgo cardiovascular y funci\u00f3n renal moderadamente reducida (SCORED). Type: \nClinical Trial, phase III. \nHULP code: Anexo-I 4943. Sponsored\u00b4s protocol code: EFC14875.\nSponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 13/02/2018\nL\u00f3pez-Send\u00f3n Hentschel JL . Estudio de Colchicina en eventos cardiovasculares. Type: \nClinical Trial, phase III. \nHULP code: 4946. Sponsored\u00b4s protocol code: COLCOT.2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n59  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansSponsored by: Montreal Heart Institute. Signed date: 25/01/2018\nMart\u00edn Arranz E . Eficacia de los bolos intravenosos de corticoides m\u00e1s tratamiento \ncon corticoides orales en comparaci\u00f3n con corticoides orales en monoterapia para el \ntratamiento de la colitis. Type: Clinical Trial, phase IV. \nHULP code: 5044. Sponsored\u00b4s protocol code: CECUM.\nSponsored by: Geteccu (Grupo Espa\u00f1ol de Trabajo En Enfermedad de Crhon y Colitis \nUlcerosa). Signed date: 21/03/2018\nMart\u00cdn Arranz MD . Ensayo abierto y a largo plazo de la seguridad del tratamiento con \nBI 655130 en pacientes con colitis ulcerosa activa moderada o grave que han finalizado \nensayos anteriores de BI 655130. Type: Clinical Trial, phase II. \nHULP code: 5142. Sponsored\u00b4s protocol code: BI655130.\nSponsored by: Boehringer Ingelheim Espa\u00f1a S.A. Signed date: 13/09/2018\nMart\u00edn Arranz MD . Estudio abierto de extensi\u00f3n y supervisi\u00f3n de la seguridad de \npacientes con colitis ulcerosa de moderada a grave previamente inscritos en Estudios \nde fase III con Etrolizuma. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4274. Sponsored\u00b4s protocol code: GA28951.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 20/04/2018\nMart\u00edn Arranz MD . Estudio de ampliaci\u00f3n de fase 3, multic\u00e9ntrico, sin enmascaramien -\nto en el que se eval\u00faa Ozanimod por v\u00eda oral para la enfermedad de Crohn activa de \nmoderada a grave. Type: Clinical Trial, phase III. \nHULP code: 5025. Sponsored\u00b4s protocol code: RPC01-3204.\nSponsored by: Celgene International SARL. Signed date: 19/11/2018\nMart\u00edn Arranz MD . Estudio de fase 3, aleatorizado, doble ciego, controlado con pla -\ncebo y de grupos paralelos para evaluar la eficacia y la seguridad de SHP647 como \ntratamiento de inducci\u00f3n en sujetos con enfermedad de Crohn de moderada a grave \n(Carmen CD 306). Type: Clinical Trial, phase III. \nHULP code: 5085. Sponsored\u00b4s protocol code: SHP647-306.\nSponsored by: Shire Human Genetic Therapies Inc. Signed date: 24/05/2018\nMart\u00edn Arranz MD . Estudio de fase 3, aleatorizado, doble ciego, controlado con pla -\ncebo y de grupos paralelos para evaluar la eficacia y la seguridad de SHP647 como \ntratamiento de mantenimiento en sujetos con enfermedad de Crohn de moderada a \ngrave (Carmen CD 307). Type: Clinical Trial, phase III. \nHULP code: 5086. Sponsored\u00b4s protocol code: SHP647-307.\nSponsored by: Shire Human Genetic Therapies Inc. Signed date: 24/05/2018\nMart\u00edn Arranz MD . Estudio de fase 3, de extensi\u00f3n de seguridad a largo plazo de \nSHP647 en sujetos con colitis ulcerosa de moderada a grave (AIDA). Type: Clinical \nTrial, phase III. \nHULP code: Anexo-I 4965. Sponsored\u00b4s protocol code: SHP647-304.\nSponsored by: Shire Human Genetic Therapies Inc. Signed date: 25/05/2018\nMart\u00cdn Arranz MD . Estudio de fase 3, multic\u00e9ntrico, aleatorizado, con enmascaramien -\nto doble y comparativo con placebo, en el que se eval\u00faa Ozanimod por v\u00eda oral como \ntratamiento de mantenimiento para la enfermedad de Crohn activa de moderada a \ngrave. Type: Clinical Trial, phase III. HULP code: 5024. Sponsored\u00b4s protocol code: RPC01-3203.\nSponsored by: Celgene International SARL. Signed date: 19/11/2018\nMart\u00edn Arranz MD . Estudio de fase III multic\u00e9ntrico, doble ciego y controlado con pla -\ncebo de la eficacia y seguridad de Etrolizumab durante la inducci\u00f3n y el mantenimiento \nen pacientes con colitis ulcerosa activa de moderada a grave resistentes o intolerantes \na los inhibidores del FNT. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4188. Sponsored\u00b4s protocol code: GA28950.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 04/06/2018\nMart\u00edn Arranz MD . Estudio de fase III, aleatorizado, multic\u00e9ntrico, doble ciego, con \ndoble simulaci\u00f3n, para evaluar la eficacia y seguridad de Etrolizumab comparado con \nInfliximab en pacientes con colitis ulcerosa activa entre moderada e intensa que no \nhan recibido tratamiento previo con inhibidores del FNT. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4273. Sponsored\u00b4s protocol code: GA29103.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 24/04/2018\nMart\u00edn Arranz MD . Estudio de inducci\u00f3n en fase III, multic\u00e9ntrico, aleatorizado, do -\nble ciego, de grupos paralelos, controlado con placebo, para evaluar Mirikizumab en \npacientes con colitis ulcerosa moderada o gravemente activa sin respuesta a los trata -\nmientos convencionales. Type: Clinical Trial, phase III. \nHULP code: 5099. Sponsored\u00b4s protocol code: I6T -MC-AMAN.\nSponsored by: Eli Lilly Co Uk Ltd. Signed date: 16/07/2018\nMart\u00edn Arranz MD . Estudio de inducci\u00f3n multic\u00e9ntrico, aleatorizado, doble ciego y \ncomparado con placebo para evaluar la eficacia y la seguridad de Padacitinib (ABT -\n494) en sujetos con enfermedad de Crohn de moderada a grave que han tenido una \nrespuesta insuficiente o intolerancia a un tratamiento convencional pero no han pre -\nsentado fracaso terap\u00e9utico con f\u00e1rmacos biol\u00f3gicos. Type: Clinical Trial, phase III. \nHULP code: 4967. Sponsored\u00b4s protocol code: M14-431.\nSponsored by: Abbott Laboratories S.A. Signed date: 24/07/2018\nMart\u00edn Arranz MD . Estudio de inducci\u00f3n multic\u00e9ntrico, aleatorizado, doble ciego y \ncomparado con placebo para evaluar la eficacia y la seguridad de Upadacitinib (ABT -\n494) en sujetos con enfermedad de Crohn de moderada a grave que han tenido una \nrespuesta insuficiente o intolerancia a un tratamiento convencional pero no han pre -\nsentado fracaso terap\u00e9utico con f\u00e1rmacos biol\u00f3gicos. Type: Clinical Trial, phase III. \nHULP code: 4966. Sponsored\u00b4s protocol code: M14-433.\nSponsored by: Abbvie Spain S.L.U. Signed date: 16/07/2018\nMart\u00edn Arranz MD . Estudio de inducci\u00f3n N\u00ba 1 - fase 3, multic\u00e9ntrico, aleatorizado, con \nenmascaramiento, doble y comparativo con placebo, en el que se eval\u00faa Ozanimod \npor v\u00eda oral como tratamiento de inducci\u00f3n para la enfermedad de Crohn activa de \nmoderada a grave. Type: Clinical Trial, phase III. \nHULP code: 5022. Sponsored\u00b4s protocol code: RPC01-3201.\nSponsored by: Celgene International SARL. Signed date: 13/09/2018\nMart\u00edn Arranz MD . Estudio de mantenimiento en fase III, multic\u00e9ntrico, aleatorizado, \ndoble ciego, de grupos paralelos, controlado con placebo sobre Mirikizumab en pacien -\ntes con colitis ulcerosa activa de moderada a grave. (LUCENT 2). Type: Clinical Trial, \nphase III. 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n60  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansHULP code: 5100. Sponsored\u00b4s protocol code: I6T -MC-AMBG.\nSponsored by: Eli Lilly Co Uk Ltd. Signed date: 16/07/2018\nMart\u00edn Arranz MD . Estudio en fase 1 abierto, aleatorizado, de grupos paralelos para \nevaluar la farmacocin\u00e9tica, la eficacia y la seguridad de CT -P13 subcut\u00e1neo y CT -P13 \nintravenoso en pacientes con enfermedad activa de Crohn y pacientes con colitis \nulcerosa activa. Type: Clinical Trial, phase I. \nHULP code: Anexo-I 4901. Sponsored\u00b4s protocol code: CT -P13 1.6.\nSponsored by: Celltrion Inc. Signed date: 16/03/2018\nMart\u00edn Arranz MD . Estudio multic\u00e9ntrico aleatorizado, doble ciego y controlado con \nplacebo de mantenimiento y de extensi\u00f3n a largo plazo, para evaluar la eficacia y la \nseguridad de Upadacitinib (ABT -494) en sujetos con enfermedad de Crohn que han \nfinalizado los Estudios M1. Type: Clinical Trial, phase III. \nHULP code: 4968. Sponsored\u00b4s protocol code: M14-430.\nSponsored by: Abbvie Deutschland GMBH. Signed date: 17/08/2018\nMart\u00edn Arranz MD . Estudio multic\u00e9ntrico de fase II/III aleatorizado, doble ciego y \ncontrolado con placebo, para evaluar la seguridad y la eficacia del tratamiento de \ninducci\u00f3n con BI 655130 en pacientes con colitis ulcerosa activa de moderada a grave \nque no han respondido al tratamiento previo con f\u00e1rmacos biol\u00f3gicos. Type: Clinical \nTrial, phase II. \nHULP code: 5011. Sponsored\u00b4s protocol code: 1368.5.\nSponsored by: Boehringer Ingelheim Espa\u00f1a S.A. Signed date: 01/06/2018\nMart\u00edn Arranz MD . Estudio multic\u00e9ntrico, aleatorizado, doble ciego, controlado con \nplacebo, prueba de concepto de Ustekinumab en pacientes con lupus eritematoso \nsist\u00e9mico activo. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4765. Sponsored\u00b4s protocol code: CNTO1275CRD3005.\nSponsored by: Janssen Cilag International NV. Signed date: 14/06/2018\nMart\u00edn Arranz MD . Estudio paralelo de fase IIA multic\u00e9ntrico, aleatorizado, doble \nciego y controlado con placebo para evaluar la eficacia y la seguridad de PRV-6527 \n(JNJ-40346527), un inhibidor del receptor del factor 1 estimulante de colonias, por v\u00eda \noral, en pacientes con enfermedad de Crohn activa moderada o grave. Type: Clinical \nTrial, phase II. \nHULP code: 5008. Sponsored\u00b4s protocol code: PRV-6527-CD2A.\nSponsored by: Provention Bio Inc. Signed date: 02/02/2018\nMart\u00edn Arranz MD . Exploraci\u00f3n de la posible interferencia de la microbiotaintestinal \nen la respuesta cl\u00ednica al Vedolizumab en pacientes con colitis ulcerosa. Type: EPA-SP . \nHULP code: PI-3276. Sponsored\u00b4s protocol code: FGA-VDE-2016-01.\nSponsored by: Fundaci\u00f3 Hospital Vall D\u2019Hebron. Signed date: 19/09/2018\nMart\u00edn Arranz MD . Registro de exposici\u00f3n a largo plazo prospectivo y observacional \nde pacientes adultos con colitis ulceregistro de exposici\u00f3n a largo plazo prospectivo y \nobservacional de pacientes adultos con colitis ulcerosa moderada a graverosa mode -\nrada a grave. Type: Clinical Trial, phase EPA-SP . \nHULP code: PI-2741. Sponsored\u00b4s protocol code: CNTO148UCO4001.\nSponsored by: Mapi Life Sciences Uk Limited. Signed date: 25/04/2018Mart\u00edn Arranz MD . Un estudio de b\u00fasqueda de dosis en fase II, multic\u00e9ntrico, aleato -\nrizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de \nIMU-838 en terapia de inducci\u00f3n y mantenimiento en colitis ulcerosa de moderada a \ngrave (Caldose-1). Type: Clinical Trial, phase II. \nHULP code: 5023. Sponsored\u00b4s protocol code: PS-IMU-838-UC.\nSponsored by: Immunic AG. Signed date: 05/06/2018\nMart\u00edn Arranz MD . Un estudio de b\u00fasqueda de dosis en fase II, multic\u00e9ntrico, aleato -\nrizado, doble ciego, controlado por placebo para evaluar la eficacia y la seguridad de \nIMU-838 en terapia de inducci\u00f3n y mantenimiento en colitis ulcerosa de moderada a \ngrave (Caldose-1). Type: Clinical Trial, phase II. \nHULP code: Anexo-I 5023. Sponsored\u00b4s protocol code: PS-IMU-838-UC.\nSponsored by: Immunic AG. Signed date: 17/09/2018\nMart\u00edn Carbonero L . Combinaci\u00f3n de dosis fija de Bictegravir/Emtricitabina/T eno -\nfovir Alafenamida frente a Dolutegravir + Emtricitabina/Fumarato de Disoproxilo de \nT enofovir en adultos no tratados anteriormente coingectados por el VIH-1 y el virus \nde la hepatitis B. Type: Clinical Trial, phase III. \nHULP code: 5110. Sponsored\u00b4s protocol code: GS-US-380-4458.\nSponsored by: Gilead Sciences Inc. Signed date: 12/07/2018\nMart\u00edn Salces M . Estudio en fase III, prospectivo, abierto, internacional y multic\u00e9ntrico \nsobre la eficacia y la seguridad de la Profilaxis con RVWF en la enfermedad grave de \nVon Willebrand. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4884. Sponsored\u00b4s protocol code: 071102.\nSponsored by: Baxalta Innovations GMGB. Signed date: 10/04/2018\nMart\u00ednez Mar\u00edn V . Apixab\u00e1n para el tratamiento del tromboembolismo venoso en \npacientes con c\u00e1ncer: un estudio prospectivo aleatorizado abierto y ciego para el \nevaluador - el estudio Caravaggio. Type: Clinical Trial, phase III. \nHULP code: 5034. Sponsored\u00b4s protocol code: FADOI.03.2016.\nSponsored by: Exom Group SRL. Signed date: 22/05/2018\nMart\u00ednez Mar\u00edn V . Apixab\u00e1n para el tratamiento del tromboembolismo venoso en \npacientes con c\u00e1ncer: un estudio prospectivo aleatorizado abierto y ciego para el \nevaluador . El estudio Caravaggio. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 5034. Sponsored\u00b4s protocol code: FADOI.03.2016.\nSponsored by: Exom Group SRL. Signed date: 26/11/2018\nMart\u00ednez Mar\u00edn V . Estudio en fase III, internacional, multic\u00e9ntrico, abierto y aleatoriza -\ndo de BLU 285 en comparaci\u00f3n con Regorafenib en pacientes con tumor del estroma \ngastrointestinal (GIST) metast\u00e1sico o irresecable localmente avanzado. Type: Clinical \nTrial, phase III. \nHULP code: 5054. Sponsored\u00b4s protocol code: BLU-285-1303.\nSponsored by: Blueprint Medicines Corporation. Signed date: 30/07/2018\nMart\u00ednez Mar\u00edn V . Estudio en fase III, internacional, multic\u00e9ntrico, abierto y aleatoriza -\ndo de BLU 285 en comparaci\u00f3n con Regorafenib en pacientes con tumor del estroma \ngastrointestinal (GIST) metast\u00e1sico o irresecable localmente avanzado. Type: Clinical \nTrial, phase III. 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n61  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansHULP code: Anexo-I 5054. Sponsored\u00b4s protocol code: BLU-285-1303.\nSponsored by: Blueprint Medicines Corporation. Signed date: 04/12/2018\nMart\u00ednez Mar\u00edn V . Observational epidemiological study of cancer-associated throm -\nbosis: registry of thrombosis and neoplasia of SEOM./Estudio epidemiol\u00f3gico obser -\nvacional descriptivo sobre la trombosis asociada al c\u00e1ncer: registro de trombosis y \nneoplasias de la SEOM. Type: EPA-SP . \nHULP code: PI-3417. Sponsored\u00b4s protocol code: SEOM-TESEO-2017-01.\nSponsored by: Fundaci\u00f3n Seom. Signed date: 07/11/2018\nMart\u00ednez M\u00e9ndez JR . Estudio de recogida de datos internacional, observacional y \nretrospectivo en el que se eval\u00faa la eficacia de las medidas de minimizaci\u00f3n de riesgos \naplicadas en pacientes quemados tratados con Nexobrid. Type: EPA-OD. \nHULP code: PI-2885. Sponsored\u00b4s protocol code: MW2013-06-0.\nSponsored by: Mediwound Ltd. Signed date: 13/02/2018\nMart\u00ednez Moreno M . Seguimiento cl\u00ednico posterior a la comercializaci\u00f3n en Eruropa \nde Synchromed II bajo la plataforma para el registro de vigilancia de producto (PSR) \nespec\u00edfico para la terapia neurol\u00f3gica - administraci\u00f3n de f\u00e1rmaco selectiva. Type: Pro -\nducto Sanitario. \nHULP code: Anexo-I 4947. Sponsored\u00b4s protocol code: PSR-TDD PMCF .\nSponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 27/06/2018\nMart\u00ednez Moreno M . Seguimiento cl\u00ednico posterior a la comercializaci\u00f3n en europa \nde Synchromed II bajo la plataforma para el registro de vigilancia de producto (PSR) \nespec\u00edfico para la terapia neurol\u00f3gica - administraci\u00f3n de f\u00e1rmaco selectiva. Type: Pro -\nducto Sanitario. \nHULP code: 4947. Sponsored\u00b4s protocol code: PSR-TDD PMCF .\nSponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 07/03/2018\nMaseda Garrido E . Estudio observacional del tratamiento cl\u00ednico de ITUC, IIAC y \nNBIH/NBAV atribuibles a infecciones por bacilos gramnegativos resistentes a carba -\npenemas (EU-CARE). Type: EPA-OD. \nHULP code: PI-3150. Sponsored\u00b4s protocol code: MER-ANT -2017-01.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 07/05/2018\nMaseda Pedrero R . Un primer estudio en humanos, a doble ciego, aleatorio, intraindi -\nvidual, controlado por placebo, con dosis m\u00faltiples de QR-313 evaluando la seguridad, \nprueba de mecanismo, la eficacia preliminar y la exposici\u00f3n sist\u00e9mica en sujetos con \nepiderm\u00f3lisis bullo. Type: Clinical Trial, phase II. \nHULP code: 5072. Sponsored\u00b4s protocol code: PQ-313-002.\nSponsored by: Proqr Therapeutics VII B.V. Signed date: 03/10/2018\nMellado Pe\u00f1a MJ.  Estrategia para el mantenimiento de la supresi\u00f3n del VIH en ni\u00f1os \ncon Elvitegravir+ Darunavir/Ritonavir (PENTA 17). Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4492. Sponsored\u00b4s protocol code: PENTA 17-SMILE.\nSponsored by: Fondazione Penta Onlus. Signed date: 18/01/2018\nMellado Pe\u00f1a MJ . Estudio de fase 2B, multic\u00e9ntrico, aleatorizado, doble ciego y \ncontrolado con placebo para evaluar la seguridad, la tolerabilidad, la eficacia y la inmunogenecidad de una pauta de 2 y 3 dosis de V160 (Vacuna Contra el Citome -\ngalovirus (CMV) en mujeres sanas seronegativas de 16 a 35 a\u00f1os de edad. Type: \nClinical Trial, phase II. \nHULP code: 5093. Sponsored\u00b4s protocol code: V160-002.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 28/05/2018\nMerino Llorens JL . Estudio eficaz: \u201ceficacia de choque de cardioversi\u00f3n/desfibrilaci\u00f3n, \nun estudio aleatorizado que compara la pendiente fija y la anchura de impulso fija \nen una poblaci\u00f3n general con desfibrilador autom\u00e1tico implantable\u201d. Type: Producto \nSanitario. \nHULP code: 5067. Sponsored\u00b4s protocol code: CRD-914/SJM-CIP-10221.\nSponsored by: Abbott Medical Espa\u00f1a S.A. Signed date: 18/04/2018\nMiguel Mendieta ED . Estudio multic\u00e9ntrico, observacional no intervencionista, trans -\nversal y retrospectivo, para evaluar el control de la actividad de la enfermedad en \ncondiciones de pr\u00e1ctica cl\u00ednica habitual en pacientes con espondilitis anquilosante y \nartritis psori\u00e1sica tratados en consultas de reumatolog\u00eda de Espa\u00f1a (Estudio Midas). \nType: EPA-OD. \nHULP code: PI-3434. Sponsored\u00b4s protocol code: CAIN457FES03.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 23/11/2018\nMontes Ram\u00edrez ML . Cohorte espa\u00f1ola de pacientes con infecci\u00f3n por VIH mayores \nde 50 a\u00f1os para el estudio de fragildad y la funci\u00f3n f\u00edsica (HIV-FUNCFRAIL). Type: \nEPA-SP . \nHULP code: PI-3056. Sponsored\u00b4s protocol code: FSG-TAR-2017-01 GESIDA.\nSponsored by: Fundaci\u00f3n SEIMC-GESIDA. Signed date: 07/03/2018\nMorado Arias M . Estudio en fase 3, aleatorizdo, controlado con placebo y doble ciego \npara evaluar la eficiencia y la seguridad de AG-348 en sujetos adultos con deficiencia \nde piruvato cinasa (PK) que no reciben transfusiones peri\u00f3dicamente. Type: Clinical \nTrial, phase III. \nHULP code: 5077. Sponsored\u00b4s protocol code: AG348-C-006.\nSponsored by: Agios Pharmaceuticals Inc. Signed date: 04/09/2018\nMorado Arias M . Registro longitudinal internacional de deficiencia de piruvato cinasa \no piruvato quinasa. Type: EPA-SP . \nHULP code: PI-3316. Sponsored\u00b4s protocol code: AG348-C008.\nSponsored by: Agios Pharmaceuticals Inc. Signed date: 24/07/2018\nMoreno G\u00f3mez JR . Edoxab\u00e1n frente al tratamiento est\u00e1ndar y sus efectos en los re -\nsultados cl\u00ednicos de los pacientes que se han sometido a una implantaci\u00f3n de v\u00e1lvula \na\u00f3rtica transcat\u00e9ter (en fibrilaci\u00f3n auricular). Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4843. Sponsored\u00b4s protocol code: DU176B-C-U4001.\nSponsored by: Daiichi Sankyo Inc. Signed date: 18/04/2018\nMoreno G\u00f3mez JR . Ensayo Cl\u00ednico aleatorizado para comparar la eficacia del Stent \nAngiolite frente a un stent farmacoactivo de segunda generaci\u00f3n como Xience en pa -\ncientes con indicaci\u00f3n de intervenci\u00f3n coronaria percut\u00e1nea. Type: Producto Sanitario. \nHULP code: Anexo-I 4517. Sponsored\u00b4s protocol code: ANGIOLITE.\nSponsored by: Cardiva2 S.L. Signed date: 19/02/20182.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n62  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansMoreno G\u00f3mez JR . Ensayo pivotal europeo COOL-AMI: un ensayo multic\u00e9ntrico, \nprospectivo, aleatorizado y controlado en el que se eval\u00faan la seguridad y la eficacia \ndel enfriamiento como tratamiento adyuvante en las intervenciones percut\u00e1neas de \npacientes con infarto agudo. Type: Producto Sanitario. \nHULP code: 5113. Sponsored\u00b4s protocol code: COOL-AMI EU EDC 35.\nSponsored by: Zoll Circulation Inc. Signed date: 05/07/2018\nMoreno G\u00d3mez JR . Estrategias de revascularizaci\u00f3n percutanea completa utilizando \nstents liberadores de Sirolimus recubiertos de polimero biodegradable en pacientes \ncon s\u00cdndrome coronario agudo y enfermedad coronaria multivaso. Type: Producto Sa -\nnitario. \nHULP code: 5189. Sponsored\u00b4s protocol code: BIOVASC.\nSponsored by: Erasmus Mc Holding B.V. Signed date: 18/12/2018\nMoreno G\u00f3mez JR . estudio cl\u00ednico unic\u00e9ntrico de una serie de casos para evaluar la \nviabilidad de integrar la hipotermia terap\u00e9utica con el sistema IVTM de Zoll como \nadjuvante de la angioplastia coronaria percut\u00e1nea en pacientes con infarto agudo de \nmiocardio. Type: Producto Sanitario. \nHULP code: Anexo-I 4749. Sponsored\u00b4s protocol code: COOL-AMI.\nSponsored by: Zoll Circulation Inc. Signed date: 19/01/2018\nMoreno G\u00f3mez JR . Estudio con tomograf\u00eda de coherencia \u00f3ptica a 9 meses en stent \nfarmacoactivo de pol\u00edmero abluminal bioestable y sirolimus. Type: Producto Sanitario. \nHULP code: 5094. Sponsored\u00b4s protocol code: IHT -DES-2018-01.\nSponsored by: Iberhospitex S.A. Signed date: 12/11/2018\nMoreno G\u00f3mez JR . Estudio Onyx One; un estudio aleatorizado y controlado con el \nStent Resolute Onyx y tratamiento de doble antiagregaci\u00f3n plaquetaria [dapt] de un \nmes para pacientes con alto riesgo de sangrado. Type: Producto Sanitario. \nHULP code: Anexo-I 4961. Sponsored\u00b4s protocol code: ONYX ONE.\nSponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 03/10/2018\nMoreno G\u00f3mez JR . Estudio Onyx One; un estudio aleatorizado y controlado con el \nStent Rresolute Onyx y tratamiento de doble antiagregaci\u00f3n plaquetaria [DAPT] de \nun mes para pacientes con alto riesgo de sangrado. Type: Producto Sanitario. \nHULP code: 4961. Sponsored\u00b4s protocol code: ONYX ONE.\nSponsored by: Medtronic Bakkeen Research Center B.V. Signed date: 05/01/2018\nMoreno G\u00f3mez JR . Evaluaci\u00f3n de la eficacia (ACC) y la seguridad de la endopr\u00f3tesis \nrecubierta con Biolimus A9TM Biofreedomtm de COCR en un ensayo aleatorizado \nen pacientes con coronariopat\u00eda (ACC con Biofreedomtm). Type: Producto Sanitario. \nHULP code: 5042. Sponsored\u00b4s protocol code: 17-EU-02.\nSponsored by: Biosensors Europe S.A. Signed date: 09/10/2018\nMozo Del Castillo Y . Estudio de fase III, aleatorizado, abierto y multic\u00e9ntrico de Ruxo -\nlitinib frente a la mejor terapia disponible en pacientes con enfermedad de injerto \ncontra hu\u00e9sped aguda y refractaria a corticosteroides en trasplante alog\u00e9nico de pro -\ngenitores hematopoy\u00e9ticos. Type: Clinical Trial, phase III. \nHULP code: 5087. Sponsored\u00b4s protocol code: CINC424C2301.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 28/05/2018Murias Loza SM . Registro observacional de Abatacept en pacientes con artritis idio -\np\u00e1tica juvenil. Type: EPA-LA. \nHULP code: Anexo-I PI-2079. Sponsored\u00b4s protocol code: IM101240.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 19/12/2018\nN\u00fa\u00f1ez L\u00f3pez MC . Estudio observacional para evaluar la fragilidad de los sujetos du -\nrante los Estudios Zoster-006 y Zoster-022 y la eficacia frente a Hz, la inmunogeni -\ncidad y la seguridad de la vacuna HZ/SU seg\u00fan el estado de fragilidad. Type: EPA-OD. \nHULP code: PI-3344. Sponsored\u00b4s protocol code: 204878 ZOSTER-064.\nSponsored by: Glaxosmithkline S.A. Signed date: 24/08/2018\nOlveira M\u00e1rt\u00edn A . Estudio en fase III, aleatorizado y doble ciego de Nivolumab adyu -\nvante frente a placebo para participantes con carcinoma hepatocelular que presentan \nun riesgo alto de reca\u00edda despu\u00e9s de la resecci\u00f3n o la ablaci\u00f3n hep\u00e1tica con intenci\u00f3n \ncurativa. Type: Clinical Trial, phase III. \nHULP code: 4989. Sponsored\u00b4s protocol code: CA209-9DX.\nSponsored by: Bristol Myers Squibb International Corporation. Signed date: 21/03/2018\nOlveira Mart\u00edn A . Estudio multic\u00e9ntrico de fase III, doble ciego, aleatorizado, a largo \nplazo y controlado con placebo para evaluar la seguridad y la eficacia del \u00c1cido Obeti -\nc\u00f3lico en sujetos con esteatohepatitis no alcoh\u00f3lica. Type: Clinical Trial, phase III. \nHULP code: 4999. Sponsored\u00b4s protocol code: 747-304.\nSponsored by: Intercept Pharmaceuticals Inc. Signed date: 24/08/2018\nOrtega Flor\u00eda AB . Ensayo cl\u00ednico de fase 4, aleatorizado, doble ciego y controlado \ncon comparador activo para estudiar la eficacia, la seguridad y la farmacocin\u00e9tica de \nDugammadex (MK-8616) para neutralizar el bloqueo neuromuscular en participantes \npedi\u00e1tricos. Type: Clinical Trial, phase IV. \nHULP code: 5161. Sponsored\u00b4s protocol code: MK-8616-089.\nSponsored by: Merck Sharp and Dohme de Espa\u00f1a S.A. Signed date: 17/10/2018\nPascual Pascual SI . Estudio de continuaci\u00f3n, doble ciego, controlado con placebo, \naleatorizado, multic\u00e9ntrico, dividido en dos partes para investigar la seguridad, tolera -\nbilidad, farmacocin\u00e9tica, farmacodin\u00e1mica y eficacia de RO7034067 en pacientes con \natrofia muscular espinal de tipo 2 y 3. Type: Clinical Trial, phase II. \nHULP code: 4664. Sponsored\u00b4s protocol code: BP39055.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 23/03/2018\nPascual Pascual SI . Estudio de extensi\u00f3n del seguimiento internacional, multic\u00e9ntrico, \ndoble ciego de 9 meses de duraci\u00f3n para evaluar la seguridad y tolerabilidad a largo \nplazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-T ooth de tipo 1A. \nType: Clinical Trial, phase III. \nHULP code: Anexo-II 4768. Sponsored\u00b4s protocol code: PXT3003-03.\nSponsored by: Pharnext . Signed date: 21/09/2018\nPascual Pascual SI . Estudio de extensi\u00f3n del seguimiento internacional, multic\u00e9ntrico, \ndoble ciego de 9 meses de duraci\u00f3n para evaluar la seguridad y tolerabilidad a largo \nplazo de PXT3003 en pacientes con enfermedad de Charcot-Marie-T ooth de tipo 1A. \nType: Clinical Trial, phase III. \nHULP code: Anexo-I 4768. Sponsored\u00b4s protocol code: PXT3003-03.\nSponsored by: Pharnext. Signed date: 12/04/20182.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n63  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansPascual Pascual SI . Tratamiento de extensi\u00f3n a largo plazo y sin enmascaramiento \nusando fosfato s\u00f3dico de dexametasona intraeritrocitaria en pacientes con ataxia te -\nlangiectasia que participaron en el estudio IEDAT -02-2015. Type: Clinical Trial, phase III. \nHULP code: 5062. Sponsored\u00b4s protocol code: IEDAT -03-2018.\nSponsored by: Erydel S.P .A. Signed date: 08/06/2018\nPaz Sol\u00eds JF . PRO(Precision Retrospective Outcomes) study A7005. Type: EPA-SP . \nHULP code: PI-3250. Sponsored\u00b4s protocol code: A7005.\nSponsored by: Boston Scientific Corporation. Signed date: 27/07/2018\nPeces Serrano R . Estudio posautorizaci\u00f3n de seguridad multic\u00e9ntrico y no interven -\ncionista de 6 a\u00f1os de duraci\u00f3n realizado en pacientes a los que se ha recetado Jinarc\u00ae \ndebido a poliquistosis renal autos\u00f3mica dominante. Type: EPA-LA. \nHULP code: PI-2881. Sponsored\u00b4s protocol code: 156-12-299.\nSponsored by: Otsuka Pharmaceutical Development & Commercializacion Inc. \nSigned date: 09/02/2018\nPeinado Peinado R . Appraise ATP: evaluaci\u00f3n de pacientes en prevenci\u00f3n primaria \nprevia implantaci\u00f3n de un DCI \u2013 evaluaci\u00f3n sistem\u00e1tica de la electroestimulaci\u00f3n anti -\ntaquic\u00e1rdica. Type: Producto Sanitario. \nHULP code: PI-3142. Sponsored\u00b4s protocol code: C1924.\nSponsored by: Boston Scientific Corporation. Signed date: 10/05/2018\nPeinado Peinado R . Estudio eficaz: Eficacia de choque de cardioversi\u00f3n/desfibrilaci\u00f3n, \nun estudio aleatorizado que compara la pendiente fija y la anchura de impulso fija en \nuna poblaci\u00f3n general con desfibrilador autom\u00e1tico implantable. Type: Clinical Trial, \nphase Producto Sanitario. \nHULP code: 5067. Sponsored\u00b4s protocol code: CRD-914/SJM-CIP-10221.\nSponsored by: Abbott Medical Espa\u00f1a S.A. Signed date: 18/04/2018\nP\u00e9rez Mart\u00ednez A . Ensayo en fase IB para evaluar Idelalisib en ni\u00f1os y adolescentes \ncon linfoma difuso de c\u00e9lulas B grandes o linfoma mediast\u00ednico de c\u00e9lulas B recidivante \no resistente en combinaci\u00f3n con rice. Type: Clinical Trial, phase I. \nHULP code: 4962. Sponsored\u00b4s protocol code: GS-US-313-1090.\nSponsored by: Gilead Sciences Inc. Signed date: 12/07/2018\nP\u00e9rez Mart\u00ednez A . Estudio aleatorizado, abierto, de seguridad y eficacia de Ibrutinib en \npacientes pedi\u00e1tricos y adultos j\u00f3venes con linfoma no Hodgkin de c\u00e9lulas maduras B \nen reca\u00edda o refractario. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4644. Sponsored\u00b4s protocol code: 54179060LYM3003.\nSponsored by: Janssen Cilag International NV. Signed date: 30/11/2018\nP\u00e9rez Mart\u00ednez A . Estudio de fase 2B, abierto y de un solo grupo para evaluar la far -\nmacocin\u00e9tica, la eficacia, la seguridad y la tolerabilidad de Letermovir en participantes \npedi\u00e1tricos desde el nacimiento hasta menos de 18 a\u00f1os con riesgo de sufrir infecci\u00f3n \ny/o enfermedad por CMV despu\u00e9s de un trasplante alog\u00e9nico de c\u00e9lulas madre hema -\ntopoy\u00e9ticas (TCMH). Type: Clinical Trial, phase II. \nHULP code: 5199. Sponsored\u00b4s protocol code: MK-8228-030.\nSponsored by: Merck Sharp & Dhome Corp. Signed date: 11/12/2018P\u00e9rez Mart\u00ednez A . Estudio multic\u00e9ntrico de fase 1/2, de aumento escalonado de la \ndosis, para evaluar la seguridad, la farmacocin\u00e9tica, la farmacodin\u00e1mica y la eficacia de \nQuizartinib, en combinaci\u00f3n con quimioterapia de reinducci\u00f3n y como tratamiento de \nmantenimiento con un solo agente. En pacientes pedi\u00e1tricos con MLA refractaria o en \nreca\u00edda de entre 1 mes y 18 a\u00f1os (y adultos j\u00f3venes de hasta 21 a\u00f1os) con mutaciones \nde FLT3-ITD. Type: Clinical Trial, phase I. \nHULP code: 5045. Sponsored\u00b4s protocol code: AC220-A-U202.\nSponsored by: Daiichi Sankyo Inc. Signed date: 05/09/2018\nP\u00e9rez Valero I . Ensayo cl\u00ednico fase IV abierto, aleatorizado dise\u00f1ado para evaluar la \nreversibilidad de la neurotoxicidad asociada al uso de Abacavir/ Lamivudina /Dolute -\ngravir en el sistema nervioso central tras el cambio a una pauta de tratamiento anti -\nrretroviral basada en Alafenamida/Emtricitabina/Darunavir/Cobicistat. Estudio Detox. \nType: Clinical Trial, phase IV. \nHULP code: 5135. Sponsored\u00b4s protocol code: GESIDA 10418.\nSponsored by: Fundaci\u00f3n SEIMC-GESIDA. Signed date: 05/11/2018\nPinto Mar\u00edn A . An\u00e1lisis retrospectivo de factores cl\u00ednicos asociados a un mayor bene -\nficio con Axitinib en c\u00e1ncer renal metast\u00e1sico. Estudio Axilong. Type: EPA-OD. \nHULP code: PI-2983. Sponsored\u00b4s protocol code: PI-2983 EPA-OD.\nSponsored by: Pfizer S.L.U. Signed date: 30/01/2018\nPinto Mar\u00edn A . Estudio de fase II para la evaluaci\u00f3n del tratamiento neoadyuvante \ncon Cabozantinib previo a la nefrectom\u00eda citorreductora en pacientes con c\u00e1ncer de \nc\u00e9lulas renales localmente avanzado o metast\u00e1sico. Type: Clinical Trial, phase II. \nHULP code: 5136. Sponsored\u00b4s protocol code: CABOPRE.\nSponsored by: Fundaci\u00f3n Oncosur. Signed date: 01/10/2018\nPinto Mar\u00edn A . Estudio de fase II, multic\u00e9ntrico, aleatorizado y abierto para evaluar la \nseguridad y la eficacia de Avelumab con Gemcitabina/Carboplatino frente a quimio -\nterapia con Gemcitabina/Carboplatino sola, en pacientes con carcinoma urotelial no \nresecable o metast\u00e1sico que no hayan recibido terapia sist\u00e9mica previa y que no sean \naptos para la quimioterapia con cisplatino. Type: Clinical Trial, phase II. \nHULP code: 4960. Sponsored\u00b4s protocol code: MS100070-0160.\nSponsored by: Associacio Catalana per a la Reserca Oncologica i les Seves Inpplicaciones \nSanitaries i Socials. Signed date: 12/03/2018\nPinto Mar\u00edn A . Estudio en fase III sobre Erdafitinib en comparaci\u00f3n con Vinflunina, \nDocetaxel o Pembrolizumab en sujetos con carcinoma urotelial avanzado y anomal\u00edas \ngen\u00e9ticas seleccionadas en FGFR. Type: Clinical Trial, phase III. \nHULP code: 4986. Sponsored\u00b4s protocol code: 42756493BLC3001.\nSponsored by: Janssen Cilag International NV. Signed date: 13/02/2018\nPinto Mar\u00edn A . Estudio fase II, internacional, multic\u00e9ntrico, prospectivo para evaluar la \neficacia, la seguridad y la calidad de vida de Pazopanib administrado diariamente por v\u00eda \noral, en pacientes con carcinoma de c\u00e9lulas renales avanzado y/o metast\u00e1sico despu\u00e9s \nde terapia previa con tratamiento con agentes inhibidores del control de la inmunidad \n(Checkpoint Inhibitors). Type: Clinical Trial, phase II. 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n64  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansHULP code: Anexo-I 4877. Sponsored\u00b4s protocol code: CPZP034A2410.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 25/07/2018\nPinto Mar\u00edn A . The dutreneo trial: a prospective study to individualize the approach \nwith Durvalumab (MEDI4736) and Tremelimumab in neoadjuvant bladder cancer pa -\ntients. Type: Clinical Trial, phase II. \nHULP code: 5201. Sponsored\u00b4s protocol code: DUTRENEO.\nSponsored by: Fundaci\u00f3n CRIS contra el C\u00e1ncer. Signed date: 06/11/2018\nPinto Mar\u00edn A . Tratamiento adyuvante del c\u00e1ncer renal con Axitinib: estudio en fase III, \naleatorizado y doble ciego del tratamiento adyuvente con Axitinib frente al placebo en \nsujetos con alto riesgo de CCR recurrente. Type: Clinical Trial, phase III. \nHULP code: Anexo-II 4046. Sponsored\u00b4s protocol code: AP311736.\nSponsored by: SFJ Pharma Ltd. LI. Signed date: 06/04/2018\nPinto Mar\u00edn A. Un ensayo multic\u00e9ntrico, abierto, fase 1B/2 de Lenvatinib (E7080) m\u00e1s \nPembrolizumab en sujetos con tumores s\u00f3lidos seleccionados. Type: Clinical Trial, phase I. \nHULP code: Anexo-I 5046. Sponsored\u00b4s protocol code: E7080-A001-111.\nSponsored by: EISAI Europe Limited. Signed date: 24/09/2018\nPinto Mar\u00edn A . Un ensayo multic\u00e9ntrico, abierto, fase 1B/2 de Lenvatinib (E7080) \nm\u00e1s Pembrolizumab en sujetos con tumores s\u00f3lidos seleccionados. Type: Clinical Trial, \nphase I. \nHULP code: 5046. Sponsored\u00b4s protocol code: E7080-A001-111.\nSponsored by: EISAI Europe Limited. Signed date: 30/04/2018\nPlaza L\u00f3pez de Sabando D . Paediatric hepatic international tumour trial. Type: Cli -\nnical Trial, phase III. \nHULP code: 5052. Sponsored\u00b4s protocol code: PHITT.\nSponsored by: University of Birmingham. Signed date: 05/11/2018\nPrados S\u00e1nchez C . Estudio abierto en fase III para evaluar la seguridad a largo plazo y \nla eficacia de la Politerapia con VX-659 en pacientes con fibrosis qu\u00edstica, homocigotos \no heterocigotos para la mutaci\u00f3n F508DEL. Type: Clinical Trial, phase III. \nHULP code: 5047. Sponsored\u00b4s protocol code: VX17-569-105.\nSponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 18/07/2018\nPrados S\u00e1nchez C . Estudio en fase III, aleatorizado, doble ciego y controlado para \nevaluar la eficacia y la seguridad de la politerapia con VX-659 en pacientes con fibrosis \nqu\u00edstica, heterocigotos para la mutaci\u00f3n F508DEL y una mutaci\u00f3n de la funci\u00f3n m\u00ednima \n(F/MF). Type: Clinical Trial, phase III. \nHULP code: 5036. Sponsored\u00b4s protocol code: VX17-569-102.\nSponsored by: Vertex Pharmaceuticals Incorporated. Signed date: 14/06/2018\nPrieto Nieto MI . Ensayo cl\u00ednico multic\u00e9ntrico, randomizado, para evaluar la eficacia y \nseguridad de la quimioterapia intraperitoneal hipert\u00e9rmica (HIPEC) con Mitomicina C \nasociada a cirug\u00eda en el tratamiento del carcinoma colorrectal localmente avanzado. \nType: Clinical Trial, phase III. \nHULP code: 5055. Sponsored\u00b4s protocol code: FCO-HIP-2015-01.\nSponsored by: Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (FIBICO-IMIBIC). \nSigned date: 27/07/2018Quesadas Sim\u00f3n A . Revisi\u00f3n observacional en serie de historias cl\u00ednicas del uso de \nRepatha\u00ae en sujetos europeos con hiperlipidemia. Type: EPA-SP . \nHULP code: Anexo-I PI-2828. Sponsored\u00b4s protocol code: AMG-EVO-2016-01.\nSponsored by: Amgen S.A. Signed date: 29/05/2018\nQuirce Gancedo SE . Registro de pacientes con asma grave no controlada (Gema-\nData). Type: EPA-SP . \nHULP code: PI-3232. Sponsored\u00b4s protocol code: VPM-SAL-2017-01.\nSponsored by: Fundaci\u00f3n Espa\u00f1ola del Pulm\u00f3n. SEPAR. Signed date: 18/05/2018\nRamos Boluda ME . Registro multic\u00e9ntrico prospectivo para pacientes con s\u00edndrome \ndel intestino corto. Type: EPA-LA. \nHULP code: PI-3299. Sponsored\u00b4s protocol code: TED-R13-002.\nSponsored by: Shire International GMBH. Signed date: 29/10/2018\nRamos Ramos JC . Estudio cl\u00ednico multic\u00e9ntrico, aleatorizado y abierto de S-649266 \no mejor tratamiento disponible para infecciones graves provocadas por pat\u00f3genos \nGram negativos resistentes a carbapenemos. Type: Clinical Trial, phase IV. \nHULP code: Anexo-I 4640. Sponsored\u00b4s protocol code: 1424R2131.\nSponsored by: Shinogi Ltd. Signed date: 16/05/2018\nRamos Ramos JC . Estudio en fase II, multic\u00e9ntrico, aleatorizado, doble ciego, para eva -\nluar la seguridad, tolerabilidad y eficacia de CD101 inyectable frente a Caspofungina \nintravenosa seguido de desescalado a Fluconazol oral, en el tratamiento de pacientes \ncon candidemia. Type: Clinical Trial, phase II. \nHULP code: Anexo-II 4715. Sponsored\u00b4s protocol code: CD101.IV.2.03.\nSponsored by: Cidara Therapeutics Inc. Signed date: 02/02/2018\nRedondo S\u00e1nchez A . Opini\u00f3n - Estudio en fase IIIB, abierto, de grupo \u00fanico y multi -\nc\u00e9ntrico de la monoterapia de mantenimiento con Olaparib en pacientes con c\u00e1ncer \nde ovario recidivante sin mutaci\u00f3n de BRCA en l\u00ednea germinal y sensible al platino que \nest\u00e1n en respuesta parcial o completa tras la quimioterapia con platino. Type: Clinical \nTrial, phase IIIb. \nHULP code: 5101. Sponsored\u00b4s protocol code: D0816C00020.\nSponsored by: Astrazeneca AB. Signed date: 15/06/2018\nRedondo S\u00e1nchez A . Ensayo cl\u00ednico fase II abierto de Enzalutamida en c\u00e1ncer de la \ngranulosa ov\u00e1rica avanzado no resecable o metast\u00e1sico. Estudio Greko III. Type: Clinical \nTrial, phase II. \nHULP code: 4941. Sponsored\u00b4s protocol code: GETHI 2016-01.\nSponsored by: Grupo Espa\u00f1ol de T umores Hu\u00e9rfanos e Infrecuentes. Signed date: 21/02/2018\nRedondo S\u00e1nchez A . Ensayo de fase I/II, abierto, con varios grupos, para investigar \nla seguridad, la tolerabilidad, la farmacocin\u00e9tica y la actividad biol\u00f3gica y cl\u00ednica de \nAGEN1884 en combinaci\u00f3n con AGEN2034 en sujetos con tumores s\u00f3lidos metast\u00e1 -\nsicos o localmente avanzados. Type: Clinical Trial, phase I. \nHULP code: 5060. Sponsored\u00b4s protocol code: C-550-0.\nSponsored by: Agenus Inc. Signed date: 12/12/2018\nRedondo S\u00e1nchez A . Ensayo fase II de Olaparib de mantenimiento tras la respuesta a 2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n65  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansTabectedina y Doxorrubicina Liposomal pegilada en c\u00e1ncer de ovario recurrente. Type: \nClinical Trial, phase II. \nHULP code: 5037. Sponsored\u00b4s protocol code: OLATRA.\nSponsored by: Grupo Espa\u00f1ol de Investigaci\u00f3n C\u00e1ncer de Ovario (GEICO). \nSigned date: 17/05/2018\nRedondo S\u00e1nchez A . Ensayo fase III, aleatorizado y doble ciego de quimioterapia basa -\nda en platino con o sin Atezolizumab, seguida de mantenimiento con Niraparib con o \nsin Atezolizumab, en pacientes con c\u00e1ncer de ovario, de trompa de falopio o peritoneal \nrecidivante e intervalo libre de tratamiento con platino (ILP) >6 meses. Type: Clinical \nTrial, phase III. \nHULP code: 5112. Sponsored\u00b4s protocol code: ENGOT -OV41/GEICO69-O.\nSponsored by: Grupo Espa\u00f1ol de Investigaci\u00f3n C\u00e1ncer de Ovario (GEICO). \nSigned date: 13/09/2018\nRedondo S\u00e1nchez A . Ensayo internacional, multic\u00e9ntrico y con grupo \u00fanico de Tisotu -\nmab Vedotina (Humax\u00ae-TF-ADC) en c\u00e1ncer de cuello de \u00fatero tratado con anterio -\nridad, recurrente o metast\u00e1sico. Type: Clinical Trial, phase II. \nHULP code: 5015. Sponsored\u00b4s protocol code: GCT1015-04.\nSponsored by: Genmad A/S. Signed date: 22/08/2018\nRedondo S\u00e1nchez A . Estudio aleatorizado fase III de quimioterapia con Platino y Pacli -\ntaxel m\u00e1s Bevacizumab y Atezolizumab frente a quimioterapia con Platino y Paclitaxel \nm\u00e1s Bevacizumab en el carcinoma de c\u00e9rvix metast\u00e1sico (estadio IVB), persistente o \nrecurrente. Type: Clinical Trial, phase III. \nHULP code: 5088. Sponsored\u00b4s protocol code: ENGOT -CX10/GEICO68 C/BEAT.\nSponsored by: Grupo Espa\u00f1ol de Investigaci\u00f3n C\u00e1ncer de Ovario (GEICO). \nSigned date: 20/07/2018\nRedondo S\u00e1nchez A . Estudio de combinaci\u00f3n en fase IB de Rucaparib (CO-338) y \nAtezolizumab (MPDL3280A) en pacientes con c\u00e1nceres avanzados del aparato repro -\nductor femenino y c\u00e1ncer de mama triple negativo. Type: Clinical Trial, phase I. \nHULP code: 4959. Sponsored\u00b4s protocol code: WO39409.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 01/03/2018\nRedondo S\u00e1nchez A . Estudio de fase 2 de Prexasertib en c\u00e1ncer de ovario resistente \no recurrente refractario a derivados del platino. Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4982. Sponsored\u00b4s protocol code: I4D-MC-JTJN.\nSponsored by: Lilly S.A. Signed date: 22/08/2018\nRedondo S\u00e1nchez A . Estudio de fase 2 de Prexasertib en c\u00e1ncer de ovario resistente \no recurrente refractario a derivados del platino. Type: Clinical Trial, phase II. \nHULP code: 4982. Sponsored\u00b4s protocol code: I4D-MC-JTJN.\nSponsored by: Lilly S.A. Signed date: 13/03/2018\nRedondo S\u00e1nchez A . Estudio en fase III aleatorizado sobre Trabectedina (ET 743) \nfrente a la quimioterapia elegida por el cl\u00ednico en pacientes con c\u00e1ncer ov\u00e1rico, peri -\ntoneal primario o tub\u00e1rico con fenotipo de mutaci\u00f3n en BRCA o BRCANESS. Type: \nClinical Trial, phase III. HULP code: 4940. Sponsored\u00b4s protocol code: MITO-23.\nSponsored by: Grupo Espa\u00f1ol de Investigaci\u00f3n C\u00e1ncer de Ovario (GEICO). \nSigned date: 16/02/2018\nRedondo S\u00e1nchez A . Estudio fase 2 aleatorizado, doble ciego, controlado con placebo \npara evaluar la eficacia y la seguridad de Farletuzumab (MORAB-003) en combinaci\u00f3n \ncon carboplatino m\u00e1s Paclitaxel o Doxorubicina Lipos\u00f3mica Pegilada (PLD) en pacien -\ntes con c\u00e1ncer de ovario . Type: Clinical Trial, phase II. \nHULP code: Anexo-I 4403. Sponsored\u00b4s protocol code: MORAB-003-011.\nSponsored by: EISAI Europe Limited. Signed date: 20/12/2018\nRedondo S\u00e1nchez A . Phase 1 dose escalation and cohort expansion study of TSR-\n042, an ANTI-PD-1 monoclonal antibody, in patients with advanced solid tumors. Type: \nClinical Trial, phase I. \nHULP code: Anexo-I 4831. Sponsored\u00b4s protocol code: 4010-01-001.\nSponsored by: T esaro Inc. Signed date: 06/02/2018\nRedondo S\u00e1nchez A . Phase II trial of Pembrolizumab in combination with Doxorubi -\ncin in advanced, recurrent or metastatic endometrial cancer: (TOPIC). Type: Clinical \nTrial, phase II. \nHULP code: 4922. Sponsored\u00b4s protocol code: 2017-002824-26.\nSponsored by: Fundaci\u00f3n Hospital Vall D\u2019Hebron. Signed date: 27/04/2018\nRedondo S\u00e1nchez A . Sarcomas de partes blandas lozalizados de alto riesgo de extre -\nmidades y pared de tronco en adultos: un enfoque integrador que incluye quimiotera -\npia est\u00e1ndar vs Histotipo-dirigida neoadyuvante. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 3411. Sponsored\u00b4s protocol code: ISG-GRUPO ESPA\u00d1OL de INVESTIGA -\nCION EN SARCOMAS10-01.\nSponsored by: Grupo Espa\u00f1ol de Investigaci\u00f3n en Sarcomas. Signed date: 27/04/2018\nRemesal Camba A . Eficacia, seguridad y tolerabilidad de T ofacitinib para el tratamiento \nde la artritis idiop\u00e1tica juvenil(AIJ) de curso poliarticular en sujetos ni\u00f1os y adolescen -\ntes. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4932. Sponsored\u00b4s protocol code: A3921104.\nSponsored by: Pfizer S.L.U. Signed date: 07/05/2018\nRemesal Camba A . Estudio abierto, secuencial, de b\u00fasqueda de dosis ascendentes y \nrepetidas de Sarilumab administrado con inyecci\u00f3n subcut\u00e1nea (S.C.) a ni\u00f1os y ado -\nlescentes con edades comprendidas entre 2 y 17 a\u00f1os con artritis idiop\u00e1tica juvenil de \ncurso poliarticular (AIJP), seguido de una fase de extensi\u00f3n. Type: Clinical Trial, phase III. \nHULP code: Anexo-I 4604. Sponsored\u00b4s protocol code: DRI13925.\nSponsored by: Sanofi-Aventis Recherche & Developpement. Signed date: 24/10/2018\nRey Blas JR . Ensayo cl\u00ednico aleatorizado, multic\u00e9ntrico, abierto, controlado, fase III, pa -\nralelo, para evaluar la eficacia y seguridad de Ivabradina versus Digoxina en el control \ncor\u00f3nico de la frecuencia card\u00edaca en pacientes con fibrilaci\u00f3n auricular en tratamien -\nto. Type: Clinical Trial, phase III. \nHULP code: 5128. Sponsored\u00b4s protocol code: BRAKE-AF .\nSponsored by: Adolfo Fontela Cerezuela. Signed date: 22/08/20182.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n66  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansRobles Marhuenda AJ . Estudio aleatorizado, doble ciego, controlado por placebo, de \n52 semanas de duracion para evitar los acontecimientos adversos de especial interes \nen adultos con lupus eritematoso sistem\u00e1tico activo, con anticuerpos positivos, que \ntoman Belimumab. Type: Clinical Trial, phase IV. \nHULP code: Anexo-II 4282. Sponsored\u00b4s protocol code: HGS1006-C1113.\nSponsored by: Human Genome Sciences Inc. Signed date: 28/09/2018\nRodr\u00edguez de Bethancourt Codes F . Caracter\u00edsticas y manejo de los pacientes diag -\nnosticados de s\u00edntomas del tracto urinario inferior por hiperplasia benigna de pr\u00f3stata \natendidos en Espa\u00f1a. Type: EPA-OD. \nHULP code: PI-3190. Sponsored\u00b4s protocol code: GSK-HBP-2018-01.\nSponsored by: Glaxosmithkline S.A. Signed date: 17/05/2018\nRodr\u00edguez Salas N . A single arm phase I-II multicenter trial with avelumab plus auto -\nlogus dendritic cell vaccine to determine safety and preliminary efficacy of the com -\nbination in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer \npatients. Type: Clinical Trial, phase I. \nHULP code: 4878. Sponsored\u00b4s protocol code: GEMCAD 1602.\nSponsored by: Grupo GEMCAD. Signed date: 29/01/2018\nRodr\u00edguez Salas N . Determinaci\u00f3n del estado mutacional de ras en biopsias l\u00edquidas \nde sujetos con c\u00e1ncer colorrectal metast\u00e1sico ras no mutado en primera l\u00ednea: estudio \nobservacional, prospectivo y multic\u00e9ntrico en Espa\u00f1a. Estudio Perseida. Type: EPA-SP . \nHULP code: PI-3166. Sponsored\u00b4s protocol code: AMG-RAS-2015-01.\nSponsored by: Amgen S.A. Signed date: 13/04/2018\nRodr\u00edguez Salas N . Estudio abierto, aleatorizado, fase 2 que compara S95005 con Be -\nvacizumab frente a Capecitabina con Bevacizumab en pacientes con c\u00e1ncer colorrectal \nmetast\u00e1sico no tratado previamente que no son candidatos a terapia intensiva. Type: \nClinical Trial, phase II. \nHULP code: Anexo-II 4580. Sponsored\u00b4s protocol code: CL2-95005-002.\nSponsored by: Laboratorios Servier S.L. Signed date: 23/07/2018\nRodr\u00edguez Salas N . Estudio aleatorizado de fase II para evaluar la eficacia de Folfiri \n+Panitumumab en el tratamiento en segunda l\u00ednea de pacientes con c\u00e1ncer colorrectal \nmetast\u00e1sico ras no mutado que han recibido Folfox + Panitumumab en primera l\u00ednea \nde tratamiento. Type: Clinical Trial, phase II. \nHULP code: 4991. Sponsored\u00b4s protocol code: GEMCAD-17-01(BEYOND).\nSponsored by: Grupo GEMCAD. Signed date: 07/05/2018\nRodr\u00edguez Salas N . Estudio de fase III, aleatorizado, secuencial y abierto, para evaluar \nla eficacia de Folfox + Panitumumab seguido por Folfiri + Bevacizumab (secuencia 1) \nfrente a Folfox + Bevacizumab seguido por Folfiri + Panitumumab (secuencia 2) en pa -\ncientes con c\u00e1ncer colorrectal metast\u00e1sico no resecable, ras nativo, tumor primario en \nlado izquierdo, no tratado previamente: CR-SEQUENCE. Type: Clinical Trial, phase III. \nHULP code: 5095. Sponsored\u00b4s protocol code: TTD-18-01.\nSponsored by: Grupo Tratamiento T umores Digestivos (GERCOR). Signed date: 30/07/2018\nRomero Ribate D . Estudio multic\u00e9ntrico, aleatorizado, controlado con placebo, \nde grupos paralelos en dos periodos de tratamiento para evaluar la seguridad de QAW039 a\u00f1adido al tratamiento existente en pacientes con asma no controlada con \nlos pasos 3, 4 y 5 de la gina. Type: Clinical Trial, phase III. \nHULP code: 5210. Sponsored\u00b4s protocol code: CQAW039A2315.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 11/12/2018\nRubio Su\u00e1rez JC . Fracturas extracapsulares del tercio proximal de f\u00e9mur con ines -\ntabilidad rotacional. Estudio comparativo de la eficiencia de diferentes sistemas para \nincrementar la estabilidad. Type: Producto Sanitario. \nHULP code: PI-3134. Sponsored\u00b4s protocol code: ICSCYL-HURH-GAMMAUb.\nSponsored by: Fundaci\u00f3n Instituto de Estudios de Ciencias de la Salud de Castilla y Le\u00f3n. \nSigned date: 08/05/2018\nS\u00e1enz de Pipa\u00f3n Marcos M . Estudio aleatorizado, doble ciego y controlado con \nplacebo para evaluar el efecto de un probi\u00f3tico en ni\u00f1os prematuros. Type: Producto \nAlimentario. \nHULP code: 5098. Sponsored\u00b4s protocol code: PRE/18.02.\nSponsored by: Probisearch S.L. Signed date: 25/09/2018\nSantos Simarro F.  Ensayo MO-PED: estudio de fase 2, aleatorizado, doble ciego y con -\ntrolado con placebo para evaluar la eficacia y la seguridad de Palovaroteno en sujetos \ncon osteocondromas m\u00faltiples. Type: Clinical Trial, phase II. \nHULP code: 5154. Sponsored\u00b4s protocol code: PVO-2A-201.\nSponsored by: Clementia Pharmaceuticals Inc. Signed date: 15/10/2018\nSanz P\u00e9rez CM . Estudio observacional prospectivo sobre el uso de dos pautas de es -\ntimulaci\u00f3n ov\u00e1rica con Folitropina Alfa (FSH) y Gonadotropina Menop\u00e1usica Humana \n(HMG) en t\u00e9cnicas de reproducci\u00f3n asistida en pacientes con potencial baja respuesta \n(Estudio Life). Type: EPA-SP . \nHULP code: PI-3418. Sponsored\u00b4s protocol code: LFB-FSH-2018-01.\nSponsored by: de la Fuente Botaine Laura. Signed date: 04/12/2018\nSastre Urg\u00fcelles A . Ensayo cl\u00ednico fase 1/2 de un brazo para evaluar la seguridad y la \neficacia del Mesilato de Eribulina en combinaci\u00f3n con Irinotec\u00e1n en ni\u00f1os con tumores \ns\u00f3lidos refractarios o recurrentes. Type: Clinical Trial, phase I. \nHULP code: 5125. Sponsored\u00b4s protocol code: E7389-G000-213.\nSponsored by: EISAI Europe Limited. Signed date: 02/10/2018\nSastre Urg\u00fcelles A . Estudio de fase I/II, multic\u00e9ntrico, abierto, a un solo brazo, de \nRuxolitinib a\u00f1adido a corticosteroides en pacientes pedi\u00e1tricos con enfermedad aguda \nde injerto contra hu\u00e9sped de grado II-IV tras trasplante alog\u00e9nico de c\u00e9lulas madre \nhematopoy\u00e9ticas. Type: Clinical Trial, phase I. \nHULP code: 5119. Sponsored\u00b4s protocol code: 5119 CINC424F12201.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 02/07/2018\nSastre Urg\u00fcelles A . Programa de registro europeo de Evoltra\u00ae: LLA pedi\u00e1trica. Type: \nEPA-LA. \nHULP code: Anexo-I 3372. Sponsored\u00b4s protocol code: CLO-08708.\nSponsored by: Genzyme Europe Bv. Signed date: 19/02/2018\nSendagorta Cudos E . Ensayo cl\u00ednico fase IV, abierto, de brazo \u00fanico y multic\u00e9ntrico \nsobre la inmunogenicidad de la vacuna nonavalente frente al virus del papiloma huma -2.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6\tClinical\tTrials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n67  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansno en hombres infectados por el VIH que tienen sexo con hombres. Estudio GESIDA \n10017. Type: Clinical Trial, phase IV. \nHULP code: 5051. Sponsored\u00b4s protocol code: GESIDA 10017.\nSponsored by: Fundaci\u00f3n SEIMC-GESIDA. Signed date: 01/06/2018\nTall\u00f3n Barranco A . Estudio de extensi\u00f3n multic\u00e9ntrico, abierto y de un solo grupo \npara evaluar la efectividad y la seguridad de Ocrelizumab en pacientes con esclerosis \nm\u00faltiple incluidos previamente en un ensayo cl\u00ednico de fase IIIB/IV de Ocrelizumab \npatrocinado por F . HOFF . Type: Clinical Trial, phase IIIb. \nHULP code: 5050. Sponsored\u00b4s protocol code: MN39158.\nSponsored by: F . Hoffmann-La Roche Ltd. Signed date: 18/06/2018\nTrigo Esteban E . Estudio de fase 2, aleatorizado, multic\u00e9ntrico, doble-ciego, eficacia \ny seguridad, para la evaluaci\u00f3n de esquemas de dosis orales de Fexinidazol para el \ntratamiento de pacientes adultos con enfermedad de chagas cr\u00f3nica indeterminada. \nType: Clinical Trial, phase II. \nHULP code: 5013. Sponsored\u00b4s protocol code: DNDI-CH-FEX-12.\nSponsored by: Drugs for Neglected Diseases Initiative. Signed date: 11/05/2018\nTrigo Esteban E . Estudio de fase 2, aleatorizado, multic\u00e9ntrico, doble-ciego, eficacia \ny seguridad, para la evaluaci\u00f3n de esquemas de dosis orales de Fexinidazol para el \ntratamiento de pacientes adultos con enfermedad de chagas cr\u00f3nica indeterminada. \nType: Clinical Trial, phase II. \nHULP code: Anexo-I 5013. Sponsored\u00b4s protocol code: DNDI-CH-FEX-12.\nSponsored by: Drugs for Neglected Diseases Initiative. Signed date: 13/11/2018\nValverde N\u00fa\u00f1ez E . Efecto del Alopurinol en pacientes con encefalopatia hip\u00f3xico-\nisqu\u00e9mica tratados con hipotermia- albino- ensayo cl\u00ednico multic\u00e9ntrico aleatorizado, \nciego, controlado con placebo. Type: Clinical Trial, phase III. \nHULP code: 4800. Sponsored\u00b4s protocol code: ALBINO.\nSponsored by: Instituto Investigaci\u00f3n Sanitaria H La Fe. Signed date: 17/01/2018\nVillanueva Pe\u00f1a R . Estudio de fase II, aleatorizado, doble ciego, controlado con place -\nbo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI \n425809 una vez al d\u00eda durante un periodo de tratamiento de 12 semanas en pacientes \ncon esquizofrenia. Type: Clinical Trial, phase II. \nHULP code: 5078. Sponsored\u00b4s protocol code: 1346.9.\nSponsored by: Boehringer Ingelheim Espa\u00f1a S.A. Signed date: 11/05/2018\nVillanueva Pe\u00f1a R . Cohorte de depresi\u00f3n resistente al tratamiento en Europa. Type: \nEPA-SP . \nHULP code: PI-3281. Sponsored\u00b4s protocol code: 54135419DEP4001.\nSponsored by: Janssen Pharmaceutica NV. Signed date: 04/10/2018\nVillanueva Pe\u00f1a R . Estudio de fase II, aleatorizado, doble ciego, controlado con place -\nbo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI \n425809 una vez al d\u00eda durante un periodo de tratamiento de 12 semanas en pacientes \ncon esquizofrenia. Type: Clinical Trial, phase II. \nHULP code: Anexo-I 5078. Sponsored\u00b4s protocol code: 1346.9.\nSponsored by: Boehringer Ingelheim Espa\u00f1a S.A. Signed date: 23/10/2018Vivancos Matellano F . Estudio aleatorizado, doble ciego y controlado con placebo \npara evaluar la eficacia y la seguridad de Safinamida 100 mg una vez al d\u00eda, como \ntratamiento complementario, en pacientes con enfermedad de Parkinson idiop\u00e1tica \n(EPI) con fluctuaciones motoras y dolor cr\u00f3nico relacionado con la enfermedad de \nParkinson. Type: Clinical Trial, phase IV. \nHULP code: 5150. Sponsored\u00b4s protocol code: Z7219M01.\nSponsored by: Zambon S.A. Signed date: 25/10/2018\nYork E . Evaluaci\u00f3n del resultado de Hemopatch: registro de observaci\u00f3n prospectivo. \nType: NO-EPA. \nHULP code: Anexo-I PI-3057. Sponsored\u00b4s protocol code: BXU011443.\nSponsored by: Baxter Healthcare Corporation. Signed date: 24/09/2018\nYork E . Evaluaci\u00f3n del resultado de Hemopatch: registro de observaci\u00f3n prospectivo. \nType: NO-EPA. \nHULP code: PI-3057. Sponsored\u00b4s protocol code: BXU011443.\nSponsored by: Baxter Healthcare Corporation. Signed date: 11/01/2018\nZamora Au\u00f1\u00f3n P . Estudio aleatorizado, doble ciego, controlado con placebo, de \nLEE011 en combinacion con Letrozol para el tratamiento de mujeres postmeno -\npa\u00fasicas con c\u00e1ncer de mama avanzado con receptor hormonal positivo, HER2-\nnegativo que no han recibido terapia previa para la enfermedad avanzada. Type: \nClinical Trial, phase III. \nHULP code: Anexo-II 4070. Sponsored\u00b4s protocol code: CLEE011A2301.\nSponsored by: Novartis Farmac\u00e9utica S.A. Signed date: 09/04/2018\nZamora Au\u00f1\u00f3n P . Estudio de fase II randomizado, multic\u00e9ntrico, abierto para evaluar \nla eficacia y seguridad de Palbociclib en combinaci\u00f3n con Fulvestrant o Letrozol en \npacientes con c\u00e1ncer de mama met\u00e1stasico HER2 negativo, ER+ (Parsifal 1). Type: Cli -\nnical Trial, phase II. \nHULP code: Anexo-III 4390. Sponsored\u00b4s protocol code: MEDOPP067.\nSponsored by: Medica Scientia Innovation Research. Signed date: 12/01/2018\nZamora Au\u00f1\u00f3n P . Estudio de fase II, abierto, aleatorizado y multic\u00e9ntrico, para evaluar \nla seguridad y la eficacia de agentes dirigidos frente a los mecanismos de reparaci\u00f3n \ndel ADN en combinaci\u00f3n con Olaparib, en comparaci\u00f3n con Olaparib en monoterapia, \nen el tratamiento de pacientes con c\u00e1ncer de mama metast\u00e1sico triple negativo con \nestratificaci\u00f3n en funci\u00f3n de sus alteraciones en los genes recombinantes de repara -\nci\u00f3n hom\u00f3loga (incluido BRCA 1/2) (Violette). Type: Clinical Trial, phase II. \nHULP code: 4954. Sponsored\u00b4s protocol code: D5336C00001.\nSponsored by: Astrazeneca AB. Signed date: 11/05/2018\nZamora Au\u00f1\u00f3n P . Estudio en fase 3 aleatorizado, abierto, de Abemaciclib en combina -\nci\u00f3n con tratamiento endocrino adyuvante est\u00e1ndar frente a monoterapia con trata -\nmiento endocrino adyuvante est\u00e1ndar, en pacientes con c\u00e1ncer de mama en estadios \niniciales, de alto riesgo, con afectaci\u00f3n ganglionar, receptores hormonales positivos, \nHER2 negativo. Type: Clinical Trial, phase III. \nHULP code: 5063. Sponsored\u00b4s protocol code: 13Y -MC-JPCF .\nSponsored by: Lilly S.A. Signed date: 03/05/20182.6 Clinical Trials\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n68  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe Hospital La Paz Institute for Health Research Biobank (IdiPAZ \nBiobank) is a platform of support service to the Institute\u2019s research, \nproduct of the integration of different pre-existing nodes with a long \nand fruitful research trajectory within the University Hospital La Paz. \nThe IdiPAZ Biobank which works to obtain, store, manage and dis -\ntribute large collections of human biological samples of diseases of \ninterest for researchers. \nThis service is created with the collaboration of the Uni -\nversity Hospital La Paz, the Foundation for Biomedical Re -\nsearch of the University Hospital La Paz (FIBHULP) and \nthe Carlos III Health Institute, being integrated into the \nNetwork of Hospital Biobanks (RetBioH). The Biobank \nof the University Hospital La Paz - Institute of Health Research of \nthe University Hospital La Paz \u2013IdiPAZ is registered in the National \nBiobank Network of the Carlos III Health Institute with the code \nB.0000684\nThe IdiPAZ Biobank belongs to the National Biobank \nNetwork (RNBB) (http://www.redbiobancos.es) to \nsupport research in science and technologies of the \nStrategic Health Action 2018-2020 of the Carlos III \nHealth Institute.\nOBJETIVES\nThe main objective of the IdiPAZ Biobank is to promote biomedical research, \nwhich will increase and improve the quality of scientific production in Spain. This \nis a specialized work in the management of human biological samples and their \nassociated data for biomedical research in accordance with the legislation in force \nin Spain, Law 14/2007 on Biomedical Research and the Royal Decree of Biobanks \n1716/2011. This guarantees the confidentiality of the samples and associated data.\nThe IdiPAZ Biobank provides researchers with an agile channel to access sam -ples, their products and data associated with quality assurances and ethical-legal \nadaptation.\nThe obtaining, and if necessary the revocation, of the patient\u2019s informed consent is \ncontrolled, giving the same all the required information. Special attention is given \nto guarantee the protection of privacy and the confidential treatment of personal \ndata contained in the IdiPAZ Biobank, clinical data and research results.\nThanks to this, the development of a continuous dynamic of analysis and evaluation \nof the needs of the users of the Biobank is favored. In addition, the activity of the \nIdiPAZ Biobank is made known and valued to society and, especially, in the field of \npatient and affected associations.\nThe IdiPAZ Biobank will provide benefits at different levels, starting with donors, \npatients, society in general and the clinicians and researchers involved. It also aims \nto facilitate communication and cooperation of different groups with common \ninterests both nationally and internationally.\nAll of this will result in a higher quality of research and an increase in scientific \nproduction, without forgetting the strict compliance with the regulations on Data \nProtection and the Rights to Privacy and Confidentiality of all patients (Organic \nLaw 3/2018 and Regulation General Data Protection 2016/679).\n2.7\tPlatforms\n2.7.1 Biobank\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n69  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansCOMPOSITION\nScientific Director: \nPaloma G\u00f3mez Campelo (PhD)\nCoordinator: \nMarina Arranz \u00c1lvarez\nSenior Experts in Pathology and Cytology: \nSandra NietoTorrero\nContact:\n biobanco.hulp@salud.madrid.org\n biobanco@idipaz.es\n Phone: Biobank Laboratory (+34) 91 207 11 91\nScientific Committee:\nDavid Hardisson Hern\u00e1ez (MD, PhD)\nFrancisco Arnalich Fern\u00e1ndez (MD, PhD)\nInmaculada Ib\u00e1\u00f1ez de C\u00e1ceres (PhD)\nEnrique Espinosa Arranz (MD, PhD)\nEduardo L\u00f3pez Granados (MD, PhD)\nEQUIPMENT\n\u2022 Eight -80\u00baC deep freezers equipped with re -\nmote alarm temperature control and a CO2 \nbackup system. Seven of these are equipped \nwith an open door control software\n\u2022 One tank of liquid nitrogen at its gas phase \nwith an alarm temperature control and a lack \nof CO2 detector\n\u2022 W-2D tube system with a data matrix codification for liquids, with a scanner to \nread col boxes and reader for the identification and the traceability of the tubes\n\u2022 Combined refrigerator of 4\u00ba C y \u2013 20\u00ba C\n\u2022 Cryostat to cut frozen samples\n\u2022 Microtome y bath/coating to cut paraffin samples\n\u2022 Laser Microdissector\n\u2022 Biological safety cabins IIA\n\u2022 Centrifuge with capacity to process samples in tubes and Eppendorfs\u2022 Automatic platform to manipulate and trace liquids\n\u2022 One mini coolers to freeze inclined biological samples below 1\u00baC\n\u2022 T wo containers to freeze and transport Isopentane\n\u2022 One container for the transport of isopentame samples\n\u2022 Vortex Mixer /agitator\n\u2022 Spectrophotometer (Nanodrop\u00ae)\n\u2022 Fungibility: basically kits and the necessary products to process and preserve \ntissues, blood, and cells.\n\u2022 Printer/photocopier/scanner\n\u2022 3 computers and a management computer system\n\u2022 Label printing system and a bar code reader connected to the management \nsoftware\nPORTFOLIO\tOF\tSERVICES\nTechnical and scientific assessment:\n\u2022 Collection and management of new collection\n\u2022 Work Methodology/ Methods\n\u2022 Quality control of DNA/ARN sample treatment\n\u2022 Expert training to use Biobank management system \n\u2022 Training and advice on the use of Biobank management software (Bio-e-Bank)\n\u2022 Information to the investigator on the custody, deposit, availability and transfer \nof samples associated with the biobank\n\u2022 Training of trainees (FCTs) of training cycles\nSample/collection management:\n\u2022 Coordinating a collection of samples in multiple study/research centers\n\u2022 Storage of pre-existing collections under LIB 14/2007\n\u2022 Storage of preexisting samples in accordance with Spain\u2019s Biobank laws LIB \n14/2007 and 1716/2011 Royal Decree\n\u2022 Management and control of Informed Consent (CI) and/or clinic\u2019s regarding \nsamples\n\u2022 Aliquot of blood/salines/plasma/other liquids\n\u2022 Sample reception and codification\nHistology techniques:\n\u2022 Making paraffin block\n\u2022 Making frozen tissue blocks\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n70  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\u2022 Paraffin/frozen cuts\n\u2022 Hematoxylin and eosin stain (H&E)\n\u2022 Other kinds of stains \n\u2022 Laser microdissection\nCell techniques:\n\u2022 Purifying and freezing of mononuclear cells of peripheral blood (PMBCs)\nMolecular Techniques:\n\u2022 DNA and RNA quantification via spectrophotometer (NANODROP)\nResearchers who wish to deposit their collections in IdiPAZ\u2019 Biobank will have \nto sign an agreement of sample deposit (in which the terms and conditions under \nwhich the Biobank will deposit the samples) and in agreement with the existing \nlegislation on the subject.On the other hand researchers who wish to use our samples will have to sign a \nTransfer Agreement (Material Transfer Agreement) in which the terms and condi -\ntions under which the Biobank will grant the samples.\nBIOBANK\u2019S\tSCIENTIFIC\tINDICATORS\nIn the year 2019, Biobank IdiPAZ has worked on 64 research projects funded by \nSpanish State aid, private foundations, industrial companies or cooperatives. The \nprincipal researchers of these projects belonged to IdiPAZ research groups and to \nexternal, national and international groups. Of these projects and together with the \ncentral node of the biobank, a total of 2,969 new samples have been stored, genera -\nting more than 11,549 aliquots so far this year. \nDuring the same period, the Biobank has opened several projects, so it has been dedi -\ncated to the recruitment of samples. In addition, 20 sample requests were processed \nand about 1,000 samples were allocated while maintaining the demand for samples.\nLa Paz Central Research and Clinical Trials Unit (Unidad Central de Investigaci\u00f3n \nCl\u00ednica y Ensayos Clinicos de La Paz, HULP-UCICEC), is one of the IdiPAZ suppor -\nted research platforms. Its purpose is to promote and support clinical research at La \nPaz University Hospital and to establish collaboration links with other investigation \ncentres. Presently HULP-UCICEC is integrated in the Spanish Clinical Research \nNetwork (SCReN).\nIts wide portfolio of services provides support to researchers in design, set-up \n(including IRBs and Competent Authority approvals), management, data analysis \nand report writing of clinical trials and research projects. As Trials Managers, assists \nthe Principal Investigators in the preparation of feasibility and financial reports, \nadministrative tasks (i.e., investigators coordination, schedule of visits), as well as \nprojects development and research, particularly in the recruitment and follow-up \nof patients and data collection, assistance in audit, inspections and adverse drug \nreactions management according to regulatory procedures, among other tasks. We \nalso perform nursing activities and laboratory management, obtaining, processing \nand shipping the samples to central laboratories. All operations are GCP compliant \nas needed.\nHULP-UCICEC also runs a Phase I-II Trial Unit; the facilities and equipment allows \nharbour early phase clinical trials both in healthy volunteers and patients (children \nand adults). COMPOSITION\nHead\nJes\u00fas Fr\u00edas Iniesta (MD, PhD)\n jesus.frias@salud.madrid.org\nUCICEC Manager\nAlberto M. Borobia P\u00e9rez (MD, PhD)\n alberto.borobia@salud.madrid.org \n Phone: (+34) 912 071 466\nScientific Coordinator\nAntonio J. Carcas Sansu\u00e1n (MD, PhD)\n antonio.carcas@salud.madrid.org\nSafety and Pharmacovigilance Coordinators\nAntonio J. Carcas Sansu\u00e1n (MD, PhD)\n antonio.carcas@salud.madrid.org\nElena Ram\u00edrez Garc\u00eda (MD, PhD)\n elena.ramirez@salud.madrid.org \nResponsible for Pharmacovigilance\nIrene Garc\u00eda Garc\u00eda (MD)\n igarciagarcia@salud.madrid.org 2.7.2 UCICEC2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n71  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansProject Manager / Senior CRA\nPaloma Moraga Alapont (MSc)\n paloma.moraga@salud.madrid.org \nVictoria Hernandez Rubio (MSc)\n vhernandezr@salud.madrid.org \nProject Manager Paediatrics Oncology Trials\nMario Mu\u00f1oz Builes (MD)\n mmunoz.amm@gmail.com \nJunior Project Manager Paediatrics Oncology Trials\nPaula Valle Simon (MD)\n paula.valle.simon@idipaz.es \nSenior Clinical Research Associate\nPaloma Moraga Alapont (MSc)\n paloma.moraga@salud.madrid.org \nVictoria Hernandez Rubio (MSc)\n vhernandezr@salud.madrid.org \nJunior Clinical Research Associate\nNuria \u00c1lvarez Ortego\n nuria.alvarez.ortego@idipaz.es\nBioinformatic\nJose Carlos Mart\u00ednez \u00c1vila (PhD)\n josecarlos.martinez.avila@idipaz.esClinical Trials Nurses\nVega Maule\u00f3n Mart\u00ednez\n vega.mauleon@idipaz.es \nRaquel de Madariaga Castell\n raquel.madariaga@idipaz.es\nLaura Vit\u00f3n Vara (MSc)\n laura.viton@idipaz.es \nBeatriz Segura D\u00edaz\n beatriz.segura@salud.madrid.org \nNursing supervisor\nPatricia Luna Casta\u00f1o\n patricia.luna@salud.madrid.org \nReceptionist /Clinical Trials Assistant\nCristina Miragall Roig\n cristina.miragall@salud.madrid.org \n Phone: (+34) 912 071 466\nFACILITIES\n\u2022 3 Work offices (9 work stations)\n\u2022 1 Meeting room (with audiovisual and teleconference systems)\n\u2022 1 Archive room\n\u2022 Phase I/II Clinical Trial Unit:\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n72  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians- A hospital ward with eight beds and four chairs (children and adults) \n- 1 Doctor\u2019s office\n- 1 Central point for sample collection\n- 1 Sitting room \n\u2022 Carlos III Satellite Unit\n- 1 Work office and doctor\u00b4s office\n- 1 Laboratory\nEQUIPMENT\n\u2022 1 ECG\n\u2022 1 Centrifuge (Carlos III Satellite Unit)\n\u2022 2 Refrigerated centrifuge\n\u2022 1 Refrigerator \n\u2022 1 Room temperature chamber (Carlos III Satellite Unit)\n\u2022 3 -20\u00baC freezers (1 in Carlos III Satellite Unit)\n\u2022 2 -80\u00baC deep freezer\n\u2022 4 Vital signs monitors\n\u2022 Defibrillator\n\u2022 T emperature recording system\n\u2022 Digital clocks synchronised by GPS\n\u2022 2 medical scales (1 in Carlos III Satellite Unit)\n\u2022 Digital blood pressure monitors and pulse oximeters\n\u2022 Digital timers\n\u2022 Crash trolley\n\u2022 2 Cure trolleys\u2022 Video surveillance system\n\u2022 11 patient calling devices\n\u2022 4 patient surveillance cameras\nPORTFOLIO\tOF\tSERVICES\nThe portfolio of services includes more than 80 tasks grouped into: \n\u2022 Methodologic support\n\u2022 Clinical trial pre-study activities\n\u2022 Study development\n\u2022 Finalization and closure tasks\n\u2022 Pharmacovigilance\n\u2022 Statistics and data management \n\u2022 Medical and nursing tasks \nRESEARCH\tACTIVITY\tOF\tUCICEC\nDuring 2018, the platform has provided assistance and support in start-up, coor -\ndination, data-management, laboratory management or nursing tasks in more than \n132 commercial clinical trials of 46 Research Groups and more than 40 independent \nclinical research projects. In this period, 6 audits have been conducted and have \nbeen successfully overcome. In 2017 UCICEC was certified to the ISO 9001:2008 \nstandard.\nHULP-UCICEC has also provided methodological support in almost 150 clinical \nindependent projects, including advice on study requirements and documentation, \nprotocol development and design and preparation of application reports for com -\npetitive projects. \nFinally, more than 10 early phase trials have been conducted in our Phase I.\nThe Experimental Surgery Section is a support unit for research and teaching. In \nthe research field, the Section develops biomedical research projects and fine-\ntunes procedures for new diagnostic and therapeutic techniques that use labora -\ntory animals. \nIn the teaching field, the Section organises and supports training courses in surgical, \nmicrosurgical, laparoscopic and anaesthetic techniques.COMPOSITION\nSection Head:\nManuel Quintana D\u00edaz\n manuel.quintana@salud.madrid.org\n Phone: (+34) 91 727 71 542.7.3 Experimental Surgery2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n73  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansVeterinarian:\nCarlota Largo Aramburu\n carlota.largo@salud.madrid.org\n Phone: (+34)91 727 71 54\nSecretary:\nIrene Cuevas Gordo\n Irene.cuevas@salud.madrid.org\n Phone: (+34) 91 727 71 54\nTechnicians and assistants: \nJavier Rubio Bol\u00edvar\nSonsoles Jim\u00e9nez Mediano\nIsabel Rodr\u00edguez Mar\u00edn\nPablo Llorente Fern\u00e1ndez\nPedro Gallego Montesano\nDaniel Ruiz P\u00e9rez\nM\u00aa del Mar Barona Garcia\nEQUIPMENT\nThe Section consists of two microsurgery rooms, \nan operating room and an animal facility. The \nmicrosurgery room has surgical loupes and mi -\ncroscopes, as well as inhalers anaesthesia systems \nfor rodents. All experimental procedures with ro -\ndents are performed in this room. Its layout, with \nfixed and mobile posts, allows for the implemen -\ntation of microsurgical and laparoscopic courses \nwith simulators.\nThe operating room is equipped with double team surgical tables and anaesthesia \nstations with monitoring equipment, which allow for two surgeries to be performed \nsimulta-neously. It is also equipped with laparoscopic, ultrasound and C-Arm X-ray \nequipment. All procedures performed on large animals are carried out here, along \nwith training courses on surgical, laparoscopic and anaesthetic techniques. The animal \nfacility has a total of five rooms for conventional accommodation of animals, in both \nthe breeding phase and for experimentation. T wo of these rooms have modular en -\nclosures for housing large species such as pigs, sheep and rabbits. The remaining three \naccommodate rodents (rat, mouse and gerbil). The housing of rodents has controlled \nventilation systems (a ventilated rack for mice and another for rats) and conventional \nsystems in shelves. It also has a sealed positive and negative pressure room.ANIMAL\tFACILITY\nThe research and teaching at IdiPAZ involving the use of laboratory animals is mana -\nged via the animal platform of IdiPAZ, and is overseen by Dr. Carlota Largo Aramburu. \nIn this department we develop biomedical research projects, training courses specific \nto the various specialties as well as procedures \nfor putting in place new diagnostic techniques or \ntherapies that involve the use of experimental ani -\nmals. In addition, the animal facility works with the \nEthics Committee for Animal Wellbeing, whose \nauthorisations is required for all procedures.\nThe animal facility is located in basement 2 of the \nIdiPAZ building within the hospital complex. The \nfacility provides a total of 10 rooms for animal \nhousing, in both breeding and experimental pha -\nses, two rooms for animal handling and experi -\nmental procedures, a room for washing material, \nwhich includes a cage washer, an autoclave and \na pressurebased washing system, and several sto -\nrage rooms for clean materials, feed and wood \nshavings for cages. In addition, for its proper \nfunctioning, the animal facility is connected with \nthe rest of the departments of Experimental Sur -\ngery where there is a double operating theatre, a \nmicrosurgery room and various additional rooms \n(dressing areas, offices, and store rooms).\nThe species typically used include: rodents (rats, \nmice and gerbils), rabbits, pigs, sheep and goats, \nand occasionally dogs, cats or guinea pigs. Re -\ncently, a fish housing unit has been established \n(zebra fish). T o avoid contamination and permit a good workflow, the rooms for hou -\nsing of large animals are physically separated from those for the rodents and the rest \nof the facilities (washing area, store rooms, or the handling room). In addition, all the \nrooms include an external video camera system to monitor the interior while avoi -\nding the unnecessary entrance of unauthorised personnel.\nThe cages provide the minimum dimensions required for housing pigs and/or small \nruminants. The structure of each cage is includes stainless steel anchored to the wall, \nwith sliding separators that allow the expansion of the space by uniting two cages. The \nrooms have the slope needed to encourage the elimination of solid residue via a drain \nlocated in the rear of the cage. All of the drains are equipped with protection systems \nto prevent the entrance of rodents or insects. For the cleanliness of the room and the \nanimals, there are hot and cold water connections via a hose. \n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n74  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe rabbit room includes modular mobile crate racks of 3, 6 or 9 cages. The rabbits \nare kept in individual stainless steel cages with plastic grids. They also have a box \nstructure inside that allows the animal to hide or go up to a higher position. The \nstainless steel feeders and drinking water are located in the cage door. Faeces and \nurine are collected in an extractible stainless steel tray. This room has a central drain \nwith similar characteristics as those in the large animal room.\nThe rodent area is separated from the rest of the facility via a gate system (without \nlocking doors) where staff can dress appropriately before entering (boots, robe, glo -\nves, hat and mask). In this area, 5 rooms are located for the housing of rats and mice \nin both breeding and experimental phases and a room for fish. There is a storeroom \nfor feed and shavings and a room for handling and the performance of procedures.\nIn addition to two large areas of animals, the animal facility includes:\n\u2022 A washroom equipped with a cage washer (Hobart), a stainless steel pool and an \nautoclave. It also has a pressure wash system for cleaning the cages and/or visits \nthat require it.\u2022 A room for handling large animals for the performance of procedures with a table \nand surgical lamp, surgical cart, monitoring equipment and a C-arm X-Ray.\n\u2022 Store room (clean material).\n\u2022 Control room with computers for environmental control.\nThe animal facility complies with all current legislation and is registered with number \nES-280790001941.\nPORTFOLIO\tOF\tSERVICES\n\u2022 Animals for experimentation (own breeding) \n\u2022 Housing and maintenance of animals\n\u2022 Leasing of spaces for conducting courses (microsurgery laboratories and opera -\nting room)\n\u2022 Performance of surgical procedures on large animals (leasing space and anaesthe -\nsia, does not include surgery)2.7\t Platforms\nOBJECTIVES\nThe IdiPAZ/FIBHULP Simulation Centre offers professionals from various fields \nthe following possibilities:\n\u2022 Learning and training on the approach for patients in critical clinical conditions: \ncardiopulmonary resuscitation, shock of various origins, acute respiratory fai -\nlure of various aetiologies, multiple trauma, arrhythmias, complicated births, \ndifficult airways, safety, and leadership.\n\u2022 Ongoing training of teams who treat patients in critical conditions: ICU, \nanaesthesia, emergency department, surgery.\n\u2022 Learning and training on managing patients with technology-dependent condi -\ntions: mechanical ventilation, extracorporeal membrane oxygenation, dialysis, \nhaemodialysis and haemofiltration and external ventricular assistance.\n\u2022 Learning and training on managing technology for diagnostic and therapeutic \nuse: echocardiography, abdominal ultrasonography, catheterisation, laparosco -\npic surgery, bronchoscopy, laryngoscopy, endoscopy and colonoscopy.\n\u2022 Learning the use of invasive techniques: arterial and central venous cannulation, \nnasogastric and vesical catheterisation, suturing, thoracentesis, paracentesis, \ntracheostomy, nerve blocks.\u2022 Learning to perform a correct medical history review and physical examination \nand communicating and contacting patients, using actors and advanced simulators.\nCOMPOSITION\nGoverning Council\nDr. Javier Cobas Gamallo\nD\u00aa. Ana Coloma Zapatero\nDra. Carlota Largo Aramburu\nD\u00aa Elena Mart\u00edn de Castro\nDr. Juan V\u00e1zquez Est\u00e9vez\nD\u00aa. Alicia Portas Mart\u00ednez \nDr. Manuel Quintana D\u00edaz\nDr. Pedro de la Oliva Senovilla\nDr. Ram\u00f3n Cantero Cid\nDra. Ana M\u00aa S\u00e1nchez Torres\nDra. Emilia Guash Ar\u00e9valo\nDr. Esteban L\u00f3pez de S\u00e1 y Areses\nDr. Ignacio Zapadiel Gutierrez2.7.4 Simulation Platform (CEASEC)Scientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n75  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansDra. Esther Rey Cuevas \nDr. Juan Jos\u00e9 R\u00edos Blanco\nDra. Dolores Elorza Fern\u00e1ndez\nChairman Governing Council \nDr. Juan Jos\u00e9 V\u00e1zquez Est\u00e9vez\nDr. Manuel Quintana D\u00edaz\nSecretary Governing Council:\nD\u00aa. Ana Coloma Zapatero\nD\u00aa. Estela S\u00e1nchez Sim\u00f3n\nContact: \nD\u00aa. Irene Cuevas Gordo\n irene.cuevas@salud.madrid.org\n Phone: (+34) 91 727 71 54\nClinical Simulation Technician: \nJavier Rubio Bol\u00edvar2.7\t Platforms\nACTIVITY\tOF\tCEASEC\nCEASEC is the Advanced Clinical Training and Simulation Center. During 2018, the \nCEASEC activity has highly increased by 45 % compared to 2017. The platform has \nprovided assistance and support for research and teaching in more than 50 courses.\nSchool Courses Simulation (Summary)\nCourse Director Date\nCurso RCP B\u00e1sico Dr. Manuel Quintana D\u00edaz January, 15th, 16th, 17th\nCurso RCP Avanzado Pedi\u00e1trico Dr. Jos\u00e9 Antonio Ruiz Dom\u00ednguez January 31st\nSIMUVAD 2018 Dr. Pedro Garrido February 1st, 2nd, 3rd\nCurso RCP B\u00e1sico Dr. Manuel Quintana February 13th\nM\u00f3dulo politrauma pedi\u00e1trico Dr. Juan Jos\u00e9 V\u00e1zquez Est\u00e9vez February 15th\nCurso de Colgajos Microvasculares en \nla rataDr. Javier Arias Gamallo  \nDra. Mar\u00eda Jos\u00e9 Mor\u00e1nFebruary 19th, 23rd\nAccesos vasculares perif\u00e9ricos Dr. Juan Jos\u00e9 Men\u00e9ndez Suso February 28th\nCurso de Asistencia Inicial al Trauma \nPedi\u00e1trico (AITP) Dr. Jos\u00e9 Antonio Ruiz Dom\u00ednguez March 15th, 16th\nRCP B\u00e1sico + DESA Dr. Manuel Quintana March 19th\nSimulaci\u00f3n en ECMO Neonatal Dra. M\u00aa Dolores Elorza March 21stIX Curso de Ecograf\u00eda en el Paciente \nPedi\u00e1trico Cr\u00edticoDr. Juan Jos\u00e9 Men\u00e9ndez Suso March 20th, 21st, 22nd\nRCP B\u00e1sico + DESA Dr. Manuel Quintana March 28th\nShock 2018 Dr. Emilio Maseda April 6th\nCurso de Microcirug\u00eda Experimental y \nColgajos Microvasculares en la RataDr. C\u00e9sar Casado S\u00e1nchez April 9th, 13th\nSIMUMED 2017 Dr. Pedro Garrido April 19th, 20th, 21st\nSoporte Vital Pedi\u00e1trico D\u00aa. Catalina Fern\u00e1ndez Carretero April 24th\nXXXI Curso Nacional Pr\u00e1ctico \nMultidisciplinario de Microcirug\u00eda \nVasculo Nervioso y sus Aplicaciones \nCl\u00ednicasDr. C\u00e9sar Casado S\u00e1nchez May 7th, 11th\nSimulaci\u00f3n en Emergencias Obst\u00e9tricas Dr. Jos\u00e9 Luis Bartha Rasero May 17th\nEcograf\u00eda Pulmonar en Cardiolog\u00eda Dr. C\u00e9sar Carballo May 21st, 22nd, 23rd\nRCP Avanzado Dr. Manuel Quintana D\u00edaz May 21st to 25th\nT\u00e9cnicas de depuraci\u00f3n extracorp\u00f3rea Dra. Carlota Largo Aramburu May 29th, 30th \nCrisis Resource Management \nRadiolog\u00eda Dr. Manuel Quintana D\u00edaz June 5th\nRCP Avanzado  Dr. C\u00e9sar Carballo June 18th, 19thScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n76  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansAtenci\u00f3n al paciente pedi\u00e1trico grave \nen el servicio de urgencias (CRM - \nCrisis resources)Dr. Jos\u00e9 Antonio Ruiz Dom\u00ednguez June 19th\nRetos en el manejo y diagn\u00f3stico del \nictusDra. Blanca Fuentes June 21st\nCaso cl\u00ednico laringoespasmo Dr. Francisco Reinoso Junio 21st, 22nd\nCurso Pr\u00e1ctico de Cirug\u00eda \nLaparosc\u00f3pica Dr. Ignacio Zapardiel September 17th\nRCP B\u00e1sica Neonatal y Ped\u00edatrica Dr. Miguel de R\u00edo September 18th, 19th \nSimulaci\u00f3n en Cuidados Intensivos \nPedi\u00e1tricosDr. Miguel del R\u00edo September 28th\nCurso de Simulaci\u00f3n en Enfermer\u00eda de \nAtenci\u00f3n al ICTUS Dra. Blanca Fuentes October 1st, 2nd, 3rd\nCurso de Asistencia Inicial al Trauma \nPedi\u00e1trico (AITP) Dr. Jos\u00e9 Antonio Ruiz Dom\u00ednguez October 18th, 19th\nCurso de Ecografia en el Paciente \nPedi\u00e1trico Cr\u00edticoDr. Juan Jos\u00e9 Men\u00e9ndez Suso October 8th, 9th, 10thCurso de Canalizaci\u00f3n ecoguiada de \naccesos vasculares perif\u00e9ricos y PICCSDr. Juan Jos\u00e9 Men\u00e9ndez Suso October 22nd\nCurso de Instructores en RCP \nPedi\u00e1trica y Neonatal Dr. Miguel de R\u00edo October 24th, 25th, 26th\nCrisis Resource Management en \nNeonatolog\u00eda Dra. M\u00aa Dolores Elorza  \nDr. Juan Jos\u00e9 V\u00e1zquez Est\u00e9vez October 25th\nSoporte Vital Inmediato D\u00aa. Catalina Fern\u00e1ndez November 5th, 6th,\nCurso de simulaci\u00f3n avanzada en el \nmanejo de paciente cr\u00edtico cardiol\u00f3gicoDr. Esteban L\u00f3pez de S\u00e1 November 12th, 13th\nCurso Avanzado de Instructores en \nSimulaci\u00f3n Cl\u00ednica Dr. Juan Jos\u00e9 V\u00e1zquez Est\u00e9vez  \nDr. Manuel Quintana D\u00edaz November 20th, 21st\nSimulaci\u00f3n en ECMO neonatal Dra. M\u00aa Dolores Elorza November 27th, 28th\nCRM Anestesiolog\u00eda Pedi\u00e1trica Dr. Francisco Reinoso November 30th\nCurso de Simulaci\u00f3n en Emergencias \nObst\u00e9tricas Dr. Jos\u00e9 Luis Bartha Rasero December 5th\nCurso de microciurg\u00eda vascular \ncerebral y By-Pass Extra IntracranealDr. Gonz\u00e1lez LlanosDecember 13th,14th, 15th, \n16th, 17th2.7\t Platforms\nThe Cell Culture Unit has been established as a core support division integrated \ninto the Hospital La Paz Institute for Health Research (IdiPAZ). This unit facilitates \nthe establishment and management of in vitro model systems and experimental-\nrelated techniques for different applications and purposes including the study of \nbiochemical processes in cells, the elucidation of the molecular and cellular me -\nchanisms involved in a biological process, the prediction of the cellular and tissue \nresponses to a specific microenvironment and/or the identification and develop -\nment of novel drugs, compounds and therapeutic targets. Therefore, this platform \nprovides a fundamental basis for the development of research initiatives in the field \nof Biomedical and Pharmacological Research and Health Sciences. \nThe Cell Culture Unit accomplishes its mission by providing users with assistan -\nce and support at scientific, technical and instrumental level through access to \nknowledge, equipment, material and human resources. According to IdiPAZ stra -\ntegic plan and other institutional guidelines, this division contributes to the trans -\nlation of biomedical research by fostering the synergies and cooperation between clinic- and basic- oriented research groups belonging to IdiPAZ as well as to ex -\nternal institutions. It also provides a dynamic and shared operational environment \noffering a convenient basis for the exchange and dissemination of the scientific \nknowledge, innovation and creativity as well as the creation of collaborations and \nalliances between researchers of various categories and disciplines. Moreover, the \nassociation and physical proximity with other core facilities such as the Imaging \nand Flow Cytometry Units, enable users to develop complementary techniques, \nto explore and upgrade innovative hypotheses and to extend and/or improve their \nobjectives.\nCOMPOSITION\nHead:\nGema Vall\u00e9s P\u00e9rez (PhD)\n gema.valles@salud.madrid.org\n Phone: (+34) 917277000 (ext. 1576)2.7.5 Cell Culture UnitScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n77  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansTechnical Support:\nBeatriz Sanz Minguel\n Phone: (+34) 917277000 (ext. 2142)\nSecretary: \nSusana Garc\u00eda P\u00e9rez\n investigacion.hulp@salud.madrid.org\n Phone: (+34) 912 071 512\nEQUIPMENT\tAND\tFACILITIES\nThe Cell Culture Unit consists of an experimentation laboratory, a cryopreservation \nroom and a warehouse. All facilities are located in the IdiPAZ building. \nThe experimentation laboratory is fitted with the following equipment:\nCabinets:\n\u2022 3 T elstar Bio-II-A biological safety cabinets \n\u2022 2 Nuaire NU-437-400E biological safety cabinets \n\u2022 1 Heraeus HS-12 biological safety cabinets \n\u2022 1 Faster BH-EN 2004 biological safety cabinet \n\u2022 1 Gelaire BSB 4A biological safety cabinet \n\u2022 1 Esco Class II BSC biological safety cabinet \n\u2022 3 Faster BIO 48 vertical laminar flow cabinets \n\u2022 1 Faster TWO 30 vertical laminar flow cabinet \nIncubators:\n\u2022 3 Thermo Forma Scientific incubators \n\u2022 2 HERAcell incubators \n\u2022 2 Biotech Galaxy S incubators \n\u2022 2 Nuaire Autoflow incubators\n\u2022 1 Sanyo O2/CO2 incubator\nThis equipment is complemented with \na centralized and alarmed gas system, \nwhich guarantees a constant and contro -\nlled supply of CO2 and N2.\nMicroscopes:\n\u2022 1 Nikon DIAPHOT TMD inverted light \nmicroscope connected to a Nikon D80 \ndigital camera.\n\u2022 1 Leica DMIL inverted light microscope connected to a Canon Powershot S70 digital camera.\n\u2022 1 Optika inverted light microscope \n\u2022 1 Motic AE2000 inverted light microscope connected to an automatic counter \nCeleromics\n\u2022 1 Lan Optics inverted light microscope\nCentrifuges:\n\u2022 2 Eppendorf 5810R refrigerated centrifuges \n\u2022 2 Eppendorf 5804 centrifuge\n\u2022 1 Hettich Universal 32R refrigerated centrifuge\n\u2022 1 Kubota 2010 centrifuge\n\u2022 Cell Separation System:\n\u2022 1 Milteny Biotec autoMACS cell separation system\nFreezing systems:\n\u2022 1 Liebherr refrigerator (4 \u00b0 C and -20 \u00b0 C)\n\u2022 1 Balay refrigerator (4 \u00b0 C and -20 \u00b0 C)\n\u2022 1 Whirlpool refrigerator (4 \u00b0 C and -20 \u00b0 C)\n\u2022 1 Beko refrigerator (4 \u00b0 C and -20 \u00b0 C)\nOther equipment:\n\u2022 1 Presoclave 75 P-Selecta autoclave\n\u2022 1 Millipore water purification system\n\u2022 1 Heidolph Reax 2000 vortex\n\u2022 1 Raypa thermostatic waterbath\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n78  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\u2022 1 Memmert thermostatic waterbath \n\u2022 2 Precisterm thermostatic waterbath\n\u2022 1 Grant JB Aqua 12 Plus thermostatic waterbath\n\u2022 Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell \ncounting cameras, etc ....\nThe cryopreservation room is equipped with:\n\u2022 2 Statebourne Biorack 3000 liquid nitrogen tank\n\u2022 1 Thermo Locator 6 Plus liquid nitrogen tank\n\u2022 1 10 K Taylor Wharton liquid nitrogen tank\n\u2022 1 MVE cryosystem 4000 liquid nitrogen tank\n\u2022 1 Cryo Diffusion B2016 liquid nitrogen tank\n\u2022 1 Cryo diffusion B2048 liquid nitrogen tank\n\u2022 1 Cryo Diffusion B2011 liquid nitrogen tank\n\u2022 1 SEO GT40 liquid nitrogen tank\n\u2022 1 MVE XLC 511 liquid nitrogen tank\nThe infrastructure for cryopreservation is completed with a liquid nitrogen \ntransfer device and an alarmed Oxygen O2 detector coupled to a mechanical \nventilation system.\nPLATFORM\tOPERATING\tSTANDARDS\nThe Cell Culture Unit provides a joint support structure for biomedical research, \nincluding infrastructure and equipment, technical assistance and scientific consultation \nto researchers who request their services. With regard to facilities and equipment \navailable, staff associated with the Unit will be responsible for their proper mainte -\nnance and operational guidelines and will provide support, training and supervision to \nusers in order to obtain optimal utilization and exploitation. The Unit is oriented to \nspecialized training, exchange and dissemination of scientific knowledge and an active \ncollaboration with users to develop cell culture-related procedures and technology. \nThis service aims not only to meet the needs of IdiPAZ researchers but also to pro -\nvide adequate support to non-IdiPAZ scientists that do not have specific facilities to \nperform their cell culture experimentation. All users must respect the internal rules \nof the Service, the established principles of prevention, health and safety, guidelines on \nhandling and management of reagents, materials and waste disposal besides the opera -\nting instructions and procedures for instruments and equipment.\nUsers (from the IdiPAZ or other facility or institution) who request services for the \nfirst time or who demand additional information, please contact to the Head of the \nPlatform.PORTFOLIO\tOF\tSERVICES\nThe Cell Culture Platform activities are focused on providing users with flexible and \nresults-oriented services in a collaborative and translational research framework. In ge -\nneral, this Division offers support for experimental approaches developed by IdiPAZ and \nnon-IdiPAZ scientists on an extensive range of matters including cell experimentation, \nconsumables and reagents, equipment and laboratory area, technical assistance, training \nand research. \nThe specific support provided by this Unit includes: \n\u2022 Scientific and technical advice, personalized support and consultation: guidance \nin experimental setup and design, study planning, optimization of techniques \nand protocols, reagents and material acquisition, cells supply, troubleshooting, \nanalysis and interpretation of results\u2026\n\u2022 Basic training and hands-on experiments (implementation of the self-service \nmode) according to biosafety, waste disposal and good laboratory practice \nguidelines\n\u2022 Access to specific facilities including instrumentation, equipment, materials and \nreagents\n\u2022 Preparation and supply of certain materials, reagents and sterile solutions. \n\u2022 Management and general supervision including good laboratory practices and \nwork habits, cleaning and waste disposal and operation and maintenance of the \nequipment\n\u2022 Performance of experimental procedures: cell separation, cell isolation for cul -\ntivation, maintenance and propagation of cell lines and primary cultures, cryo -\npreservation and resuscitation, viability and proliferation, etc..\n\u2022 Control and maintenance of cryopreserved stock cells\n\u2022 Elaboration and management of protocols and guidelines, operating procedu -\nres, reports and other required mandatory documentation\n\u2022 Detection, identification and treatment of contaminations in cell cultures\n\u2022 In addition to these standard services, this platform offers collaboration with \nindividual researchers as an effective way to improve and to expand the port -\nfolio of technology and services offered. Furthermore, and as part of its com -\nmitment to warrant users the optimal development of their research projects, \nthe contact to other centralised equipment and affiliated facilities, infrastructu -\nres and common equipment is also provided\nPricing services available on the web:\nhttp://www.idipaz.es/PaginaDinamica.aspx?IdPag=191&Lang=EN2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n79  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe main role of the Sanger sequencing laboratory is to pro -\nvide support for medical research in the field of Molecular \nBiology. The goal is to support to research groups both inside \nour Institute and elsewhere that require the infrastructure \nCE. \nOur laboratory is located inside INGEMM. This allows for fre -\nquent interactions with the hospital\u2019s various research groups, \nand thus allows for the laboratory members to stay up to date on state-of-the-art \ntechniques in genetics. Therefore, the laboratory is an translational-research model. \nNowadays, the Sanger sequencing method is regarded it as the gold standard for \nvalidation of Next-Generation Sequencing single nucleotide variants. In order to \nachieve the goals stated above, our laboratory owns the necessary equipment \nand infrastructure for performing tasks such as conventional sequencing (Sanger \nmethod), marker DNA genotyping, and other molecular biology techniques based \non capillary electrophoresis. The equipment can use up to 5 simultaneous colours \non the same sample when it migrates into the genetic analysers. Therefore, we are \nable to detect more than 30 polymorphic markers per sample.\nThe laboratory is regularly involved in quality control audits on the Sanger sequen -\ncing and genotyping, as well as result homologation. Such audits are performed at \nboth national and international levels (e.g., EMQN). In addition, Sanger Sequencing \nFacility has been adapted to the ISO 9001:2015 Standard during 2018. \nCOMPOSITION\nLab Manager\nMar\u00eda del Roc\u00edo Mena de la Cruz (PhD)\n mariarocio.mena@salud.madrid.org\n Phone: 91 207 10 10 (Ext. 230)\nTechnician\nInmaculada Rueda Arenas\n inma.rueda@salud.madrid.orgEQUIPMENT\n\u2022 Eppendrof 5415D Centrifuge.\n\u2022 Veriti T ermocycler(Applied Biosystems).\n\u2022 Genetics Analyzers 3130xl y 3730xl (Applied \nBiosystems-Life T echnologies).\nSoftware:\n\u2022 Sequencing Analysis v5.3.1\n\u2022 Sequence Scanner v1.0\n\u2022 GeneMapper v4.0\n\u2022 Peak Scanner v1.0\n\u2022 Variant report v1.0\nPORTFOLIO\tOF\tSERVICES\n\u2022 Nucleic Acid quantitation (T ecan, Nanodrop)\n\u2022 PCR purification for Sanger sequencing (Exosap)\n\u2022 Sanger Sequencing\n\u2022 Fragments Analysis:\n- QF-PCR\n- MLPAs (multiplex ligation-dependent probe amplification).\n- Microsatellite instability (MSI)\n- AZF\n- SnapShot\n- TP-PCR2.7.6 Sanger Sequencing Facility2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n80  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansImage and Immunohistochemistry Unit, as a part of the network of IdiPAZ core fa -\ncilities, play an essential role in enabling scientists and clinicians to realise their goals \nin biomedical research. The laboratory mission is to provide a centralized service \ndedicated to assisting with the highest quality histology, immunohistochemistry and \nimaging equipment, as well as scientific and technical support to researchers. The \nUnit collaborates in creating a link between basic and clinical research to reach the \ntranslational research milestones, in addition of Institute training and education plans. \nTherefore, Image and immunohistochemistry Unit is open to all researchers, inclu -\nding; IdiPaz and their affiliates, commercial and not-for-profit biotechnology compa -\nnies, and other academic institutions.\nSpecialized staff provides histological and molecular technical support to the re -\nsearchers\u2019 requirements, which in turn produces high quality data interpretation \nto support grant applications and national and international scientific publications. \nCurrently a broad range of techniques ranging from classical histology, to molecu -\nlar techniques as immunohistochemistry, immunofluorescence and image and digital \nanalysis are available at the facility. The general rules of the platform is that trained \nand authorized users have free access to the platform; IdiPaz staff in a Do-It-yourself \nmanner and in a fee-for-service manner to all the rest. The Unit, located in the IdiPaz \nbuilding at the La Paz University Hospital, consists of two sections, the Immunohis -\ntochemistry and the Microscopy laboratories. \nImmunohistochemistry laboratory, housed in the first floor of IdiPaz building, offers \nprotocols and automated high-throughput equipment allowing citospines, fixation \ntechniques (paraffined or freezed), sectioning of tissues (microtomes and cryostats), \nand classical or advanced immuno-staining (Dako Autostainer). Microscopy Lab is in \nthe -1 floor of IdiPaz building and offers facilities to perform a range of real time and \nend-point assays, including cell number, proliferation, apoptosis, cell size, and shape \nand viability measures. The equipment of Microscopy\u2019s lab allows to do conventional, \nfluorescence, confocal and high-content microscopy, includes a Leica TCS SPE inver -\nted confocal, Leica DM6000 inverted fluorescence microscope, a microscope inver -\nted Nikon Eclipse Ti with in vivo incubation system and a microscope Nanosight with a system of tracking nanoparticles. In addition, the lab offers \nimage analysis programmes (NIS Elements AR, Nanosight 3.1, \nLASAF , Image ProPlus and ImageJ.\nCOMPOSITION\nHead:\nMar\u00eda Teresa Vallejo Cremades (PhD)\ntvallejo.hulp@salud.madrid.org\nPhone: (+34) 917277526\nTechnician:\nOnys Camps Ortega\n Phone: (+34) 917277526\nSecretary:\nSusana Garc\u00eda P\u00e9rez\n investigacion.hulp@salud.madrid.org\n Phone: (+34) 91 207 15 12\nRESOURCES,\tEQUIPMENT\tAND\tMANAGEMENT\t\nOF\tTHE\tLABORATORY\nThe laboratory staff will present the basic rules to new users for good practices \nand safety in the laboratory. Users should not use the equipment until the labora -\ntory personnel have checked their correct training. Users must schedule the time \nof work in any equipment and booking reserve it is mandatory in all the facility. Ac -\ncess to the Microscopy requires the magnetic individual. The services of the image \ncore facility are available to all scientists in collaboration, Do-It-Y ourself model or \nin a fee model (in this case, it must be consulted the head of the laboratory, the lab \nwill support the service depending on staff availability).\n\u2022 Equipment of Image and Immunohistochemistry Unit\nImmunohistochemistry Laboratory:\n\u2022 Tissue processor providing efficient, reliable and timely processing of paraffin \nwax (Leica TP1020)\n\u2022 Embedding unit for high quality paraffin blocking (Leica EG1160)\n\u2022 Selecta Wax dispenser, paraffin wax dispenser with adjustable temperature \nfrom ambient to 100 \u00baC\n\u2022 2 microtomes for specimen sectioning Leica RM2255\n\u2022 1 microtome for specimen sectioning Shandon AS3252.7.7 Image laboratory\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n81  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\u2022 Leica EG 1150C Cold plate\n\u2022 2 thermostatic water Leica HI 1210 baths\n\u2022 1 thermostatic water Selecta Thermofn bath\n\u2022 Automated Immunohistochemistry autostainer (Autostainer Plus DAKO)\n\u2022 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CM1950)\n\u2022 PTLink DAKO\n\u2022 Crison pH meter\n\u2022 Liebher upright freezer (-20\u00baC and 4\u00baC)\n\u2022 Liebher economy freezer (-20\u00baC)\n\u2022 Shandon Cytospin 2\n\u2022 Memmert BE 500 oven\n\u2022 Memmert UN 30 oven\n\u2022 Selecta Agimatic-E magnetic stirrer with heating\n\u2022 Pippetors\n\u2022 Olympus CH microscope, for practical laboratory applications\n\u2022 Gilson pipette sets\n\u2022 NUAIRE laboratory fume hood.\nDissection equipped and staining area with manual options for Do-It-Y ourself stai -\nning and cover slipping.\nThe laboratory is equipped with shared facilities from Translational Oncology and \nAnatomopathology Breast and Gynecological Cancer groups that use them for \ndiagnostic and clinical research purpose (ESCO fume hood and Crison Microto -\nme). Permission to use must be asked to the head of these laboratories.\nThe Microscopy laboratory equipment includes:\n\u2022 Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Ilumi -\nnation source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers \ndiode 635; Dishes, Standard microscope slides.\n\u2022 NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, \nin vivo imaging and High Content (equipped with incubation chamber) \n- Camera IMAGING SOURCE \n- Camera Camera ANDOR Neo SCHOS refrigerated. \n- Lauda Ecoline Star incubator edition 003 \n- Hotplate (OKO LAB) \n- D gas (Okolab) \n- Microscope culture plates adapter \n\u2022 Leica DMI6000B inverted microscope. Filter cubes: A4(UV), L5 (green), N3 \n(red) and Y5 (far red)\u2022 Olympus BX41 (Bright feld) upright microscope with an attached Digital camera\n\u2022 Zeiss Axioplan 2 upright microscope with fve objectives from 5x to 100x, pha -\nse contrast and fuorescent capabilities\n\u2022 Zeiss Axio Lab.Al microscope fve objectives from 5x to100x. ERC5S Axocan \ncamera.\n\u2022 Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles\u2019s size \nbased on the scattering of light, includes a microscope, a LM10 viewing unit, a \nMarlin camera, an objective x20 and is connected to a image analysis software.\n\u2022 Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera \nattached)\n\u2022 Image ProPlus 5.0 image analysis software\n\u2022 Leica LAS AF image analysis software\n\u2022 Analysis station with Huygens deconvolution software, Image J, LASAF Lite \nprogramme and related image analysis software.\n\u2022 Nanosight NTA 3.1 analytical software.\nThe laboratory is equipped with shared facility from Neuroscience group (Leica \nTCS SPE inverted confocal). \nRESEARCH\tHIGHLIGHTS\nIn 2018, Image unit maintained their quality standards in order to support and \ncollaborate with the groups belonging to the research areas of IdiPAZ; Neuroscien -\nces, Infectious disease and immunity, \nCancer and human molecular genetics, \nCardiovascular, Organ system patholo -\ngies and Surgery, transplant and health \ntechnologies. The results of these co -\nllaboration are reflected in projects \ngranted (publics or privates, national \nor international grants), scientific dis -\nsemination (thesis) and high impact \ninternational publications.\nIn the last year, we have maintained the number of users inside Hospital La Paz \n(HULP , clinical and basic researchers), associated IdiPaz groups (UAM), and exten -\nded research groups (UCM, CSIC etc). The Operation Time in 2018 (calculated as \nthe total time of use per year of some equipment from Microscopy lab and from \nimmunohistochemistry) has been almost equal than in 2017.\nThe platform began during 2018 to develop a system of quality management fo -\nllowing the ISO9001:2015 STANDARD. In addition, the staff of the unit assist to \nthe SPAOM Spanish-Portuguese Meeting for Advanced Optical Microscopy orga -\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n82  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansnized by the Spanish Network \nof Advanced Optical Micros -\ncopy (REMOA) in Granada \nwith a poster communication. \nThis allows us to implement \nthe collaboration with other \nimage core platforms and the \nknowledge of recent advances \nin the field of bioimaging tech -\nniques. The platform maintains \nthe training activities as tutor \ncentre trainees of the Commu -\nnity of Madrid, maintaining a co -\nllaboration agreement with two \ninstitutes for their students \nperform regulated practices.\nPORTFOLIO\tOF\tSERVICES\n\u2022 Collection and processing for fixing and decalcification of samples\n\u2022 Sample processing in paraffin by hand or automatic\n- Complete paraffin embedding processing\n- Serial cut in microtome and tissue assembly\n\u2022 Antibodies\u2019 validation\n\u2022 Buffer preparation and distribution of consumables\n\u2022 Sample processing frozen\n- Preparation of freeze blocks\n- Serial sections of blocks freeze and cuts collected on slides or floating\n\u2022 Staining\n- Hematoxylin - eosin\n- Masson trichrome\n- Nissl\n- PAS\n- Acetylcholinesterase\n\u2022 Cytochemical and immunohistochemical techniques\n- Decalcification of samples required\n- Dewaxing cuts, performing staining\n- Immunohistochemical staining automated system Autostainer\n- Immunofluorescence in frozen tissue and paraffin. Protocols\n- Dehydration and slide assembly\u2022 Image acquisition. Viewing and \ndigital format acquisition\n- Light microscopy\n- Light microscopy with phase \ncontrast\n- Epifluorescence\n- Confocal microscopy\n- Advanced Microscopy in living cell\n\u2022 Fluorescence localization by confocal microscopy\n\u2022 3D reconstruction\n\u2022 In vivo  image acquisition of biological samples (incubation system for the tem -\nperature and CO 2)\n\u2022 Morphometry in biological samples\n\u2022 Large images acquisitions (scanning the entire slide) for bright field and fluores -\ncence\n\u2022 Collaboration for sample processing protocols for microscopy (fastening, stai -\nning, marking, etc.) and advice for planning projects that could require the use \nof microscopy\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n83  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe IdiPAZ Flow Cytometry Laboratory is becoming consolidated as a great tool in \nthe centre\u2019s research approach. The laboratory is dedicated to providing all IdiPAZ \nmembers Access to affordable and high-quality flow cytometry services, together \nwith the decisive scientific expertise to utilize this technology in research. We Excel \nat a wide variety of flow cytometry applications:\n\u2022 Sample proccessing for extra- and intracelular staining\n\u2022 Functional assays\n\u2022 Phenotypic analysis of subpopulations\n\u2022 Preliminary studies for a posterior clinical application\n\u2022 Complex multi-color flow cytometry analyses\nCOMPOSITION\nHead:\nV\u00edctor M. Toledano Real\n victor.toledano@idipaz.es\n Phone: (+34) 91 727 00 00 (ext. 2484)\nSecretary:\nSusana Garc\u00eda P\u00e9rez\n investigacion.hulp@salud.madrid.org\n T el: (+34) 912 071 512\nEQUIPMENT\nThe Flow Cytometry Laboratory of IdiPAZ has the following facilities:\n\u2022 One Beckman Coulter Navios cytometer analyser is a clinical system that deli -\nvers analytical excellence by coupling extraordinary sensitivity, resolution and dy -\nnamic range with high-speed data collection. With superior detection capabilities, \nthe Navios provides accurate measurements, especially for rare events, which is \ncritical to clinical diagnosis and monitoring. The fully-featured, easy-to-use Navios \nsoftware provides tools to improve the quality of results as well as optimize \nworkflow efficiencies in a clinical lab.\n- This analyser has three lasers; Blue solid state Diode: 488nm, 22mwlaser out -\nput, Red solid state Diode: 638nm, 25mwlaser output \nand Violet solid state Diode: 405nm, 40mw laser output. \nThe Navios can analyse ten colours simultaneously in \nsamples marked with the following fluorochromes:\u2022 FL1: \nFITC, GFP , Cy2, Alexa 488 \u2022 FL2: PE, Cy3 \u2022 FL3: PI, ECD, PE-TEXAS RED, RED RFD \u2022 FL4: PE-Cy5, PerCP , Per-CP5.5, TC 7AAD, SPRD \u2022 \nFL5:PE-Cy7 \u2022 FL6: APC, Alexa 647 \u2022 FL7: APC-Alexa700, Alexa 700 \u2022 FL8: APC-\nCy7, APC-Alexa750, APC-Alexa780 \u2022 FL9: Pacific Blue, eFluor 450 Cyan, Cyan, \nViolet RFD \u2022 FL10: Pacific Orange, AmCyan\n- The Navios is connected to computer using the Navios acquisition and analysis \nprogramme.\n\u2022 T wo Becton Dickinson FACSCalibur\u2122 cytome -\nter analysers is a platform allows users to per -\nform both cell analysis and cell sorting in a single \nbenchtop system. The system supports a wide \nvariety of research and clinical applications and is \ncomplemented by a broad suite of intuitive soft -\nware solutions to streamline analysis for a wide range of applications including \nenumeration of lymphocyte subsets, stem cells, residual white blood cells, and \nreticulocytes.\n- Each analyser has two lasers, a 488nm argon laser and a 635nm solid-state red \ndiode laser. The FACSCalibur \u2122 can analyse four colours simultaneously in \nsamples marked with the following fluorochromes: \u2022 FL1: FITC, Alexa 488 \u2022 FL2: \nPE, PI \u2022 FL3: PE-Cy5, PerCP , Per-CP5.5 \u2022 FL4: APC, APCCy7, Alexa 647\n- The two cytometers are connected to Macintosh G4 OS.9.2.2 computers \nusing the CellQuest\u2122 acquisition and analysis programme, and Macintosh G5 \nOSX with CellQuestPro\u2122 acquisition and analysis software\n\u2022 One cytometer analyser Becton Dickinson FACSCelesta. It is designed to make \nmulticolored flow cytometry more accessible and allow researchers to benefit \nfrom technological innovations in equipment and reagents. These parallel advan -\nces in optical and reagent technology allow multi-laser equipment to complement \nthe new bright fluorochromes, allowing for a deeper and more powerful insight \ninto cell analysis.\n- This analyser has three lasers; BUV12: 4 Blue(488nm) / 2 ultra violet (355nm) / \n6 violet (405nm). Can analyse twelve colours simultaneously in samples marked \nwith the following fluorochromes: FITC; PE; Brilliant Blue 515 (BB515); Brilliant \nBlue 700 (BB700); PERCP; PERCP CY5.5; \nPE CY5; PE CY7; Brilliant Ultra Violet \n395 (BUV 395); Brilliant Ultra Violet 496 \n496); Brilliant Ultra Violet 563 (BUV 563); \nBrilliant Ultra Violet 661 (BUV 661); Bri -\nlliant Ultra Violet 737 (BUV 737); Brilliant \nViolet 421 (BV 4219; Brilliant Violet 480 2.7.8 Flow Cytometry Laboratory\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n84  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians(BV 480); Brilliant Violet 510 (BV 510); Brilliant Violet 605 (BV 605); Brilliant \nViolet 650 (BV 650); Brilliant Violet 711 (BV 711); Brilliant Violet 786 (BV 786); \nV450; V500; PACIFIC BLUE; PACIFIC ORANGE. \n- The FACSCelesta is connected to computer using the DIVA acquisition and \nanalysis programme\n\u2022 The laboratory also has an additional Mac G5 OSX analysis station with Cell -\nQuestPro\u2122 acquisition and analysis softwareActivity of the flow \ncytometry platform \ndistributed by usage \nhours (%) of each \ngroup. \nThe radioactive facility of IdiPAZ laboratories is authorised by the Nuclear Safety \nCouncil (Consejo de Seguridad Nuclear, CSN) to operate with non-encapsulated \nsources radioisotopes: 14C, 3H, 33P , 32P , 125I, 51Cr. Personnel of the Radiological \nProtection Department of HULP conduct radiological protection and periodically mo -\nnitor laboratory contamination levels. They are also responsible for the removal and \nmanagement of waste products and the management of users\u2019 personal dosimeters:\nCOMPOSITION\nPerson Responsible\nNuria Vilaboa D\u00edaz\n nuria.vilaboa@salud.madrid.org \n Phone: (+34) 91 207 10 34   \nDavid Vicent L\u00f3pez\n david.vicent@salud.madrid.org\n Phone: (+34) 91 207 10 30 \nSecretary\nSusana Garc\u00eda P\u00e9rez\n investigacion.hulp@salud.madrid.org \n Phone: (+34) 91 207 15 12EQUIPMENT\nContains exclusive areas for the use of \u00df and \u03b3 isotopes; aliquot withdrawal and \nstorage of radiolabeled compounds; and equipment for exclusive use with radioac -\ntive material. The laboratory has the following equipment: \u2022 CO2 incubator \u2022 Cell \nharvester \u2022 Beta counter \u2022 Hybridisation oven \u2022 Gel dryer \u2022 SpeedVac\u00ae concentra -\ntor \u2022 Screens and containers specifically for \u03b3 and \u03b2 radiation emitters \u2022 High-ener -\ngy \u03b3 and \u03b2 conta -\nmination detectors \n(Geiger counter). 2.7.9 Radioisotope Laboratory\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n85  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe Biostatistics Section has the mission of giving methodological support to the \nprofessionals of the \u201cLa Paz\u201d Universitary Hospital and, in general, to the IdiPAZ pro -\nfessionals, and to provide technical solutions for the optimization of clinical processes \nby incorporating the necessary technologies for this:\nCOMPOSITION\nTeam leader\nClinical Biostatistics\nMariana D\u00edaz Almir\u00f3n\n mariana.diaz@salud.madrid.org\nStaff\nClinical Biostatistics\nItsaso Losantos Garc\u00eda\n itsaso.losantos@salud.madrid.org\n Phone: (+34): 912071 791\nBioengineer\nFrancisco Gay\u00e1 Moreno\n francisco.gaya@salud.madrid.org\n Phone: (+34): 912071 791\nClinical Epidemiologist\nJes\u00fas D\u00edez Sebast\u00edan\n jdiezs@salud.madrid.org \n Phone: (+34)917277570\nCOMPUTER\tTOOLS\nMain programs used for data analysis:\n\u2022 SAS 9.3 (Copyright \u00a9 2012, SAS Institute Inc., Cary, NC, USA)\n\u2022 SAS Enterprise Guide 5.1 (Copyright \u00a9 2012, SAS Institute Inc., Cary, NC, USA)\n\u2022 R version 3.5.0 R Core T eam (2018). R: A language and environment for statis -\ntical computing. R Foundation for Statistical Computing, Vienna, Austria. URL \nhttps://www.R-project.org/.\n\u2022 SPSS 9 (Copyright 1999 by SPSS Inc. ) \n\u2022 SYSTAT 11 (Copyright (c) 2004 by SYSTAT Software Inc., Richmon, CA, USA.)\n\u2022 nQuery Advisor 5.0 (Copyright (c) 1995-2002) \u2022 PEST 4.0 Planning and Evaluation of Sequential Trials (Medical and pharmaceu -\ntical Statistics Research Unit. The University of Readyng, UK)\n\u2022 Review Manager (RevMan) Version 5.0. (Meta-an\u00e1lisis) Copenhagen: The Nor -\ndic Cochrane Centre, The Cochrane Collaboration, 2008.\n\u2022 Joinpoint Regression Program, Version 4.5.0.1. June, 2017; Statistical Research \nand Applications Branch, National Cancer Institute.\nPORTFOLIO\tOF\tSERVICES\n\u2022 Study design\n\u2022 Creation of data collection systems (such as ms Access)\n\u2022 T echnical support in the development of studies. \n\u2022 Assistance in the design, analysis and interpretation of validation studies of \ndiagnostic tests in the clinical hospital context\n\u2022 Development of information processing systems (clinical image, readings of mea -\nsuring devices, implementation of statistical methods ...) Analysis of results: Multi -\nvariate Analysis (Discriminant Analysis, Correspondence Analysis, Factor Analysis, \nSurvival Analysis, Analysis with competitive risks. ..), Generalized Linear Models \nincluding Models with Mixed Effects and Generalized Equation Models, develo -\npment of Risk Models for classification and prediction, construction of scoring \nsystems for risk assessment, Analysis of growth curves, clinical trial methodology , \nmethods of sequential data analysis, analysis of high-dimensional data (Analysis of \nmicroarrays). Bicl\u00faster analysis. Resampling methods (Bootstrap, Jackknife, ...)\n\u2022 Presentation and dissemination of results\n\u2022 Realization of training activities\nACTIVITY\tCARRIED\tOUT\tDURING\t2018\nDistribution by \u2018Center\u2019\n \n14,57,813,85,259\n4,853,9\n5,2\n17,2\n4,5\n11,92,2\n0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit\n2017\n2018\n34,221,2\n62,213,3\n34,24,5\n6,7\n58,4\n4,518,537,85,9\n14,8\n0,7\n0 10 20 30 40 50 60 70Clinical TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018\n69,423,2\n68,7196,13,71,8\n1,14,81,5\n0 10 20 30 40 50 60 70 80Sta\ufb00-feaMirAtd-due- MatronaResearcherOther 20172018\n29,7109012,23,7\n197,490,811,73,1\n0 10 20 30 40 50 60 70 80 90 100DesignSample SizeData AnalysisData basesOthers 20172018\n54,655,8\n56,343,8\n0 10 20 30 40 50 60NOYES2.7.10  Biostatistic Section2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n86  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\nDistribution by \u2018Research Dissemination Objectives\u2019\n 14,57,813,85,259\n4,853,9\n5,2\n17,2\n4,5\n11,92,2\n0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit\n20172018\n34,221,2\n62,213,3\n34,24,5\n6,7\n58,4\n4,518,537,85,9\n14,8\n0,7\n0 10 20 30 40 50 60 70Clinical TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers\n2017\n2018\n69,423,2\n68,7196,13,71,8\n1,14,81,5\n0 10 20 30 40 50 60 70 80Sta\ufb00-feaMirAtd-due- MatronaResearcherOther 20172018\n29,7109012,23,7\n197,490,811,73,1\n0 10 20 30 40 50 60 70 80 90 100DesignSample SizeData AnalysisData basesOthers 20172018\n54,655,8\n56,343,8\n0 10 20 30 40 50 60NOYES\nDistribution by \u2018Research Statement\u2019\n 14,57,813,85,259\n4,853,9\n5,2\n17,2\n4,5\n11,92,2\n0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit\n20172018\n34,221,2\n62,213,3\n34,24,5\n6,7\n58,4\n4,518,537,85,9\n14,8\n0,7\n0 10 20 30 40 50 60 70Clinical TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018\n69,423,2\n68,7196,13,71,8\n1,14,81,5\n0 10 20 30 40 50 60 70 80Sta\ufb00-feaMirAtd-due- MatronaResearcherOther\n 2017\n2018\n29,7109012,23,7\n197,490,811,73,1\n0 10 20 30 40 50 60 70 80 90 100DesignSample SizeData AnalysisData basesOthers 20172018\n54,655,8\n56,343,8\n0 10 20 30 40 50 60NOYESDistribution by \u2018Required Support\u2019\n 14,57,813,85,259\n4,853,9\n5,2\n17,2\n4,5\n11,92,2\n0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit\n20172018\n34,221,2\n62,213,3\n34,24,5\n6,7\n58,4\n4,518,537,85,9\n14,8\n0,7\n0 10 20 30 40 50 60 70Clinical TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018\n69,423,2\n68,7196,13,71,8\n1,14,81,5\n0 10 20 30 40 50 60 70 80Sta\ufb00-feaMirAtd-due- MatronaResearcherOther 20172018\n29,7109012,23,7\n197,490,811,73,1\n0 10 20 30 40 50 60 70 80 90 100DesignSample SizeData AnalysisData basesOthers\n 2017\n2018\n54,655,8\n56,343,8\n0 10 20 30 40 50 60NOYES\nPertaining to a research line\n 14,57,813,85,259\n4,853,9\n5,2\n17,2\n4,5\n11,92,2\n0 10 20 30 40 50 60 70GeneralHrtInfantilMaternidadOthersSscc- Research Unit\n20172018\n34,221,2\n62,213,3\n34,24,5\n6,7\n58,4\n4,518,537,85,9\n14,8\n0,7\n0 10 20 30 40 50 60 70Clinical TrialsPublicationsDoctoral ThesesResearch projectsCongressesClinical managementOthers20172018\n69,423,2\n68,7196,13,71,8\n1,14,81,5\n0 10 20 30 40 50 60 70 80Sta\ufb00-feaMirAtd-due- MatronaResearcherOther 20172018\n29,7109012,23,7\n197,490,811,73,1\n0 10 20 30 40 50 60 70 80 90 100DesignSample SizeData AnalysisData basesOthers 20172018\n54,655,8\n56,343,8\n0 10 20 30 40 50 60NOYES2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n87  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\nIdiPAZ\u2019s Documentalist Platform aims to control and analyze the scientific pro -\nduction generated through the activity of the researchers from the Institute. This \ncontrol is carried out thanks to the use of different tools specifically created for \nthis purpose and whose results are published in the bibliometric reports that \nappear on our website. In these reports you can observe the scientific production \nof each one of the research groups that form part of IdiPAZ. \nHowever, the information contained in the reports has not yet been validated by \nthe groups, hence its provisional nature. The information supervised and validated \nby the directors of each group will be officially published in the Annual Research \nReport together with the rest of the information from the different committees \nand platforms that make up our Institute. The Documentation Platform also pro -\nvides assistance to all IdiPAZ members who need help regarding access and use \nof databases, bibliographic searches, bibliometric indicators or any other related \nsubject. As an additional service, for some time now, we have also been in charge \nof printing the posters that our researchers present at congresses around the \nworld:COMPOSITION\nHead\nRa\u00fal Rom\u00e1n Ca\u00f1izares \n documentalista@idipaz.es \n Phone: (+34) 91 207 15 12 \nPORTFOLIO\tOF\tSERVICES\n\u2022 Draw up of IdiPAZ\u2019s Annual Research Report\n\u2022 Support to researchers in their access and use of databases, literature searches, etc. \n\u2022 Design and creation of tools to control the scientific production\n\u2022 Development of Bibliometric Reports\n\u2022 Evaluation of researchers\n\u2022 Bibliometric assessment of Research Groups \n\u2022 Advice on literature search tools\n\u2022 Advice on the use of bibliometric techniques\n\u2022 Poster printing for congress \nThe PAIN Platform-Early-Stage Researches Support Platform (Plataforma de \nApoyo al Investigador Novel) from IdiPAZ that aims to promote the design and \ndevelopment of research projects in several health areas, with high methodolo -\ngical quality, to enable our professionals in early-stage research. Additionally, the \nmission of the PAIN Platform is to promote the training and development of early \ncareer researchers of IdiPAZ. \nCOMPOSITION\nHead\nPaloma G\u00f3mez Campelo \n pgomezc@salud.madrid.org \n Phone: (+34) 91 207 15 12PORTFOLIO\tOF\tSERVICES\n\u2022 Methodological and epidemiological \nsupport to the study design of the \nprofessionals in early-stage research \n\u2022 T echnical and methodological support \nin developing a research protocol for a \nstudy\n\u2022 Analysis of the grounds for refusal of rejected  \nprojects\n\u2022 Methodological support to write grant proposals to access all \navailable funding programs\n\u2022 T echnical support in writing other scientific docu ments2.7.11  Documentalist\n2.7.12  Pain Platform2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n88  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe IdiPAZ Internationalisation Platform constitutes a service tool for supporting \nIdiPAZ researchers who wish either to increase their influence or to keep being \nreference in the Health Research international arena, with particular focus in the \nEuropean funding schemes and framework programmes.\nThe main objective is to promote the different research groups of IdiPAZ at in -\nternational level. Thus, identifying possible synergies between groups and centres, \nnew partners and funding sources, as well as forging strategic alliances.\nCOMPOSITION\nTeam\nJos\u00e9 Luis Narro Villanueva\n institutional.relations@idipaz.es\n Phone: +34 91727 75 76\nMarisa Tejedor Botello\n relacionesinternacionales@idipaz.es\n Phone: +34 91727 75 76\nSantiago Rello Varona\n international.projects@idipaz.es\n Phone: +34 91207 17 90\nMarta Mar\u00edn Barba\n international.grants@idipaz.es\n Phone: +34 91207 17 90\nOBJECTIVES\n\u2022 T o conduct active monitoring of international funding programs for Research \n& Innovation.\n\u2022 T o flag and disseminate relevant opportunities and calls for IdiPAZ research \ngroups.\n\u2022 T o identify and actively participate in international networks of interest for the \ncentre.\n\u2022 T o introduce and disseminate the capabilities of the centre and its research \ngroups.\n\u2022 T o recognise, define, validate and develop project ideas that emerge in the \ncentre.\n\u2022 T o support and encourage participation in information events.\u2022 T o organise and host information and training sessions on specific required \nareas.\n\u2022 T o advise on the proposal preparation and the negotiation phase with the \nEuropean Commission\n\u2022 T o manage the approved projects.\nPROGRAMMES\nHorizon 2020\nH2020 is the leading European program for funding research and innovation pro -\njects in various subject areas. For the period 2014-2020 it accounts with a budget \nof nearly \u20ac 80,000 million.\nMost activities are implemented through competitive calls managed by the Eu -\nropean Commission\u2019s Research Executive Agency. H2020 calls are fundamentally \noriented research rooted in priorities established in bi-annual work programs.\nThe program structure can be seen reflected in the following figure:2.7.13  Internationalization Platform2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n89  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansHorizon Europe\nThe future framework programme for R&I will come into force in 2021 and last \nuntil the end of 2027. The EC ambitions a budget of \u20ac 100,000 million and a drive \ntowards Innovation and societal impact to address the UN\u2019s Sustainable Develop -\nment Goals through the new instrument of Research Missions.\nEU Health Programme\nThe Health Program of the EU is the main instrument available to the European \nCommission to carry out its Health Strategy for the Union. It is implemented \nthrough annual work plans, in which the criteria and funding priorities are esta -\nblished.\nThe total budget of the third program is 449.4 million euros for the period 2014-\n2020.\nIMI\nThe Innovative Medicines Initiative (IMI) is the world\u2019s biggest public-private part -\nnership in the life sciences. It joins the European Union (represented by the Eu -\nropean Commission) and the European pharmaceutical industry (represented by \nEFPIA, the European Federation of Pharmaceutical Industries and Associations). \nThrough its \u20ac 3,300 million budget for 2014-2020, IMI facilitates open collabora -\ntion in research to advance the development of, and accelerate patient access to, \npersonalised medicines for the health and wellbeing of all, especially in areas of \nunmet medical need.\nCOST\nCOST is the oldest (established in 1971) and widest European intergovernmental \nframework for transnational Cooperation in Science and T echnology.\nIts aim is to enable breakthrough scientific developments leading to new concepts \nand products. Thereby it contributes to strengthen Europe\u2019s research and inno -\nvation capacities. These networks, COST Actions, represent the main instrument \navailable to the program for its implementation.\nThe calls are continuously open with two court dates per year.Other programmes\n\u2022 INTERREG-SUDOE\n\u2022 ERA-NETs\nDOCUMENTATION\nWebs\nFunding & Tenders:  it is the entry point for electronic administration of EU-\nfunded research and innovation projects.\nCORDIS:  it is the European Commission\u2019s primary public repository and portal \nto disseminate information on all EU-funded research projects and their results \nin the broadest sense.\nEshorizonte2020:  it is the H2020 Spanish portal.\nEURAXESS: it is a unique pan-European initiative providing access to a com -\nplete range of information and support services to researchers wishing to pursue \ntheir research careers in Europe or stay connected to it.\nEuropean IPR Helpdesk:  it offers free of charge, first-line support on IP and \nIPR matters to beneficiaries of EU funded research projects and EU SMEs involved \nin transnational partnership agreements, especially within the Enterprise Europe \nNetwork (EEN).\nEATRIS:  European Infrastructure for Translational Medicine, it provides a new \ndevelopment pathway, open to researchers and companies in need of support for \nadvancing biomedical innovations.\nECRIN:  European Clinical Research Infrastructure Network, it is a public, non-\nprofit organisation that links scientific partners and networks across Europe to \nfacilitate multinational clinical research.\nDocuments\nGu\u00eda del participante H2020\nAnnotated Model Grant Agreement - AMGA December 2018 version\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n90  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansCURRENT\tACTIVE\tPROJECTS\t2.7\t Platforms\nAcronym TitleLink to project  \n(CORDIS or similar)Specific web Logo Program IP\nCOMBACTE-\nCAREA New Public-Private Funded \nProject to Combat Carbapenem \nResisitancehttps://cordis.europa.eu/project/\nrcn/203671_en.htmlhttps://www.combacte.com/\nabout/about-combacte-care-\ndetail/  \nIMIJos\u00e9 Ram\u00f3n \nArribas\nENABLEEuropean Gram-negative \nAntibacterial Enginehttps://cordis.europa.eu/project/\nrcn/203716_en.htmlhttps://enable-project.eu/\n IMI Jes\u00fas Mingorance\nEpiADEffect of early and adult-life \nstress on the brain epigenome: \nrelevance for the occurrence of \nAlzheimer\u2019s Disease.http://www.\nneurodegenerationresearch.eu/\nwp-content/uploads/2017/10/JPND-\nProject-Fact-Sheet_2017_EpiAD.pdfERA-NET \nJPNDAna Frank\nERN RARE-\nLIVEREuropean Reference Network on \nhepatological diseaseshttp://www.rare-liver.eu/\n H2020 Loreto Hierro\nERN \nTransplantChild \n(Coordinado por el \nHULP)European Reference Network on \ntransplantation in childrenhttp://www.transplantchild.\ncom/\nEU Health \nProgrammePaloma Jara\nERN-TransplantChild Support Core \nSystems for IT Platforms serviceshttps://ec.europa.eu/inea/en/\nconnecting-europe-facility/cef-\ntelecom/2017-es-ia-0102CEF TELECOM Paloma Jara\nID-EPTRIEuropean Paediatric Translational \nResearch Infrastructurehttps://cordis.europa.eu/project/\nrcn/213793_en.html https://eptri.eu/\n H2020Mar\u00eda Jos\u00e9 \nMellado\nNICOFANicotinamide for the treatment \nof Friedreich ataxiahttp://www.erare.eu/node/1245ERA-NET \nE-RareFrancisco Javier \nRodr\u00edguez de \nRivera Garrido\nCraniofacial Microsomia: Genetic \nCauses and Pathway Discoveryhttp://grantome.com/grant/NIH/U01-\nDE025862-01A1 NIH-RO1 Pablo Lapunzina\nORTHOUNIONORTHOpedic randomized clinical \ntrial with expanded bone marrow \nMSC and bioceramics versus \nautograft in long bone nonUNIONshttps://cordis.europa.eu/project/\nrcn/207447_en.htmlhttps://orthounion.eu/\n H2020Enrique G\u00f3mez \nBarrenaScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n91  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansqMARQuantification of the intestinal \nload of a targeted set of \nresistance genes to Monitor \nAntibiotic Resistance in paediatric \ntransplant patientshttps://cordis.europa.eu/project/\nrcn/215416_en.htmlX:\\Fundacion\\\nFUNDACI\u00d3N\\TODOS LOS \nPROYECTOS\\Proyectos de \nADMINISTRACI\u00d3N P\u00daBLICA\\\nUNI\u00d3N EUROPEA\\ACTIVOS\\\nDAHDOUH, ELIAS_qMAR\nMSCA-IF-EF Elias Dahdouh\nRESSTOREREgenerative Stem cell therapy \nfor STroke in Europehttps://cordis.europa.eu/project/\nrcn/198791_en.html\nH2020Exuperio Diez \nTejedor\nSAPHeINImplementing SAPHetydoc for the \nwide adoption of eINvoicinghttps://ec.europa.eu/inea/en/\nconnecting-europe-facility/cef-\ntelecom/2016-eu-ia-0109CEF TELECOM Ana del Prado\nVIRUSCAN Optomechanics for Virologyhttps://cordis.europa.eu/project/\nrcn/205930_en.htmlhttps://viruscanproject.eu/\n H2020 Jes\u00fas Mingorance\nWEAKIDClinical validation of miniature \nwearable dialysis machinehttps://cordis.europa.eu/project/\nrcn/207629_es.html\nH2020 Rafael Selgas\nH2020PAZImpulso a la participaci\u00f3n en \nH2020 de IdiPAZ\nMINECO \u2013  \nEuropa Redes y \nGestoresJos\u00e9 Ram\u00f3n \nArribas2.7\t Platforms\nLast November the Ministry of Economy and Competitiveness notified the final \nresolution approving the project \u201cPromoting the participation in H2020 of IdiPAZ- \nH2020PAZ\u201d presented in the call \u201cEuropa Redes y Gestores 2017\u201d.\nThe final aim of the project H2020PAZ is to encourage and facilitate the participa -\ntion of IdiPAZ researchers in European research, technological development and \ninnovation programs, making possible the coordination and leadership of large pro -\njects that improve the rates of success and return of the institute. \nIn this sense, the H2020PAZ project has two main objectives: to consolidate and \nexpand the current structure of the Internationalization Platform of IdiPAZ and to encourage the participation of the research groups of the institute in international \nresearch programs - especially H2020-, technological development and innovation, \nby the different tasks and activities defined in this proposal.\nIn order to achieve these main objectives, the project is structured into four task \ngroups with their respective sub-tasks and activities directly related to the specific \nobjectives identified. The task groups are: Awareness raising and training; Participa -\ntion in proposals; Foreign promotion; and Project Management.\nH2020PAZ will have a duration of 2 years, beginning on January 1st, 2017 but the \nending date has been extended to December 31st, 2019.Scientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n92  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansPORTFOLIO\tOF\tSERVICES\n\u2022 Participation in international networks of interest to the centre\n\u2022 Targeted dissemination of funding and project involvement opportunities\n\u2022 Organization of information sessions and training courses\n\u2022\tPreparation\t and\tdissemination\t of\tscientific\tand\ttechnological\t profiles\tof\tthe\t\nresearch groups\n\u2022\tAdvice\ton\tthe\tdefinition\tof\tthe\tproject\tidea\tand\tthe\tpreparation\tof\tproposals\u2022\tIdentification\t of\tproject\tproposals\tunder\tpreparation\t in\twhich\tthe\tcentre\tcan\t\nbe involved\n\u2022\tIdentification\t of\tpartners\tfor\tprojects\tcoordinated\t or\tparticipated\t by\tresear -\nchers at the centre\n\u2022 Support in the negotiation phase with the European Commission - EC before \nthe signing of the grant agreement - GA\n\u2022 Management of funded projects2.7\t Platforms\nThe Tissue Engineering and 3D Printing Platform purpose is to promote the de -\nvelopment of biomedical jresearch and solutions based on tissue engineering and \nbioprinting and offer different services as 3D printing technologies, computer ima -\nging, virtual planning and computer aided design to the professionals.\nResearch\tand\tactivity\tareas\tof\tthe\tplatform\tare:\n\u2022 Synthetic\tbiology,\tbioprinting\t of\ttissues\tand\torgans\t\u2192 development of a skin model\n\u2022 Establishment of a live organoid biobank from patients\u2019 samples\n\u2022 Lab on a Chip (LOC) and Organ on a Chip (OOC) devices\n\u2022 Tissue engineering approaches to develop tissue models and organs\n\u2022 Development of new medical devices (biomodels, surgical guides, prosthesis \nand implants) based on emerging technologies as 3D printing\n\u2022 Computer imaging, virtual planning and 3D printing to plan surgeries\nCOMPOSITION\nDirector\nRam\u00f3n Cantero Cid\nScientific advisor\nMaria P . De Miguel Gonz\u00e1lez\nLab manager\nDaniel Cerme\u00f1o Pampliega\n PITI3D@idipaz.es\nResearch assistant\nMario Ju\u00e1rez Rodr\u00edguezEntrepreneur\nCarlos Biec Amigo\n info.piti3d@gmail.com\n\t Phone:\t(+34)\t91\t207\t15\t12\t(ext\t2484)\nEQUIPMENT\n\u2022\tBioprinter\t Unit\t(V1\tREGEMAT\t 3D)\tfor\tthermoplastics, \tmicroextrusion, \tUV\t\ncuring, temperature control and injection of cell laden biomaterials\n\u2022\tFused\tdeposition\tmodelling\t(FDM)\t3D\tprinter\tfor\tprototyping\nPORTFOLIO\tOF\tSERVICES\n\u2022 Bioprinting of meshes structures with or without cells\n\u2022 3D cell cultures\n\u2022\tCell\tviability\tand\tproliferation\t assays\tto\tassess\tbiocompatibility\t of\treactives\tand\t\nmaterials\n\u2022 Development of biofabrication processes\n\u2022 Development of Lab on a Chip (LOC) and Organ on a Chip (OOC)  \ndevices\n\u2022 Computer imaging and tissue segmentation from TAC and MRI\n\u2022 3D virtual planning\n\u2022 Computer Aided Design (CAD)\n\u2022\t3D\tprinting\tof\tbiomodels,\tsurgical\tguides,\tprosthesis\tand\timplants\tin\tpolymers\t\nand metals\n\u2022 Biomaterials processing and manufacturing\n\u2022 Education and training in the areas of activities2.7.14  Tissue Engineering and 3D Printing PlatformScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n93  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansThe IdiPAZ Food, Nutrition and Health Platform (NUTRinvest) is a structure \ncreated\tto\tprovide\tscientific-technical\t service\tand\tsupport\tin\tHuman\tResearch\t\nand Specialized Advice in Nutrition and Food issues.\nThe Platform provide service of Specialized Advice in Nutrition and Food at 3 \nlevels:\t1.\tIndustries\t(agro-food\t or\tpharmaceutical\t sector)\tinteresting\t in\tthe\tnew\t\nproducts\tdevelopment\t with\tan\timproved\tnutritional\t profile;\t2.\tCompanies\t inter-\nested in creating new technological tools to facilitate the acquisition of guidelines \nand\thealthy\thabits\t(web,\tapp,\tetc.)\tand\t3.\tIndividual\tinterested\t in\tknowing\ttheir\t\nnutritional status through a precision and individualized nutritional assessment.\nCOMPOSITION\nHead \nCarmen G\u00f3mez Candela (PhD, MD)\n cgcandela@salud.madrid.org \nProject manager\nBricia L\u00f3pez Plaza, PhD, MSc  \n briciaplaza@idipaz.es \nClinical Research Associate\nSamara Palma Milla (Endocrinologist) (PhD, MD)  \nsamara.palma@salud.madrid.org \nCristina Santurino Fontecha (PhD)  \ncristina.santurino@idipaz.es \nEdwin Fern\u00e1ndez Cruz (PhD)  \nedwin.fernandez.cruz@idipaz.es \nMarlhyn Valero P\u00e9rez (Nutricionist)  \nmarlhyn.valero@idipaz.es\t\nNatalia Garc\u00eda V\u00e1zquez (Pharmacist)  \nngarcia.hulp@salud.madrid.org \nMarina Morato Mart\u00ednez (Nutricionist)  \nmarina.morato@salud.madrid.org \nOBJECTIVE\nT o implement clinical trials or epidemiological studies well designed in the area of \nhuman\tnutrition,\tin\torder\tto\tvalidate\tthe\tactivity\tand\tefficacy\tof\tbioactive\tcompounds, \t\nnutrients,\tfoods,\tdietary\tpatterns\tor\tartificial\tnutrition,\ton\tdifferent\tparameters\t rela-\nted\tto\tthe\thealth\tpromotion, \tthe\tdisease\tprevention\tor\tits\ttherapeutic\tactivity.MAIN\tSECTORS\n\u2022 Agri-food/pharmaceutical industries interested in designing or validating the \neffectiveness of new products.\n\u2022\tInstitutions/government\t agencies\twith\tan\tinterest\tin\texpanding\tknowledge\t in\tthe\t\narea of nutrition for the generation/implementation of political measures in Pu -\nblic Health.\n\u2022 Public or private institutions that want to develop computer applications, or in -\nformation\tor\tcommunication\t programs\tin\tthe\tfield\tof\tNutrition\tof\tinterest\tto\t\nhealth professionals, consumers or patients.\n\u2022 Researchers with interest in the inclusion of nutritional variables in their research \nprojects.\n\u2022 Individuals interested in obtain information about their nutritional health and who \nwish\tto\treceive\tprecision\tand\tindividualized\tnutrition\tthrough\tdetailed\tanalysis.\nEQUIPMENT\n\u2022\tDual-energy\tx-ray\tabsorptiometry\t(DXA)\n\u2022\tBioelectric\tImpedance\tSystem\t(BIA)\n\u2022 Holtain Skinfold Calipers\n\u2022 Tanita digital healthcare scales\n\u2022\tExecutive\tDiameter\t Tape\n\u2022\tIndirect\tcalorimetry\n\u2022 Accelerometers\nPORTFOLIO\tOF\tSERVICES\n\u2022\tScientific\tadvice\tto\timprove\tnutritional\tprofiles\tof\tfoods\tor\tnutritional\tformulas\n\u2022\tScientific-technical\tsupport\tin\tthe\tarea\tof\tHuman\tNutrition\tresearch\n\u2013 Create well designed Project Plan for Clinical Trials and other human studies\n\u2013\tManagement\t and\tSubmission\t of\tapplications\t to\tthe\tEthics\tCommittee: \tThe\t\nplatform\tprepares\tand\tmanagement\t all\tthe\tdocuments\t required\tby\tobtain\tthe\t\napproval of the Ethics Committee (Informed consent form, Letters from ethics \ncommittees. \tStudy\tquestionnaire\t (copies\tof\tany\tquestionnaires\t or\tdraft\tques-\ntionnaires), Case Record Forms (CRFs), Budget details, etc.)\n\u2013\tField\twork\texecution\t(all\tactivities\tare\tcarried\tout\tby\tmembers\tof\tthe\tplatform\t\nteam\twith\tconsolidated\tqualifications\tin\tthe\tarea)\n-\tDietary\tstudies:\tthrough\tthe\tuse\tof\tvalidated\ttools\t(Food\trecords\t(24h,\t3-7\t2.7.15  Food, Nutrition and Health Platform2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7 Platforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n94  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansdays),\tFood\tFrequency\t Questionnaires, \tWeighted\tfood\trecords,\tDIAL\tsoft-\nware,\tcalorimetry...)\n- Diagnostic\t and\tscreening\tnutritional\tstudies:\tusing\tvalidated\tmethodology\t (Sub-\njective Global Assessment (SGA), Nutritional Status Assessment (NSA), Malnu -\ntrition Universal Screening T ool (MUST), Mini Nutrition Assessment (MNA)\n-\tAnthropometric\t studies:\tWeight,\tHeight,\tCircumferences, \tFolds,\tBioelectrical\t\nImpedance, \tDXA\u2026\n-\tBiochemical\t studies\t(blood,\turine,\tfeces):\tmeasurements\t of\thealth\tmar-\nkers related to the area of nutrition (glucose metabolism parame -\nters,\tcurves\tfor\tcalculating\t the\tglycemic\tindex,\tlipid\tmetabolism, \t\ninflammation, \toxidationa\tand\thormonal\tbiomarkers...)\n-\tPhysical\tactivity\tstudies:\tthrough\tthe\tuse\tof\tvalidated\tques-\ntionnaires\t(IPAQ, \tMINNESOTA...)\n-\tFunctional\t capacity\tstudies:\tthrough\tdynamome -\ntry\tand\tvalidated\tquestionnaires\n-\tSensory\tperception\t studies:\tthrough\tthe\t\nuse of validated questionnaires\n-\tSatiety\tcontrol\tstudies:\tusing\t\nbiochemical markers and \nhandling of validated ques -\ntionnaires\n-\tQuality\t of\tlife\tstudies:\t\nthrough the use of valida -\nted questionnaires\n- Gastrointestinal T olerance \nStudies:\tthrough\tthe\tuse\tof\t\nvalidated questionnaires\n- Nutrigenetics and Metabo -\nlic Studies with our colla -\nborating centers\n\u2013\tProduction\t of\tscientific\tand\tte-\nchnical report\u2022 Development of computer applications for websites or mobile apps in the nutri -\ntion / food area\n\u2022 Individual nutritional status evaluations and proposals for individualized nutrition \nintervention programs\n\u2022 T o contribute and design components for nutrition education strategies and pro -\ngrams\n2.7\t Platforms\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n95  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.8\t Scientific \t\nProduction\nJournal ISSNTotal of \ndocumentsImpact  \nfactorQuartile\nACS COMBINATORIAL SCIENCE 2156-8952 1 3.2Q2\nACTA BIOMATERIALIA 1742-7061 1 6.638 Q1\nACTA CL\u00cdNICA B\u00c9LGICA 1784-3286 10.96 Q3\nACTA ONCOL\u00d3GICA 0284-186X 13.298 Q2\nACTA ORTHOPAEDICA ET TRAUMATOLOGICA \nTURCICA1017-995X 10.896 Q4\nACTA\tORTOP\u00c9DICA\tMEXICANA 2306-4102 1 Not\tIndexed\nACTA PEDI\u00c1TRICA 0803-5253 22.265 Q2\nACTAS DERMO-SIFILIOGR\u00c1FICAS 0001-7310 9 Not\tIndexed\nACTAS UROL\u00d3GICAS ESPA\u00d1OLAS 0210-4806 51.136 Q4\nAGE AND AGEING 0002-0729 14.511 Q1\nAIDS 0269-9370 34.499 Q1\nAIDS PATIENT CARE AND STDS 1087-2914 13.742 Q2\nAIDS\tREVIEWS 1139-6121 92.357 Q3\nAIMS NEUROSCIENCE 2373-8006 1 Not\tIndexedALERGIA ASTMA IMMUNOLOGIA 1427-3101 1 Not\tIndexed\nALIMENTARY PHARMACOLOGY & \nTHERAPEUTICS0269-2813 1 7.731 Q1\nALLERGOLOGIA ET IMMUNOPATHOLOGIA 0301-0546 11.64 Q4\nALLERGOLOGIE 0344-5062 10.15 Q4\nALLERGY 0105-4538 16.771 Q1\nALLERGY AND ASTHMA PROCEEDINGS 1088-5412 12.124 Q3\nALZHEIMERS & DEMENTIA 1552-5260 1 14.423 Q1\nALZHEIMERS & DEMENTIA 2352-8729 1 Not\tIndexed\nAMERICAN JOURNAL OF BOTANY 0002-9122 12.481 Q1\nAMERICAN JOURNAL OF CARDIOLOGY 0002-9149 22.843 Q2\nAMERICAN JOURNAL OF CLINICAL NUTRITION 0002-9165 3 6.568 Q1\nAMERICAN JOURNAL OF DERMATOPATHOLOGY 0193-1091 11.106 Q4\nAMERICAN JOURNAL OF HEMATOLOGY 0361-8609 16.137 Q1\nAMERICAN JOURNAL OF HUMAN GENETICS 0002-9297 3 9.924 Q1\nAMERICAN JOURNAL OF MEDICAL GENETICS PART A 1552-4825 22.197 Q3\nAMERICAN JOURNAL OF MEDICINE 0002-9343 24.76 Q12.8.1 Journal AnalysisScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n96  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansAMERICAN JOURNAL OF OPHTHALMOLOGY 0002-9394 24.483 Q1\nAMERICAN JOURNAL OF PHYSIOLOGY -RENAL \nPHYSIOLOGY1931-857X 1 3.323 Q1\nAMERICAN JOURNAL OF PREVENTIVE MEDICINE 0749-3797 14.435 Q1\nAMERICAN JOURNAL OF RESPIRATORY AND \nCRITICAL CARE MEDICINE1073-449X 2 16.494 Q1\nAMERICAN JOURNAL OF TRANSPLANTATION 1600-6135 1 7.163 Q1\nAMERICAN SOCIETY OF NEURORADIOLOGY 1936-959X 13.256 Q2\nAMYOTROPHIC LATERAL SCLEROSIS AND \nFRONTOTEMPORAL DEGENERATION2167-8421 22.883 Q2\nANALES DE PEDIATRIA 1695-9531 261.166 Q3\nANALYTICAL CHEMISTRY 0003-2700 2 6.35 Q1\nANDROLOGY 2047-2919 1 3.106 Q1\nANESTHESIA AND ANALGESIA 0003-2999 13.489 Q2\nANGEWANDTE CHEMIE-INTERNATIONAL \nEDITION1433-7851 1 12.257 Q1\nANGIOLOGIA 0003-3170 2 Not\tIndexed\nANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 1081-1206 33.56 Q2\nANNALS OF HEMATOLOGY 0939-5555 22.85 Q3\nANNALS OF INTERNAL MEDICINE 0003-4819 1 19.315 Q1\nANNALS OF ONCOLOGY 0923-7534 1 14.196 Q1\nANNALS OF PEDIATRIC CARDIOLOGY 0974-2069 1 Not\tIndexed\nANNALS OF THE RHEUMATIC DISEASES 0003-4967 3 14.299 Q1\nANTICANCER RESEARCH 0250-7005 21.935 Q4\nANTIMICROBIAL AGENTS AND CHEMOTHERAPY 0066-4804 24.715 Q1\nANTIOXIDANTS\t&\tREDOX\tSIGNALING 1523-0864 35.828 Q1\nANTIVIRAL THERAPY 1359-6535 22.305 Q3\nAPLEY & SOLOMON'S SYSTEM OF ORTHOPAEDICS \nAND\tTRAUMA,\t10TH\tEDITIONxxxx-xxxx 1 Not\tIndexed\nAPMIS 0903-4641 12.225 Q2\nAPPLIED PHYSICS LETTERS 0003-6951 13.521 Q1\nAPPLIED RADIATION AND ISOTOPES 0969-8043 11.343 Q2\nARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS 0003-9861 13.559 Q2\nARCHIVES OF BONE AND JOINT SURGERY -ABJS 2345-4644 4 Not\tIndexed\nARCHIVES OF GYNECOLOGY AND OBSTETRICS 0932-0067 12.199 Q2\nARCHIVES OF OSTEOPOROSIS 1862-3522 12.469 Q2\nARCHIVOS ARGENTINOS DE PEDIATR\u00cdA 0325-0075 10.506 Q4\nARCHIVOS DE BRONCONEUMOLOG\u00cdA 0300-2896 144.214 Q1\nARCHIVOS\tDE\tCARDIOLOG\u00cdA\tDE\tM\u00c9XICO 1405-9940 1 Not\tIndexed\nARCHIVOS DE LA SOCIEDAD ESPA\u00d1OLA DE \nOFTALMOLOG\u00cdA1989-7286 1 Not\tIndexed\nARCHIVOS ESPANOLES DE UROLOG\u00cdA 0004-0614 160.335 Q4ARTERIOSCLEROSIS THROMBOSIS AND \nVASCULAR BIOLOGY1079-5642 1 6.618 Q1\nARTHRITIS & RHEUMATOLOGY 2326-5191 1 9.002 Q1\nARTHRITIS RESEARCH & THERAPY 1478-6354 14.148 Q2\nASCLEPIO-REVISTA DE HISTORIA DE LA MEDICINA Y \nDE LA CIENCIA0210-4466 1 Not\tIndexed\nASIAN JOURNAL OF ANESTHESIOLOGY 2468-824X 1 Not\tIndexed\nASIAN JOURNAL OF UROLOGY 2214-3882 1 Not\tIndexed\nATENCION PRIMARIA 0212-6567 11.346 Q3\nAUDIOLOGY AND NEURO-OTOLOGY 1420-3030 12.053 Q2\nAUTOPHAGY 1554-8627 1 11.059 Q1\nBENEFICIAL MICROBES 1876-2883 1 2.939 Q2\nBIOCHEMICAL GENETICS 0006-2928 11.931 Q3\nBIOCHEMICAL JOURNAL 0264-6021 14.331 Q1\nBIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR \nBASIS OF DISEASE0925-4439 44.328 Q1\nBIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR \nCELL RESEARCH0167-4889 14.739 Q1\nBIOCONJUGATE CHEMISTRY 1043-1802 14.349 Q1\nBIODRUGS 1173-8804 1 4.903 Q1\nBIOLAW\tJOURNAL-RIVISTA\tDI\tBIODIRITTO 2284-4503 1 Not\tIndexed\nBIOLOGY\tOF\tBLOOD\t AND\tMARROW\t\nTRANSPLANTATION1083-8791 33.599 Q2\nBIOMED RESEARCH INTERNATIONAL 2314-6133 12.197 Q3\nBIOMEDICINES 2227-9059 1 Not\tIndexed\nBIOMOLECULES 2218-273X 14.694 Q1\nBLADDER CANCER 2352-3727 1 Not\tIndexed\nBLOOD PURIFICATION 0253-5068 12.363 Q2\nBLOOD\tREVIEWS 0268-960X 26.125 Q1\nBMC CANCER 1471-2407 1 2.933 Q3\nBMC FAMILY PRACTICE 1471-2296 12.431 Q2\nBMC GASTROENTEROLOGY 1471-230X 12.252 Q3\nBMC GENOMICS 1471-2164 13.501 Q2\nBMC HEALTH SERVICES RESEARCH 1472-6963 11.932 Q3\nBMC MEDICAL GENETICS 1471-2350 21.74 Q3\nBMC MEDICINE 1741-7015 1 8.285 Q1\nBMC NEPHROLOGY 1471-2369 22.088 Q3\nBMC\tPHARMACOLOGY\t&\t TOXICOLOGY 2050-6511 12.103 Q3\nBMC PUBLIC HEALTH 1471-2458 12.567 Q2\nBMJ case reports 1757-790X 1 Not\tIndexed\t\nBMJ OPEN 2044-6055 12.376 Q22.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n97  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansBONE & JOINT JOURNAL 2049-4394 1 4.301 Q1\nBRAIN INJURY 0269-9052 11.665 Q2\nBRAIN STRUCTURE & FUNCTION 1863-2653 1 3.622 Q1\nBREAST CANCER RESEARCH AND TREATMENT 0167-6806 23.471 Q2\nBRITISH JOURNAL OF CANCER 0007-0920 15.416 Q1\nBRITISH JOURNAL OF CLINICAL PHARMACOLOGY 0306-5251 13.867 Q1\nBRITISH JOURNAL OF DERMATOLOGY 0007-0963 1 6.714 Q1\nBRITISH JOURNAL OF HAEMATOLOGY 0007-1048 25.206 Q1\nBRITISH JOURNAL OF RADIOLOGY 0007-1285 21.939 Q3\nBURNS 0305-4179 12.247 Q2\nCANADIAN JOURNAL OF GASTROENTEROLOGY \nAND HEPATOLOGY2291-2789 11.714 Q4\nCANCER 0008-543X 15.238 Q1\nCANCER LETTERS 0304-3835 16.508 Q1\nCANCER TREATMENT REVIEWS 0305-7372 1 8.332 Q1\nCARBON 0008-6223 17.466 Q1\nCARCINOGENESIS 0143-3334 14.004 Q2\nCARDIOLOGY JOURNAL 1897-5593 11.743 Q3\nCARDIOVASCULAR & HEMATOLOGICAL AGENTS IN \nMEDICINAL CHEMISTRY1875-6182 1 \tNot\tIndexed\t\nCARDIOVASCULAR & HEMATOLOGICAL DISORDERS \nDRUG TARGETS2212-4063 1 \tNot\tIndexed\t\nCARDIOVASCULAR DRUGS AND THERAPY 0920-3206 14.181 Q1\nCELL DEATH & DISEASE 2041-4889 15.959 Q1\nCELL DEATH AND DIFFERENTIATION 1350-9047 1 8.086 Q1\nCELLS 2073-4409 15.656 Q1\nCELLULAR IMMUNOLOGY 0008-8749 13.291 Q2\nCEREBRAL\tCORTEX 1047-3211 15.437 Q1\nCIRCULATION 0009-7322 1 23.054 Q1\nCIRUG\u00cdA CARDIOVASCULAR 1134-0096 2 \tNot\tIndexed\t\nCIRUG\u00cdA ESPA\u00d1OLA 0009-739X 10.835 Q4\nCIRUG\u00cdA PEDI\u00c1TRICA 0214-1221 11 \tNot\tIndexed\t\nCLINICA CHIMICA ACTA 0009-8981 12.735 Q2\nCL\u00cdNICA E INVESTIGACI\u00d3N EN ARTERIOSCLEROSIS 0214-9168 3 \tNot\tIndexed\t\nCLINICAL & TRANSLATIONAL ONCOLOGY 1699-048X 152.441 Q3\nCLINICAL\tAND\tEXPERIMENTAL\t ALLERGY 0954-7894 34.471 Q2\nCLINICAL\tAND\tEXPERIMENTAL\tRHEUMATOLOGY 0392-856X 53.238 Q2\nCLINICAL AND TRANSLATIONAL ALLERGY 2045-7022 24.232 Q2\nCLINICAL AND TRANSLATIONAL \nGASTROENTEROLOGY2155-384X 14.803 Q1\nCLINICAL BREAST CANCER 1526-8209 12.762 Q3CLINICAL CANCER RESEARCH 1078-0432 2 8.911 Q1\nCLINICAL CHEMISTRY 0009-9147 3 6.891 Q1\nCLINICAL CHEMISTRY AND LABORATORY MEDICINE 1434-6621 33.638 Q1\nCLINICAL ENDOCRINOLOGY 0300-0664 12.897 Q3\nCLINICAL EPIGENETICS 1868-7075 15.496 Q1\nCLINICAL GASTROENTEROLOGY AND \nHEPATOLOGY1542-3565 2 7.958 Q1\nCLINICAL GENETICS 0009-9163 34.104 Q1\nCLINICAL INFECTIOUS DISEASES 1058-4838 2 9.055 Q1\nCLINICAL JOURNAL OF PAIN 0749-8047 12.893 Q2\nCLINICAL KIDNEY JOURNAL 2048-8505\t 12.975 Q1\nCLINICAL MICROBIOLOGY AND INFECTION 1198-743X 3 6.425 Q1\nCLINICAL NEUROPHARMACOLOGY 0362-5664 11.272 Q4\nCLINICAL NUTRITION 0261-5614 17 6.042 Q1\nCLINICAL NUTRITION ESPEN 2405-4577 1 \tNot\tIndexed\t\nCLINICAL REHABILITATION 0269-2155 12.738 Q1\nCLINICAL RESEARCH IN CARDIOLOGY 1861-0684 24.907 Q1\nCLINICAL RHEUMATOLOGY 0770-3198 1 2.293 Q3\nCLINICAL SCIENCE 0143-5221 25.237 Q1\nCOCHLEAR IMPLANTS INTERNATIONAL 1754-7628 1 \tNot\tIndexed\t\nCOMMUNICATIONS BIOLOGY 2399-3642\t 1 \tNot\tIndexed\t\nCRITICAL CARE 1466-609X 26.959 Q1\nCRITICAL CARE MEDICINE 0090-3493 26.971 Q1\nCRITICAL\tREVIEWS\tIN\tONCOLOGY\tHEMATOLOGY 1040-8428 15.012 Q1\nCTS-CLINICAL AND TRANSLATIONAL SCIENCE 1752-8054 13.989 Q2\nCUADERNOS DE BIO\u00c9TICA 1132-1989 1 \tNot\tIndexed\t\nCURRENT ALLERGY AND ASTHMA REPORTS 1529-7322 13.982 Q2\nCURRENT CARDIOVASCULAR IMAGING REPORTS 1941-9066 1 \tNot\tIndexed\t\nCURRENT GENE THERAPY 1566-5232 12.218 Q3\nCURRENT HEMATOLOGIC MALIGNANCY REPORTS 1558-8211 12.397 Q3\nCURRENT HIV/AIDS REPORTS 1548-3568 14.382 Q1\nCURRENT\tMEDICAL\tIMAGING\tREVIEWS 1573-4056 10.533 Q4\nCURRENT OPINION IN ALLERGY AND CLINICAL \nIMMUNOLOGY1528-4050 23.014 Q3\nCURRENT OPINION IN OBSTETRICS & \nGYNECOLOGY1040-872X 12.411 Q2\nCURRENT OPINION IN ORGAN TRANSPLANTATION 1087-2418 12.574 Q3\nCURRENT PHARMACEUTICAL DESIGN 1381-6128 12.412 Q3\nCURRENT UROLOGY REPORTS 1527-2737 12.079 Q3\nCYTOMETRY PART B-CLINICAL CYTOMETRY 1552-4949 12.938 Q1\nCYTOPATHOLOGY 0956-5507 21.473 Q32.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n98  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansCYTOTHERAPY 1465-3249 14.297 Q1\nDATA IN BRIEF 2352-3409 1 \tNot\tIndexed\t\nDEPRESSION\t AND\tANXIETY 1091-4269 14.86 Q1\nDEVELOPMENT 0950-1991 1 5.763 Q1\nDIABETES CARE 0149-5992 2 15.27 Q1\nDIABETES METABOLIC SYNDROME AND OBESITY -\nTARGETS AND THERAPY1178-7007 13.319 Q2\nDIABETES RESEARCH AND CLINICAL PRACTICE 0168-8227 1 3.239 Q2\nDIAGNOSTIC CYTOPATHOLOGY 8755-1039 21.402 Q2\nDIGESTIVE AND LIVER DISEASE 1590-8658 13.037 Q2\nDISABILITY AND REHABILITATION 0963-8288 12.054 Q2\nDISEASE MODELS & MECHANISMS 1754-8403 14.028 Q1\nDRUG SAFETY 0114-5916 13.526 Q1\nDRUGS IN R&D 1174-5886 1 Not\tIndexed\nEBIOMEDICINE 2352-3964 1 6.68 Q1\nEFORT\tOPEN\tREVIEWS 2058-5241 4 \tNot\tIndexed\t\nEJSO 0748-7983 1 \tNot\tIndexed\t\nELIFE 2050-084X 1 7.551 Q1\nEMBO MOLECULAR MEDICINE 1757-4676 1 10.624 Q1\nEMERGENCIAS 1137-6821 33.35 Q1\nEMERGING INFECTIOUS DISEASES 1080-6040 2 7.185 Q1\nENDOCRINE RESEARCH 0743-5800 11.629 Q4\nENDOCRINOLOG\u00cdA DIABETES Y NUTRICI\u00d3N 2530-0180 50.934 Q4\nENDOCRINOLOGY 0013-7227 1 3.8Q2\nENFERMEDADES INFECCIOSAS Y MICROBIOLOG\u00cdA \nCL\u00cdNICA0213-005X 181.685 Q4\nENTROPY 1099-4300 12.419 Q2\nENVIRONMENTAL POLLUTION 0269-7491 1 5.714 Q1\nENVIRONMENTAL RESEARCH 0013-9351 1 5.026 Q1\nEPIDEMIOLOGY AND INFECTION 0950-2688 12.047 Q2\nEPIGENETICS 1559-2294 14.584 Q1\nEPIGENOMES 2075-4655 1 Not\tIndexed\nEPIGENOMICS 1750-1911 34.404 Q1\nERJ OPEN RESEARCH 2312-0541 1 Not\tIndexed\nESC HEART FAILURE 2055-5822 13.407 Q2\nEURASIAN JOURNAL OF MEDICINE 1308-8734 2 Not\tIndexed\nEUROINTERVENTION 1774-024X 24.018 Q2\nEUROPACE 1099-5129 5 6.1Q1\nEUROPEAN ARCHIVES OF OTO-RHINO-\nLARYNGOLOGY0937-4477 11.75 Q2EUROPEAN HEART JOURNAL-ACUTE \nCARDIOVASCULAR CARE2048-8726 13.734 Q2\nEUROPEAN HEART JOURNAL-CARDIOVASCULAR \nIMAGING2047-2404 25.26 Q1\nEUROPEAN JOURNAL OF ANAESTHESIOLOGY 0265-0215 14.14 Q1\nEUROPEAN JOURNAL OF CLINICAL INVESTIGATION 0014-2972 32.784 Q1\nEUROPEAN JOURNAL OF CLINICAL NUTRITION 0954-3007 13.114 Q2\nEUROPEAN JOURNAL OF GASTROENTEROLOGY & \nHEPATOLOGY0954-691X 22.198 Q3\nEUROPEAN JOURNAL OF GYNAECOLOGICAL \nONCOLOGY0392-2936 10.245 Q4\nEUROPEAN JOURNAL OF HAEMATOLOGY 0902-4441 22.217 Q3\nEUROPEAN JOURNAL OF HEART FAILURE 1388-9842 1 13.965 Q1\nEUROPEAN JOURNAL OF HUMAN GENETICS 1018-4813 23.65 Q2\nEUROPEAN JOURNAL OF INTERNAL MEDICINE 0953-6205 33.66 Q1\nEUROPEAN JOURNAL OF MEDICAL GENETICS 1769-7212 32.022 Q3\nEUROPEAN JOURNAL OF NUTRITION 1436-6207 14.449 Q1\nEUROPEAN JOURNAL OF PEDIATRIC SURGERY 0939-7248 51.148 Q4\nEUROPEAN JOURNAL OF PEDIATRIC SURGERY \nREPORTS2194-7619 2 Not\tIndexed\nEUROPEAN JOURNAL OF PEDIATRICS 0340-6199 32.188 Q2\nEUROPEAN JOURNAL OF RHEUMATOLOGY 2147-9720 1 Not\tIndexed\nEUROPEAN JOURNAL OF TRAUMA AND EMERGENCY \nSURGERY1863-9933 11.781 Q2\nEUROPEAN RESPIRATORY JOURNAL 0903-1936 2 11.807 Q1\nEUROPEAN SPINE JOURNAL 0940-6719 42.513 Q2\nEUROPEAN STROKE JOURNAL 2396-9873 1 Not\tIndexed\nEUROSURVEILLANCE 1560-7917 4 7.421 Q1\nEXPERIMENTAL\tEYE\tRESEARCH 0014-4835 12.998 Q1\nEXPERT\tOPINION\tON\tBIOLOGICAL\t THERAPY 1471-2598 13.585 Q2\nEXPERT\tOPINION\tON\tDRUG\tSAFETY 1474-0338 2 3.22 Q2\nEXPERT\tOPINION\tON\tORPHAN\tDRUGS 2167-8707 10.763 Q4\nEXPERT\tREVIEW\tOF\tCLINICAL\tPHARMACOLOGY 1751-2433 22.776 Q2\nEXPERT\tREVIEW\tOF\tHEMATOLOGY 1747-4086 32.505 Q3\nFARMACIA HOSPITALARIA 1130-6343 1 Not\tIndexed\nFASEB JOURNAL 0892-6638 1 5.391 Q1\nFOOD & FUNCTION 2042-6496 33.241 Q1\nFOOD\tAND\tCHEMICAL\t TOXICOLOGY 0278-6915 13.775 Q1\nFOOD CONTROL 0956-7135 2 4.248 Q1\nFRONTIERS IN AGING NEUROSCIENCE 1663-4365 23.633 Q2\nFRONTIERS IN IMMUNOLOGY 1664-3224 134.716 Q2\nFRONTIERS IN MOLECULAR NEUROSCIENCE 1662-5099 13.72 Q22.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n99  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansFRONTIERS IN ONCOLOGY 2234-943X 14.137 Q2\nFRONTIERS IN PEDIATRICS 2296-2360 12.349 Q2\nFRONTIERS IN PHARMACOLOGY 1663-9812 23.845 Q1\nFRONTIERS IN PHYSIOLOGY 1664-042X 43.201 Q2\nFRONTIERS IN SURGERY 2296-875X 1 Not\tIndexed\nFUTURE CARDIOLOGY 1479-6678 1 Not\tIndexed\nFUTURE ONCOLOGY 1479-6694 12.279 Q3\nGACETA SANITARIA 0213-9111 11.653 Q3\nGASTRIC CANCER 1436-3291 15.554 Q1\nGASTROENTEROLOG\u00cdA Y HEPATOLOG\u00cdA 0210-5705 41.126 Q4\nGENE 0378-1119 12.638 Q2\nGENE REPORTS 2452-0144 1 Not\tIndexed\nGENETICS IN MEDICINE 1098-3600 4 8.683 Q1\nGLIA 0894-1491 35.829 Q1\nGLOBAL SPINE JOURNAL 2192-5682 1 Not\tIndexed\nGRAEFES ARCHIVE FOR CLINICAL AND \nEXPERIMENTAL\tOPHTHALMOLOGY0721-832X 12.25 Q2\nGUT 0017-5749 1 17.943 Q1\nHAEMATOL\u00d3GICA 0390-6078 3 7.57 Q1\nHAEMOPHILIA 1351-8216 43.59 Q2\nHEARING RESEARCH 0378-5955 1 2.952 Q1\nHEART 1355-6037 15.082 Q1\nHEPATOLOGY 0270-9139 1 14.971 Q1\nHISTOPATHOLOGY 0309-0167 13.294 Q2\nHISTORIA Y MEMORIA DE LA EDUCACI\u00d3N 2444-0043 1 Not\tIndexed\nHIV MEDICINE 1464-2662 33.734 Q2\nHLA 2059-2302 12.785 Q2\nHORMONE RESEARCH IN PAEDIATRICS 1663-2818 12.324 Q2\nHOSPITAL\tPRACTICE\t(1995) 2154-8331 2 Not\tIndexed\nHSS JOURNAL 1556-3316 2 Not\tIndexed\nHUMAN GENETICS 0340-6717 15.207 Q1\nHUMAN MOLECULAR GENETICS 0964-6906 14.544 Q1\nHUMAN MOVEMENT SCIENCE 0167-9457 11.928 Q2\nHUMAN MUTATION 1059-7794 44.453 Q1\nHYPERTENSION 0194-911X 3 7.017 Q1\nINDIAN JOURNAL OF SURGERY 0972-2068 10.55 Q4\nINFECTION 0300-8126 12.927 Q2\nINFECTION CONTROL AND HOSPITAL \nEPIDEMIOLOGY0899-823X 12.856 Q2\nINJURY -INTERNATIONAL JOURNAL OF THE CARE OF \nTHE INJURED0020-1383 31.834 Q2INTENSIVE CARE MEDICINE 0342-4642 5 18.967 Q1\nINTENSIVE\tCARE\tMEDICINE\tEXPERIMENTAL 2197-425X 1 Not\tIndexed\nINTERNATIONAL JOURNAL OF ANTIMICROBIAL \nAGENTS0924-8579 34.615 Q1\nINTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS 0391-3988 11.232 Q4\nINTERNATIONAL JOURNAL OF CANCER 0020-7136 34.982 Q1\nINTERNATIONAL JOURNAL OF CARDIOLOGY 0167-5273 13.471 Q2\nINTERNATIONAL JOURNAL OF CHRONIC \nOBSTRUCTIVE PULMONARY DISEASE1178-2005 13.274 Q2\nINTERNATIONAL JOURNAL OF CLINICAL AND \nHEALTH PSYCHOLOGY1697-2600 13.317 Q1\nINTERNATIONAL JOURNAL OF CLINICAL \nPHARMACY2210-7703 11.692 Q4\nINTERNATIONAL JOURNAL OF CLINICAL PRACTICE 1368-5031 12.613 Q2\nINTERNATIONAL JOURNAL OF DERMATOLOGY 0011-9059 21.794 Q3\nINTERNATIONAL JOURNAL OF EMERGENCY \nSERVICES2047-0894 1 Not\tIndexed\nINTERNATIONAL JOURNAL OF EPIDEMIOLOGY 0300-5771 3 7.339 Q1\nINTERNATIONAL JOURNAL OF GYNECOLOGICAL \nCANCER1048-891X 21.746 Q3\nINTERNATIONAL JOURNAL OF MOLECULAR \nSCIENCES1422-0067 54.183 Q2\nINTERNATIONAL JOURNAL OF OBESITY 0307-0565 14.514 Q1\nINTERNATIONAL JOURNAL OF PEDIATRIC \nOTORHINOLARYNGOLOGY0165-5876 11.225 Q3\nINTERNATIONAL JOURNAL OF PUBLIC HEALTH 1661-8556 12.373 Q2\nINTERNATIONAL JOURNAL OF RHEUMATIC \nDISEASES1756-1841 21.938 Q4\nINTERNATIONAL JOURNAL OF SURGERY 1743-9191 13.158 Q1\nINTERNATIONAL JOURNAL OF SYSTEMATIC AND \nEVOLUTIONARY MICROBIOLOGY1466-5026 22.166 Q3\nISCIENCE 2589-0042 1 Not\tIndexed\nJAAD CASE REPORTS 2352-5126 1 Not\tIndexed\nJACC-CARDIOVASCULAR INTERVENTIONS 1936-8798 3 9.544 Q1\nJAIDS-JOURNAL\tOF\t ACQUIRED\tIMMUNE\tDEFICIENCY\t\nSYNDROMES1525-4135 23.863 Q1\nJAMA DERMATOLOGY 2168-6068 1 7.995 Q1\nJAMA OTOLARYNGOLOGY-HEAD & NECK \nSURGERY2168-6181 1 3.502 Q1\nJAMA PSYCHIATRY 2168-622X 1 15.916 Q1\nJIMD REPORTS 2192-8304 2 Not\tIndexed\nJMIR SERIOUS GAMES 2291-9279 13.351 Q2\nJNCI-JOURNAL OF THE NATIONAL CANCER \nINSTITUTE0027-8874 2 13.757 Q12.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n100  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansJOURNAL OF AGRICULTURAL AND FOOD \nCHEMISTRY0021-8561 1 3.571 Q1\nJOURNAL OF ALLERGY AND CLINICAL \nIMMUNOLOGY0091-6749 4 14.11 Q1\nJOURNAL OF ALLERGY AND CLINICAL \nIMMUNOLOGY-IN PRACTICE2213-2198 1 7.55 Q1\nJOURNAL OF ALZHEIMERS DISEASE 1387-2877 13.517 Q2\nJOURNAL OF ANATOMY 0021-8782 12.638 Q1\nJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 0305-7453 2 5.113 Q1\nJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS 1526-9914 11.544 Q3\nJOURNAL OF ARTHROPLASTY 0883-5403 23.524 Q1\nJOURNAL OF ASTHMA AND ALLERGY 1178-6965 14.694 Q1\nJOURNAL OF BIOLOGICAL CHEMISTRY 0021-9258 14.106 Q2\nJOURNAL\tOF\tBODYWORK\t AND\tMOVEMENT\t\nTHERAPIES1360-8592 2 Not\tIndexed\nJOURNAL OF CARDIOVASCULAR MAGNETIC \nRESONANCE1097-6647 15.07 Q1\nJOURNAL OF CARDIOVASCULAR PHARMACOLOGY 0160-2446 12.371 Q3\nJOURNAL OF CELLULAR AND MOLECULAR \nMEDICINE1582-4934 14.658 Q1\nJOURNAL\tOF\tCEREBRAL\tBLOOD\tFLOW\t AND\t\nMETABOLISM0271-678X 16.04 Q1\nJOURNAL\tOF\tCLINICAL\t AND\tEXPERIMENTAL\t\nNEUROPSYCHOLOGY1380-3395 11.994 Q3\nJOURNAL OF CLINICAL ENDOCRINOLOGY & \nMETABOLISM0021-972X 25.605 Q1\nJOURNAL OF CLINICAL HYPERTENSION 1524-6175 22.444 Q3\nJOURNAL OF CLINICAL IMMUNOLOGY 0271-9142 34.128 Q2\nJOURNAL OF CLINICAL INVESTIGATION 0021-9738 2 12.282 Q1\nJOURNAL OF CLINICAL LIPIDOLOGY 1933-2874 13.581 Q2\nJOURNAL OF CLINICAL ONCOLOGY 0732-183X 3 28.245 Q1\nJOURNAL OF CLINICAL VIROLOGY 1386-6532 13.02 Q2\nJOURNAL OF COMPARATIVE NEUROLOGY 0021-9967 1 3.239 Q1\nJOURNAL OF CRITICAL CARE 0883-9441 12.783 Q2\nJOURNAL OF CROHNS & COLITIS 1873-9946 17.827 Q1\nJOURNAL OF DERMATOLOGY 0385-2407 13.377 Q1\nJOURNAL OF ENDOCRINOLOGY 0022-0795 14.381 Q1\nJOURNAL\tOF\tEXPERIMENTAL\tORTHOPAEDICS 2197-1153 1 Not\tIndexed\nJOURNAL OF GENETIC COUNSELING 1059-7700 22.446 Q3\nJOURNAL OF GERIATRIC ONCOLOGY 1879-4068 23.164 Q2\nJOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE 2213-7165 12.469 Q3\nJOURNAL OF GYNECOLOGIC ONCOLOGY 2005-0380 12.914 Q1\nJOURNAL OF HEAD TRAUMA REHABILITATION 0885-9701 12.667 Q1JOURNAL\tOF\tHEALTHCARE\tQUALITY\tRESEARCH 2603-6479 2 Not\tIndexed\nJOURNAL OF HOSPITAL INFECTION 0195-6701 23.704 Q1\nJOURNAL OF HYPERTENSION 0263-6352 44.209 Q1\nJOURNAL OF INFECTIOUS DISEASES 0022-1899 65.045 Q1\nJOURNAL OF INORGANIC BIOCHEMISTRY 0162-0134 1 3.224 Q1\nJOURNAL OF INTENSIVE CARE 2052-0492 1 Not\tIndexed\nJOURNAL OF INTERNAL MEDICINE 0954-6820 16.051 Q1\nJOURNAL OF INTERVENTIONAL CARDIAC \nELECTROPHYSIOLOGY1383-875X 11.534 Q4\nJOURNAL OF INVESTIGATIONAL ALLERGOLOGY \nAND CLINICAL IMMUNOLOGY1018-9068 113.802 Q2\nJOURNAL OF LAPAROENDOSCOPIC & ADVANCED \nSURGICAL\tTECHNIQUES1092-6429 11.322 Q3\nJOURNAL OF LIPID RESEARCH 0022-2275 14.743 Q1\nJOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL \nTHERAPEUTICS0161-4754 11.274 Q3\nJOURNAL OF MATERNAL-FETAL & NEONATAL \nMEDICINE1476-7058 41.569 Q3\nJOURNAL OF MEDICAL ENTOMOLOGY 0022-2585 11.907 Q1\nJOURNAL OF MEDICAL GENETICS 0022-2593 15.899 Q1\nJOURNAL OF MICROBIOLOGICAL METHODS 0167-7012 11.801 Q3\nJOURNAL OF MINIMALLY INVASIVE GYNECOLOGY 1553-4650 12.414 Q2\nJOURNAL OF MOLECULAR AND CELLULAR \nCARDIOLOGY0022-2828 25.056 Q1\nJOURNAL OF NANOBIOTECHNOLOGY 1477-3155 15.345 Q1\nJOURNAL OF NEUROINTERVENTIONAL SURGERY 1759-8478 13.925 Q1\nJOURNAL OF NEUROLOGY NEUROSURGERY \nAND PSYCHIATRY0022-3050 1 8.272 Q1\nJOURNAL OF NEURO-OPHTHALMOLOGY 1070-8022 12.509 Q2\nJOURNAL OF NEUROPATHOLOGY AND \nEXPERIMENTAL\tNEUROLOGY0022-3069 13.46 Q1\nJOURNAL OF NEUROSURGERY -SPINE 1547-5654 12.998 Q1\nJOURNAL OF NUTRITIONAL BIOCHEMISTRY 0955-2863 14.49 Q1\nJOURNAL OF OBSTETRICS AND GYNAECOLOGY 0144-3615 20.588 Q4\nJOURNAL OF ORAL & FACIAL PAIN AND HEADACHE 2333-0384 21.443 Q3\nJOURNAL OF PAIN 1526-5900 15.424 Q1\nJOURNAL OF PAIN AND SYMPTOM MANAGEMENT 0885-3924 13.378 Q1\nJOURNAL OF PAIN RESEARCH 1178-7090 22.236 Q3\nJOURNAL OF PARENTERAL AND ENTERAL \nNUTRITION0148-6071 13.612 Q1\nJOURNAL OF PATHOLOGY 0022-3417 25.942 Q1\nJOURNAL OF PEDIATRIC ENDOCRINOLOGY & \nMETABOLISM0334-018X 11.239 Q32.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n101  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansJOURNAL OF PEDIATRIC GASTROENTEROLOGY \nAND NUTRITION0277-2116 43.015 Q1\nJOURNAL OF PEDIATRIC INFECTIOUS DISEASES 1305-7707 10.197 Q4\nJOURNAL OF PEDIATRIC NEUROLOGY 1304-2580 4 Not\tIndexed\nJOURNAL OF PEDIATRIC SURGERY 0022-3468 62.092 Q2\nJOURNAL OF PINEAL RESEARCH 0742-3098 1 15.221 Q1\nJOURNAL OF PSYCHOPHARMACOLOGY 0269-8811 14.221 Q1\nJOURNAL OF PUBLIC HEALTH 1741-3842 1 Not\tIndexed\nJOURNAL OF RHEUMATOLOGY 0315-162X 23.634 Q2\nJOURNAL\tOF\tSHOULDER\t AND\tELBOW\tSURGERY 1058-2746 12.865 Q1\nJOURNAL OF THE AMERICAN COLLEGE OF \nCARDIOLOGY0735-1097 6 18.639 Q1\nJOURNAL OF THE AMERICAN COLLEGE OF \nNUTRITION0731-5724 12.08 Q3\nJOURNAL OF THE AMERICAN GERIATRICS SOCIETY 0002-8614 14.113 Q1\nJOURNAL OF THE AMERICAN HEART ASSOCIATION 2047-9980 44.66 Q1\nJOURNAL OF THE AMERICAN MEDICAL DIRECTORS \nASSOCIATION1525-8610 34.899 Q1\nJOURNAL OF THE ASSOCIATION OF PHYSICIANS \nOF INDIA0004-5772 1 Not\tIndexed\nJOURNAL OF THE EUROPEAN ACADEMY OF \nDERMATOLOGY AND VENEREOLOGY0926-9959 3 5.113 Q1\nJOURNAL OF THORACIC AND CARDIOVASCULAR \nSURGERY0022-5223 1 5.261 Q1\nJOURNAL OF THROMBOSIS AND HAEMOSTASIS 1538-7933 14.662 Q1\nJOURNAL OF TRAUMA AND ACUTE CARE SURGERY 2163-0755 13.377 Q1\nJOURNAL OF TRAVEL MEDICINE 1195-1982 14.155 Q1\nJOURNAL OF UROLOGY 0022-5347 15.647 Q1\nJOURNAL OF VASCULAR AND INTERVENTIONAL \nRADIOLOGY1051-0443 22.828 Q2\nJOURNAL OF VASCULAR SURGERY -VENOUS AND \nLYMPHATIC DISORDERS2213-333X 12.696 Q2\nJOURNAL OF VIRAL HEPATITIS 1352-0504 14.016 Q1\nJOURNAL OF VIROLOGY 0022-538X 14.324 Q1\nJOURNAL OF VIRUS ERADICATION 2055-6640 1 Not\tIndexed\nJOURNALS OF GERONTOLOGY SERIES \nA-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES1079-5006 24.711 Q1\nJOVE-JOURNAL\tOF\t VISUALIZED\tEXPERIMENTS 1940-087X 11.108 Q3\nKIDNEY & BLOOD PRESSURE RESEARCH 1420-4096 12.123 Q2\nLANCET 0140-6736 7 59.102 Q1\nLANCET CHILD & ADOLESCENT HEALTH 2352-4642 1 Not\tIndexed\nLANCET GASTROENTEROLOGY & HEPATOLOGY 2468-1253 1 12.856 Q1\nLANCET HIV 2352-3018 2 14.753 Q1LANCET INFECTIOUS DISEASES 1473-3099 2 27.516 Q1\nLANCET NEUROLOGY 1474-4422 1 28.755 Q1\nLANCET PUBLIC HEALTH 2468-2667 1 11.6 Q1\nLEUKEMIA 0887-6924 19.944 Q1\nLIVER TRANSPLANTATION 1527-6465 1 4.159 Q1\nMALARIA JOURNAL 1475-2875 12.798 Q1\nMARINE DRUGS 1660-3397 13.772 Q1\nMATERNAL AND CHILD HEALTH JOURNAL 1092-7875 11.736 Q2\nMATURITAS 0378-5122 23.654 Q1\nMAYO CLINIC PROCEEDINGS. INNOVATIONS, \nQUALITY\t&\tOUTCOMES2542-4548 1 Not\tIndexed\nMEDIATORS OF INFLAMMATION 0962-9351 33.545 Q2\nMEDICAL HYPOTHESES 0306-9877 11.322 Q4\nMEDICAL MYCOLOGY 1369-3786 3 2.851 Q1\nMEDICAL MYCOLOGY CASE REPORTS 2211-7539 1 Not\tIndexed\nMEDICINA CL\u00cdNICA 0025-7753 161.277 Q3\nMEDICINA INTENSIVA 0210-5691 51.982 Q3\nMEDICINA ORAL PATOLOG\u00cdA ORAL Y CIRUG\u00cdA \nBUCAL1698-6946 11.284 Q3\nMEDICINE 0025-7974 51.87 Q2\nMETABOLOMICS 1573-3882 13.167 Q2\nMINERVA ANESTESIOL\u00d3GICA 0375-9393 22.84 Q2\nMINERVA GINECOL\u00d3GICA 0026-4784 1 Not\tIndexed\nMINERVA UROL\u00d3GICA E NEFROL\u00d3GICA 0393-2249 12.477 Q2\nMOLECULAR AND CELLULAR BIOLOGY 0270-7306 13.735 Q2\nMOLECULAR CANCER 1476-4598 1 10.679 Q1\nMOLECULAR CANCER THERAPEUTICS 1535-7163 14.856 Q1\nMOLECULAR CARCINOGENESIS 0899-1987 13.411 Q2\nMOLECULAR CELL 1097-2765 1 14.548 Q1\nMOLECULAR GENETICS AND METABOLISM 1096-7192 13.61 Q2\nMOLECULAR IMMUNOLOGY 0161-5890 13.064 Q2\nMOLECULAR METABOLISM 2212-8778 26.181 Q1\nMOLECULAR NEUROBIOLOGY 0893-7648 14.586 Q1\nMOLECULAR ONCOLOGY 1878-0261 15.962 Q1\nMUSCULOSKELETAL SCIENCE AND PRACTICE 2468-7812 11.125 Q2\nMYCOSES 0933-7407 11.278 Q2\nNATURE 0028-0836 2 43.07 Q1\nNATURE COMMUNICATIONS 2041-1723 4 11.878 Q1\nNATURE MEDICINE 1078-8956 1 30.641 Q1\nNATURE REVIEWS CARDIOLOGY 1759-5002 1 17.42 Q12.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n102  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansNATURE REVIEWS ENDOCRINOLOGY 1759-5029 2 24.646 Q1\nNEFROLOG\u00cdA 0211-6995 71.439 Q4\nNEONATOLOGY 1661-7800 12.544 Q1\nNEOPLASIA 1476-5586 13.837 Q2\nNEPHROLOGY DIALYSIS TRANSPLANTATION 0931-0509 34.198 Q1\nNEUROBIOLOGY OF AGING 0197-4580 14.398 Q1\nNEUROCIRUG\u00cdA 1130-1473 30.519 Q4\nNEUROLOG\u00cdA 0213-4853 62.038 Q3\nNEUROLOGY 0028-3878 28.689 Q1\nNEUROPEDIATRICS 0174-304X 11.654 Q3\nNEUROSURGICAL FOCUS 1092-0684 12.891 Q2\nNEW ENGLAND JOURNAL OF MEDICINE 0028-4793 7 70.67 Q1\nNUCLEIC ACIDS RESEARCH 0305-1048 1 11.147 Q1\nNUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS 1525-7770 11.167 Q4\nNUTRICI\u00d3N CL\u00cdNICA Y DIET\u00c9TICA HOSPITALARIA 0211-6057 1 Not\tIndexed\nNUTRICI\u00d3N HOSPITALARIA 0212-1611 110.759 Q4\nNUTRIENTS 2072-6643 64.171 Q1\nONCOG\u00c9NESIS 2157-9024 15.995 Q1\nONCOIMMUNOLOGY 2162-402X 25.333 Q1\nONCOLOGIST 1083-7159 25.252 Q1\nONCOTARGET 1949-2553 105.168 Q1\nONCOTARGETS AND THERAPY 1178-6930 13.046 Q2\nOPEN FORUM INFECTIOUS DISEASES 2328-8957 23.371 Q2\nOPEN ORTHOPAEDICS JOURNAL 1874-3250 1 Not\tIndexed\nOPHTHALMOLOGICA 0030-3755 11.781 Q3\nOPHTHALMOLOGY. RETINA 2468-7219 1 Not\tIndexed\nORPHANET JOURNAL OF RARE DISEASES 1750-1172 23.687 Q2\nOSTEOPOROSIS INTERNATIONAL 0937-941X 13.819 Q2\nOTOLARYNGOLOGY -HEAD AND NECK SURGERY 0194-5998 12.31 Q2\nOXIDATIVE\tMEDICINE\t AND\tCELLULAR\tLONGEVITY 1942-0900 24.868 Q2\nPACE-PACING AND CLINICAL ELECTROPHYSIOLOGY 0147-8389 11.34 Q4\nPAIN PRACTICE 1530-7085 12.486 Q3\nPAIN RESEARCH & MANAGEMENT 1203-6765 11.701 Q4\nPARASITOLOGY RESEARCH 0932-0113 12.067 Q2\nPATHOBIOLOGY 1015-2008 11.831 Q3\nPATIENT PREFERENCE AND ADHERENCE 1177-889X 12.097 Q2\nPEDIATRIC ALLERGY AND IMMUNOLOGY 0905-6157 1 4.654 Q1\nPEDIATRIC DERMATOLOGY 0736-8046 101.178 Q3\nPEDIATRIC EMERGENCY CARE 0749-5161 11.119 Q3\nPEDIATRIC INFECTIOUS DISEASE JOURNAL 0891-3668 42.317 Q2PEDIATRIC RADIOLOGY 0301-0449 12.022 Q2\nPEDIATRIC RESEARCH 0031-3998 10 2.88 Q1\nPEDIATRIC SURGERY INTERNATIONAL 0179-0358 11.397 Q3\nPEDIATRICS 0031-4005 3 5.401 Q1\nPEERJ 2167-8359 12.353 Q2\nPERCEPTUAL AND MOTOR SKILLS 0031-5125 11.049 Q4\nPHARMACOEPIDEMIOLOGY AND DRUG SAFETY 1053-8569 12.87 Q1\nPHARMACOGENOMICS 1462-2416 12.265 Q3\nPHARMACOGENOMICS JOURNAL 1470-269X 23.503 Q2\nPHARMACOLOGICAL RESEARCH 1043-6618 2 5.574 Q1\nPHARMACOLOGICAL REVIEWS 0031-6997 1 18.84 Q1\nPHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY 1572-1000 12.589 Q3\nPHYSICA MEDICA-EUROPEAN JOURNAL OF \nMEDICAL PHYSICS1120-1797 12.532 Q2\nPHYSICAL THERAPY IN SPORT 1466-853X 1 2Q2\nPHYSIOTHERAPY THEORY AND PRACTICE 1532-5040 21.158 Q4\nPLOS GENETICS 1553-7404 15.224 Q1\nPLOS MEDICINE 1549-1676 2 11.048 Q1\nPLOS NEGLECTED TROPICAL DISEASES 1935-2735 1 4.487 Q1\nPLOS ONE 1932-6203 182.776 Q2\nPM&R 1934-1482 11.902 Q2\nPOSTGRADUATE MEDICINE 0032-5481 22.237 Q2\nPRECLINICAL\tMRI: \tMETHODS\t AND\tPROTOCOLS 1064-3745 1 Not\tIndexed\nPROCEEDINGS OF THE NATIONAL ACADEMY OF \nSCIENCES OF THE UNITED STATES OF AMERICA0027-8424 29.58 Q1\nPROGRESS IN TRANSPLANTATION 1526-9248 10.958 Q4\nPULMONARY PHARMACOLOGY & THERAPEUTICS 1094-5539 12.669 Q1\nQUALITY\tOF\tLIFE\tRESEARCH 0962-9343 12.488 Q2\nRADIOLOG\u00cdA 0033-8338 1 Not\tIndexed\nREDOX BIOLOGY 2213-2317 5 7.793 Q1\nREPRODUCTIVE SCIENCES 1933-7191 12.559 Q2\nRESPIRATION 0025-7931 22.935 Q2\nRESPIRATORY MEDICINE 0954-6111 23.237 Q2\nRESPIRATORY RESEARCH 1465-993X 13.829 Q2\nRESUSCITATION 0300-9572 1 4.572 Q1\nREUMATOLOG\u00cdA CL\u00cdNICA 1699-258X 8 Not\tIndexed\nREVISTA\tALERGIA\tM\u00c9XICO\t(TECAMACHALCO, \t\nPUEBLA,\tM\u00c9XICO:\t1993)0002-5151 1 Not\tIndexed\nREVISTA CL\u00cdNICA ESPA\u00d1OLA 0014-2565 71.043 Q3\nREVISTA DA ASSOCIACAO MEDICA BRASILEIRA 0104-4230 10.801 Q4\nREVISTA\tDE\tGASTROENTEROLOG\u00cdA\tDE\tM\u00c9XICO 0375-0906 1 Not\tIndexed2.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n103  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansREVISTA DE NEUROLOG\u00cdA 0210-0010 50.485 Q4\nREVISTA\tDE\tPSIQUIATR\u00cdA\t Y\tSALUD\tMENTAL 1888-9891 12.927 Q2\nREVISTA ESPA\u00d1OLA DE ANESTESIOLOG\u00cdA Y \nREANIMACI\u00d3N0034-9356 7 Not\tIndexed\nREVISTA ESPA\u00d1OLA DE CARDIOLOG\u00cdA 0300-8932 275.126 Q1\nREVISTA ESPA\u00d1OLA DE CIRUG\u00cdA ORTOP\u00c9DICA Y \nTRAUMATOLOG\u00cdA1988-8856 2 Not\tIndexed\nREVISTA ESPA\u00d1OLA DE ENFERMEDADES DIGESTIVAS 1130-0108 91.858 Q4\nREVISTA ESPA\u00d1OLA DE GERIATR\u00cdA Y \nGERONTOLOG\u00cdA1578-1747 8 Not\tIndexed\nREVISTA ESPA\u00d1OLA DE MEDICINA NUCLEAR E \nIMAGEN MOLECULAR2253-654X 40.928 Q4\nREVISTA ESPA\u00d1OLA DE PATOLOG\u00cdA 1988-561X 2 Not\tIndexed\nREVISTA\tESPA\u00d1OLA\tDE\tQUIMIOTERAPIA 0214-3429 30.76 Q4\nREVISTA ESPA\u00d1OLA DE SALUD P\u00daBLICA 1135-5727 20.635 Q4\nREVISTA IBEROAMERICANA DE MICOLOG\u00cdA 1130-1406 21.597 Q4\nREVISTA LATINO-AMERICANA DE ENFERMAGEM 1518-8345 10.979 Q3\nREVISTA PORTUGUESA DE CARDIOLOG\u00cdA 0870-2551 10.785 Q4\nREVISTA ROL DE ENFERMER\u00cdA 0210-5020 2 Not\tIndexed\nRHEUMATOLOGY 1462-0324 35.149 Q1\nRHEUMATOLOGY AND THERAPY 2198-6584 1 Not\tIndexed\nRHEUMATOLOGY INTERNATIONAL 0172-8172 4 2.2Q3\nRMD OPEN 2056-5933 1 Not\tIndexed\nRQR\tENFERMER\u00cdA\tCOMUNITARIA 2253-9832 1 Not\tIndexed\nSCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE \nIN SPORTS0905-7188 23.631 Q1\nSCIENTIFIC REPORTS 2045-2322 154.011 Q1\nSEMERGEN 1578-8865 4 Not\tIndexed\nSEMINARS IN ARTHRITIS AND RHEUMATISM 0049-0172 15.072 Q1\nSKIN RESEARCH AND TECHNOLOGY 0909-752X 11.657 Q3\nSLEEP MEDICINE REVIEWS 1087-0792 1 10.517 Q1\nSOMATOSENSORY AND MOTOR RESEARCH 0899-0220 21.235 Q4\nSPANISH JOURNAL OF PSYCHOLOGY 1138-7416 10.749 Q4\nSPINE 0362-2436 22.903 Q1\nSPINE DEFORMITY 2212-1358 1 Not\tIndexed\nSPINE JOURNAL 1529-9430 33.196 Q1\nSTEM CELL RESEARCH 1873-5061 3 3.929 Q1\nSTEM CELL RESEARCH & THERAPY 1757-6512 14.627 Q1STEM CELLS INTERNATIONAL 1687-966X 13.902 Q2\nSTROKE 0039-2499 2 6.046 Q1\nSUPPORTIVE CARE IN CANCER 0941-4355 12.754 Q1\nTARGETED ONCOLOGY 1776-2596 13.683 Q2\nTHERAPEUTIC ADVANCES IN GASTROENTEROLOGY 1756-283X 13.961 Q2\nTHERAPEUTIC ADVANCES IN HEMATOLOGY 2040-6207 13.105 Q2\nTHERAPEUTIC HYPOTHERMIA AND TEMPERATURE \nMANAGEMENT2153-7658 11.673 Q4\nTHROMBOSIS AND HAEMOSTASIS 0340-6245 54.733 Q1\nTHROMBOSIS JOURNAL 1477-9560 1 Not\tIndexed\nTHROMBOSIS RESEARCH 0049-3848 13.266 Q2\nTOBACCO INDUCED DISEASES 1617-9625 11.889 Q3\nTORTURE 1997-3322 1 Not\tIndexed\nTOXINS 2072-6651 13.895 Q1\nTRANSFUSION 0041-1132 13.111 Q2\nTRANSFUSION AND APHERESIS SCIENCE 1473-0502 11.412 Q4\nTRANSLATIONAL ANDROLOGY AND UROLOGY 2223-4683 12.113 Q2\nTRANSLATIONAL CANCER RESEARCH 2218-676X 11.07 Q4\nTRANSLATIONAL PSYCHIATRY 2158-3188 15.182 Q1\nTRANSLATIONAL RESEARCH 1931-5244 1 4.915 Q1\nTRANSPLANTATION 0041-1337 1 4.593 Q1\nTRENDS IN CANCER 2405-8025 18.884 Q1\nTRENDS IN MOLECULAR MEDICINE 1471-4914 1 11.028 Q1\nTROPICAL DOCTOR 0049-4755 10.591 Q4\nULTRASOUND IN MEDICINE AND BIOLOGY 0301-5629 12.205 Q2\nUROLOGIC ONCOLOGY -SEMINARS AND ORIGINAL \nINVESTIGATIONS1078-1439 22.863 Q2\nUROLOGY 0090-4295 11.861 Q3\nVACCINE 0264-410X 13.269 Q2\nVASCULAR PHARMACOLOGY 1537-1891 1 3.33 Q2\nVIRCHOWS\t ARCHIV 0945-6317 12.868 Q2\nVIRUSES-BASEL 1999-4915 43.811 Q2\nWORLD\tJOURNAL\tOF\tEMERGENCY\tSURGERY 1749-7922 23.798 Q1\nWORLD\tJOURNAL\tOF\tGASTROENTEROLOGY 1007-9327 13.411 Q2\nWORLD\tJOURNAL\tOF\tSTEM\tCELLS 1948-0210 13.534 Q2\nWORLD\tJOURNAL\tOF\tUROLOGY 0724-4983 22.761 Q2\nWORLD PSYCHIATRY 2051-5545 1 34.024 Q12.8\t Scientific\tProduction\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n104  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.8.2 High Impact Publications2.8\t Scientific\tProduction\nNeuroscience\tArea\nCardiovascular Area\nInfectious Diseases and Immunity \nArea\nP\u00e9rez-Sales P ,\tJan\tden\tOtter\tJ,\tHardi\tL,\tWenzel\tT,\tDiaconu\tG,\tCors\tG,\t\nKastrup\tM.\tWPA\tPosition\tstatement\ton\tbanning\tthe\tparticipation\t of\t\npsychiatrists\t in\tthe\tinterrogation\t of\tdetainees.\tWorld\tPsychiatry.\t2018;\t\n17(2):\t237-8.\tEditorial\tMaterial. \tIF:\t34.024;\tD1\nCuadrado A , Manda G, Hassan A, Alcaraz MJ, Barbas C, Daiber A, Ghezzi \nP , Leon R, L\u00f3pez MG, Oliva B, Pajares M, Rojo AI, Robledinos-Anton N, \nValverde\tAM,\tGuney\tE,\tSchmidt\tHHHW.\tTranscription\t factor\tNRF2\tas\ta\t\ntherapeutic\t target\tfor\tchronic\tdiseases:\tA\tsystems\tmedicine\tapproach.\t\nPharmacol\tRev. \t2018;\t70(2):\t348-383.\tReview.\tIF:\t18.84;\tD1\nSusser E, Mart\u00ednez-Ales G .\tPutting\tpsychosis\tinto\tsociocultural\t context\t\nan\tinternational\t study\tin\t17\tlocations.\tJAMA\tPsychiatry.\t2018;\t75(1):\t\n9-10.\tEditorial\tMaterial. \tIF:\t15.916;\tD1\nPajares M , Rojo AI, Arias E, D\u00edaz-Carretero A, Cuervo AM, Cuadrado \nA. Transcription factor NFE2L2/NRF2 modulates chaperone-mediated \nautophagy\tthrough\tthe\tregulation\tof\tLAMP2A.\tAutophagy.\t2018;\t14(8):\t\n1310-22.\tArticle.\tIF:\t11.059;\tD1\nRojo AI , Pajares M, Garc\u00eda-Yag\u00fce AJ, Buend\u00eda I, Van Leuven F , Yamamoto \nM, L\u00f3pez MG, Cuadrado A .\tDeficiency\t in\tthe\ttranscription\t factor\tNRF2\t\nworsens\tinflammatory\t parameters\t in\ta\tmouse\tmodel\twith\tcombined\t\ntauopathy\tand\tamyloidopathy. \tRedox\tBiol.\t2018;\t18:\t173-80.\tArticle.\tIF:\t\n7.793;\tD1\nCuadrado A , Kugler S, Lastres-Becker I . Pharmacological targeting of \nGSK-3 and NRF2 provides neuroprotection in a preclinical model of \ntauopathy.\tRedox\tBiol. \t2018;\t14:\t522-34.\tArticle.\tIF:\t7.793;\tD1Loma-Osorio P , Sionis A, Monedero MC, Mart\u00ednez-Selles M, Mart\u00edn-\nBen\u00edtez JC, Ariza A, Uribarri A, Garc\u00eda-Acuna JM, Villa P , P\u00e9rez PJ, Storm \nC, Dee A, L\u00f3pez-Send\u00f3n JL . A multicentre randomized pilot trial on \nthe effectiveness of different levels of cooling in comatose survivors of \nout-of-hospital\t cardiac\tarrest:\tthe\tFROST-I\ttrial.\tIntens\tCare\tMed.\t2018;\t\n44(11):\t1807-15.\tArticle.\tIF:\t18.967;\tD1\nFerrari\tR,\tCamici\tPG,\tCrea\tF,\tDanchin\tN,\tFox\tK,\tMaggioni\tAP,\tManolis\tAJ,\t\nMarzilli M, Rosano GMC, L\u00f3pez-Send\u00f3n JL . A \u2018diamond\u2019 approach to \npersonalized\t treatment\tof\tangina.\tNat\tRev\tCardiol.\t2018;\t15(2):\t120-32.\t\nArticle.\tIF:\t17.42;\tD1\nBerenguer J, Gil-Mart\u00edn A, Jarr\u00edn I, Moreno A, Dom\u00ednguez L, Montes M, \nAld\u00e1miz-Echevarr\u00eda\t T,\tT\u00e9llez\tMJ,\tSantos\tI,\tBen\u00edtez\tL,\tSanz\tJ,\tRyan\tP,\tGaspar\t\nG, \u00c1lvarez B, Losa JE, T orres-Perea R, Barros C, San Mart\u00edn JV, Arponen \nS,\tde\tGuzm\u00e1n\tMT,\tMonsalvo\tR,\tVegas\tA,\tGarc\u00eda-Benayas\t MT,\tSerrano\t\nR, Gotuzzo L, Men\u00e1ndez MA, Belda LM, Malmierca E, Calvo MJ, Cruz-\nMartos E, Gonz\u00e1lez-Garc\u00eda JJ .\tAll-oral\tdirect-acting\t antiviral\ttherapy\t\nagainst\thepatitis\tC\tvirus\t(HCV)\tin\thuman\timmunodeficiency\t virus/HCV-\ncoinfected\t subjects\tin\treal-world\t practice:\tMadrid\tcoinfection\t registry\t\nfindings.\tHepatology. \t2018;\t68(1):\t32-47.\tArticle.\tIF:\t14.971;\tD1\nMulleman D Balsa A . Adalimumab concentration-based tapering strate -\ngy:\tas\tgood\tas\tthe\trecommended\t dosage.\tAnn\tRheum\tDis.\t2018;\t77(4):\t\n473-475.\tEditorial\tMaterial. \tIF:\t14.299;\tD1\nNavarro-Comp\u00e1n V, Ramiro S, Landewe R, Dougados M, Miceli-Richard \nC,\tRichette\tP,\tvan\tder\tHeijde\tD.\tIn\tpatients\twith\taxial\tspondyloarthritis\t\ninflammation\t on\tMRI\tof\tthe\tspine\tis\tlongitudinally\t related\tto\tdisease\tacti-\nvity\tonly\tin\tmen:\t2\tyears\tof\tthe\taxial\tspondyloarthritis\t DESIR\tcohort.\tAnn\t\nRheum\tDis. \t2018;\t77(3):\t470-2.\tLetter.\tIF:\t14.299;\tD1\nGarc\u00eda-Morato MB , Santos FJA, Briones AC, Moreno AB, Mate AD, Do -\nm\u00ednguez-Soto A, Merino MJB, Molina LD, Ca\u00f1izales JT, Marin AV, Garc\u00eda \nEV, Rodr\u00edguez MF , Sabando DPL, Jim\u00e9nez-Reinoso A, del Castillo YM, \nSantaeufemia FJS, de Lucas-Laguna R, C\u00e1rdenas PP , Polo LC D\u00edaz MC, \nVales-G\u00f3mez\t M,\tSantiago\tER,\tCerd\u00e1n\tAF,\tBlanco\tJN,\tCorbi\tAL,\tReyburn\t\nHT, Regueiro JR, L\u00f3pez-Granados E, Pena RR . New human combined \nimmunodeficiency\t caused\tby\tinterferon\tregulatory\t factor\t4\t(IRF4)\tde-\nficiency\tinherited\tby\tuniparental\t isodisomy.\tJ\tAllergy\tClin\tImmun.\t2018;\t\n141(5):\t1924-27.\tArticle.\tIF:\t14.11;\tD1\nRedondo C, Mart\u00ednez-Feito A, Plasencia-Rodr\u00edguez C, Navarro-Comp\u00e1n Banegas JR,\t Ruilope\tLM,\tWilliams\tB.\tAmbulatory\t blood\tpressure\tand\tmor-\ntality\treply.\tNew\tEngl\tJ\tMed. \t2018;\t379(13):\t1287-8.\tLetter.\tIF:\t70.67;\tD1\nBalfag\u00f3n G, Blanco-Rivero J, M\u00e1rquez-Rod\u00e1s I. Preventive therapies for \nchronic\tmigraine.\tNew\tEngl\tJ\tMed.\t2018;\t378(8):\t773-4.\tLetter.\tIF:\t70.67;\tD1\nBanegas JR ,\tRuilope\tLM,\tde\tla\tSierra\tA,\tVinyoles\tE,\tGorostidi\tM,\tde\t\nla\tCruz\tJJ,\tRuiz-Hurtado\t G,\tSegura\tJ,\tRodr\u00edguez-Artalejo\t F,\tWilliams\tB.\t\nRelationship\t between\tclinic\tand\tambulatory\t blood-pressure\t measure -\nments\tand\tmortality.\tNew\tEngl\tJ\tMed.\t2018;\t378(16):\t1509-20.\tArticle.\t\nIF:\t70.67;\tD1\nL\u00f3pez-de-Sa E , Ju\u00e1rez M, Armada E, S\u00e1nchez-Salado JC, S\u00e1nchez PL, Scientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n105  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.8\t Scientific\tProduction\nLarge\tSystem\tPathologies\tArea\nSurgery, Transplant and Health \nTechnologies Area\nCancer\tand\tHuman\tMolecular \t\nGenetics Area\nV, Nuno-Nuno L, Peiteado D, Villalba A, Jochems A, Pascual-Salcedo D, \nBalsa A.\tGolimumab\t tapering\tstrategy\tbased\ton\tserum\tdrug\tlevels\tin\t\npatients\twith\tspondyloarthritis. \tArthritis\tRheumatol. \t2018;\t70(8):1356-\n8.\tLetter.\tIF:\t9.002;\tD1\nCobo I, Martinelli P , Fl\u00e1ndez M, Bakiri L, Zhang MF , Carrillo-de-Santa-Pau \nE, Jia JP , Lobo VJSA, Megias D, Felipe I, del Pozo N, Millan I, Thommesen \nL,\tBruland\tT,\tOlson\tSH,\tSmith\tJ,\tSchoonjans\t K,\tBamlet\tWR,\tPetersen\tGM,\t\nMalats\tN,\tAmundadottir\t LT,\tWagner\tEF,\tReal FX . Transcriptional regula -\ntion\tby\tNR5A2\tlinks\tdifferentiation\t and\tinflammation\t in\tthe\tpancreas.\t\nNature.\t2018;\t554(7693): \t533-7.\tArticle.\tIF:\t43.07;\tD1\nGarc\u00eda-R\u00edo F. \tSpirometry-based\t diagnostic\tcriteria\tthat\tare\tnot\tage-\nappropriate\t lack\tclinical\trelevance\treply.\tAm\tJ\tResp\tCrit\tCare.\t2018;\t\n197(7):964-5. \tLetter.\tIF:\t16.494;\tD1\nGarc\u00eda-R\u00edo F .\tThe\tz-score\tdoes\tnot\tpredict\tmortality\tbecause\tof\tcon-\nfounding\tby\tage\treply.\tAm\tJ\tResp\tCrit\tCare.\t2018;\t197(1):\t141-2.\tLetter.\t\nIF:\t16.494;\tD1\nV\u00e1zquez GF, Reiter RJ, Agil A. Melatonin increases brown adipose tissue \nmass\tand\tfunction\tin\tZucker\tdiabetic\tfatty\trats:\timplications\t for\tobesity\t\ncontrol.\tJ\tPineal\tRes. \t2018;\t64(4):\te12472.\tArticle.\tIF:\t15.221;\tD1\nTiana M , Acosta-Iborra B, Puente-Santamar\u00eda L, Hernansanz-Agust\u00edn P , \nWorsley-Hunt\t R,\tMasson\tN,\tGarc\u00eda-R\u00edo\t F,\tMole\tD,\tRatcliffe\tP,\tWasser -\nman\tWW,\tJim\u00e9nez\tB,\tdel Peso L .\tThe\tSIN3A\thistone\tdeacetylase\t com-\nplex\tis\trequired\tfor\ta\tcomplete\ttranscriptional\t response\tto\thypoxia.\t\nNucleic\tAcids\tRes.\t2018;\t46(1):\t120-33.\tArticle.\tIF:\t11.147;\tD1Su\u00e1rez-de-la-Rica A , Gilsanz F , Maseda E, Montravers P , Lasocki S, Les -\ncot\tT,\tDupont\tH.\tIs\tvery\tshort-course\t antibiotic\ttherapy\tpossible\tin\t\npostoperative intra-abdominal infections? Discussion on \u201cShort-course \nantibiotic\ttherapy\tfor\tcritically\till\tpatients\ttreated\tfor\tpostoperative\t\nintra-abdominal\t infection:\tthe\tDURAPOP\t randomised\t clinical\ttrial\u201d.\t\nLetter.\t2018;\t44(5):695-6. \tLetter.\tIF:\t18.967;\tD1\nMaseda E,\tGrau\tS,\tLuque\tS,\tCastillo-Mafla\t MP,\tSuarez-de-la-Rica\t A,\t\nMontero-Feijoo A, Salgado P , Gim\u00e9nez MJ, Garc\u00eda-Bernedo CA, Gilsanz \nF,\tRoberts\tJA.\tPopulation\t pharmacokinetics/pharmacodynamics\t of\tmica-\nfungin\tagainst\tCandida\tspecies\tin\tobese\tcritically\till\tand\tmorbidly\tobese\t\ncritically\till\tpatients. \tArticle.\t2018;\t22:\t94.\tArticle.\tIF:\t6.959;\tQ1\nMart\u00edn-Saavedra F,  Escudero-Duch C, Prieto M, S\u00e1nchez-Casanova S, \nL\u00f3pez\tD,\tArruebo\tM,\tVoellmy\tR,\tSantamar\u00eda\t J,\tVilaboa\tN.\tPro-angiogenic\t\nnear\tinfrared-responsive\t hydrogels\tfor\tdeliberate\ttransgene\texpression. \t\nActa\tBiomater. \t2018;\t78:\t123-36.\tArticle.\tIF:\t6.638;\tD1\nRodr\u00edguez-Merch\u00e1n EC . Treatment of musculo-skeletal pain in haemo -\nphilia.\tBlood\tRev. \t2018;\t32(2):\t116-21.\tReview.\tIF:\t6.125;\tQ1\nPascual ES, S\u00e1nchez AC, Zurita MB.\tLarge\tcongenital\tcoronary\tfistula.\t\nEditorial\tMaterial. \t2018;\t71(4):\t292.\tEditorial\tMaterial. \tIF:\t5.126;\tQ1natural\thistory\tand\tphenotype.\tGenet\tMed.\t2018;\t20(8):\t882-9.\tArticle.\t\nIF:\t8.683;\tD1\nHisado-Oliva A , Ruzafa-Mart\u00edn A, Sentchordi L, Funari MFA, Bezanilla-\nL\u00f3pez C, Alonso-Bernaldez M, Barraza-Garc\u00eda J, Rodr\u00edguez-Zabala M, \nLerario AM, Benito-Sanz S, Aza-Carmona M, Campos-Barros A, Jorge \nAAL, Heath KE.\tMutations\tin\tC-natriuretic\t peptide\t(NPPC):\ta\tnovel\t\ncause\tof\tautosomal\t dominant\tshort\tstature.\tGenet\tMed.\t2018;\t20(1):\t\n91-7.\tArticle.\tIF:\t8.683;\tD1\nBarriuso J , Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, \nGarc\u00eda-Carbonero R, Grande E, Jim\u00e9nez-Fonseca P , Marazuela M, Rodr\u00ed -\nguez-Antona C, Aller J. Prognostic and predictive biomarkers for soma -\ntostatin\tanalogs\tpeptide\treceptor\tradionuclide\t therapy\tand\tserotonin\t\npathway\ttargets\tin\tneuroendocrine\t tumours.\tCancer\tTreat\tRev.\t2018;\t\n70:\t209-22.\tReview.\tIF:\t8.332;\tD1\nSantamar\u00eda PG, Florist\u00e1n A, Fontanals-Cirera B, V\u00e1zquez-Naharro A, \nSantos V, Morales S, Yuste L, Peinado H, Garc\u00eda-Gomez A, Portillo F , Her -\nnando E, Cano A.\tLysyl\toxidase-like\t 3\tis\trequired\tfor\tmelanoma\t cell\t\nsurvival\tby\tmaintaining\t genomic\tstability.\tCell\tDeath\tDiffer.\t2018;\t25(5):\t\n935-50.\tArticle.\tIF:\t8.086;\tD1\nVillahoz S, Yunes-Leites PS, M\u00e9ndez-Barbero N, Urso K, Bonzon-Kuli -\nchenko E, Ortega S, Nistal JF , V\u00e1zquez J, Offermanns S, Redondo JM, \nCampanero MR .\tConditional\t deletion\tof\tRcan1\tpredisposes\t to\thyper -\ntension-mediated\t intramural\thematoma\t and\tsubsequent\t aneurysm\tand\t\naortic\trupture. \tNat\tCommun. \t2018;\t9:\t4795.\tArticle.\tIF:\t11.878;\tD1\nRodr\u00edguez-Laguna L , Ib\u00e1\u00f1ez K, Gordo G, Garc\u00eda-Mi\u00f1aur S, Santos-\nSimarro F , Agra N, Vallesp\u00edn E, Fern\u00e1ndez-Montano VE, Mart\u00edn-Arenas R, \ndel Pozo A, Gonz\u00e1lez-Pecellin H, Mena R, Rueda-Arenas I, G\u00f3mez MV, \nVillaverde\tC,\tBustamante\t A,\tAyuso\tC,\tRuiz-P\u00e9rez\tVL,\tNevado\tJ,\tLapunzi -\nna P , L\u00f3pez-Guti\u00e9rrez JC, Mart\u00ednez-Glez V .\tCLAPO\tsyndrome:\tidenti -\nfication\tof\tsomatic\tactivating\tPIK3CA\tmutations\tand\tdelineation\t of\tthe\tScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n106  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\n2.9 CIBERs  \nand RETICs\nAcronym CIBER Funding Organisation Principal Researcher IdiPAZ Group End Date\nCIBER-bbnNetworked Biomedical Research Center for Bio-\nengineering, Biomaterials and NanomedicineCarlos III Health Institute Vilaboa D\u00edaz, Nuria Elda Bone\tPathophysiology\tand\tbiomaterials 3/12/2019\nCIBERehdNetworked Biomedical Research Center for \nHepatic and Digestive DiseasesCarlos III Health Institute Garc\u00eda-Samaniego\tRey, \tJavier Associated Clinician 31/12/2019\nCIBERerNetworked Biomedical Research Center for Rare \nDiseasesCarlos III Health InstituteL\u00f3pez Trascasa, MargaritaDiagnosis and Treatment of Diseases \nAssociated with Abnormalities of the \nComplement\tSystem31/12/2018\nLapunzina Bad\u00eda, Pablo Cell\tTherapy\tand\tGene\tMetastasis 31/12/2018\nCIBERespNetworked Biomedical Research Center for Public \nHealth\tand\tEpidemiologyCarlos III Health Institute Rodr\u00edguez Artalejo, Fernando Cardiovascular\tEpidemiology\tand\tNutrition 31/12/2018\nCIBERnedNetworked Biomedical Research Center for \nNeurodegenerative DiseasesCarlos III Health Institute Cuadrado Pastor, AntonioNeuroprotective Strategies in \nNeurodegenerative Diseases31/12/2018\nCIBERcvNetworked Biomedical Research Center for \nCardiovascular DiseasesCarlos III Health Institute Salaices S\u00e1nchez, Mercedes Vascular\tPhysiology\tand\tPharmacology 31/12/2022\nCIBERonc Networked Biomedical Research Center for Cancer Carlos III Health InstituteCano Garc\u00eda, Amparo Mechanisms of T umour Progression 31/12/2022\nMu\u00f1oz T erol, Alberto Mechanisms of T umour Progression 31/12/2022\nFeli\u00fa Batlle, Jaime Trasnlational\tOncology 31/12/20222.9.1 CIBER- Network Biomedical Research CenterScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n107  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.9 CIBERs and RETICs\nFunding Organisation Acronym CIBER Funding Organisation Principal Researcher IdiPAZ Group End Date\nPT13/0006/0012 ITEMASMedical\tTechnology\tInnovation\t\nPlatformCarlos III Health Institute de Castro Carpe\u00f1o, JavierExperimental\t Therapies\tand\t\nBiomarkers in Cancer31/12/2018\nPT13/0010/0003 ReTBioH Biobanks Platform Carlos III Health Institute G\u00f3mez Campelo, Paloma Innate Immune Response 31/12/2018\nPT13/0002/0015 UCICECResearch and Clinical Trials Units \nPlatformCarlos III Health Institute Fr\u00edas Iniesta, Jes\u00fas Clinical\tPharmacology 31/12/2018\nPT17/0005/0025 ITEMAS Plataforma ITEMAS Carlos III Health Institute de Castro Carpe\u00f1o, JavierExperimental\t Therapies\tand\t\nBiomarkers in Cancer31/12/2020\nPT17/0015/0025 RNBB Red de Biobancos Carlos III Health Institute G\u00f3mez Campelo, Paloma Innate Immune Response 31/12/2020\nPT17/0017/0013 SCReNPlataforma de Unidades de \nInvestigaci\u00f3n\tCl\u00ednica\ty\tEnsayos\t\nCl\u00ednicosCarlos III Health Institute Fr\u00edas Iniesta, Jes\u00fas Clinical\tPharmacology 31/12/2020\nRD16/0019/0005INVICTUS \nPLUSVascular and Cerebral Diseases \nNetworkCarlos III Health Institute D\u00edez\tTejedor,\tExuperioNeurology\tand\tCerebrovascular\t\nDiseases31/12/2021\nS2013/MIT-2862 MULTIMATMateriales multifuncionales para los \nretos de la sociedadAutonomous\tCommunity\t\nof MadridVilaboa D\u00edaz, Nuria EldaBone\tPathophysiology\tand\t\nBiomaterials31/12/2018\nRD16/0025/0018 RIS Research Network for AIDS Carlos III Health Institute Gonz\u00e1lez Garc\u00eda, Juan AIDS and Infectious Diseases 31/12/2021\nRD16/0006/0033 ARADYALAsthma, Adverse and Allergic \nReactionsCarlos III Health Institute Laguna Mart\u00ednez, Jos\u00e9 Julio Associated Clinician 31/12/2021\nRD16/0022/0006 SAMIDResearch Network for Maternal and \nChild Health and DevelopmentCarlos III Health Institute Mart\u00ednez Mart\u00ednez, Leopoldo Congenital\tMalformation\tSurgery 31/12/2021\nRD16/0027/0002 RICETTropical Disease Cooperative \nResearch NetworkCarlos III Health Institute Mora Rillo, Marta AIDS and infectious diseases 31/12/2021\nRD16/0009/0008 REDINRENResearch Network for Renal \nDiseasesCarlos III Health Institute Selgas Guti\u00e9rrez, Rafael Nephrology 31/12/2021\nRD16/0022/0004 SAMIDResearch Network for Maternal and \nChild Health and DevelopmentCarlos III Health Institute Caba\u00f1as Gonz\u00e1lez, Fernando Congenital\tMalformation\tSurgery 31/12/2021\nRD16/0012/0012 RIERInvestigational Network in \nInflammation\tand\tRheumatic\tDiseasesCarlos III Health Institute Miranda Car\u00fas, Mar\u00eda Eugenia Immuno-Rheumatology 31/12/2021\nSAF2015-71304-\nREDTResearch Network NRF2 as a Node \nof the PathogenesomeMinisterio de Ciencia, \nInnovaci\u00f3n\ty\tUniversidadesCuadrado Pastor, AntonioNeuroprotective Strategies in \nNeurodegenerative Diseases31/12/2019\nSAF2017-90604-\nREDTNuRCaMeInRed T em\u00e1tica de Receptores \nNucleares en C\u00e1ncer, Metabolismo e \nInflamaci\u00f3nMinisterio de Ciencia, \nInnovaci\u00f3n\ty\tUniversidadesMu\u00f1oz T erol, Alberto Mechanisms of T umour Progression 31/12/20192.9.2 RECTICs- Networks for Cooperative Research in HealthScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n108  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians\nKarolinska Lund Hospital (Skane Univ Hospital)\nVilnius UH Santariskiu Klinikos\nChildren's Memorial Health Institute\nHannover Medical School\nPapa Giovanni XXIII Bambino Gesu\nOspiedaliera di Podova ISMETT\nH Sta Mar\u00eda Hospital de Coimbra\nCentro Hospitalario do Porto EPE (CHP)\nHospital Universitario la Paz\nParis Necker Bicetre\nWhilhelmina Children Hospital\nSaint Luc\nKCH (King's College Hospital NHS foundation Trust)\n2.10 Institutional  \n\tProjects\nThe\tEuropean\tReference\tNetwork\t(ERN)\tTransplantChild\t (www.transplantchild.eu)\t was\taccredited\t by\tthe\tEuropean\tCommission\t in\t2017\tto\ttackle\ta\tlow\tprevalence\t complex\t\nprocedure and condition as the paediatric transplantation of all kind of solid organ and hematopoietic stem cell transplantation.\nThe\tnumber\tof\tpaediatric\ttransplantations\t performed\t worldwide\t continues\tto\tincrease.\tData\tshows\tthat\tmore\tthan\t5.000\tchildren\treceive\tsome\tkind\tof\ttransplant\tin\tEurope\t\neach\tyear.\tRegardless\t the\ttype\tof\ttransplant,\tall\ttransplanted\t children\tshare\ta\tcommon\tlife-long\tmedical\tcondition:\tthe\tneed\tof\timmunosuppression\t treatment\tto\tprevent\tgraft\t\nrejection.\tThe\tsecondary\teffects\tof\ta\tlife\ton\timmunosuppressive\t treatment\tcan\tlead\tto\tinfections,\tmalignancy\t and\tchronic\trejection.\tFurthermore, \tnon-adherence\t to\ttreatment,\t\nwhich\tis\tworse\tin\tadolescents, \tcan\timpact\tin\tthe\tquality\tof\tlife\tof\tthese\tpatients\tand\ttheir\tfamilies\tand\teventually\tcould\tlead\tto\tchronic\trejection\tand\tre-transplantation.\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10 Institutional Projects\n2.11 Internationalization\n2.12 Comunication\n109  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansStrategic areas \nLa\tPaz\tUniversity\t Hospital-IdiPAZ, \tcoordinates\t the\tresources\t and\texisting\t\nknowledge\t from\tthe\t18\thospitals\tfrom\t11\tEuropean\tMember\tStates,\tinvolved\tin\t\nthe ERN TransplantChild in order to harmonize, generate and disseminate the \nknowledge related to transplantation throughout Europe, following these strategic \nareas:\t\n\u2022 Facilitate the patient empowerment through its participation in the activities \nof\tthe\tnetwork,\tease\taccess\tto\tinformation, \tdissemination\t of\texperience, \tre-\nsearch,\texchange\tof\tnecessary\tknowledge\tto\tfacilitate\ttheir\tdecision-making.\n\u2022\tImprovements\t in\thealthcare:\tprevention, \tsurgical\tinterventions, \tpatients\u2019\tfo-\nllow-up and health care for transplanted patients.\n\u2022 Improve health outcomes regarding the immune transplant process and phe -\nnomena\tof\trejection\tand\ttolerance\tusing\tclinical\tpractice\tguidelines\tby\tmulti-\nprofessional teams involved in care. \n\u2022\tThe\tgaps\tidentification, \talignment\tand\tprioritization\t of\tareas\tof\tresearch\tand\t\ninnovation facilitate continuous improvement in transplant patient care and \nhealth outcomes.\n\u2022\tDisseminate\t knowledge\t through\tsociety\tand\tother\tstakeholders, \tand\tclinical\t\nteams at different levels (including education and training activities).\nIdiPAZ\tAdded\tValue\t\nLa\tPaz\tUniversity\tHospital\thas\tone\tof\tthe\tmost\thighly\tspecialized\t multidisciplinary\t\ntransplant\tteams\tin\tEurope\tand\tis\tthe\tonly\tone\tin\tSpain\taccredited\t to\tdo\tall\tkind\tof\tpaediatric\ttransplants\t with\tsurvival\tand\tquality\tindicators\tcomparable\t to\tthe\tbest\t\nhospitals in the world. \nIdiPAZ-La\tPaz\tUniversity\tHospital\u2019\tcommitment\t to\tthis\tnetwork\tis\tsignificant,\tnot\t\nonly\tfor\tthe\tmembers\tof\tthe\tExecutive\tOperating\tCommittee, \tbut\tthe\tgroups\tand\t\ndepartments\tinvolved\tin\tthe\tactivities\tdeveloped\tby\tthe\tnetwork:\n\u2022 Participation in the screening of publications for the elaboration of the Clinical \nPractice Guideline in Immunosuppression Management\n\u2022 Sharing and participation in the discussions of clinical cases in the dedicated \nEuropean Platform (CPMS)\n\u2022\tFacilitating\t information\t of\tthe\texisting\tregistries\tfor\tthe\tdevelopment\t of\tthe\t\nfirst\tEuropean\tRegistry\ton\tPaediatric\t Transplantation\t(PETER)\n\u2022 Participation as speakers in the I International Course on Paediatric Transplan -\ntation, sharing their knowledge and cases studies.\nMembers\tAdded\tValue\nThe clinical advice must be accessible to all EU hospitals, providing to patients \naccess to the best available diagnosis and treatment procedures, bearing in mind \nthe\tquality\tof\tlife\tof\tpatients\tand\ttheir\tfamilies.\tThe\tmembers\tof\tTransplantChild\t\nare\tworking\ttogether\tto\timprove\tthe\tlife\tof\tthese\tchildren\tin\tdifferent\tways,\tbut\t\nwe\twould\tlike\tto\thighlight\tthe\tfollowing:\n\u2022\tProviding\t and\treceiving\t\u201cvirtual\u201d\tadvice\ton\tchallenging\t cases\tby\tusing\tthe\tdedi-\ncated\tEurope-wide\t consultation\t technology, \tresponding\t to\tthe\tmost\tadvanced\t\nEU\tstandards\tin\tterms\tof\tsecurity\tand\tdata\tprotection..\n\u2022\tCreation\t of\tthe\tfirst\tEuropean\tRegistry\tfor\tpaediatric\ttransplanted\t patients\t\n(PETER). This will increase research potential but also it will enable ERN to \nperform multicentre clinical studies and clinical trials. \n\u2022\tDue\tto\tthe\tlow\tprevalence\t of\tpaediatric\ttransplantation\t scientific\tevidence\tis\t\nscarce. Putting together the effort and cases from all the members of the net -\nwork,\twill\tallow\tdeveloping\t Clinical\tPractice\tGuidelines\t based\tin\tthe\texpert\u2019s\t\nopinions and the evidence gathered together. Also, the preparation of Clinical \nAudit on PTLD.\n\u2022 Spread knowledge between professionals involved in paediatric transplanta -\ntion, but also to patients and patients\u2019 relatives. The participation and activities \ndeveloped\tby\tPatients\tAssociations\t and\tAdvocacy\tgroups,\tbecome\teven\tmore\t\nimportant\t in\tTransplantChild\t since\tthe\tnetwork\tis\tabout\tto\tdeploy\tPatients\t\nReported\tExperience\t (PREMs)\tand\tPatients\tReported\tOutcomes\t (PROMs)\t\nManagement indicators.2.10\t Institutional\tProjects\nScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n110  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.11 Internationalization\nAMERICA\nAMERICA\nEUROPA\nAFRICA\nASIA\nOCEANIA\nEUROPE\nAFRICA\nASIA\nOCEANIA\nAMERICA\nAMERICA\nEUROPA\nAFRICA\nASIA\nOCEANIA\nEUROPE\nAFRICA\nASIA\nOCEANIAArgentina\nBrazil\nCanada\nChile\nEcuador\nHonduras\nMexico\nUnited States of \nAmerica\nAMERICA\nAMERICA\nEUROPA\nAFRICA\nASIA\nOCEANIA\nEUROPE\nAFRICA\nASIA\nOCEANIA\nBangladesh\nChina\nIndia\nIsrael\nJapan\nLebanon\nPhilippines\nSingapore\nSouth Korea\nTaiwan\nThailand\nTurkey\nAMERICA\nAMERICA\nEUROPA\nAFRICA\nASIA\nOCEANIA\nEUROPE\nAFRICA\nASIA\nOCEANIAUganda\nAMERICA\nAMERICA\nEUROPA\nAFRICA\nASIA\nOCEANIA\nEUROPE\nAFRICA\nASIA\nOCEANIA\nAustralia\nAMERICA\nAMERICA\nEUROPA\nAFRICA\nASIA\nOCEANIA\nEUROPE\nAFRICA\nASIA\nOCEANIAAustria\nBelgium \nBulgaria\nCroatia\nCzech Republic\nDenmark\nEngland\nEstonia \nFinland\nFrance\nGermany\t\nGreece\nHungary\nIreland\nItaly\t\nLuxembourg\nNetherlands\nNorway\nPoland\nPortugal\nRomania\nScotland\nSerbia\nSweden\nSwitzerland\nUkraine\nUnited Kingdom\nWalesScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n111  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nClinicians2.12 Comunication\nCommunication\tand\tanother\tscientific\t\ndissemination activity \nIdiPAZ was present in different media (journals, magazines, webs, radio, TV., etc.), \nwhich\tcontributed\t to\thighlight\tthe\tactivity\tdeveloped\t by\tthe\tInstitute\tthroughout\t\n2018.\tA\tnumber\tof\tour\tresearchers\t have\tbeen\tinterviewed\t by\tthe\tmains\tmass\tmedia\t\nto broadcast all the knowledge generated in our institute. Besides, the presence of \nour\tnews\tin\tpopular\tplatforms\tsuch\tas:\tTwitter,\tInstagram\tand\tFacebook\thelp\tus\tto\t\nexpand\tour\tresearch\twork\tto\tsociety\tvia\tthe\tmost\tcommonly\t used\tmeans\ttoday.\t\nAlong\tthese\tlines,\tthe\tscientific\tdirection\tof\tour\tinstitute\tis\textraordinarily\t active\tin\t\nsocial networks and the media, which has made our center one of the best known \nby\tsociety.\nIdiPAZ\tappear\tin\ta\ttotal\tof\t216\tpublications\t of\twritten\tpress,\tand\tin\tour\twebsite,\t\u201cIdi-\nPAZ\tin\tthe\tmedia\u201d\tit\tis\tincluded\ta\tcoverage\tof\t394\tdigital\tpress\tmentions\tof\tthis\tyear:\t\nhttp://www.idipaz.es/PaginaDinamica.aspx?IdPag=650&Lang=ES. \t\nAlso, eight own news were published at the website of the Insitute (www.idipaz.es), \nand\tthe\tCommunity\t of\tMadrid\tat\tthe\twebsite\tof\tConsejer\u00eda\t de\tSanidad\tincluded\tsix\t\nnews from IdiPAZ researchers (https://www.comunidad.madrid/actualidad):\n\u2022 2018/09/06- Presentado estudio sobre reinfecciones en pacientes con He-\npatitis C y VIH en la Comunidad de Madrid . \u201cEl estudio titulado \u201cReinfecci\u00f3n \npor\tel\tVHC\tdespu\u00e9s\tdel\ttratamiento\t eficaz\tcon\tantivirales\t de\tacci\u00f3n\tdirecta\t\nfrente\tal\tVHC\ten\tindividuos\tcoinfectados\t por\tVIH\ty\tVHC\ten\tMadrid-CoRe\u201d\t (en\t\ningl\u00e9s:\tHCV\tReinfection\t Following\tEffective\tAll-oral\tDAA\tTherapy\tin\tHIV/HCV\t\nCoinfected Individuals in Madrid-CoRe) ha sido presentando en la 22\u00aa Confe -\nrencia\tInternacional\t sobre\tel\tSIDA\tcelebrada\ten\t\u00c1msterdam\t del\t23\tal\t27\tde\tjulio\t\nde\t2018.\tHan\tparticipado\t 21\thospitales\t del\tServicio\tMadrile\u00f1o\t de\tSalud\tcon\t\nexperiencia\ten\tel\ttratamiento\tde\tpacientes\tcon\tcoinfecci\u00f3n\t VIH/VHC.\u201d\n\u2022 2018/08/03- Contamos con la primera unidad de Terapias Avanzadas para \ntratar el c\u00e1ncer en ni\u00f1os y adolescentes . \u201cEl Hospital Universitario La Paz \nacaba de poner en marcha la Unidad CRIS de T erapias Avanzadas para C\u00e1ncer \nInfantil. Esta unidad, pionera en la Comunidad de Madrid, est\u00e1 situada en la octava \nplanta\tdel\tHospital\tMaterno-Infantil\t y\tviene\ta\tcompletar\tal\tservicio\tde\tHemato-\nOncolog\u00eda\tactual\tcon\tdiez\tnuevas\thabitaciones: \tseis\tpara\tadolescentes\ty\tensayos\t\ncl\u00ednicos\ty\tcuatro\tdise\u00f1adas\tcon\taislamiento\t de\t\u00faltima\tgeneraci\u00f3n\t para\tpacientes\tinmunodeprimidos\t y\ttratamientos\t complejos.\tEstas\thabitaciones\t se\tsuman\ta\tlas\t\n16\tya\texistentes,\tcuatro\tde\tellas\tpara\ttrasplante\tde\tprogenitores\t hematopoy\u00e9ti -\ncos.\tAdem\u00e1s,\tcuenta\tcon\tun\tespacio\tpara\tensayos\tcl\u00ednicos\tubicado\ten\tlos\tlabora -\ntorios\tde\tIdiPAZ,\tdel\tInstituto\tde\tGen\u00e9tica\tM\u00e9dica\ty\tMolecular\t(INGEMM)\t y\ten\t\nla\tUnidad\tde\tEnsayos\tCl\u00ednicos\tdel\thospital, \tUCICEC.\n\u2022 2018/08/03- IdiPAZ participa en el Programa Healthstart con dos de los \ndoce proyectos seleccionados . \u201cEl Hospital La Paz, a trav\u00e9s del IdiPAZ, partici -\npar\u00e1\tcon\tdos\tproyectos\ten\tel\tPrograma\tHealthstart\t organizado\t por\tla\tFundaci\u00f3n\t\npara\tel\tConocimiento\t madri+d\tjunto\tcon\tla\tPlataforma\t de\tInnovaci\u00f3n\t en\tTec-\nnolog\u00edas\tM\u00e9dicas\ty\tSanitarias\t(ITEMAS)\tpara\timpulsar\temprendimiento\t y\tcrea-\nci\u00f3n\tde\tspin-offs\tbasadas\ten\ttecnolog\u00edas\t sanitarias.\tDos\tde\tlos\tdoce\tproyectos\t\nseleccionados en esta III Edici\u00f3n del Programa est\u00e1n liderados por personal de \nIdiPAZ.\u201d\n\u2022 2018/06/26- El presente y el futuro de la tecnolog\u00eda 3D, a debate en el \nHospital La Paz . \u201cLa Plataforma de Innovaci\u00f3n del Hospital Universitario La Paz \nha celebrado la tercera edici\u00f3n de sus jornadas de innovaci\u00f3n. Bajo el t\u00edtulo \u201cLa \nPaz\t3.D:\tgesti\u00f3n\tde\tla\ttridimensionalidad\u201d\t el\tobjetivo\tha\tsido\treunir\ta\tlos\tpro-\nfesionales\tsanitarios\ty\tla\tindustria\tpara\tdebatir\tsobre\tel\tpresente\ty\tfuturo\tde\tla\t\ntridimensionalidad\t y\tsu\tgesti\u00f3n\ten\tel\tsector\tsanitario\tcontrastando\t experiencias, \t\nconocimiento\te\tinnovaci\u00f3n.\u201d\n\u2022 2018/06/11- El IdiPAZ coordina el Registro Nacional de Pacientes con Frac-\ntura de Cadera . \u201cEl IdiPAZ (Instituto de Investigaci\u00f3n de La Paz) coordina el \nRegistro Nacional de Fracturas de Cadera (RNFC) por fragilidad en el anciano. \nEl\tregistro\tcuenta\tya\tcon\tlos\tdatos\tde\tm\u00e1s\tde\t7.000\tpacientes\tprocedentes\t de\t\n54\thospitales\tde\tla\tmayor\u00eda\tde\tlas\tcomunidades\t aut\u00f3nomas\t de\tEspa\u00f1a.\tEl\tprinci -\npal objetivo de este registro es mejorar la calidad asistencial. Los resultados se \ncomparan\tcon\totros\tcentros\ttanto\tnacionales\tcomo\tinternacionales.\u201d\n- 2018/02/12- Se presenta en el Hospital La Paz-IdiPaz un sello dedicado a la \ninvestigaci\u00f3n biom\u00e9dica \t\u201cLa\tSociedad\tEstatal\tde\tCorreos\ty\tTel\u00e9grafos\tpresenta\t\nen\tLa\tPaz\tuna\tcolecci\u00f3n\tfilat\u00e9lica\tdedicada\ta\tla\tinvestigaci\u00f3n\t biom\u00e9dica\ten\tEspa\u00f1a,\t\nque\tincluye\tun\tsello\tde\t35\tx\t24.5\tmm.\ty\tun\tmatasellos.\tEl\tacto\tha\tcontado\tcon\tla\t\npresencia del presidente de Correos, la Secretaria General T\u00e9cnica del Ministe -\nrio de Fomento, la directora general de Investigaci\u00f3n de la Consejer\u00eda de Sanidad \ny\tel\tdirector\tcient\u00edfico\tdel\tInstituto\tde\tInvestigaci\u00f3n\tde\tla\tPaz.\u201cScientific \nReport \n1\n2\n3\n4Executive \nsummary\n2.1 Global Analysis\n2.2 Research Structure\n2.3 Training Report and \nTeaching\n2.4 Innovation and \nTransfer Activities\n2.5 Quality Committe\n2.6 Clinical Trials\n2.7\tPlatforms\n2.8\tScientific\tProduction\n2.9 CIBERs and RETICs\n2.10\t Institutional\tProjects\n2.11 Internationalization\n2.12 Comunication\n112  \n1\n2\n3\n4Introduction\n1\n2\n3\n4\nInformation \nGroups  \nby Area\n1\n2\n3\n4\nAssociated \nCliniciansIn\tthe\twebsite,\tthe\tactivity\thas\tbeen\timproving\tyear\tafter\tyear\tsince\tits\timplementa -\ntion\tin\t2011, \tso\tat\tthe\tend\tof\t2018, \tit\texceeded\t240,000\tvisits. \t\nNews that includes the work of our researchers, data about courses, grants, and \nother news of interest to the public, are published in the main social networks, whe -\nre\tIdiPAZ\thas\tits\town\tprofile\tsince\tOctober\t2018:\n@IdipazScience  \n   \n   \n   \nCurrently,\tthe\tnumber\tof\tfollowers\twas\t851\ton\tTwitter,\t76\ton\tFacebook,\tand\t237\ton\t\nInstragram.\nRegarding\t to\tScienbtific\t communication, \tmore\tthan\tsymposiums, \tworkshop,\tetc.\t\nwere\torganized\tat\tIdiPAZ\tin\t2018,\tand\tfinally,\tScientific\tSeminars\tof\tIdiPAZ\twas\tcer-\ntified\tby\t\u201cAcreditaci\u00f3n\t de\tActividades\t de\tFormaci\u00f3n\t Continuada\t de\tlas\tProfesiones\t\nSanitarias\u201d\t by\tthe\tComunity\tof\tMadrid\t(07-AFOC-003327.1/2018). \tIn\t2018,\t20\tse-\nminars were celebrated. \nCoordinators: Laura Salda\u00f1a Quero; Paloma G\u00f3mez Campelo and Susana Garc\u00eda P\u00e9rez.2.12 Comunication\nJanuary December\nDate Speaker Title\n12/01/2018 Jaime Mill\u00e1nPapel de la polaridad del hepatocito en la respuesta \ninflamatoria del h\u00edgado\n19/01/2018 Carlos Ram\u00edrez La cuarta R de la experimentaci\u00f3n animal\n26/01/2018 Anee Miren Andr\u00e9sTrasplante intestinal y rechazo: estudio experimental \ncon c\u00e9lulas troncales mesenquimales derivadas de tejido \nadiposo para su prevenci\u00f3n y perspectivas cl\u00ednicas \nfuturas en la b\u00fasqueda de la tolerancia inmunol\u00f3gica\n09/02/2018Jos\u00e9 Luis L\u00f3pez Send\u00f3n \nHenstchel\u00bfQu\u00e9 es la calidad? \u00bfPara qu\u00e9 sirve? \u00bfC\u00f3mo se mide? \n\u00bfQuien la tiene que medir?\n16/02/2018 Virginia\tAmesty Medicina regenerativa aplicada a la urolog\u00eda23/02/2018 Daniel Ortega Ponce Hipertermia magn\u00e9tica y  su aplicaci\u00f3n en biomedicina\n02/03/2018 Silvia Mart\u00edn PuigHypoxia and Cardiovascular System: New Mouse Models \nto investigate Human Diseases\n09/03/2018Elena Sendagorta \nCud\u00f3sEl futuro ya est\u00e1 aqu\u00ed\n16/03/2018 Jorge Bonastre Juli\u00e0 Investigaci\u00f3n en Cirug\u00eda Pl\u00e1stica, una realidad\n06/04/2018Miguel Gonz\u00e1lez, M\u00aa \nPazHacia el desarrollo de una c\u00f3rnea humanizada por \nmedio de ingenier\u00eda celular\n13/04/2018 Francisco Garcia RioCausas y consecuencias del s\u00edndrome de apnea del \nsue\u00f1o\n20/04/2018 Mar\u00eda Luisa Toribio Leucemia linfobl\u00e1stica aguda de c\u00e9lulas T\n27/04/2018Miguel \u00c1ngel Rico \nDazaMedicamento NC1 de terapias avanzadas. Requisitos \npara su fabricaci\u00f3n y aplicaci\u00f3n en el HUPHM\n18/05/2018Santiago Rodr\u00edguez de \nC\u00f3rdobaBasic concepts about complement, complement related \ndiseases and anti-complement therapies\n25/05/2018 Fernando CorralesAplicaciones de la prote\u00f3mica funcional en biomedicina. \nEl caso del h\u00edgado\n19/10/2018 Rafael Correa RochaTerapia celular con c\u00e9lulas Treg obtenidas de tejido \nt\u00edmico (thyTreg) para prevenir el rechazo en ni\u00f1os \ntrasplantados de coraz\u00f3n. Un nuevo paradigma en el \ntratamiento de enfermedades inmunol\u00f3gicas\n26/10/2018 Arancha Llama PalaciosEstudio de las bacterias periodontales mediante \nherramientas prote\u00f3micas\n23/11/2018 Jes\u00fas Mingorance CruzAn\u00e1lisis cuantitativo de la colonizaci\u00f3n intestinal por \nenterobacterias multirresistentes\n30/11/2018 Almudena Val BlascoRole of nucleotide-binding oligomerization domain type \n1 (nod1) in human and experimental heart failure\n21/12/2018 Laetitia PereiraPapel de nuevos mediadores reguladores del calcio \nintracelular en la enfermedad metab\u00f3licaScientific \nReport \nHospital Universitario La Paz\nFundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica\nwww.idipaz.es", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}